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Abstract 
 
The overall objectives of this research were to devise a viable synthetic route to 
conjugates, in which 9-aminoacridine 4-carboxamide was tethered through its 4-
position to peptide nucleic acids (PNAs), and to evaluate their abilities to act as novel 
inhibitors of HIV-1 integrase (IN).  It was reasoned that such compounds could inhibit 
the process catalysed by IN either directly by binding to the enzyme or indirectly by 
binding to the proviral DNA substrate through threading intercalation.  
The first route to these conjugates investigated involved synthesis of the intermediates 
9-oxoacridan-4-carboxylic acid and the thyminyl-PNA monomer ethyl ester.  Both 
these compounds were successfully prepared following established literature 
procedures.  In order to explore the conditions required for coupling 9-oxoacridan-4-
carboxylic acid  and the thyminyl-PNA monomer ethyl ester, a model study was 
undertaken involving preparation of the known threading intercalator, 9-amino-DACA.  
Following literature precedence, 9-oxoacridan-4-carboxylic acid was treated first with 
excess thionyl chloride to yield 9-chloroacridine-4-carboxyl chloride.  Subsequently, 
this was reacted selectively with N,N-dimethylethylenediamine to give 9-chloro-
DACA. Finally, treatment of a phenolic solution of 9-chloro-DACA with gaseous 
ammonia successfully afforded 9-amino-DACA in a 26% over-all yield.  
Unfortunately, on applying a similar approach for synthesis of the 9-aminoacridine-4-
carboxamide PNA conjugate, none of the desired compound could be identified. 
In a second alternative strategy a number of alkyl-9-oxoacridan-4-carboxylate 
precursors (methyl, iso-propyl and t-butyl) were synthesised and subsequently 
activated, via 9-triazolylation, to allow for substitution in the 9 position with benzyl 
amine.  This resulted in the successful synthesis of the iso-propyl- and t-butyl-9-
benzylaminoacridine-4-carboxylate intermediates.  Subsequent attempts to generate the 
4-carboxyl group in both intermediates, via alkyl-ester cleavage, were only successful 
via a basic hydrolysis of the iso-propyl ester. Unfortunately, attempts to activate the 4-
carboxyl group of the resulting 9-benzylaminoacridine-4carboxylic acid via 4-N-
hydroxysuccinimide (NHS) ester formation, to enable subsequent substitution in the 4 
position with a PNA monomer, were unsuccessful.  The nature of the 9-amino 
substituent was found to be of importance as it was shown that for 9-anilinoacridine-4-
carboxylic acid, NHS activation of the 4-carboxyl was successful and led to synthesis 
iii 
of a 9-anilinoacridine-4-carboxamide PNA conjugate.   This result prompted us to 
revise our strategy and led to the synthesis of 9-t-Boc- and 9-Alloc-aminoacridine-4-
NHS esters that subsequently both were coupled successfully to a thyminyl-PNA 
monomer.  Subsequent deprotection steps for the 9-Alloc protected PNA-acridine 
conjugate proved to be cumbersome but fortunately, for the t-Boc protected PNA-
acridine conjugate t-Boc cleavage with TFA followed by an aqueous basic ethyl ester 
hydrolysis of the PNA monomer’s C-terminus resulted in completion of a 9-step 
synthetic route (4% over-all yield) towards the target 9-amino-4-PNA-acridine 
conjugate, 2-(N-(2-(9-aminoacridine-4-carboxamido)ethyl)-2-(thymin-1-yl)acetamido) 
acetic acid.  
The IN inhibitory activities of 9-amino-DACA and one intermediate 9-aminoacridine-
containing compound were evaluated in a cell based antiviral assay.  Although their 
absolute potencies of inhibition were in the micromolar range, their novel scaffold 
warrants their further investigation as potential anti-IN inhibitors 
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Glossary 
 
 
AIDS: Acquired immune deficiency syndrome 
Alloc: Allyloxycarbonyl 
AZT: 3’-azidothymidine  
BAF: Barrier-to-autointegration factor 
BSA:  N,O-Bis(trimethylsilyl)acetamide 
cDNA: Complementary DNA 
CDI: Carbonyldiimidazole  
CCD: Catalytic core domain  
CTD: C-terminal domain  
CC50: Half maximal cytotoxic concentration 
DNA: Deoxyribonucleic acid 
ds: double stranded 
DKA: Diketo acid 
DAPY: Diarylpyrimidine 
DACA: N-[2-(dimethylamino)ethyl]-acridine-4-carboxamide 
DMF: Dimethylformamide 
DCM: Dichloromethane 
DMSO: Dimethylsulfoxide 
DTT: Dithiothreitol 
DPIC: Diphenyliodonium carboxylate 
EI: Entry inhibitors  
EED: Embryonic ectoderm development 
EC50: Half maximal effective concentration 
ERA: European Research Area 
FISH: Fluorescent in situ hybridisation  
FDA: Food and drug administration 
Fab: Fragment antigen binding 
gp: glycoprotein 
HEPES:  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HMBC: Hetero-nuclear multiple bond correlation 
HIV: Human immunodeficiency virus 
x 
HMGA1: High mobility group protein A1 
HBTU: 2-(1H-Benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate  
HSQC: Hetero-nuclear single quantum coherence  
HDAC: Histone deacetylase  
HRP2: Hepatoma-derived growth factor related protein 2 
HSP: Heat shock protein 
HAART: Highly active anti-retroviral therapy 
IR: Infrared 
IC50: Half maximal inhibitory concentration 
IN: Integrase 
INBI: Integrase binding inhibitors 
INI1:  Integrase interactor 1 protein 
LTR: Long terminal repeats  
LEDGF: Lens epithelium derived growth factor 
LVG: Leaving group 
MA: Matrix 
NHS: N-hydroxysuccinimide  
NRTI: Nucleoside (and nucleotide) reverse transcriptase inhibitors  
NNRTI: Non-nucleoside reverse transcriptase inhibitors  
NNIBP: Non-nucleoside inhibitor binding pocket  
NTD: N-terminal domain  
NADPH: Nicotinamide adenine dinucleotide phosphate 
NC: Nucleocapsid  
NOESY: Nuclear Overhauser effect spectroscopy 
NMR: Nuclear magnetic resonance 
PBS: Phosphate buffered saline  
PI: Protease inhibitors  
PIC: Pre-integration complex  
PPE: Poly-phosphoric ethyl ester 
PNA: Polyamide nucleic acids  
RNA: Ribonucleic acid 
RT: Reverse transcriptase  
RER: Rough endoplasmic reticulum 
RT: Reverse transcriptase 
xi 
ROESY: Rotational Overhauser effect spectroscopy  
ss: single stranded 
TRIoH: Targeting replication and integration of HIV 
TLC: Thin layer chromatography 
THF: Tetrahydrofuran 
TopPipU:  2-(2-Oxo-1(2H)-pyridyl)-1,1,3,3-bis-
pentamethyleneuroniumtetrafluoroborate   
TFA: Trifluoroacetic acid 
t-Boc: t-Butyloxycarbonyl 
UNG: Uracil-N-glycosylase  
Vpr: Viral protein R 
Z: Carboxybenzyl
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Chapter 1: Introduction 
 
1.1 Preamble 
 
AIDS or Acquired Immunodeficiency Syndrome is caused by HIV or Human 
Immunodeficiency Virus and was discovered in 1983 by Luc Montagnier from the 
Pasteur Institute in Paris, France.  Since the early eighties the disease has taken on 
pandemic proportions and worldwide over 33 million people are thought to carry the 
virus.  AIDS is one of the ten main causes of death in the world and has an immense 
socio-economic impact, particularly in certain hard-hit sub-Saharan countries with adult 
HIV prevalence of over 15%. 
This forms a huge challenge for those wishing to contribute scientifically to the solution 
of the AIDS problem and continuing efforts are made on a European political level to 
join multidisciplinary scientific forces in order to tackle this growing global health 
threat. 
In 2003 different partners from business and academic backgrounds, of which Dr. 
Howarth’s Nucleic Acids Lab was one, joined efforts in a European Commission ‘6th 
Framework Programme’ integrated project known as TRIoH (Targeting Replication 
and Integration of HIV: Project number: LSHB-CT-2003-503480).  The main objective 
of the 6th Framework Programme was to further accommodate the creation of a 
European Research Area (ERA) by improving integration and co-ordination of so far 
largely fragmented research.  Under this European umbrella TRIoH focused on the 
integration of different research efforts from different European partners to develop 
novel anti-HIV molecules targeting viral replication and integration.   
This dissertation is a record of my contribution to Dr. Howarth’s partnership in the 
TRIoH consortium.  It comprises general background information on HIV/AIDS, the 
current therapeutic approach and the existing collection of HIV antiretroviral drugs and 
their mechanisms of action. I take a more in-depth look at HIV’s integrase enzyme, its 
structure and function as well as the development of integrase inhibitors and their mode 
of action.   As an introduction to a new approach we took in the development of novel 
potential HIV-Integrase inhibitors, referred to as PNA-Acridine threading intercalators, 
I discuss the properties and therapeutic potential of DNA intercalators and Polypeptide 
Nucleic Acids (PNA) and how a conjugation of PNA with a DNA intercalator like 
acridine holds the potential to inhibit HIV integrase through binding to the enzyme 
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donor substrate (viral DNA) and/or the actual enzyme. Finally, a comprehensive 
discussion of the followed synthetic strategies towards the development of PNA-
acridine conjugates and the chemistry involved is reported.   
 
1.2 Acquired Immune Deficiency Syndrome or AIDS 
 
1.2.1 Key facts about AIDS 
 
AIDS, or Acquired Immune Deficiency Syndrome, is caused by HIV, the Human 
Immunodeficiency Virus.  It is characterized by a gradual deterioration of the immune 
function.  HIV causes the destruction of lymph nodes and related immunologic organs 
and disables a specific type of immune cell, called CD4+ T cells, during the course of 
the infection.[1] These T-helper cells, as they are also called, are crucial to the function 
of the immune system because they send activating signals to other immune cells that 
take part in the complex immune response following infection.  Therefore, the immune 
system’s failure, understandably, has devastating effects on the human body, leaving it 
open to attack from even the most harmless of infections. 
 
The term AIDS applies to the most advanced stage of HIV infection in which patients 
have less than 200 CD4+ T cells per mm3 of blood (a healthy person has between 800 
and 1200 CD4+ T cells per mm3 of blood).[1] Early symptoms of HIV infection 
include fever, headache, tiredness and the presence of enlarged lymph nodes.  Often 
these are mistaken for other viral infections.  It can take between 3 months to over 10 
years after contracting HIV infection before the actual onset of AIDS occurs.  This is 
accompanied by a gradual increase in the severity of the above symptoms, going from a 
lack of energy, severe weight loss and persistent yeast infections to mental problems 
such as confusion and forgetfulness, severe and persistent diarrhoea and development 
of cancers such as Kaposi’s sarcoma and certain types of lymphomas. 
 
HIV is transmitted through unsafe sex with an infected partner, during which the virus 
enters the body through the lining of the vagina, vulva, penis, rectum or mouth.[1]  
Transmission can also occur through contact with infected blood, for example through 
sharing of contaminated needles or syringes among drug users.  Between 25 to 33% of 
untreated HIV positive pregnant women will transmit HIV to their babies during birth 
or pregnancy.  This risk is strongly reduced when the anti-AIDS drug 3’-
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azidothymidine (AZT) is taken by the mother during pregnancy and by the baby for the 
first 6 months after birth.  There is no evidence that HIV can be spread through sweat, 
tears, urine or faeces.  In addition, although HIV has been found in the saliva of 
infected people, there is no evidence supporting transmission via this route, neither can 
HIV be contracted through casual contacts, such as sharing of food, utensils, towels, 
bedding, swimming pools, telephones and toilet seats or from biting insects. 
 
1.2.2 Epidemiology  
 
At the end of 2007, it was estimated that 33.2 (30.6-36.1) million people in the world 
were living with HIV/AIDS; 28.2-33.6 million adults (with a 50/50 distribution 
between the genders) and between 2.2 and 2.6 million children below the age of 15 
years.[2] More than 67 percent of these people (i.e. 20.9-24.3 million) live in Sub-
Saharan Africa and another 12 percent (3.3-5.1 million) live in South and South-East 
Asia.  Western and Central Europe and North America combined represent just over 6 
percent (1.1-3.0 million) of the worldwide prevalence.  In 2007, it was reported, 
between 1.9 and 2.4 million people died of HIV/AIDS related illnesses.  Furthermore it 
has been estimated that 1.8 to 4.1 million people became newly infected with HIV 
during 2007.  More than 80 percent of newly diagnosed adult HIV infections resulted 
from heterosexual intercourse whereas more than 90 percent of HIV infections in 
infants and children were a result of mother-to child (vertical) transmission. 
 
1.2.3 HIV’s viral structure, replication cycle and genome structure  
 
(i) HIV structure 
 
HIV is an enveloped RNA virus and a retrovirus, which means its genetic material, 
RNA, needs to be ‘transcribed’ into DNA for the virus to be able to replicate.[3]  HIV 
is also a lentivirus (a genus within the retrovirus family).  The members of this family 
are characterized by a long incubation period (‘lenti’ is Latin for slow).  The HIV virus 
acquires its phospholipid envelope while budding out of the host cell (e.g. a helper-T 
cell) during replication.  The spherical virus has a diameter of about 100 nm (Figure 
1.1 illustrates the HIV structure).  72 peg-like structures (peplomers), viral RNA 
encoded, protrude from the viral envelope.  Each peg consists of two types of 
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glycoprotein (gp 41 and gp 120): trimeric gp 41 molecules constitute the stem of the 
peg while trimeric gp 120 molecules form the cap.  Inside the envelope there is a matrix 
made up of p17 protein molecules.  The matrix surrounds a hollow, cone shaped capsid 
(composed of p24 protein and human cyclophilin A protein molecules), harbouring two 
(+)-sense single RNA strands and copies of three important enzymes in HIV’s lifecycle 
i.e.: HIV reverse transcriptase, HIV protease and HIV integrase. P9 protein molecules 
form a nucleocapsid sheath in complex with the RNA strands. 
 
phospholipid envelope
matrix (p17)
capsid (p24)
human cyclophilin A
HIV protease
HIV integrase
HIV reverse
transcriptase
single RNA 
strand
Nucleocapsid (p9)
gp41
gp120
 
 
Figure 1.1: HIV structure (D.R. Adams: used by permission) 
 
(ii) HIV replication cycle 
 
 The main target for HIV in the human immune system seems to be the helper T cell (T-
lymphocyte) but other cells, like macrophages and monocytes, can become infected as 
well and all can harbour large numbers of viruses.[3] HIV’s entry into the T cell 
requires the binding of gp 120, on the HIV surface, to the CD4 receptor molecules and 
to a co-receptor, both on the host cell’s surface. (Step 1 in Figure 1.2: the HIV 
replication cycle; co-receptors are not shown in Figure 1.2).   
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Figure 1.2: HIV replication cycle (D.R. Adams: used by permission)
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Two different co-receptors, CCR5 and CXCR4 have been found to be involved.  They 
are involved early in the infection, during the asymptomatic phase or late in the 
infection, during the symptomatic phase respectively.  Viruses isolated from individuals 
early in the infection have been shown to typically infect macrophages in the 
laboratory, rather than T cells.  However, the latter can be infected by viruses taken 
from patients in late infection stage.  Once HIV has bound to the host cell (e.g. a T-
lymphocyte), its viral envelope fuses with the host’s cell membrane and the viral RNA 
and enzymes are released into the host’s cytoplasm (i.e. the fusion process: step 2 in 
Figure 1.2).  During this process the viral matrix disintegrates and the cyclophilin A 
molecules, part of the viral capsid, dislocate the latter (the uncoating process: step 3 in 
Figure 1.2).  In turn this opens up the capsid core to the host cell’s cytoplasm.  The 
viral enzyme reverse transcriptase (RT) now has access to the host cell’s nucleotide 
building blocks and transcribes the viral RNA into its Watson-Crick complementary 
single-stranded DNA (ss-DNA).  DNA synthesis and RNA hydrolysis are co-ordinated 
so that RNA is removed only after it has served as a template.  The resulting viral ss-
DNA forms the template for viral double-stranded DNA (ds-DNA) synthesis which is 
also effected by RT.  Thus, RT carries out three kinds of reactions: 1) RNA-directed 
DNA synthesis, 2) Hydrolysis of RNA, 3) DNA-directed DNA synthesis.  DNA 
synthesis is carried out by the polymerase moiety of RT whereas RNA hydrolysis is 
performed by the RNAse H moiety.  All this occurs inside an expanded capsid structure 
and is generally referred to as reverse transcription (step 4 in Figure 1.2).  The next 
step in the HIV lifecycle involves the viral enzyme integrase.  HIV integrase catalyses 
the integration of the viral ds-DNA into the host’s cellular chromosome (splicing) after 
which the viral DNA is referred to as the provirus (a state in which infection becomes 
irreversible) (integration: step 5 in Figure 1.2).  The “blending in” allows the virus to 
be latent and effectively evade host responses.  Transcription of the provirus by 
hijacking the host’s cellular synthesis machinery leads to the generation of viral RNA 
(steps 6a and 6b in Figure 1.2).  Initially viral mRNA coding for viral accessory 
proteins and the env gene is produced (step 6b).  In a later stage genomic viral RNA 
and mRNA for expression of the viral gag and pol genes is generated (step 6a). In the 
subsequent translation processes (steps 7 in Figure 1.2) the first viral proteins to be 
synthesised are Rev and Tat (regulatory proteins with names similar to their associated 
genes).  Rev protein facilitates RNA export to the cytoplasm and by doing so prevents 
splicing of longer viral RNA transcripts, which in turn allows for production of 
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structural proteins and RNA genome.  Tat protein increases transcription of all the HIV 
genes.  The env gene transcript is translated by ribosomes on the rough endoplasmic 
reticulum (RER) thereby producing, inside the RER, the gp160 precursor of gp41 and 
gp120 (step 7a).  In the cytoplasm the gag gene transcript is translated into Gag protein, 
the precursor to viral matrix protein (p17), capsid protein (p24) and nucleocapsid 
protein (p9) (step 7b).  Also cytoplasmatic, the pol gene transcript is translated into 
Gag-Pol protein, the precursor to the viral enzymes reverse transcriptase, integrase and 
protease (step 7c).  In a first maturation step the Env protein (gp 160) progresses from 
the endoplasmic reticulum to the Golgi apparatus, in which glycosylation and 
subsequent formation of the mature gp41-gp120 complex takes place (steps 8a and 8b 
in Figure 1.2).  The subsequent virion assembly (steps 9 in Figure 1.2) initially 
involves expression of the viral glycoprotein spikes (gp41-gp120) on the host cell 
membrane via fusion of the latter with Golgi generated, peplomer carrying vesicles 
(steps 9a and 9b).  The generated patch of ‘spiked’ host cell membrane allows for 
localised cytoplasmatic recruitment of the immature viral components: Gag and Gag-
Pol, cyclophilin A and two copies of full-length RNA (step 9c).  This organised 
assembly causes the viral particles to bud from the host cell membrane, thereby making 
use of the latter to function as viral envelope (the release process: step 10 in Figure 
1.2).  A final maturation (step 8c) takes place, during or soon after budding, by the 
action of HIV protease, which processes Gag and Gag-Pol to produce their functional 
forms. This maturation step is required for the virus to become fully infective. 
The HIV replication cycle, comprising viral entry into the host cell, replication, 
assembly, subsequent release of new viral particles and infection of other cells, can take 
as little as 36 hours.[4] 
 
(iii) HIV genome structure 
LTR LTR
 
 
Figure 1.3: organisation of the HIV genome (D.R. Adams: used by permission) 
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The above representation of the HIV genome (top orange strip) contains a total of 9 
genes (thinner, labelled strips), some of which are fragmented and/or overlapping with 
other genes.  The total coding region in the HIV genome takes up about 9.2 kb.[3] The 
two regions at both ends of the genome flanking the functional genes are referred to as 
long terminal repeats (LTR) (see Figure 1.3).  LTR are non-coding regions that play a 
role in integration of viral ds-DNA into the host genome and in regulation of 
transcription initiation. The 9 genes are known as gag, pol, env, nef, vpr, rev, tat, vif 
and vpu.  
gag: holds the information for core and structural proteins i.e. matrix protein (p17), 
capsid protein (p24) and nucleocapsid protein. 
pol: holds the information for the viral enzymes reverse transcriptase, integrase and 
protease (both gag and pol products are processed by viral protease to generate the 
functional protein forms). 
env: holds the information for the glycoprotein spikes (the gp120-gp41 complex). The 
env product gp160 is split into the gp120-gp41 complex by a host cell protease. 
The remaining genes, nef, vpr, rev, tat, vif and vpu, are single genes that code for 
similarly named proteins (Nef, Vpr, Rev, Tat, Vif and Vpu).  They are regulatory, 
non-structural genes controlling different parts of the viral life-cycle. 
 
1.2.4 Current Treatment 
 
There are a total of 32 FDA approved medications (single drug + co-formulations) for 
anti-HIV treatment which target a number of different processes in the HIV life-
cycle.[5] These anti-HIV drugs are divided into five different classes: (i) fusion or entry 
inhibitors (EIs); (ii) nucleoside (and nucleotide) reverse transcriptase inhibitors 
(NRTIs); (iii) non-nucleoside reverse transcriptase inhibitors (NNRTIs); (iv) protease 
inhibitors (PIs) and (v) integrase inhibitors.[5] 
 
(i) Entry and fusion inhibitors: 
 
These inhibitors function by blocking the HIV virus entry into human cells.  The first 
FDA approved and marketed fusion inhibitor was enfuvirtide (Figure 1.4).  Enfuvirtide 
is a synthetic peptide of 36 natural amino acids (with an acylated N-terminus and a 
carboxamide C-terminus) that binds to HIV-1’s glycoprotein 41, thereby interfering 
with its capacity to combine viral and cellular membranes, thus effectively blocking 
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membrane fusion.[6] Another peptide-based candidate in clinical trials is known as 
TRI-1144 (Figure 1.4), a 38 amino acid peptide that partially overlaps with the 
enfuvirtide sequence but appears to have better potency and pharmacokinetic properties 
and is less prone to resistance development.[7] 
 
Ac-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-
Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2 
Enfuvirtide  
 
Thr-Thr-Trp-Glu-Ala-Trp-Asp-Arg-Ala-Ile-Ala-Glu-Tyr-Ala-Ala-Arg-Ile-Glu-Ala-
Leu-Leu-Arg-Ala-Leu-Gln-Glu-Gln-Gln-Glu-Lys-Asn-Glu-Ala-Ala-Leu-Arg-Glu-Leu 
TRI-1144 
 
 
Figure 1.4: 1° structure of TRI-1144 (in clinical trials) and Enfuvirtide (FDA 
approved) 
 
A second FDA approved and marketed entry inhibitor is known as Maraviroc (Figure 
1.5), which is an antagonist of the chemokine co-receptor CCR5 on the CD4+ T cell 
membrane.[8] Maraviroc thereby prevents binding of HIV’s gp 120 to CCR5 and 
blocks subsequent membrane fusion events required for viral entry.  
 
N
N
N
N
NHO
 
 
Figure 1.5: entry inhibitor Maraviroc 
 
Furthermore, a number of potential new fusion/entry inhibitors are currently in 
development, targeting either HIV’s gp 41 and gp120 or helper T cells’ CD4 receptor 
and CCR5 and CXCR4 co-receptors. 
 
(ii) Nucleoside (and nucleotide) reverse transcriptase inhibitors (NRTIs) 
 
There are currently 13 FDA approved medications containing nucleoside (and 
nucleotide) reverse transcriptase inhibitors (NRTIs) available, as single drug (nine) or 
as a co-formulation (four).  NRTIs are nucleoside (or nucleotide) analogues that 
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suppress replication of retroviruses by interfering with the HIV reverse transcriptase 
enzyme.  
 
Approved single drug NRTIs are zidovudine (AZT), stavudine (d4T), lamivudine 
(3TC), emtricitabine (FTC), didanosine (ddI), zalcitabine (ddC), abacavir (ABC) and 
tenofovir D (TDF) [5] (Figure 1.6).  During reverse transcription, by HIV reverse 
transcriptase, these nucleoside/nucleotide analogues (also referred to as chain 
terminators) are incorporated into the viral DNA, but because they lack the 3’-OH of a 
natural nucleoside/nucleotide unit, which is required to make the phospho-ester linkage 
with the incoming deoxynucleoside triphosphate, DNA synthesis is prematurely 
terminated.  
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Figure 1.6: Nucleoside (and nucleotide) reverse transcriptase inhibitors (NRTIs) 
 
Currently, there are 4 new NRTIs undergoing clinical trials.[5] An intriguing NRTI 
known as KP-1212 (the prodrug of which is KP-1461) (Figure 1.6) works by a 
mechanism new to the nucleoside analogues.  It is a non-chain terminating mutagen.  
Due to its capacity to randomly incorporate itself in the viral DNA and pair with 
multiple bases it generates multiple mutations, thereby rapidly rendering the virus 
unviable.[9] However, recently clinical trials for KP-1461 have been terminated. 
 
(iii) Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
 
Non-nucleoside reverse transcriptase inhibitors or NNRTIs, like NRTIs suppress HIV 
replication by interfering with HIV’s reverse transcriptase enzyme.[10]  NNRTIs are 
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non-competitive inhibitors of RT, i.e. they do not compete with RT natural substrates 
but exert their effect by binding to reverse transcriptase at a site different form the 
catalytic binding site.  This induces a conformational change that disrupts the catalytic 
site which in turn renders the enzyme incapable of normal interaction with the viral 
RNA, slowing down or blocking DNA-dependant and RNA dependant polymerase 
activities.  
 
FDA approved NNRTIs are nevirapine, efavirenz, delavirdine and etravirine (Figure 
1.7).[5]  Etravirine was approved early in 2008 (10 years after the last NNRTI, 
efavirenz, had been approved).[5]  Etravirine, a diarylpyrimidine (DAPY), is a second 
generation NNRTI and was developed after studies on first generation NNRTIs 
revealed that increased inhibitor flexibility could induce binding to the so-called non-
nucleoside inhibitor binding pocket (NNIBP) in a number of different 
conformations.[11]  Most importantly this increased conformational freedom meant the 
NNRTIs could intrinsically adapt to mutation induced changes to the binding pocket, 
making them very potent inhibitors of key drug-resistant HIV-1 strains.[12], [13] 
Another not yet approved diarylpyrimidine, rilpivirine (Figure 1.7), also shows potent 
activity against NNRTI resistant HIV and is currently undergoing clinical trials [14].  
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Figure 1.7:  Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
 
(iv) protease inhibitors (PIs) 
 
PI’s target the HIV’s protease enzyme.  This enzyme is responsible for proteolytic 
cleavage of HIV’s polypeptide precursors into mature enzymes and structural proteins.  
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Generally this means, by binding to this enzyme, these PIs render the HIV’s protease 
incapable of performing its catalytic function.  Thus, upon budding, the liberated 
immature viral particles containing catalytically inactive protease are unable to undergo 
maturation to produce an infective form.[15] 
 
HIV protease is an aspartate protease (which belongs to one of two mechanistically 
different protease classes) in which a water molecule, activated/deprotonated by the 
two aspartyl β-carboxy groups at the protease’s active site, nucleophilically attacks the 
carbonyl of the scissile peptide bond.  As a result of this proteolytic process a 
tetrahedral transition state is generated.[16] (see Figure 1.8a for a protease mechanism 
suggested by Suguna et al.[17]) This knowledge led to the development of ‘natural 
substrate-like’ protease inhibitors carrying non-cleavable iso-steres mimicking the 
tetrahedral transition state of this hydrolysis step. 
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Figure 1.8a: aspartate protease mechanism (as suggested by Suguna et al.[17]) 
 
Currently there are 10 FDA approved and marketed PIs: saquinavir mesylate, ritonavir, 
indinavir, nelfinavir, amprenavir, lopinavir, atazanavir, fosamprenavir, darunavir and 
tipranavir (Fig. 1.8b).[5]  
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Figure 1.8b: FDA approved HIV-protease inhibitors (PI’s) 
 
Saquinavir (mesylate) was the first PI to be granted FDA approval and is a selective, 
competitive, reversible inhibitor of HIV-protease.[18] It has a non-hydrolysable 
hydroxyethylamine group in place of the natural substrate’s hydrolysable peptide bond 
(linking phenylalanine and proline residues in the natural substrate).[16] The same 
hydroxyethylamine iso-steric moiety is also present in atazanavir, nelfinavir, darunavir 
and phosamprenavir. 
Another occurring non-hydrolysable iso-steric moiety is hydroxyethylene (indinavir, 
ritonavir, lopinavir).  
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Tipranavir is a non-peptide, more recently developed PI (FDA approved in 2005).[5]  
Ritonavir was initially thought of/used as an HIV PI but turned out to have the 
beneficial effect of inhibiting the metabolism of other PI’s by the host liver enzyme 
cytochrome P450-3A4, hence it is now also increasingly used in co-formulations as a 
booster for other HIV PI’s.[19]  
 
(v) Integrase inhibitors 
 
Currently only one integrase inhibitor (raltegravir) has obtained FDA approval [5].  
Hence, in the range of HIV-antivirals currently available integrase inhibitors are 
somewhat under-represented.  The two main reasons for this are, early assay conditions 
that never adequately distinguished between authentic and false leads (due to 
insufficient specificity), but also an under-representation of the integrase inhibitor 
pharmacophore in existing compound libraries.[20] The current state of affairs 
regarding these inhibitors will be discussed later in this chapter in a separate section 
1.2, together with the integrase enzyme, its structure and its mechanism. 
 
Other investigational anti HIV drugs 
 
Besides the targets and their inhibitors described above a number of new targets have 
emerged for which potential new inhibitors are currently undergoing clinical trials.  
Three examples of investigational drugs are: Bevirimat, Poly(I)-Poly(C12U) (aka 
Ampligen) and Valproic Acid. (Figure 1.8c)  
 
Bevirimat, a maturation inhibitor first-in-its-class, has shown strong activity against 
wild-type HIV-1 but more importantly, also against certain antiretroviral-resistant 
strains.[5] During maturation a newly translated HIV polyprotein precursor, encoded by 
the viral gag gene, is processed by the HIV protease (gag codes for the basic structural 
viral proteins).  This processing comes down to a cutting up of the gag into separate 
units that can only then obtain their final conformations to become (mature) viral 
enzymes or structural proteins.  Unlike protease inhibitors, bevirimat targets the gag 
protein and by doing this prevents protease from making a critical cleavage that would 
result in the generation of the mature capsid protein p24.  The subsequently formed 
viral particles are non-infectious, hence viral replication is no longer possible.[21]  
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Figure 1.8c: Investigational anti-HIV drug Bevirimat, Valproic acid and Ampligen 
 
A second investigational drug is Poly(I)-Poly(C12U), also know as ampligen (5'-
Inosinic acid, homopolymer, complex with 5'-cytidylic acid polymer with 5'-uridylic 
acid (1:1)).  Ampligen is a (synthetic) biological response modifier with widespread 
anti-viral activity, including HIV.[5] Biological response modifiers (BRM’s), natural or 
synthetic, can actuate the body’s natural response to different infections.  Ampligen is a 
double-stranded RNA (dsRNA) capable of activating dormant cellular defences against 
tumours and viruses.[5]  
 
The third example of a potential anti-HIV drug in clinical trials is Valproic Acid.  It is a 
histone deacetylase (HDAC)-1 inhibitor, which has the downstream effect of 
stimulating latent T cells to release HIV.  In turn this allows for circulating 
antiretrovirals to attack the re-emerged virus.[5] The normal function of histone 
deacetylase is to increase the binding affinity (by deacetylating the amines of histones) 
between histones and the DNA backbone, which condenses DNA structure and 
prevents transcription. 
 
Highly Active Anti-Retroviral Therapy (HAART) 
 
The current strategy in the treatment of HIV infection consists of patient tailored 
combinations of antiretrovirals (usually three or four antiretrovirals from different drug 
classes).  This is referred to as Highly Active Anti-Retroviral Therapy (HAART).  
Usual combinations (referred to as a triple cocktail) consist of two nucleoside (and 
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nucleotide) reverse transcriptase inhibitors (NRTIs) and one non-nucleoside reverse 
transcriptase inhibitor (NNRTIs) or protease inhibitor (PI).[22], [23]  When HAART 
treatment started in 1996 initial drug regimens (for newly infected patients showing 
signs of immuno deficiency) consisted of over twenty tablets daily (1996), after which 
treatment slowly evolved to three tablets daily (2003), to two tablets daily of a 
combined fixed dose of anti-retrovirals (2004) and finally in 2006, one tablet daily 
containing three different classes of anti-HIV drugs.[24] 
 
The logic behind the HAART (drug combination) strategy is founded in the viral 
biosynthetic characteristics.  It has been shown that a high level of genetic 
heterogeneity characterises the human immunodeficiency virus.[25] Frameshift and 
point mutations generated during reverse transcription are believed to generate most of 
this genetic variability. The short replication cycle and high rate of biosynthetic errors 
generates a very rapidly mutating virus. HIV reverse transcriptase mismatches 
approximately 1 in every 7500 bases when synthesising (-)DNA from an RNA 
template.  Similar biosynthetic errors occur naturally in all living organisms but in most 
cases are subsequently corrected by proofreading enzymes.  This safeguard system 
leads to an error rate of 1 in a million to 1 in 10 billion for DNA replication in 
eukaryotes.[26] However, when HIV reverse transcriptase converts viral RNA into 
viral DNA no proofreading enzymes are recruited and errors are left uncorrected.  It is 
this apparent biosynthetic flaw that makes the HIV virus (as it does for other viruses) so 
resilient against antiviral drugs. Most mutations do not convey any advantage to the 
virus, if not a disadvantage (by weakening them and/or rendering them incapable of 
reproducing). However, due to the high mutation rate and short life-cycle there are 
sufficient opportunities for the virus to acquire a true advantage once infection of the 
host organism has taken place. This can e.g. be a single point mutation leading to a 
different amino acid in the 1° structure (and hence part of the higher 3° or 4° structure) 
of one of the viral protein components against which a particular drug might be acting.  
Due to the presence of a different amino acid, the interaction of the drug with the viral 
protein component is changed and the drug’s therapeutic effect might no longer be 
present. In this case the virus has become resistant against that particular drug and the 
number of virions with this particular trait will rapidly increase in the host organism. If 
however a patient is taking a combination of antiretrovirals, when resistance against 
one of the drugs arises, the other drugs will still suppress proliferation of that mutation.  
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Because no single antiretroviral has been shown to suppress HIV for long, 
combinations of antiretrovirals need to be taken for a lasting effect, which is referred to 
as the Highly Active Anti-Retroviral Therapy (HAART). 
 
HAART has significantly improved conditions for patients in terms of suppressing 
AIDS-related diseases and increasing life expectancies.[27]  Although the advantages 
of HAART are clear, there are some disadvantages as well.  Not all potential 
combinations of the above mentioned drug classes are possible (e.g. certain drugs 
reduce each others activity), side-effects of particular cocktails can be severe and 
dosing schedules can be complicated. The latter two complications are important 
factors in adherence failure which, together with low level residual replication of the 
virus, is currently leading to the emergence of multiple drug-resistant HIV strains.  This 
is set to jeopardize the benefits of these potent drug cocktails [27] and is one of the 
reasons why it is of great importance to keep searching for new anti-HIV drugs, 
preferably targeting alternative steps in the HIV life-cycle.  Hopefully, increasing 
numbers of useful combinations of new antiretrovirals will increase inhibition potency 
and reduce the risk of cross-resistance emergence (i.e. resistance against drugs that are 
related in their mechanism of action because of chemical similarities or similar modes 
of binding). 
 
1.3 Integrase 
 
1.3.1 Integrase as a target in anti-HIV drug development 
 
Integrase was identified as a valid drug target based on the following observations: 
specific inhibitors of HIV-1 integrase inhibited HIV infection in vitro and this was 
related to a significant reduction of integrated provirus in host cell DNA, [28] 
mutations in the enzyme’s active site given the opportunity to proliferate during 
treatment with integrase inhibitors rendered the enzyme significantly less susceptible to 
those inhibitors, and in human clinical trials the use of specific integrase inhibitors has 
shown that integrase inhibition leads to a reduced viral load.[29] 
Integrase has gradually gained more interest as a biological target that used to be 
underrepresented among targets of the existing drug collection.  At present there is only 
one approved integrase inhibitor on the market which makes this enzyme an appealing 
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biological target for further drug development.  As already mentioned, integrase is 
required for the integration of the viral ds-DNA into the host’s chromosome.  Research 
into the function, mechanism and possible inhibition of integrase has been ongoing now 
for over 12 years. 
Besides the obvious merits of inhibiting an additional viral target (circumventing drug 
resistance because it would require multiple viral mutations), the absence of a human 
version of integrase means that integrase inhibitors would potentially be highly 
selective and should be of low toxicity.[30] These properties, however, cannot exclude 
possible interactions that integrase inhibitors may have with mechanistically related 
human enzymes.  During the early stages of diketo acid development (a class of 
integrase inhibitors) these compounds were found to inhibit the human enzyme RAG 
1/2 recombinase (this enzyme is involved in somatic recombination in developing 
lymphocytes, which enables the generation of antibody diversity), although at 
concentrations 20-fold higher than needed for integrase inhibition.[31] Although 
initially considered unlikely to be successful, sustained research into these diketoacid 
compounds has now produced the first approved HIV-integrase inhibitor on the market, 
known as raltegravir.[5]  
Generally, integration of the viral DNA is interesting as a drug target because this can 
be seen as a point of no return.[32] However, the fact that it is an all-or-none event can 
also be considered a drawback, since it occurs only once in the HIV life-cycle.  
Integrase drug development needs to take into account the multiple DNA-protein 
interactions in the pre-integration complex (PIC), which may obstruct inhibitors from 
reaching the catalytically active sites [27] (or other potential activity-impairing sites).  
On the other hand this also means more potential targets to interfere with as more 
interactions are required for functionality.  The window in time just after infection, 
during which PIC formation can be prevented, is however limited.[27]  
Finally, another factor that needs to be taken into account is that integrase is known to 
alter its conformation upon DNA binding.[33] Hence, co-crystallisation data of the 
complete integrase-DNA complex would be useful to provide information which can be 
utilised for enzyme structure based drug design.[27] 
 
1.3.2 Integrase Structure  
 
Integrase (of HIV-1) is a 32 kDa enzyme and consists of a single polypeptide chain 
with 288 amino acid residues.[30] It is released from a larger viral polypeptide, 
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encoded by the pol gene (which also codes for protease and reverse transcriptase), by 
viral protease during maturation.[34] Integrase is folded into three distinct functional 
domains: The zinc binding N-terminal domain (NTD) (residues 1-50), the catalytic core 
domain (CCD) (residues 50-212) and the non-specific DNA binding C-terminal domain 
(CTD) (residues 212-288) (Figure 1.9a).[34] For a long time obtaining a crystal 
structure for the full length integrase was problematic due to low solubility of the 
enzyme and to date no structure has been reported for the complete integrase molecule 
nor for its complex with DNA.  It was not until the discovery of a F185K mutant 
(obtained via site-directed mutagenesis), for which solubility of the catalytic core 
domain (CCD) increased significantly, that the crystal structure of the CCD (of the 
F185K mutant) was obtained.[35] 
 
H H         C C       D                      D             E    
Zn binding domain catalytic domain (core)
12 16       40 43 50 64                      116            152 212    220                  270 288
Non-specific DNA 
binding domain
 
 
Figure 1.9a: the three functional domains of HIV integrase 
 
Since then more X-ray structures have been determined for the CCD, as well as for the 
combined N-terminal-core catalytic domains and for the combined core catalytic-C-
terminal domains.[33],[40] 
 
The structure of the separate NTD was elucidated through 2 and 3-dimensional NMR 
spectroscopy experiments on NTD dimers in solution. (See Figure 1.9b for the solution 
structure of the HIV-2 integrase NTD). The N-terminal domain of HIV-1 integrase 
contains a conserved (DNA-binding) Zinc finger motif (i.e. the conserved HHCC motif 
composed of two histidine residues at position 12 and 16 and two cysteine residues at 
40 and 43).[34] The NTD monomer consists of four α-helices stabilised by 
hydrophobic interactions and one Zn2+ cation tetrahedrally coordinated to the two 
conserved histidine (H12 and H16) and two cysteine residues (C40 and C43).  In its 
dimeric form (in solution) HIV’s NTD takes on two interconverting folded states (in 
which reversal of the relative positions of H12 and H16 is one important difference). 
The NTD dimers are stabilised by hydrophobic forces.  The four helices of the 
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monomer are part of a helix-turn-helix motif common to DNA recognition.  The Zn2+ 
cation is essential for the enzyme’s highly ordered α-helix secondary structure and 
point mutations of the conserved His or Cys residues (and subsequent loss of order due 
to the cation absence) significantly reduce 3’-processing and strand-transfer reactions 
(the two main catalytic steps of IN) but doesn’t interfere with disintegration capacity.  
The latter observations suggest that NTD is not the only DNA binding moiety and the 
IN active site is not part of the NTD.[36],[37] 
 
a) b)
 
 
Figure1.9b: a) ribbon diagram of the HIV-2 integrase N-terminal domain monomer                 
b) coordination topology of the Zinc centre. (Source: Eijkelenboom, A.P. et al., 1997, 
[38])  
 
Experiments with chimeric (HIV-1 and visna virus) integrase suggest non-specific 
DNA binding for the NTD.[39] Multimerization of the full length integrase and 3’-
processing and strand-transfer steps (in vitro) are all enhanced in the presence of Zn2+. 
Hence the general consensus is that this is due to essential interactions between the N-
terminal domain and the catalytic core domain.[40] The N-terminal domain also binds 
with two more cellular transcription factors (INI1 and LEDGF/p75) in the PIC.[34]  
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Initial crystal structure elucidations of the catalytic core domain (CCD) were not as 
useful as hoped for.  The first CCD crystal structure (for the F185K mutant) was solved 
by Dyda et al. but showed disrupted in vivo virion assembly.[35] For later crystal 
structures this problem was resolved by using a F185H mutant (that also retained full 
integrase activity). A number of structures exist for the core domain, differing mostly in 
detail but in particular regarding the conformation of a loop (residues 140-152) adjacent 
to the active site.  This loop is thought to be flexible, only adopting a relevant 
conformation in the presence of DNA substrate.[46]  The loop’s flexibility is believed 
to be essential for integration because replacement of the loop’s conformational hinges 
(residues G140 and G149) with alanine leads to loss of catalytic activity while DNA 
binding capacity is retained.  The general consensus is that the loop’s involvement in 
the catalytic process occurs after DNA binding.[41]  
 
 
Figure 1.9c: Ribbon diagram of a monomer of the HIV-IN CCD double mutant F185K, 
W131E showing the seven β-strands, six α-helices and the catalytic triad residues Asp 
64, Asp 116 and Glu 152. (Source: Goldgur, Y. et al., 1998, [51]) 
 
In a crystal structure of a double CCD mutant (F185K + W131E) the core domain was 
shown to consist of an α/β structure containing a seven strand β-sheet together with six 
α-helices.[51] (See Figure 1.9c above for a ribbon diagram of HIV-IN CCD double 
mutant F185K, W131E) 
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In all the crystal structures two core domains will associate to form a two-fold axis 
related dimer with a 1400 Å² solvent excluded interface.[46]  The catalytic core domain 
has three conserved residues known as the catalytic triad motif DDE, made up of two 
aspartate residues at positions 64 and 116 and a glutamate at 152 (Figure 1.9c).[34] 
These three acidic amino acid residues, conserved generally among integrases, make up 
the enzyme’s active site and form a shallow cavity on the protein’s surface.  Mutation 
of any of these residues confers complete loss of activity and infectivity of the 
virus.[42],[43],[44],[45] It is presumed that in the active site the catalytic triad 
coordinates to Mg2+ (or Mn2+), in complex with viral and host DNA.[46]  Although 
only one metal has been observed so far in HIV-IN crystal structures, involvement of 
two metal ions has been suggested in a catalytic mechanism where they act to activate 
hydroxy nucleophiles.[47],[48]  The metal ions’ positions in the active site were 
postulated based on the DNA polymerase I mechanism. One Mg2+ was observed 
between D64 and D116, the other Mg2+ is believed to be positioned between D116 and 
E152 and to bind only in the presence of DNA.[49],[50],[51] In the full IN enzyme the 
CCD is believed to play a crucial role in 3’-processing and strand-transfer reactions and 
in recognizing target and viral DNA.[52],[53],[54]  
 
 
 
Figure 1.9d: Ribbon diagram of a monomer of Int220-270 (the CTD) showing 5 
anitparallel β-sheets (Source: Lodi, P.J. et al., 1995, [55])  
 
A large part of the structure of the C-terminal domain (residues 220-270) has been 
elucidated by NMR spectroscopy.  In solution the CTD forms a dimer in which the 
individual monomers are arranged antiparallel. Each CTD monomer consists 
predominantly of five antiparallel β-sheets (see Figure 1.9d above). The CTD binds 
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DNA non-specifically [46] and has a high number of positively charged lysine and 
arginine residues, consistent with DNA binding.[56],[57],[58],[59]  It is also the least 
conserved part of IN.  Besides its requirement for 3’-processing and strand-transfer 
reactions, CTD’s role in multimerization and DNA binding was identified after 
mutational analyses revealed CTD residues crucial to these 
interactions.[60],[61],[62],[63] Further experiments have shown interactions of the 
CTD with viral DNA adjacent to the CAGT sequence (at the LTR termini).  Recent 
research clarified that all three domains (NTD, CCD and CTD) bind target 
(chromosomal) DNA. [50],[64] The CTD also interacts with the viral reverse 
transcriptase and a cellular protein (EED) in the PIC. [34] 
 
 
 
Figure 1.9e: model of the viral DNA (green) docked to an Integrase dimer (made up of 
a yellow and purple monomer).(Source: De Luca, L. et al., 2003, [66]) Amino acids in 
direct contact with the DNA are shown as spheres (for the yellow IN monomer: 
residues K156, K159, K160, K186 and K188 in the catalytic core domain and R20 in 
the N–terminal domain; for the purple IN monomer: S230, R231, W243, K244, K263 
and K264 in the C-terminal domain). The catalytic triad D64, D116 and E152 (in the 
yellow IN monomer) are shown in blue, the bound Mg2+ metal ions are grey spheres.  
The 3’-OH of the conserved viral adenosine is pointing towards the acid catalytic 
residues.  
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Crystal structures were elucidated for the combined CCD-CTD (a five-fold mutant) and 
combined NTD-CCD (a triple mutant) showing CCD dimeric structures similar to the 
single CCD domain dimers.  Both CTD and NTD structures, linked to CCD, differed 
however from their single domain dimer structure.[65] Structures of both IN1-212 (NTD-
CCD) and IN52-288 (CDD-CTD) allowed for a model for the full length integrase to be 
proposed.[66]  In viral DNA docking studies with the proposed IN model DNA-IN 
interactions were observed between CCD and NTD of one monomer and the CTD of 
another monomer.(see Figure 1.9e above) In the same study the conserved CA 
dinucleotide (at the LTR termini) was positioned near the catalytic triad DDE.  
 
1.3.3 Integrase Mechanism 
 
After reverse transcription of the viral RNA in the host’s cytoplasm, integrase dimers 
tightly bind to each of the two conserved sequences 5’-GCAGT-3’ found at the ends of 
the viral ds-DNA long terminal repeats (LTR).[67] Long terminal repeats flank the 
centrally located HIV genes.  Retroviral LTR are non-coding, direct repeats with almost 
identical sequences, between 500 and 1000 nucleotides in length, and contain regions 
important for regulation of transcription initiation and polyadenylation.[27],[68].  
In order to enable incorporation of the viral ds-DNA into the host’s DNA, integrase 
first removes (by endonucleolytic cleavage) from the conserved CAGT sequence at the 
3’ ends of the viral LTR the two terminal conserved pGpT dinucleotides (adjacent to 
the conserved 3’-CA sequences).  This step is known as 3’-processing and it takes place 
in the host’s cytoplasm (Figure 1.10a) The reaction is a single-step hydrolysis of the 
phosphodiester bond (linking the adenosine and guanosine nucleotides) and requires a 
divalent metal ion and a nucleophile.[69] The nucleophile, which can be a H2O 
molecule or even small alcohols or amino acids, is activated in vitro by Mg2+ or Mn2+, 
although in vivo Mg2+ is believed to be the active cation.[70],[71],[72] The 3’-
phosphodiester of the conserved adenosine (in the CAGT sequence) is attacked by an 
activated hydroxy group, which results in the release of the terminal 5’-GT-3’ 
dinucleotides.  This produces recessed 3’-CA-OH ends on the viral ds-DNA and is the 
start of the formation of a larger nucleoprotein complex known as the pre-integration 
complex (PIC).[27]  After this first (3’-processing) catalytic step, integrase remains 
associated with the retroviral DNA in the PIC and this entire complex is translocated 
across the host’s nuclear membrane.  The microtubule network is thought to play a role 
in translocation of the PIC toward the nucleus but there is no full understanding yet of 
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the nuclear import mechanism.[73] Once in the host’s nucleus it is thought the two 
DNA-bound integrase dimers form a tetramer which allows the PIC to associate with 
the host DNA (Figure 1.10a).[74] Although the latter view is widely accepted it has 
also been suggested that not a dimer but a tetramer is the minimal integrase molecule 
present in human HIV-infected cells and an integrase octamer is involved in the nuclear 
strand-transfer step.[75] Subsequently in the strand-transfer step, the integrase tetramer 
(or octamer) cleaves the target host DNA with a 5 base-pair stagger and the viral 
DNA’s 3’-CA OH-ends are ligated to the (newly generated) 5’-O-phosphate ends of the 
host DNA.  This is known as the strand-transfer or joining step (Figure 1.10a and 
Figure 1.10b).[76] Integration of the viral DNA has been shown to occur in transcribed 
genes, albeit randomly.[34] 
 
integrase dimer viral ds-DNA
2 + C A N NN N A C 5’
5’ 3’
3’ + 2 pNpN
3’ processing
Mg2+
cytoplasm
nucleus
Integrase
tetramerisation
host ds-DNA
integrase tetramer
viral ds-DNA
strand transfer + 
repair
dXTP, Mg 2+ provirus
host ds-DNA + 2 pNpN
 
 
Figure 1.10a:  Illustration of proposed integrase mechanism(s) (only the integrase 
component of the PIC is shown) (dXTP = any natural deoxynucleosidetriphosphate) 
 
In the final step, the retroviral dinucleotides at the 5’ ends of the LTR termini are 
removed, the 5 base-pair gaps in the chromosomal DNA are filled and the 5’-retroviral 
DNA termini are ligated to the 3’-ends of the host’s chromosomal DNA.[77] All this is 
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referred to as ‘repair’ (Figure 1.10a and Figure 1.10b) and is accomplished by host 
DNA repair enzymes and HIV integrase. HIV is also capable of catalysing the reverse 
reaction or disintegration but this has only been observed in vitro and the physiological 
significance remains unclear. Remarkably, disintegration is the only reaction catalysed 
by recombinant molecules carrying only the integrase catalytic core domain, the 
significance of which is that only a complete integrase enzyme (as part of the PIC) will 
catalyse the diversity of reactions involved in integration.[70] 
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Figure 1.10b: illustration of the strand-transfer step in the integrase mechanism 
 
The current consensus is that there are two PIC DNA binding sites; a donor site 
(binding viral DNA) and an acceptor site (binding the host chromosome).[34] It is 
believed the 3’-processing allows for a conformational change in the integrase that 
enables the host chromosome to bind and allows for the subsequent strand-transfer 
reaction to take place.[34]  It is the latter step that is inhibited by raltegravir, currently 
the only marketed integrase inhibitor.      
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1.4 Integrase inhibitors 
 
Compared to NRTI’s, NNRTI’s and PI’s, the development of integrase inhibitors has 
taken a long time and has been particularly arduous.  Besides the lack of specificity in 
early assays and the lack of a lead compound, other reasons for the slow progress were 
the lack of a crystal structure for the full length protein complexed with the viral and 
host DNA, and a misplaced confidence in the potential of prolonged HAART to 
eradicate HIV.  Nevertheless, when monotherapy turned out to be insufficient in 
significantly prolonging the life of HIV-1 infected individuals, inhibition of integrase 
was very early on considered as a possible strategy to tackle HIV.  Early research 
focused on biochemical studies in order to shed light on the complex biology of the 
provirus.  Preliminary approaches in searching for integrase inhibitors involved the use 
of ribozymes designed to cleave the integrase gene [78] and small DNA binding 
molecules.[79] One of the first molecules to target the enzyme rather than its DNA 
substrate was aurintricarboxylic acid (see Figure 1.11), one of a number of tested 
polyhydroxylated aromatics which inhibited integrase at micromolar levels but lacked 
activity in cell-based assays.[80],[81] Further research involved development of 
screening assays for specific integrase inhibitors and the discovery of new valuable 
sources for compounds, which pushed forwards early integrase inhibitor development.  
For some time the focus remained on targeting the viral DNA substrate of integrase, 
resulting in the discovery of one of the first integrase inhibitors, a G-quartet 
oligonucleotide referred to as AR177, which made it as far as human clinical trials.[82] 
AR177 (or 5’-GTGGTGGGTGGGTGGGT-3’) is made up of deoxyguanosine and 
thymidine and contains single phosphorothioate linkages at its 5’ and 3’ ends for 
stability.  AR177 showed potent activity against integrase at nanomolar 
concentrations.[83] Somewhat ambiguously no significant mutations were found in the 
integrase coding region but rather in the region coding for gp120, suggesting 
interference at the point of viral entry rather than integration.[84] Also, more 
polyhydroxylated aromatic compounds were tested and found to inhibit integrase. 
Examples were β-conidendrol, cucurmin and the dicaffeoylquinic acids 3,5-
dicaffeoylquinic acid and 1-methoxyoxalyl-3,5-dicaffeoylquinic acid (see Figure 
1.11).[85],[86] The latter two compounds, derived from medicinal plants, were among 
the first to show both integrase inhibition and inhibition of HIV-replication in vitro.[87]  
Although the hydroxylated aromatics at this stage never fulfilled the expectations, they 
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would serve as lead compounds for studies in the following years. In 1994 an important 
(as it would turn out later) discovery was made by Merck researchers when they found 
a number of naturally occurring fungal compounds that had integrase inhibitory 
activity.[88],[89]  The first fungal compound showing inhibition of integrase was 
discovered in an extract of Fusarium heterosporum (isolated from marine sources).[88], 
[90] This compound had long been known as a mycotoxin and derived its name, 
equisetin (Figure 1.11), from F. equiseti, one of many Fusarium species that produced 
it.[91] Strand-transfer inhibition IC50 value for equisetin was 7 µM and the compound 
was patented as an integrase inhibitor in 1996.[92] Related compounds like phomasetin 
(from the terrestrial fungus Phoma spp.) (Figure 1.11) and its tetrahydroderivative had 
similar integrase inhibitory activities.[90] The presence of a β-hydroxyketo group in 
these fungal compounds would later turn out to be an essential structural requirement 
for integrase inhibitory potency.[88] From 1996 onwards a period followed of intense 
research into more fungal compounds.  One particular compound referred to as an 
integracide (isolated from Fusarium spp. extracts) (Figure 1.11) showed inhibition of 
HIV-1 replication in vitro with a EC95 value of 25 µM but unfortunately also showed 
unacceptable levels of cytotoxicity.[88] A different strain of Fusarium spp. contained 
chaetochromins (Figure 1.11), a class of compounds for which certain semi-synthetic 
derivatives showed EC50 values of less than 10 µM (for HIV-1 replication in vitro).  
Also, promising IC50 values (for integrase inhibition) were found for certain lichen 
acids (IC50~5µM) (Figure 1.11),[79] and for some synthetic acids like styrylquinolines 
(IC50~1µM) (Figure 1.11), although the latter turned out not to be true integrase 
inhibitors (but acting somewhere between reverse transcription and integration).[93] At 
Merck insights grew into integrase inhibition by (equally potent) fungal 
sesquiterpenoids like equisetin, phomasetin, oteromycin and integric acid (Figure 
1.11).  Innovative experiments in which equisetin and integric acid inhibited integrase, 
in assays mimicking for the first time conditions in HIV-1 infected cells closer to 
reality, led Merck researchers to identify the crucial structural elements characterizing a 
new class of integrase inhibitors.  Compounds in this class consist of a sesquiterpenoid 
backbone linked to a (2,4-pyrrolidinedione) tetramic acid-like moiety bearing a 
coplanar β-hydroxyketo group (in equisetin and phomasetin) or diketo group (in 
oteromycin), or in the case of integric acid a carboxylate group thought (by Merck) to 
functionally replace the tetramic acid like moiety.   
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Figure 1.11: Early integrase inhibitors 
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The most successful class of compounds carrying some of these structural elements is 
currently referred to as diketo acids (DKA, see Figure 1.13 for the structure of a 
generic diketo acid), although the name ‘γ-keto α-enol acids’ more accurately reflects 
their biologically active form. Diketo acids were independently discovered by Merck 
and Shionogi Company.  An essential compound developed by Shionogi was 5-CITEP 
(Figure 1.12), a DKA analogue bearing a chloro-substituted indole and a tetrazole as an 
isosteric replacement for the carboxyl group (compared to the generic DKA structure in 
Figure 1.13).  5-CITEP showed a selective inhibition of the strand-transfer step (IC50: 
0.65-3 µM) with a 3’-processing IC50 value of 35 µM.[94],[95].  5-CITEP was the first 
strand-transfer inhibitor for which a crystal structure of the compound bound to the 
integrase CCD was elucidated.[94] From the electron density map it was clear that 5-
CITEP was positioned in the active site between the catalytic acidic residues D64, 
D166 and E152. This observation suggested 5-CITEP could be competing with the 
DNA substrate and in doing so prevented the natural substrate to bind to the active site.  
5-CITEP, in complex with the integrase CCD, assumed a planar conformation, 
indicating the keto-enol form was the biologically active tautomer.[94] It was also 
noted that 5-CITEP’s enolic hydroxy group was in hydrogen-bonding distance from the 
catalytic triad residue E152.  A structurally related compound S-1360 (Figure 1.12), 
developed by Shionogi Company and GlaxoSmithKline, with a furan moiety in place of 
the indole group, was the first strand-transfer inhibitor to reach clinical trials. [78] This 
diketo acid bioisostere S-1360 (Figure 1.12) inhibits the strand-transfer reaction with 
an IC50 value of 0.02 µM.[30] The EC50 value is 0.2 µM and the CC50 value is 12 µM 
(the drug concentration cytotoxic to 50% of the cells used in the in vitro assay).[30]  
After a review of the trials data, development of S-1360 (Figure 1.12) was ended 
because low efficacy emerged due the compound being rapidly cleared from the body 
after being metabolised and rendered inactive by human liver enzymes known as aldo-
keto reductases (carbonyl reducing, NADPH-dependant and cytosolic).[96] S-1360 
(Figure 1.12) remained useful in experiments investigating mutations responsible for 
generation of strand-transfer inhibitor resistance.[97] Two more DKA bioisosteres, 
developed by Merck and Shionogi, showed potent and specific inhibition of the strand-
transfer step. They are referred to as L-731,988 and L-708,906 (Figure 1.12), and have 
IC50 values for strand-transfer inhibition around 80 nM.  Mutants resistant to the latter 
inhibitors showed mutations clustered around the active site in the integrase CCD.[98]  
Dependence, for L-731,988 (Figure 1.12), of inhibition capacity on target DNA 
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concentration confirmed the presumed competitive binding to the active site, initially 
observed in the crystal structure of 5-CITEP in complex with the integrase CCD.[33] 
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Figure 1.12:  Diketoacid-based integrase inhibitors. 
 
Calculations on the latter crystal structure also confirmed the importance of the keto-
enol group in the sense that the observed interactions of 5-CITEP were consistent with 
predictions of how a keto-enol moiety would be positioned when coordinated to the 
metal ions also presumed to bind the acidic catalytic residues D64, D166 and E152.[99] 
Structure-activity relationship studies, using wild type HIV, revealed potent strand-
transfer inhibition was maintained when replacing the carboxylate (as in the generic 
DKA structure, Figure 1.13) with a tetrazole moiety, but only in the presence of Mn2+ 
(not for the other possible Mg2+cofactor).[100]  Presence of an indole (in the 
hydrophobic moiety of the generic DKA structure) was associated with increased metal 
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dependency of inhibitory capacity, a condition absent for inhibitors with a substituted 
phenyl moiety (as in L-708,906, Figure 1.12).  The SAR studies concluded that 
regarding inhibitor activity/structure conditions, Mg2+ imposes stricter limitations than 
Mn2+.  Continued attempts to improve established inhibitory capacities of DKA-based 
compounds, by Merck researchers, led to a number of new molecules of which the most 
potent was L-870,812 (Figure 1.12).  Compared to the generic DKA structure, in L-
870,812 an 8-hydroxy-1,6-naphthyridine moiety replaces both the carboxylate and the 
α-enol moiety with respectively heterocyclic nitrogen and a phenolic –OH, the γ-ketone 
is replaced with a benzyl amide and a cyclic sulphonamide on the naphthyridine moiety 
optimises its oral bioavailability, pharmacokinetic parameters and cardiac safety.  The 
retained coplanarity of the essential structural features confirmed the earlier 
hypothetical condition for biological activity. [101] [102] L-870,810 (Figure 1.12), 
inhibits integrase activity, in vitro, with an IC50 of 0.01 µM and gave an EC95 of 0.019 
µM (inhibition of viral replication) and a CC50 >5 µM in a cell culture assay.[30] These 
assay values indicated a favourable (high) therapeutic index (ratio of toxic drug dose to 
therapeutic drug dose, CC50/EC50).  However, after long term dosing in dogs, an 
unacceptable level of toxicity was revealed and so further clinical development of L-
870,810 was put on hold.[103]  In 2006, researchers from Japan Tobacco Company 
came up with a newly designed scaffold, as present in a 4-quinolone-3-glyoxylic acid 
(Figure 1.12), that respected the coplanarity condition (of γ-keto, α-enol and carboxylic 
acid in DKAs) presumed essential for strand-transfer inhibition specificity.[104]  
Surprisingly, it turned out that the 4-quinolone-3-glyoxylic acid scaffold showed no 
activity, but a 4-quinolone-3-carboxylic acid (Figure 1.12) with a coplanar monoketo 
acid motif did!  This was a quite dramatic discovery and provided new insights into the 
binding properties of these specific strand-transfer inhibitors. Of note, the α-ketone of 
4-quinolone-3-glyoxylic acid cannot tautomerise, suggesting this leads to loss of 
activity regardless of the coplanarity of the involved functionalities. 
It can be concluded that so far the DKAs and their bioisosteres have been the most 
successful compounds in the quest for integrase inhibitors and the (potential) associated 
inhibition of HIV replication.  Currently, one DKA-derived integrase inhibitor is in 
early clinical trials and two are undergoing advanced clinical trials.  They are 
respectively known as GSK364735, GS-9137 (Elvitegravir) and MK-0518 (Figure 
1.12), the latter of which has obtained FDA approval in October 2007 and is 
commercially known as Raltegravir (or Isentress), effectively the first and so far only 
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integrase inhibitor marketed.  MK-0158 (Figure 1.12) was developed by Merck and is 
structurally related to one of its less successful predecessors L-870,810 (Figure 1.12).  
MK-0518 (Raltegravir) (Figure 1.12) has an IC95 of 33 nM.[105] Further clinical trials 
to assess different long-term effects are ongoing.  GS-9137 (Figure 1.12) was 
developed by Japan Tobacco Company and Gilead Sciences and has the 4-quinolone-3-
carboxylic acid scaffold with the monoketo acid motif.  GS-9137 (Figure 1.12) has an 
EC50 value of 0.9 mM in an acute HIV infection assay.  The final inhibitor in clinical 
trials, GSK364735 (Figure 1.12), developed by GlaxoSmithKline and Shionogi inhibits 
the integrase strand-transfer reaction with an IC50 of 9 nM.[106], [107] 
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Figure 1.13:  Essential pharmacophore elements of the generic diketo acid template 
involved in coordination to Mg2+ in the integrase active site.[20] 
 
Regarding the possible mechanism of DKA-based integrase strand-transfer inhibition, a 
interesting suggestion was made by Pommier et al.[108]   It was suggested integrase 
has two different DNA binding sites, one for the viral (donor) DNA and one for the 
host (acceptor) DNA.  Binding of the viral (donor) DNA and the subsequent 3’-
processing reaction induces a conformational change in the PIC due to which the 
binding site for the acceptor DNA becomes accessible to the latter.  At this point, 
binding of a DKA-based inhibitor at the interface between the catalytic triad and the 
acceptor DNA, by chelating to the metal cations (Mg2+ or Mn2+) in complex with the 
catalytic acid residues (as in Figure 1.13), prevents proper binding of the host DNA 
and subsequent integration.  This hypothetical inhibitory mechanism is referred to as 
interfacial inhibition.[108]   
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A different class of integrase inhibitors is referred to as the pyrano-dipyrimidines, the 
most potent member of which is known as V-165 (Figure 1.14).  V-165 inhibits viral 
replication at micromolar concentrations and has a favourable therapeutic index of 14.  
SAR Studies conclude the sulfhydryl and p-nitro moieties are crucial for activity.  Time 
of addition experiments suggest V-165 (Figure 1.14) inhibits integration as well as 
reverse transcription but V-165’s major target was shown to be the 3’-processing 
reaction.[109] Currently, also a number of older compounds are being re-evaluated, 
among them the coumarins (Figure 1.14) which are a class of hydroxylated aromatics 
with potent IN-inhibitory activity that do not contain a catechol moiety previously 
shown to be highly cytotoxic.[110]  It was shown in a recent study these coumarin 
inhibitors inhibit integrase in a non-competitive way by binding to specific α-helices of 
the integrase CCD, thereby preventing formation of functional integrase multimeric 
complexes.[110]  
Peptides and antibodies have also, for over ten years, been subject to investigations into 
their integrase inhibitory potential.  In 1995, screening of a synthetic peptide 
combinatorial library led to the discovery of the first peptide (with sequence 
HCKFWW) to show inhibitory activity, at micromolar concentrations, for both 3’-
processing and strand-transfer reactions.[111] More recently, peptides were developed 
based on the sequence of α-helices at the dimerization interface of the CCD.  Two such 
peptide inhibitors, INH1 (ATGQETAYFLLKLAGKA-CONH2) and INH5 
(DQAEHLKTAVQMAVFIHNYKA-CONH2), consisting of part of the sequence of 
respectively helix α1 and helix α5 (both part of the dimerization interface of CCD) 
were each shown to prevent formation of functional IN oligomers (IC50 values for 
integrase inhibition were 80 nM and 280 nM for INH5 and INH1 respectively).[112]   
A study of the inhibitory mechanism pointed out that INH5 interacts with helix α1 and 
could serve as a lead in the development of new integrase inhibitors. A number of 
natural peptides also have been shown to have integrase inhibitory activity. Examples 
are the complestatins [113] (isolated from Streptomyces bacterial extracts) and the 
integramides [114] (isolated from fungal extracts of Dendrodochium sp.) (Figure 1.14) 
with good IC50 values in the micromolar range but unfortunately cytotoxic in the 
relevant assays. 
 A number of IN-specific antibodies (identified after screening a library of monoclonal 
antibodies raised against purified IN) were shown to have IN-inhibitory capacity.[115] 
Different IN-inhibiting antibodies were found that separately bound to each of the three 
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IN domains, NTD, CCD and CTD.  For one antibody, mAB17, the epitope was 
determined as part of the helix-turn-helix motif of the NTD domain of IN.   
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Figure 1.14: Integrase inhibitors 
 
Destabilization of the terminal helix, due to antibody binding, was believed to 
contribute to the inhibition.  Both mAB17 and its Fab fragment inhibited the 3’-
processing step, although the Fab fragment was 10 times less potent (IC50 of 4.5 and 0.4 
µM for mAB17 and its Fab respectively).  The epitope region within the conserved 
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sequence Asp25-Glu35 forms a potential target for the development of new small 
molecule IN inhibitors. 
Currently, also a lot of effort is being made to potentially inhibit integration by 
targeting the numerous viral and cellular cofactors, and their mutual interfaces, 
involved in the PIC and contributing to the overall integration process.[20],[34]  
The most important of these cofactors are: 
1) BAF or barrier-to-autointegration factor, believed to stimulate chromosomal 
integration and preventing autointegration of the viral cDNA. As part of the PIC it 
bridges and condenses viral cDNA.  BAF is a host cellular protein, under normal 
conditions involved in chromatin organization.  It is hypothesized that interference with 
BAF in HIV infected cells would stimulate autointegration and in doing so inhibit viral 
replication.  One suggested strategic targets for this interference would be the interface 
of BAF with MA (matrix) protein, with which BAF also associates in the functional 
PIC. [116], [34] 
2) HMGA1 or high mobility group protein A1 is believed to enable a concerted 
integration (into the host DNA) of the viral cDNA by bridging and condensing the 
cDNA in the PIC. HMGA1 is a host protein, under normal conditions binding DNA 
and involved in chromosomal organization. Targeting the HMGA1 interface with DNA 
could potentially inhibit chromosomal integration due to the lack of a functional PIC. 
[34] 
3) INI1/hSNF5 or integrase interactor 1 protein (the human homologue of yeast SNF5) 
is also thought to interact with IN in the PIC.  INI1/hSNF5 is believed to become part 
of the PIC after it is exported out of the cell nucleus and/or it is brought into the cell by 
the virus.  Under normal conditions INI1/hSNF5 is a transcriptional activator and part 
of a chromatin remodelling complex.  Targeting the interfaces in which this cofactor is 
involved in the PIC could potentially lead to inhibition of chromosomal integration and 
viral replication.[34] 
4) LEDGF/p75 or lens epithelium derived growth factor interacts with IN in the PIC.  
This host nuclear protein is thought to be involved in nuclear import of the PIC and 
attachment of the latter to the host chromosome.[50] Under normal conditions LEDGF 
is involved in regulation of gene expression and cellular stress response.  Of the four 
co-factors mentioned above only LEDGF/p75 has been shown to function not only in 
vitro but also in vivo as a cellular co-factor for integration.[117] It was recently shown 
that certain LEDGF/p75 derived peptides inhibit the DNA-binding of IN due to a shift 
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in the IN oligomerization equilibrium rendering the enzyme incapable of 3’-end 
processing, the first ‘part’ of IN catalytic activity.  Two peptides, LEDGF/p75 361–370 
(WNSLKIDNLDV) and LEDGF/p75 402–411 (WKKIRRFVSQVIM) showed 
inhibition of HIV-1 replication in cultured cells with EC90 values below 2.5 µM.[118] 
Recently, four more host (human) proteins have been implicated to function as cellular 
co-factors to the integration process (they have all been shown to interact with IN) and 
hence could be contributing to PIC formation and functionality.[34] They are: 1) the 
Polycomb group embryonic ectoderm development (EED) protein (normally involved 
in repressing gene translation), 2) Hepatoma-derived growth factor related protein 2 
(HRP2), 3)  HSP60 (a heat shock protein), and 4) the p300 acetyltransferase (involved 
in acylation of histone lysine residues, regulating DNA transcription rates).  Each of 
these human protein interfaces with IN, or other PIC components, is being considered a 
target for inhibition of the integration process. 
Additionally, a number of viral proteins are believed to be part of the PIC.[34] They 
are: 1) Matrix (MA) protein p17 (shown to interact with IN and BAF and to be 
involved in PIC nuclear import).[119] The obvious targets are the MA/IN and the 
MA/BAF interface, interference with which could lead to inhibition of PIC nuclear 
import.  2) Vpr or viral protein R: involved in PIC nuclear import, responsible for 
apoptosis in proliferating cells and induction of viral replication in non-dividing cells 
like macrophages, capable of reducing viral mutations by interacting with uracil-N-
glycosylase (UNG) which excises mismatched uracil from DNA.[120] Vpr interaction 
with UNG is one of the proposed targets for potential inhibition of viral replication, 3) 
NC and RT: the final stages of reverse transcription and the start of the integration 
process are believed to coincide and the consensus is that HIV-reverse transcriptase, 
after reverse transcription, remains associated with integrase and nucleocapsid (NC) in 
the PIC.[27],[121],[122] Nucleocapsid is a nucleic acid chaperone and a viral co-factor 
of reverse transcriptase, involved in stimulation of integration.  A recent study, 
investigating the IN-inhibitory capacity of HIV-RT, led to the discovery of RT derived 
peptides capable of IN inhibition.[123] Because full-length HIV-RT showed inhibitory 
capacity under in vitro circumstances without the presence of other cofactors (that are 
normally part of the PIC) it was suggested this might represent an alternative way to 
prevent autointegration. This might be the function of RT in the PIC as well, since there 
is a considerable time-span between PIC formation and actual integration, and all 
components for autointegration are present in the PIC.  Following this discovery a 
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library of HIV-RT derived peptides were tested for IN-inhibitory activity.  The two 
most potent inhibitors are known as Peptide 4286 (KILEPFRKQNPDIVIYQYMD) and 
Peptide 4321 (NQIIEQLIKKEKVY), respectively originating from the RT DNA 
polymerase domain and from the RT ribonuclease H domain. They inhibited 3’-
processing with respective EC50 values of 4.8 and 6.9 µM, and strand-transfer reactions 
with respective EC50 values of 4.5 and 5 µM.[123]  It was concluded for Peptide 4286, 
based on computer aided molecular docking experiments, IN-inhibition was the result 
of steric hindrance of the active site of IN.  
 
Research interest into the potential of PIC related cofactors and/or interfaces as new 
targets towards development of anti-HIV drugs has significantly increased over the last 
years.  Hopefully this effort will lead to the successful development of long anticipated 
new anti-HIV drugs and in doing so complement the current range of antivirals. 
 
In the next sections aspects of both PNA and acridines, two classes of compounds that, 
structurally, are part of the potential new integrase inhibitors we intended to develop in 
this research project, are introduced; i.e. what are they made of, what are their 
properties and  how can they potentially inhibit integrase.  
 
1.5 PNA-acridine conjugates: DNA threading intercalators and potential new 
integrase inhibitors? 
 
In what follows a new approach is introduced in the development of potential new 
integrase-inhibiting antivirals.  The strategy involved the use of a known DNA 
intercalator, a 9-aminoacridine-4-carboxamide, substituted with a polyamide nucleic 
acid or PNA.  DNA intercalators and PNA are separately introduced and their current 
therapeutic values and usages are discussed. Subsequently, it is explained why 
combining these two classes of compounds, in the form of PNA-acridine conjugates, 
holds the potential to indirectly inhibit IN catalytic functions by targeting the LTR 
sequences at the termini of the viral DNA and in doing so obstructing interactions 
between viral DNA and IN in the PIC. 
 
1.5.1 DNA intercalators: definition, properties and examples. 
 
DNA intercalators are flat, aromatic compounds generally consisting of two or more 
fused 6-membered rings (heterocycles and/or aryl rings) that bind DNA by insertion 
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between successive base-pairs.  The nature of the DNA-intercalator interaction was 
clarified by Lerman as a result of X-ray fibre diffraction and hydrodynamic studies of 
the proflavine-DNA complex (proflavine is a flat, aromatic acridine derivative) (Figure 
1.15).[130] The X-ray fibre diffraction pattern revealed retention of the regular base-
pair stacking in the DNA, perpendicular to the helix axis, but loss of the long range 
helix regularity.  Also, it was found that intercalation increased viscosity and lowered 
the sedimentation coefficient of the complex.[130] These observations were 
rationalized by proposing that the planar proflavine molecule (Figure 1.15) became 
inserted between the base-pairs of DNA.[130]  
 
N NH2NH2
Proflavine
Sugar-phosphate
backbone
Base pairs
Intercalator molecule
 
 
Figure 1.15: model of intercalation of three proflavine (acridine-3,6-diamine) 
molecules between different successive base-pairs of B-type DNA.   
 
A major structural distortion occuring during intercalation is a local unwinding of the 
helix at the site of intercalation, ranging from 10 to 26°.  Helix unwinding is caused by 
rotation about torsional bonds in the phosphodiester backbone necessary to 
accommodate for the intercalators aromatic ring system, the consequence of which is a 
length increase of approximately 3.4Å (the thickness of an aromatic ring) (see Figure 
1.15 for a model of intercalation) [130]  The amount of helix unwinding is very much 
dependant on the type of intercalator, e.g. proflavine and related acridines typically 
cause an unwinding of about 17°, whereas ethidium bromide (Figure 1.16) unwinds the 
helix by 26° (Ethidium bromide is commonly used as a fluorescent nucleic acid stain 
e.g. in gel electrophoresis experiments).  Intercalation and the associated DNA-
intercalator complex formation, is driven by a combination of electrostatic, entropic, 
hydrogen-bonding, van der Waals and hydrophobic interactions, and usually is 
reversible.[124] The strongest driving force undoubtedly is the energetically favourable 
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transfer of a predominantly nonpolar molecule from an aqueous solution into the 
predominantly nonpolar environment in between successive base-pairs.  This goes hand 
in hand with the entropically favourable release of H2O molecules from the 
intercalator’s hydration layer, into the bulk solution.  Although the helix conformational 
changes (unwinding, length increase) are unfavourable, this is countered by a 
favourable decrease in localized charge density due to the moving apart of charged 
backbone phosphate groups.  Furthermore, due to the polyanionic character of the helix, 
and the consequent presence of a sheath of counter-cations (e.g. Na+) to provide 
neutrality and stability of the helix in aqueous solution, expulsion of one of the latter 
single cations into the solvent due to binding of a cationic intercalator, is entropically 
favoured and at its maximum for the largest difference in salt concentration between the 
condensation sheath (~1 M) and the solvent.  Interactions that contribute favourably to 
the enthalpy part of the free energy (associated with intercalation) are the non-covalent 
interactions between the intercalator and the helix, like van der Waals interactions, H-
bonding, electrostatic and hydrophobic interactions.   
For different non-threading acridine intercalators experiments have shown intercalation 
occurs via different mechanisms.[124] The mechanism for proflavine intercalation, for 
example, consists of a fast initial bimolecular attachment to the helix surface and one or 
two more, slower intercalation steps.[125] Experiments on ethidium bromide revealed a 
distinctly different mechanism in which intercalation occurs in a single step i.e. without 
externally bound intermediate stages.[126] Investigations into base-sequence specificity 
of non-threading intercalators like ethidium and proflavine, show a preference for 
mixed and alternating pyrimidine-purine sequences, and relative exclusion from 
stretches of A and T (most likely due to the latter’s more rigid structure).[127],[128] 
Furthermore it has been shown, for ethidium, propidium, proflavine and 9-
aminoacridine (Figure 1.15 and Figure 1.16), that within the former pyrimidine-purine 
stretches there is a preference to intercalate between pyrimidine-3’,5’-purine successive 
base-pairs rather than between purine-3’,5’-pyrimidine sequences; according to 
molecular orbital calculations the result of an energetically more favourable unwinding 
process.[129] It can be generally concluded that the sequence preference of  the above 
mentioned intercalators is not determined by a capacity to recognize a ‘long range’ 
base-pair sequence, but by the ability to differentiate between different ‘short range’ 
polynucleotide structures.[128] 
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Since the discovery of DNA intercalators, threading and non-threading, in the early 
years of the search for chemotherapeutic agents, a large number of planar, aromatic 
ligands have been shown to bind to DNA in an identical manner, although the 
mechanistic link between biological activity of compounds and DNA intercalation was 
not  realized from the start.[130] Intercalating agents have the capacity to inhibit the 
template functions (i.e. DNA and RNA synthesis) of DNA both in vivo and in vitro, and 
are poisons of the enzyme topoisomerase, which carry out the essential function of 
relieving tension built up in the duplex due to the active template functions (hence 
intercalators are potentially cytotoxic).[130]  DNA is thus the natural target for these 
intercalating compounds with the potential to kill cells, be it prokaryotic (as in bacteria) 
or eukaryotic (as in certain parasites or as in cancer cells) [124].  
Historically important examples of therapeutic intercalators belong to the acridine 
compound class; proflavine (Figure 1.15) and 9-aminoacridine (Figure 1.16) were 
both used in wound asepsis before the era of antibiotics and are currently still used for 
topical antibacterial purposes, quinacrine (Figure 1.16) was used as antihelminthic and 
both quinacrine and the related chloroquine (Figure 1.16) played an important role in 
malaria treatment. Actinomycin (Figure 1.16), the first antibiotic isolated in 1940 by 
Waksman and Woodruff, is an intercalator and has proven its value in treatment of a 
particular childhood kidney cancer known as Wilm’s tumour.  Subsequent research into 
and development of intercalating antitumour agents delivered more acridine-based 
compounds with therapeutic value.  Important examples are: amsacrine (Figure 1.16) 
(used for treatment of leukaemia), nitracrine (Figure 1.16) (used for treatment of 
mammary and ovarian tumours), and the anthracycline antibiotic adriamycin (Figure 
1.16) and analogues (used in treatment of a variety of cancers).  
Due to additional interactions with DNA, threading intercalators are DNA-intercalating 
agents that show increased stability of the associated DNA-threading intercalator 
complex and hence will have a longer residence time at particular DNA sites (with 
consequent relevance to potential biological activity).[131] Besides the usual π-
stacking, extra stabilization of the complex occurs through favourable interactions (a 
combination of possible ionic, hydrogen-bonding and van der Waals interactions) 
between the intercalator substituents and DNA major and/or minor groove 
functionalities [124], which often confers some base-sequence binding preference to the 
complex, as exemplified (see next section 1.4.2) by nogalamycin and 9-amino-DACA 
(respectively a natural and a synthetic threading intercalator).   
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Figure 1.16: Nucleic Acid Intercalators 
 
Studies of intercalators binding kinetics have shown a clear association between longer 
drug/DNA residence times and cytotoxicity/antitumour activity.[132] Threading 
intercalation is a binding mode in which the intercalating moiety simultaneously directs 
substituents into both grooves of a duplex. This requires one of the side-chains to thread 
through the base-pairs during the complex formation, a process facilitated by 
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‘breathing’ of the DNA duplex. The bulkiness of the penetrating substituent slows 
down the process but will lead to increased post–threading stabilisation of the complex. 
[132]   
 
1.5.2 Examples of threading intercalators: Nogalamycin and 9-amino-DACA 
 
Synthetic threading intercalators are often based on natural products like nogalamycin 
(Figure 1.17), an anthracycline antibiotic (isolated from extracts of Streptomyces 
nogalator var. nogalator) with activity against certain tumours and Gram-positive 
bacteria.[133]  Nogalamycin consist of an aglycone chromophore (rings A, B, C and D) 
with at each end a bulky sugar substituent: a nogalose sugar moiety (and a methyl ester 
group) attached to the A ring and a bicyclic amino sugar linked to the D ring (Figure 
1.17).  
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Figure 1.17: Nogalamycin 
 
It was shown that nogalamycin forms a stable intercalation complex in which 
association and dissociation with/from the helix is a relatively slow process, compared 
to non-threading intercalators, due to the unusual dumbbell shape of the antibiotic.[134] 
For the bulky nogalamycin to intercalate the DNA helix, the latter has to transiently 
open up (breathing), a process for which two different mechanisms were suggested. A 
first mechanism suggests transient melting of several base-pairs, which would create an 
opening large enough to accommodate for insertion of the bulky side-chains.[135] In a 
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second mechanism transient unstacking of base-pairs (without disruption of base-
pairing), in combination with extension of the helix and buckling of base-pairs should 
allow for a large enough opening to facilitate large side-chain moieties to pass between 
the helix strands.[136] Intercalation occurs preferentially between dinucleotides GpT 
and TpG in stretches composed of alternating purine-pyrimidine sequences, GpCpA 
being the most preferred combination.[137] Furthermore, H-NMR experiments also 
revealed the orientation of nogalamycin in which the aglycon is intercalated, the 
nogalose sugar moiety directed into the minor groove and the fused bicyclic 
aminosugar positioned in the major groove of the DNA hexamer d(GCATGC)2.[138] 
 
A
 
Figure 1.18: Nogalamycin intercalated between the terminal C(1)-G(12) base-pair 
(drawn with thick hollow bonds) and the lower base-pair G(2)-C(11) (drawn with thin 
bonds) of a DNA hexamer d(m5CGTsAm5CG)2. (Nogalamycin is drawn with thick solid 
bonds and is shaded) (Source: Williams et al., 1990, [136]) 
 
The latter experiment also suggests that the long axis of the aglycone is almost 
perpendicular to the long axis of the adjacent base-pairs, a conclusion that was 
confirmed in the crystal structure of nogalamycin in complex with the DNA hexamer 
d(m5CGTsAm5CG)2 (see Figure 1.18).[136] From the latter crystal structure the 
following interaction could be observed: the aglycon rings B, C and D (as in Figure 
1.17) are stacked with the A ring protruding into the minor groove; in the major groove 
two base-pair bridging H-bonds are formed between the drug’s 2”-OH (donor) and N7 
of G(uanosine)2 and between the drug’s 4”-OH (acceptor) and N4 of C(ytidine)11 
Chapter 1: Introduction 
45 
(Figure 1.18); also in the major groove there is an indirect H-bond (via a H2O 
molecule) interaction between the charged N3” of nogalamycin and N6 of 
A(denosine)10 (not shown in Figure 1.18); in the minor groove the carbonyl oxygen of 
the drug’s A ring accepts an H-bond from N2 of G(uanosine)12 (Figure 1.18); also in 
the minor groove the nogalose sugar O4’ (see Figure 1.17) indirectly (via a H2O 
molecule) is  H-bonded to the O3’ of T(hymidine)3  and the sugar ring C7’ shows van 
der Waals contact with the O4’ of ribose of A(denosine)10 (not shown in Figure 1.18).  
In solution, it was shown interaction of the nogalose ring with the helix minor groove is 
weak enough for the sugar ring to flip between several isoenergetic conformational 
states. [136] 
 
The acridine derivative N-[2-(dimethylamino)ethyl]-9-aminoacridine-4-carboxamide, 
or 9-amino-DACA (Figure 1.19), is a synthetic threading intercalator and an 
established anti-cancer drug (antileukaemic) that preferentially intercalates at GC-rich 
areas.[139] The 9-amino-DACA carboxamide side-chain threads through the DNA-
duplex, entering from the minor groove, after which the chromophore settles between 
the base-pairs and the threader gets lodged in the major groove, stabilized by hydrogen 
bonding involving the threader’s NH-groups and major groove functionalities.[140] 
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Figure 1.19: 9-amino-DACA 
 
In the crystal structure of the related 9-amino-6-bromo-DACA with the DNA hexamer 
d(CG(5-BrU)ACG)2 two molecules of 9-amino-6-bromo-DACA each intercalate 
between separate d(CG)2 base-pairs.[141] No distortion of the base-pair hydrogen 
bonds was observed.  The long axis of the drug is aligned with the long axis of the 
base-pairs and there is an optimal overlap/stacking interaction between the side-chain-
bearing ring of the drug and the guanine and cytosine six-membered ring on either site 
of the intercalator (Figure 1.20).  Each intercalated molecule causes a helix unwinding 
of 12°.  
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Major Groove
Minor Groove
 
 
Figure 1.20: Overlap between 9-amino-6-bromo-DACA and the adjacent GC base-
pairs of the DNA hexamer d(CG(5-BrU)ACG)2.  (Source: Todd, A.K. et al., 1999) 
[141] 
 
The intercalator-helix interactions observed in the crystal structure of 9-amino-6-
bromo-DACA in complex with the DNA hexamer d(CG(5-BrU)ACG)2  revealed a so-
called ‘DNA-induced’ side-chain orientation established through a conserved bound 
H2O molecule and a negative charge (from a backbone phosphate group) at the site of 
intercalation (Figure 1.21), facilitated by the near coplanarity of the carboxamide 
moiety with the acridine plane.[141] 
 
Br
 
 
Figure 1.21:  The major interactions of 9-amino-6-bromo-DACA in its complex with a 
DNA hexamer d(CG(5-BrU)ACG)2. (Source: Todd, A.K. et al., 1999) [141] 
 
One should acknowledge the importance of the 9-amino functionality in stabilizing this 
‘DNA-induced’ anchoring of the compound’s carboxamide side-chain. The 9-amino 
group significantly increases the basicity of the ring N10 (pKa 8.3 compared to pKa 3.5 
in the 9-deamino analogue), causing the latter to be protonated which in turn allows 
formation of the N(10)H hydrogen bond to the carboxamide oxygen and the 
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involvement of the conserved water molecule in bridging the carboxamide NH to a 
backbone phosphate group. Of note, comparative DNA binding studies revealed a 
binding affinity, for the 9-amino compound, six times greater than for the 9-deamino 
analogue.[142] A single hydrogen bond is also formed between the -NH(CH3)2+ group 
of the side-chain and the N7 of one of the guanine bases of the intercalation site (see 
Figure 1.21).  The two side-chain nitrogen atoms are held in a gauche conformation.  
The delocalized charge on the acridine’s (protonated) N10 is further spread out over the 
carboxamide moiety via a hydrogen bond with the latter’s carbonyl oxygen (acceptor).  
Subsequently, the crystal structure of 9-amino-DACA in complex with the DNA 
hexamer d(CGTACG)2 was solved at a slightly lower resolution of 1.6Å (compared to 
1.3 Å) and revealed an almost identical conformation/interaction of the intercalator 
(compared to the above described crystal structure) with the DNA hexamer.[143]  The 
only significant difference was the presence of a three-centred H-bonding between the -
NH(CH3)2+ group of the side-chain and the N7 and O6 of the guanine base of the 
intercalation site (instead of the single H-bond to N7).  The described interactions with 
functionalities in the helix major groove hold the intercalator’s side-chain in its 
depicted unique conformation which is believed to contribute to inhibition of the 
topoisomerase enzyme by 9-NH2-DACA by effectively altering the local electrostatic 
potential and blocking the helix major groove.  Structure-activity relationship studies 
show that both the nature and the position of the substituents (including the 4-
carboxamide moiety peri to the ring nitrogen) are critical for 9-NH2-DACA’s potent 
biological (topoisomerase inhibiting) activity and kinetic stability of the DNA 
complex.[141]  
 
1.5.3 Polyamide Nucleic Acids (PNA): definition, properties and examples 
 
Polyamide nucleic acids (PNA) (Figure 1.22) are nucleic acid analogues in which the 
sugar-phosphate backbone of the natural nucleic acid has been replaced by a synthetic 
backbone composed of N-(2-aminoethyl)glycine subunits.[144]  PNA are achiral and 
uncharged and were developed in the search for oligonucleotide-based therapeutics 
exhibiting improved properties, relative to natural phosphodiester oligonucleotides, 
such as increased nucleic acid-binding affinities, biological stabilities and cellular 
uptake.[145] PNA is not degraded inside a living cell due to its chemical stability and 
resistance to hydrolytic (enzymatic) cleavage.[146] PNA is capable of sequence-
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specific recognition of single-stranded DNA and RNA targets and the resulting hybrid 
complexes exhibit extraordinary thermal stability, a property attributed to the lack of 
electrostatic repulsion between the neutral PNA strand and the anionic nucleic acid 
backbone.[144] 
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Figure 1.22:  Illustration of PNA and DNA fragments (in antiparallel orientation i.e. 
the PNA N-terminus and C-terminus corresponds with the respective oligonucleotide 
5’-terminus and 3’-terminus) 
 
PNA obey the Watson-Crick base-pairing when hybridising with a single 
complementary nucleic acid strand and can do so in parallel and antiparallel 
orientation.[146] The resulting PNA:nucleic acid complexes, when in antiparallel 
orientation, compared to the corresponding DNA-RNA and DNA-DNA duplexes, show 
increased (hetero)duplex melting temperatures, more so for PNA-RNA (melting 
temperature Tm increases with ~1.5 K/base) than for PNA-DNA complexes (Tm 
increases with ~1.0 K/base).[146] For example, Tm measurement experiments involving 
the PNA oligomer H-TGTACGTCACAACTA-NH2 gave the following results: the 
DNA-PNA duplex has a Tm of  70°C for the antiparallel orientation and a Tm of 56°C 
for the parallel orientation, the corresponding 15-mer DNA-DNA duplex has a Tm of 
53°C.[144] Hence, the stability of the (antiparallel) ds-DNA is almost equal to that of 
the parallel PNA-DNA complex, the latter however forms much slower (several hours) 
than the much stabler antiparallel PNA-DNA hybrid, which can form in tens of 
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seconds.[147]   Base mismatches destabilise PNA-DNA heteroduplexes to a larger 
extent than for the corresponding DNA duplexes; in a DNA-DNA duplex a single 
mismatched base lowers the Tm with 11°C on average while for a DNA-PNA duplex 
the same mismatch would lower Tm by an average of 15°C.[144]   
 
The above findings reflect the increased stability and sequence-specificity of the PNA 
heteroduplexes in comparison to the nucleic acid duplexes.  PNA are also capable of 
hybridising with their complementary nucleic acid strands at temperatures and ionic 
strengths where it is impossible for DNA duplexes to form.[148].  This was clearly 
illustrated by Tomac et al. in an experiment showing a significant increase of Tm for a 
DNA-DNA hybrid (> 20 K for a 10-mer) when increasing NaCl concentration from 
0.01 to 0.5 M.[149] The same salt concentration increase caused the Tm to decrease by 
8 K for the corresponding PNA-DNA hybrid, which thereby acquired approximately 
the same stability as the ds-DNA at 0.5 M NaCl. Again, the PNA neutral backbone is 
responsible for the difference in heteroduplex Tm dependence of salt concentration, 
compared to the ds-DNA. Increased counter-ion association for DNA-DNA formation 
and counter-ion displacement for DNA-PNA formation explain the observed Tm 
differences.  Interestingly, the latter differences can be exploited in PNA-based probing 
experiments for particular nucleic acid sequences as ionic strength manipulation can 
eliminate competition of complementary nucleic acid strands or melt undesired 
secondary structures.[150]  In PNA-nucleic acid duplexes the DNA strand closely 
resembles a B-form structure while RNA conformation is much closer to the A-form, 
particularly regarding the sugar pucker, which is C3’-endo compared to the B-form 
C2’-endo sugar pucker.[144] 
 
A number of specific molecular complexes have been observed when certain PNAs 
bind to single-stranded or double-stranded RNA and DNA targets.  Generally, 
homopyrimidine PNAs form very stable (PNA)2-DNA triplexes (Tm > 70°C) with 
complementary DNA stretches with stability depending on the PNA length and 
increasing by about 10°C per base-pair.[144] This was demonstrated with PNA-T8, 
which by binding to a single poly(dA) strand forms a right-handed (PNA)2-DNA triplex 
in which one PNA strand engages in Watson-Crick bonding with the DNA strand (in 
anti-parallel orientation) while the second PNA strand binds parallel to the DNA strand 
via Hoogsteen H-bonds (Figure 1.23).  
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For C-rich homopyrimidine PNA and GC-rich DNA duplexes only, a wide helical 
PNA-(DNA)2 triplex has been reported in which the PNA nucleobases engage in 
Hoogsteen-hydrogen bonding to the DNA purines.[144]  Curiously, this type of triplex 
(Hoogsteen interaction of ss-PNA bases with ds-DNA) was the type originally 
intended/expected in the development of PNA (as alternative oligonucleotide-based 
therapeutics) but is much less stable than the (PNA)2-DNA triplexes and is pH-
dependent (optimum between pH 5.0 and 5.5) due to protonation of PNA cytosine 
(allowing for the second Hoogsteen hydrogen bond involved in the C.G*C+ base triplet, 
the other base triplet being T.A*T.) (Figure 1.23)  
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Figure 1.23: CG*C, TA*T and CG*J nucleobase triplets (as in (PNA)2-DNA, (DNA)2-
PNA or bis-PNA-DNA triplexes. (* = Hoogsteen H-bonds, J = pseudo-isocytosine) 
 
 (PNA)2-RNA triplexes have been observed in biological experiments in which they 
were found capable of inhibiting CAT-mRNA (Chloramphenicol acetyl transferase 
mRNA) translation.[144] (PNA)2-RNA triplexes have stabilities comparable to their 
DNA counterparts [151]   
A stable triplex strand-invasion complex has been observed for homopyrimidine PNA 
binding to a homopurine ds-DNA target.[144] During strand invasion an initial single 
PNA strand recognizes and binds its complementary sequence in the homopurine DNA 
strand.  Simultaneously the DNA homopyrimidine sequence is displaced and remains a 
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single-stranded ‘looped out’ structure (P-loop) while the second PNA strand binds to 
the PNA-DNA duplex to form the stable PNA-DNA-PNA triplex. (Figure 1.24) 
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Figure 1.24: PNA and bis-PNA strand invasion leading to PNA2-DNA and bis-PNA-
DNA triplex formation 
 
Strand invasion is favoured by the presence of A-rich stretches and by low ionic 
strengths (< 50 mM NaCl). The process is also very sequence-specific, with one-base 
mismatch in a 10-mer PNA (at 20°C) leading to a 100-fold decrease in DNA binding 
affinity and a two-base mismatch leading to almost complete loss of binding 
affinity.[152]  
An even greater triplex stability (Tm-values of ~100°C for a 10-mer) can be achieved by 
so-called bis-PNAs, in which the Watson-Crick PNA strand is linked to the Hoogsteen 
PNA strand via ethylene glycol type linkers.[153] Moreover, bis-PNA-DNA triplexes 
show a strongly decreased hysteresis in their Tm-curve relative to the unlinked PNA-
DNA-PNA triplex (from > 20°C to ~2°C).  In current applications, when targeting 
small homopurine stretches, the preferred constructs are bis-PNAs in which cytosine 
bases are replaced with pseudo-isocytosine (aka J-bases) in the Hoogsteen strand in 
order to make the (intended) triplex pH independent (Figure 1.23).  
 
Right-handed (PNA)2-DNA triple helices were first observed/discovered through 
circular and linear dichroism spectroscopic experiments.[154] (PNA)2-DNA crystal 
structures showed however significant differences with their naturally occurring (albeit 
seldom) DNA triplex counterparts, the most striking difference being the single strand 
DNA conformation resembling the A-form (and not its native B-form as in the Watson-
Crick duplex part of a DNA triplex or in a PNA-DNA duplex).[155]  For reasons 
believed to be associated with  greater torsional freedom of PNAs compared to DNA, 
PNA rarely forms B-like structures.[144]  Because of the greater flexibility of PNAs it 
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is believed to conformationally adapt to its more rigid complementary nucleic acid 
structures but in PNA-PNA duplexes it takes on its own preferred conformation 
referred to as P-form, characterized by a very large pitch (18 base-pairs per turn) and a 
large diameter of 28 Å (in comparison, B-DNA has 10 base-pairs per turn and a 
diameter of ~20 Å) [156]  
 
A second type of strand-invasion complex has been reported only for very purine-rich 
PNA, which are capable of invading a ds-DNA and forming an extremely stable 
(single) duplex invasion complex (Figure 1.25a).[157]  
The final type of strand invasion referred to as double duplex invasion (Figure 1.25a) 
involves so-called pseudocomplementary PNA.  The latter comprises two 
pseudocomplementary PNA strands containing the non-standard nucleobases 
diaminopurine and thiouracil (replacing respectively adenine and thymine), forming 
virtual base-pairs which are destabilised due to steric hindrance (and hence prevent 
formation of undesired PNA-PNA duplexes) but are capable of recognizing their AG or 
GC counterparts in the ds-DNA (Figure 1.25b).   
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Figure 1.25a: ds-DNA + ss-PNA strand-invasion double duplex (top) and single 
duplex formation (bottom); 
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Figure 1.25b: Watson-Crick H-bonding (:) in a strand-invasion double duplex (D:T 
and A:sU) involving non-standard nucleobases 2,6-diaminopurine (D) and thiouracil 
(sU) and the sterically hindered unstable (virtual) base-pair D:sU in 
pseudocomplementary PNA. 
 
Experiments by Lohse et al. [158] showed successful and complementary double 
duplex binding, to the target ds-DNA, of pseudo complementary PNA decamers 
(GTAGATCACT/AGTGATCTAC) in which adenine and thymine were respectively 
replaced by non-standard nucleobase 2,6-diaminopurine (D) and 2-thiouracil (sU).  It 
was concluded from Tm measurements on 10-mer PNA that a minimum of 40% AT 
content in the DNA target was required for a stable double duplex formation to occur. 
Without the restriction the Hoogsteen homopyrimidine motif imposed (cf. 
homopyrimidine-based strand-invasion triplex) this means more than 83% of all 
possible ds-DNA 10-mer sequences can potentially be targeted.[158] 
Hence, the lack of sufficient binding free energy of mixed-sequence PNA (containing 
the standard nucleobases (A,T,G,C) to invade B-DNA can be partially overcome by 
using non-standard nucleobases.[159]  Currently more research is ongoing into how 
any mixed purine-pyrimidine sequence in ds-DNA could be a target for PNA.  An 
interesting approach dealing with this problem was reported on by Rapireddy et al.  
They constructed so-called conformational preorganized helical dodecameric chiral γ-
PNA (Figure 1.26) capable of strand-invasion of mixed-sequence B-DNA (via Watson-
Crick base-pairing) and showing strong sequence-specificity (i.e. no strand invasion 
was observed for single base mismatched target ds-DNA).[144] γ-PNA differs from 
PNA in that it contained chiral (R)-N-(2-aminopropyl)glycine subunits instead of the 
usual achiral N-(2-aminoethyl)glycine subunits and it (γ-PNA) pre-organises itself into 
a right-handed helical structure, as was shown by circular dichroism spectra of the 
dodecameric γ-PNA.[160]  Compared to the randomly folded PNA structure for which 
complex formation with ds-DNA requires an entropy penalized structural 
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reorganization, the secondary structure of γ-PNA was shown to have improved ds-DNA 
invasion kinetics and thermodynamics.[161], [162] However, although thermal stability 
of mixed sequence (dodecameric) (γ)-PNA-DNA hybrids was significantly higher for 
γ-PNA than for PNA (Tm: 90°C vs. 59°C), invasion of ds-DNA only occurred with γ-
PNA dodecamers bearing an acridine moiety linked to the L-lysine side-chain on the C-
terminal unit (Figure 1.26).[144] This clearly emphasises the importance of the 
acridine intercalating moiety in stabilising the strand-invasion complex presumably by 
preventing PNA-DNA end fraying, a conclusion already suggested earlier, by Bentin 
and Nielsen [163], for acridine-bearing homopyrimidines.[159] Acridine can be even 
more beneficial as part of PNA-conjugate, as exemplified by the effect on  
characteristic poor cell-delivery properties of PNAs. The latter has been a drawback 
associated with PNAs since their early development.[146] 
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Figure 1.26: Chiral γ-PNA (left) and its link to acridine in the dodecameric PNA-
acridine H-LLys-GACCACAGAT-LLys(Acr)-LLys-NH2 (right) (as reported by 
Rapireddy et al.).[159] 
 
It is well known that high molecular mass compounds (like PNA can be) can pose 
problems regarding their passage through cell membranes.  This problem may be 
overcome by conjugating PNA to suitable ligand molecules that could enhance cellular 
uptake. Recent research again has shown the significance of acridine, this time to 
address cell-delivery problems.  Ex-vivo experiments showed cationic liposome-
mediated cellular delivery (cytoplasm as well as nucleus) of PNA oligomers was 
significantly improved by attachment of lipophilic poly (hetero) aromatic compounds, 
acridine in particular (see Figure 1.27 for the applied linker between the acridine  and 
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the PNA).[164] Other strategies to improve cellular delivery include attachment of 
short peptide sequences, oligonucleotide sequences, antibodies or steroids.[165],[166] 
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Figure 1.27: 9-aminoacridine attached to a PNA via an aliphatic linker. 
 
An additional limitation with PNAs is that, as they are charge-neutral, they exhibit low 
water solubility.[146] However, this may be resolved by slight backbone modifications 
(e.g. introduction of positively charged lysine residues), as exemplified by the earlier 
mentioned dodecameric γ-PNA developed by Rapireddy et al. (Figure 1.26) 
 
In vitro and ex vivo studies using PNA oligomers have demonstrated that they have the 
capacity, by means of their antisense and antigene properties, to interfere with 
replication, transcription and translation.  This is due to the fact that PNA-nucleic acid 
complexes interfere with or block the enzyme/protein-nucleic acid interactions 
necessary for the above template-based functions to proceed.[146] In the light of our 
own project this is an interesting feature with respect to PIC formation in HIV’s life-
cycle, as PNA-nucleic acid interaction could potentially interfere with this process 
essential for HIV replication.  Although constant progress is being made, the main 
problem in the successful development of PNA-based therapeutics remains their poor 
cell-delivery properties.  More successful are the practical PNA applications in 
molecular biology, diagnosis and detection or their use as biosensors for nucleic acids. 
One example from molecular biology is its use as an artificial restriction system.  In 
this application two (strand-invading) PNA oligomers targeting two adjacent sequences 
on ds-DNA opposite strands will generate two single displaced strands, which can then 
subsequently be cleaved by the single-strand-specific nuclease S1.[167]  The latter 
nuclease together with the PNA oligomers hence constitutes a restriction system in 
which the recognition sequence is determined by the PNA sequences employed.  
Another example, illustrating the use of PNA as a detection tool, concerns a fluorescent 
in situ hybridisation (FISH) experiment in which a fluorescein-labeled PNA probe 
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enabled quantitative analysis of vertebrate telomere (something that was not possible 
quantitatively with oligonucleotides due to inefficient hybridization).[168] The latter 
PNA-FISH application, established by Lansdorp et al., subsequently resulted in the use 
of telomeric PNA-probes for in situ studies of cancer and ageing.  Micro arrays making 
use of PNA probes instead of DNA probes are an example of its application as nucleic 
acid biosensors.  In the latter application PNA have shown improved selectivity, 
sensitivity and stability compared to their DNA counterparts.[150] 
 
Generally PNA are considered valuable chemical tools in various fields of biology.  
PNA remain strong potential candidates in the search for new (alternative) 
oligonucleotide-based antisense and antigene therapeutics, the realisation of which will 
be the fruit of successful collaborations at the chemistry/biology interface. 
 
Both the DNA-binding properties of PNA and the intercalating 9-amino-DACA and 
their capacity to inhibit DNA template functions were the main inspiration to our 
research project.  In it we sought to develop a new potential inhibitor of HIV-integrase 
by combining (conjugating) the acridine intercalator properties with the characteristics 
of polyamide nucleic acids (or PNA).  The following sections discuss the significance of 
9-aminoacridine conjugates in the life sciences and the general synthetic strategies 
towards them.  Subsequently the potential of our novel PNA-(9-amino)-acridine 
conjugates as HIV-integrase inhibitors and our efforts towards their synthesis will be 
discussed. 
 
1.5.4 9-Aminoacridine conjugates: significance in the Life Sciences 
 
9-aminoacridines have been of enormous significance in treatment of several diseases 
since the early 20th century (e.g. quinacrine and amsacrine, used for treatment of 
respectively malaria and leukaemia, see earlier subsection 1.5.1). 
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Figure 1.28: general structure of a 9-aminoacridine conjugate 
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Structure-activity relationship studies of 9-aminoacridines have pinpointed the 9-amino 
substitution as crucial to its biological activity.[169] Not surprisingly 9-aminoacridines 
have been conjugated to numerous biomolecules in order to generate agents with 
altered/improved properties in terms of activity, bioavailability and applicability.[170] 
A general representation of the 9-aminoacridine conjugates is depicted in Figure 1.28. 
 
1.5.5 9-Aminoacridine conjugates: general synthetic strategies and some specific 
applications 
 
Mid 20th century, the synthesis of 9-aminoacridine was described, starting from the 
non-substituted acridine, under Chichibabin reaction conditions (amination of 
pyridine).[171] (see Scheme 1.1) 
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Scheme 1.1: Synthesis of 9-aminoacridine under Chichibabin reaction conditions 
 
Reaction however takes place in liquid NH3 and these are harsh conditions for 
numerous functional groups. When other ring substitutions, besides the 9 amino group, 
are intended, their introduction (or an anchor for them) preferentially occurs before 
establishing the 3-ring acridine system. One way of accomplishing this is by using 
substituted N-phenylanthranilic acids and then generating the acridine system by 
subsequent ring closure via aromatic electrophilic substitution. Depending on reaction 
conditions, this leads to either substituted 9-chloroacridines, primed in the 9-position 
for further substitution, or to 9-acridones which require further activation (towards 
substitution in the 9-position)(see Scheme 1.2 below).[170] Ring closure can be 
established with sulphuric acid [172] but, in the presence of acid-labile groups, the 
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tetraethyl tetrametaphosphate (in chloroform) is the preferred dehydrating agent.[173] 
Heating the (R,R’-substituted) N-phenylanthranilic acid in phosphorus oxychloride 
yields the labile 9-chloroacridine derivative [174] which can/should be used directly in 
a subsequent 9-substitution step. 
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Scheme 1.2: acridine-generating ring-closure reactions of (R,R’-substituted) N-
phenylanthranilic acids. 
 
Two commonly used strategies in establishing the 9-amino substituent, using either the 
9-acridones or the 9-chloroacridines, are represented in Scheme 1.3 below 
 
N
H
O
R R'
N
Cl
R R' N
N
R'''R''
R R'
N
LVG
R R' N
N
R'''R''
R R'
NHR''R'''
.HCl
Phenol, heat
POCl3, H-LVG, base NHR''R'''
LVG= leaving group
heat
 
 
Scheme 1.3: common routes to establishing 9-aminoacridines 
 
The top reaction in Scheme 1.3 was first described by Dupre and Robinson.[175] It is a 
nucleophilic substitution of the 9-chloro substituent by the free amine and it is catalysed 
by phenol (via the reactive 9-phenoxyacridine intermediate).[174] However, other 
alcohols can be used as catalyst as well, e.g. methanol can be used at lower reaction 
temperatures, and in some cases gives a better yield and less by-products compared to 
phenol.[176] The bottom reaction in Scheme 1.3 involves in situ POCl3 activation, 
which puts a reactive leaving group (LVG) in the 9 position, e.g. 9-imidazol-1-yl [177] 
or 9-(1H-1,2,4-triazol-1-yl) [180] which subsequently can be substituted with the 
amine.  Due to the relatively ease with which a 9-amino group is established, the 
majority of conjugates are those in which the (bio)molecule of interest is linked solely 
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to the 9-amino group.  Some relevant examples are, e.g.: 2,6-diaminopurine conjugated 
to the acridine moiety via different guanidine-carrying linkers (Figure 1.29).  They 
showed the ability to potentiate cytotoxicity for alkylating anti-tumour compounds by 
occupying abasic sites in certain cancer cells (mouse leukaemia and human pulmonary 
adenocarcinoma)  in cell-based assays.[178] 
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Figure 1.29: two anti-tumour active, diaminopurine-containing 9-aminoacridine 
conjugates. [178] 
 
In another example, 11-mer oligonucleotide-acridine conjugates (with the oligomers 
resembling the extremities of the HIV-1 integrase LTR) showed the capability of 
inhibiting HIV-1 integrase catalytic activity, in vitro, in the IC50 µmolar range, 
provided they were conjugated to acridine.[179] E.g. GGTTTTTGTGT-Acr (in which 
the oligonucleotide is linked to acridine’s 9-amino) showed IC50 values of 2.5 and 2µM 
for 3’-processing and strand transfer respectively.  These oligonucleotide-acridine 
conjugates induced the efficient dissociation of preassembled integrase-DNA 
complexes.  Although it was shown that this conjugate binds directly to integrase at a 
site different from its DNA_binding site, there was also evidence of at least a partial 
competitive inhibition (i.e. presuming base-sequence recognition).  The latter 
conclusion was based on observed increased inhibitory activity in competitive 
conditions rather than with preassembled integrase-DNA complexes.[179] 
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9-Aminoacridine conjugates in which the biomolecule(s) of interest are not (only) 
attached via the 9-amino group have been much less the subject of research so far.  One 
interesting exception to this is Beal’s work on synthesis of a small acridine-peptide 
conjugate library for the purpose of screening their potential as DNA/RNA binding 
therapeutics.[180] A combinatorial library of acridine-peptide conjugates (Figure 1.30) 
was synthesised, using solid-phase synthesis in which the appropriately activated 9-
anilinoacridine-4-carboxylic acid was linked, via a 4-carboxyl/carboxamide anchor, to 
the solid support bound peptides.   
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Figure 1.30: Acridine-peptide conjugate library synthesised by Beal et al. 
 
Although 9-aminoacridine compounds, in spite of their enormous potential in drug 
development, are currently treated somewhat stepmotherly by the pharmaceutical 
industry due to their toxicity, colour and fluorescence properties, their merits are 
undisputed.  Currently, clinical trials on 9-aminoacridine derivatives with potential anti-
tumour activity,[170] and their therapeutic potential in e.g. treatment of prion diseases 
[181],[182] and protozoal parasites [183] confirm their continuing importance in drug 
research.  
 
 
The premises of this research project firmly acknowledge the value of the acridine 
moiety and the therapeutic potential of the less prevalent acridine 4,9-substitution 
pattern in the development of 9-aminoacridine conjugates for anti-retroviral purposes.  
This is discussed in the next and final part of this introduction. 
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1.5.6 PNA-acridine conjugates as potential new integrase inhibitors 
 
In the development of novel 9-aminoacridine conjugates, for the purpose of HIV 
integrase inhibition, our aim was to devise and execute a synthetic route in which a 
PNA moiety is conjugated to the acridine and to do this in the somewhat less tried but 
not less meritorious 9-aminoacridine-4-(bio)-molecule substitution pattern, as e.g. was 
applied by Beal et al. [180] in his acridine-peptide conjugate library (see Figure 1.30 in 
subsection 1.5.4) and as present in the very potent anti-leukaemia drug, 9-amino-
DACA (see Figure 1.19 in subsection 1.4.2).  The 4,9-substitution pattern converts the 
acridine from a classical intercalator to a potential threading intercalator [184],[185] 
which is of particular interest if one wishes to increase intercalator residence time.  The 
latter in turn has been shown to be positively correlated to bioactivity (see subsection 
1.5.1). Moreover, a 4-carboxamide-linked substituent (of the acridine) exerts control 
over DNA binding as it allows for specific contacts between the substituent and 
accessible base functionalities in the major groove.[143],[141] In subsection 1.5.2 these 
interactions, and the importance of the acridine’s 9-amino group in them, were 
discussed for 9-amino-DACA.  In subsection 1.5.3 it was argued that, besides 
increasing the stability of complexation of PNA with ds-DNA, the acridine moiety in 
particular has proven to carry the additional benefit of improving cellular delivery of 
PNA oligomers (cytoplasm as well as nucleus).  We now sought to develop the 
chemistry towards combining the obvious therapeutic potential of this type of 
intercalator with the DNA binding properties of peptide nucleic acids or PNA.  PNA, 
with the appropriate complementary base-sequence, could in this way potentially 
selectively target the ends of HIV viral ds-DNA long terminal repeats, thereby 
inhibiting HIV integrase activity by obstructing/interfering with the normal viral DNA- 
integrase binding interactions.  Hence, in the design of the conjugate it was proposed 
that the acridine moiety would bind to the ds-DNA through intercalation, whilst the 
PNA would thread through the DNA helix and form hydrogen bonds with the adjacent 
complementary nucleobase stretches (as in the PNA/ds-DNA interactions discussed in 
subsection 1.5.3) and this enabled by the threading acridine 4,9-substitution pattern.  
Figure 1.31 below depicts the general structure of our primary PNA-acridine targets.  
Figure 1.31 also suggests a potential viral DNA binding mode (i.e. major/minor groove 
preference) of our primary PNA-acridine synthetic targets based on 9-amino DACA’s 
threading mode and illustrates an altered 9-amino substituent which holds the potential 
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to effect additional recognition/interaction with the viral DNA minor groove 
functionalities. This can be e.g. an amino acid or a second PNA moiety directly, or via 
a linker moiety, connected to the acridine. 
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Figure 1.31: General structure of primary PNA-acridine targets.  
 
Although there are limitations (when using ‘regular’ PNA, depicted in Figure 1.22 in 
subsection 1.5.3) to the nature and length of sequences that can be (sequence-
specifically) targeted due to the fact that stable PNA-dsDNA complexes have only been 
observed for homopyrimidine PNA (triplex invasion complex) (see Figure 1.24 in 
subsection 1.5.3) or very purine rich PNA (single duplex invasion complex) (see 
Figure 1.25a in subsection 1.5.3), this was not our main concern in the development of 
a synthetic pathway towards the 9-amino-4-PNA-acridine conjugates.  Moreover, 
modified PNA might resolve these issues of non-compatibility with random ds-DNA by 
using e.g. pseudocomplementary PNA (see Figure 1.25b in subsection 1.5.3) or the 
pre-organized chiral γ-PNA (see Figure 1.26 in subsection 1.5.3). As mentioned, the 
DNA-binding properties of PNA and 9-amino-DACA as well as their capacity to 
inhibit DNA template functions were the main inspiration for this project. By 
exchanging 9-amino-DACA’s 4-carboxamide side-chain with a PNA oligomer while 
retaining the 9-amino functionality we were hoping this would further increase drug/ds-
DNA complex stability and bioactivity inherent to 9-amino-DACA.  This was an 
obvious desirable trait in the development of potential new anti-retrovirals.  Hence, 
retainment/availability of the primary 9-amino substituent was considered a desirable 
feature in our conjugates and synthetic routes were devised accordingly.  Constructing 
the PNA-acridine conjugate, with the intended 4,9 substitution pattern, as in Figure 
1.32, did however raise a number of interesting complications e.g. regarding the 
acridine ring nitrogen (N10) basicity and the necessity to control this. 
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Figure 1.32: 9-amino-DACA compared to the envisaged PNA-acridine conjugates  
 
The bulk of the next chapter, ‘Results & Discussion’, deals with the challenges and 
pitfalls encountered in our endeavours to synthesise the envisaged PNA-acridine 
conjugates.  More specifically, the next chapter discusses the chemistry towards the 
development of new PNA-acridine conjugates and gives a detailed account of a novel 
9-step synthetic pathway towards a PNA monomer-acridine conjugate. The applied 
chemistry is solution-based but we believe it could be applied in a solid-phase synthetic 
strategy for acridine-PNA libraries for screening of (sequence-specific) IN-inhibitory 
activity. 
In first instance our hope is that the envisaged PNA-acridine conjugates will lead to 
specific new and potent HIV-integrase inhibitors and in second instance that they will 
also prove worthy to be considered for other nucleic acid targeting purposes. 
 
The next chapter ‘Results and Discussion’ deals with the chemical synthetic strategies, 
encountered problems and subsequent solutions towards the development of the 
envisaged PNA-acridine conjugates.  Each of the synthesised intermediates is discussed 
separately. 
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Chapter 2: Results and Discussion 
 
2.1 Objectives 
 
Our objective was to synthesise potentially HIV-integrase inhibiting PNA-acridine 
conjugates.  Our approach was such that we intended to synthesise the acridine moiety 
and the PNA monomer/oligomers separately and subsequently combine these building 
blocks thereby making several potential PNA-acridine threading intercalators.  We set 
out to synthesise 9-aminoacridines conjugated to a (pseudo)bio-molecule (PNA) in the 
acridine’s 4-position.  In Scheme 2.1, a generalised retrosynthetic analysis shows two 
ways in which the relevant substitutions in the acridine’s 4 and 9 position could be 
established. 
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Scheme 2.1:  Retrosynthetic analysis of two routes to 9-amino-4-PNA-acridine 
conjugates 
 
The top route in Scheme 2.1 has the least steps and establishes the PNA substituent 
before the 9-amino functionality.  In this route, different reactivities of the same leaving 
group (LVG) in both 4 and 9 position of the acridine allow for chemoselectivity.  In the 
bottom route the order of substitution is reversed (i.e. 9-amino established before 4-
PNA) and an extra step is required.  Variations on both routes were investigated and are 
discussed in the following sections.  Synthesis of the depicted mutual starting
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compound for both routes (alkyl-9-oxoacridan-4-carboxylate on the right) is well 
established (hence omitted here but discussed later). 
 
2.2 Synthetic strategies towards PNA-acridine conjugates. 
 
When synthesising substituted acridines, more specifically 9-aminoacridines-4-
carboxamides, generally the three-ring aromatic acridine moiety is synthesised carrying 
oxygen-based functionalities in the 4 and 9 positions (e.g. alcohol, carbonyl or carboxyl 
groups), which can then be appropriately substituted.  One of the main issues in our 
project was to find the order in which the oxygen-based functionalities would ideally be 
converted and/or protected in order to obtain our 9-aminoacridine conjugates 
reproducibly and in a reasonable yield.  In our attempts to achieve this, three different 
synthetic strategies were investigated.  The three routes were based on literature 
precedents and are referred to as the ‘Denny route’, the ‘Beal route’ and a ‘revised Beal 
route’, after the principal authors who reported similar chemical conversions in their 
work.  The ‘Denny route’ conforms to the top part of Scheme 2.1, while the ‘Beal 
route’ and ‘revised Beal route’ conform to the bottom strategy in Scheme 2.1.  Over the 
following sections, each of the strategies will be discussed together with our findings. 
 
2.3 The ‘Denny route’ 
 
In 1984 William Denny reported on the synthesis of 9-aminoacridine-4-carboxamides 
as a new class of anti-tumour agents, the most promising of which was N-[2-
(dimethylamino)ethyl]-9-aminoacridine-4-carboxamide, also known as 9-amino-DACA 
6 (see Scheme 2.3 below).[131] As mentioned earlier, 9-amino-DACA, due to its DNA 
binding properties (discussed in subsection 1.5.2) was one of the inspirations behind 
this research project.  We decided to initially focus on preparing 9-amino-DACA, in 
order to familiarise ourselves with each of the reactions in this synthetic pathway (we 
obtained an over-all yield of 23.2% for the HCl salt of  9-amino-DACA, compared to 
27.4% for Denny).  9-amino-DACA was also considered to be a good control 
compound to evaluate for anti-IN activity.  To the best of our knowledge anti-IN 
activity has not been reported for 9-amino-DACA.  
The key features of the ‘Denny route’, with regard to establishing the desired 
substitutions in the acridine 4 and 9 positions, were conversion of the oxygen carrying 
functionalities in the acridine 4 and 9 position into respectively an acid chloride and an 
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aromatic chloride functionality, followed by respectively 4-carboxamide and 9-amino 
formation (see Scheme 2.2 below).  The chemistry involved in these conversions is 
discussed in detail for the synthesis of 9-amino-DACA 6 in the following section. 
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Scheme 2.2: key transformations in the ‘Denny route’ 
 
2.4 Synthesis of 9-amino-DACA (according to an adapted Denny protocol) [186], 
[187] 
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Scheme 2.3: synthetic route to 9-NH2-DACA 
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A detailed discussion of each of the steps i to viii in Denny’s route to 9-amino-DACA 7 
(see Scheme 2.3 above), coupled with our observations, now follows.  
 
2.4.1 Step i: generating the first intermediate, 2-(2-Methoxycarbonylphenylamino)-
benzoic acid (1) 
 
The first step in the synthetic pathway towards 9-amino-DACA (7) involved reaction of 
diphenyliodonium-2-carboxylate (DPIC) with methyl anthranilate, in the presence of 
Cu(II)acetate catalyst, to afford 1 (see Scheme 2.4). 
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Scheme 2.4 
 
Both DPIC and methyl anthranilate were commercially available.  In this reaction, the 
aromatic primary amino substituent of methyl anthranilate nucleophilically attacked at 
C1 of diphenyliodonium-2-carboxylate which lead to the displacement of the 
phenyliodonium substituent.  This reaction was successfully accomplished in our 
hands, using a similar procedure to that reported by Denny, to afford 1 in an 80 % 
yield.  This was an improvement compared to Denny’s reported yield of 65% for 1. 
[187]  DPIC was used here because it lead to significantly higher yielding  and cleaner 
reactions than in the classic Ullmann-Goldberg route in which 2-chlorobenzoic acid 
was used (instead of DPIC) in the preparation of the ortho-substituted benzoic acid 1. 
One limitation when using DPIC in the synthesis of 1 was that temperature had to be 
kept below 130°C (above this temperature DPIC decomposes mainly to phenyl o-
iodobenzoate and above 160°C the main decomposition product is benzyne.[188] Some 
unusual aspects of the DPIC reaction, as depicted in Scheme 2.4, were its high 
specificity for nucleophilic attack on the carboxylate-bearing ring and the fact that the 
reaction was copper(II) catalyzed, in contrast with the usually copper(I) catalyzed 
Ar2I+-salt reactions (in which the degree of selectivity for which aryl will be substituted 
is reduced, due to the reduction by copper(I), to the radical species Ar2I.).[189] In this 
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light the high selectivity in the direction of cleavage (of the copper(II) catalysed DPIC 
reaction) certainly supported the proposed SN Ar mechanism rather than a radical 
mechanism.  Although no mechanism had been suggested by which copper(II) catalysis 
occurs, a possible involvement of the catalyst could be that the ionic interaction 
between the carboxylate substituent and Cu2+ cation increased the electrophilic 
character of the position ortho to the carboxylate group, which consequently increased 
the susceptibility of this ortho position to nucleophilic attack.  The catalytic 
requirement for copper(II), not copper(I), could be explained by the fact that an 
increased negative charge on the carboxylate group (due to its –M effect) would not be 
stabilised by Cu+ to the extent it would be by Cu2+.  This difference might be important 
as an increased (partial) positive charge on the ortho carbon (of the carboxylate bearing 
ring) was energetically unfavourable (adjacent to -I+-) and for this to be 
countered/stabilized, interaction of the carboxylate with Cu2+ was possibly necessary.  
On the other hand, perhaps it may have been that Cu2+ withdrew electron density from 
both carboxylate and iodonium lone pairs thus enhancing the electrostatic repulsion 
between the ortho carbon (partial) positive charge and the iodonium charge.  
Admittedly, these hypotheses do not completely clarify why Cu+ would not also, to 
some extent, be a catalyst for this reaction. 
 
At a later stage in our project the synthesis of the first intermediate (1) had to be 
performed via the lower-yielding Ullmann-Goldberg reaction with commercially 
available o-chlorobenzoic acid as a substitute for the diphenyliodonium-2-carboxylate 
(due to it being commercially discontinued).  This was done according a procedure 
reported by Palacios and Comdom (see Scheme 2.5 below) who described this 
Ullmann-Goldberg reaction with aromatic amines related to our methyl anthranilate, the 
closest match being anthranilic acid for which they reported a 79% yield of the 
conjugated product.[190] 
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Scheme 2.5 
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In our hands, using methyl anthranilate for the amine, the yield for 1 was only 31%.  In 
this procedure the product (1) was deemed sufficiently pure to be used in a next step 
without further purification.  Although the yield was unsatisfactory we decided to stick 
to this procedure because cost of the starting materials was low and they were easily 
recoverable and reusable.   
 
 
Although Cu powder was used as the catalyst source, it was reported the actual catalyst 
was copper(I) because of the following observations: absence of air strongly reduced 
the activity of metallic copper and CuI catalysed the reaction in the presence of KI (a 
condition under which Cu2+ cannot exist).[191],[192],[193] Regarding the involvement 
of the catalyst in the reaction mechanism opinions seemed to be divided.  Little support 
existed for a free-radical course of the reaction.[194]  Consensus seemed to lie with an 
SN mechanism in which catalysis was believed to occur via intramolecular coordination 
of the halogen to copper(I), which in turn increased the polarity of the C-Cl bond and 
activated it toward nucleophilic substitution in the position ortho to the carboxylate 
group.[195] (See Figure 2.1 for the partial mechanism suggested in the literature [196]) 
 
OO
Cu
Cl
NH2
 
 
Figure 2.1:  Suggested involvement of copper(I) catalyst in a typical Ullmann-
Goldberg reaction between o-chlorobenzoic acid and aniline. (Source: Gagan, J. M. F., 
1973, [196]) 
 
2.4.2 Step ii: ring-closure step generating methyl-9-oxoacridan-4-carboxylate (2) 
 
The second step (ii) in the synthesis of 9-amino-DACA (7) involved cyclization of 1 to 
yield methyl-9-oxoacridan-4-carboxylate (2) (see Scheme 2.6 below).  This was 
accomplished readily by heating a solution of 1 and an excess of tetraethyl 
tetrametaphosphate (2”) (see Figure 2.2 below for structure of 2”) in dry chloroform to 
reflux.  The tetraethyl tetrametaphosphate (2”) used in this reaction was first freshly 
prepared according to the literature method by Pollmann and Schramm.[139]  
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Scheme 2.6 
 
The IR spectrum recorded for the obtained tetraethyl tetrametaphosphate 2” showed an 
absorption band at 1310 cm-1 which was characteristic of P=O stretching in cyclic 
phosphate esters [197], and a band at 950-1100 cm-1 which was characteristic for P-O-
C alkyl stretching.  No absorption band was present at 1200-1250 cm-1 which indicated 
the absence of open chained (hydrolysed) polyphosphate esters.[139] The tetraethyl 
tetrametaphosphate 2” was obtained in a 94% yield and could directly be used in step 
ii, as suggested by Pollmann and Schramm and based on comparison of reported IR 
spectra of tetraethyl tetrametaphosphate with our own IR spectrum for 2”. 
 
 
 
 
 
 
Figure 2.2: The prepared tetraethyl tetrametaphosphate 2” is a mixture of the depicted 
compounds. 
 
In step ii (Scheme 2.6) dry conditions were important as hydrolysis of tetraethyl 
tetrametaphosphate (2”) could jeopardize ring closure of 1.  Pollmann and Schramm 
had reported splitting of the P-O-P linkage(s) of tetraethyl tetrametaphosphate by 
hydroxy-containing compounds; examples were H2O, ethanol and phosphoric 
acid.[139] In our case, presumably the –OH of the carboxyl group of 1 reacted with 
tetraethyl tetrametaphosphate, splitting a P-O-P linkage, and formed a mixed acid 
anhydride between 1 and tetraethyl tetrametaphosphate (2”).  This was then followed 
by ring closure of 1 via an SE Ar step and subsequent loss of the ethyl polyphosphate 
groups (see Scheme 2.7 below for our suggested reaction mechanism). 
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Scheme 2.7: Suggested reaction mechanism for ring closure of 2-(2-
methoxycarbonylphenylamino)benzoic acid (1) using tetraethyl tetrametaphosphate 
(2”) 
 
After work-up, compound 2 was obtained in a 93 % yield, which was slightly below the 
yield of 96% reported by Denny et al. [187] (no further purification was required).  In 
the 1H-NMR spectrum of 2, reduction of the number of aromatic protons from 8 (in 1) 
to 7 protons indicated successful ring closure.  The high value of the most downfield 
signal at 11.60 ppm (assigned to the NH-proton) was attributed to the NH-proton being 
engaged in intra-molecular H-bonding with the carbonyl oxygen of the 
methoxycarbonyl substituent at C4.  This presumably would have locked 2 into its 
tautomeric form, as represented in the left part of Figure 2.3 (the other tautomer having 
full aromaticity, and an –OH group at C9).  The existence of this intra-molecular H-
bonding, where the proton is shared between the side-chain carbonyl oxygen and the 
acridine ring nitrogen, was also observed in the X-ray crystal structures obtained for 
similarly substituted acridines, iso-propyl-9-oxoacridan-4-carboxylate (22) and methyl-
9-benzyloxycarbonylaminoacridine-4-carboxylate (45).  These shall be discussed later 
in the thesis in subsections 2.10.2 and 2.14.2 respectively. 
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Figure 2.3:  Tautomerism, intra-molecular H-bonding and ionic interactions in 
acridines 2 and 3. 
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2.4.3 Steps iii and iv: generating the 9-oxoacridan-4-carboxylic acid (3) 
 
In step iii in the synthesis of 9-amino-DACA (7), the sodium salt of compound 3 was 
obtained by basic aqueous hydrolysis of compound 2 (see Scheme 2.8).   
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Scheme 2.8  
 
The work-up (step iv) reported by Denny et al. [187], involving acidification of the 
resulting basic solution with glacial acetic acid, proved to be problematic due to a 
persistent acetic acid contamination in the crude product 3.  In order to overcome this 
problem, we decided to use Dowex H+-exchange resin, which had been swollen in 
absolute ethanol, and was added to the basic reaction mixture instead. This procedure 
neatly converted the sodium salt into the product 3.  Our modified work-up gave rise to 
3 in a slightly enhanced yield (94%) compared to that reported by Denny et al. 
(87%).[187] 
A 1H-NMR analysis of the spectrum of 3 verified the disappearance of the methyl 
protons of 2 and showed an unusually high signal at 13.95 ppm. The latter signal was 
assigned to N(10)H and its high value attributed to a partial positive charge it carried 
(see canonical forms of 3 in Figure 2.3) because, in 3, there was ionic interaction 
between the carboxylate functionality and the protonated ring nitrogen N(10)H.  To the 
best of our knowledge, 1H-NMR analysis of compound 3 has not been reported in the 
literature.  Compound 3 was deemed sufficiently pure to be used in the subsequent step 
without further purification.   
 
2.4.4 Steps v and vi: activation of the acridine acid (3) towards subsequent 
carboxamide formation. 
 
The next step (v) in the synthesis of 9-amino-DACA involved treatment of 3 with 
excess thionyl chloride in the presence of a catalytic amount of DMF to afford the 
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corresponding 4,9-dichloroderivative 4 (99% yield).  The DMF catalysis was required 
here to accommodate, for the (aromatic) 9-oxo/hydroxy→9-chloro conversion, 
nucleophilic chloride attack on the aromatic system (i.e. on the C(9) of the intermediate 
[(aryloxy)HC=N(CH3)2]+).  Since compound 4 could easily undergo hydrolysis, it was 
used directly in the next step (vi) of the synthetic pathway without further purification 
(see Scheme 2.9).   
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Scheme 2.9 
 
The sensitivity to hydrolysis of 4 involved both the 9-chloro and the (obvious) acid 
chloride group.  It was reported by Raulins that for 9-chloroacridines hydrolysis to 9-
oxoacridines is usually effected by boiling with dilute acid but that the ease of 
hydrolysis is also dependant on the substituents present, with electron-withdrawing 
groups (like the acid chloride group in 4) generally enhancing the rate.[198] This was 
confirmed by the recuperation of small amounts of 3 in the chromatographic 
purification of crude compound 5. 
Subsequently, in step vi, compound 4 was treated with excess dimethylethylenediamine 
to establish the carboxamide-substituent in the acridine’s 4-position, thus generating 
compound 5.  The carboxamide functionality in 5 was established via an 
addition/elimination reaction of the primary amine with the acid chloride functionality 
of 4.  We found the crystallisation procedure reported in the literature [186] for 
purification of 5 proved to be cumbersome so instead we applied column 
chromatography which gave rise to 5 in a 67% yield.  This was slightly below the yield 
of 71% reported by Denny et al.  
Subsequent analysis of the 1H-NMR spectrum of 5 showed the expected signals for the 
side chain protons (-CH3 at 2.45 ppm and -(CH2)2 at 2.72 and 3.79 ppm), confirming 
the reaction had been successful.  The high value of the amide proton signal at 11.90 
ppm again was an indication of involvement in hydrogen bonding, as mentioned before, 
with the heterocyclic nitrogen. (See Figure 2.4 below)  
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Once again, to the best of our knowledge, ours is the first 1H-NMR analysis of 
compound 5.   
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Figure 2.4: Intramolecular H-bonding in acridine derivative 5  
 
2.4.5 Steps vii and viii: generating the 9-amino-DACA free base and its HCl salt 
 
Step vii in the synthetic pathway towards 9-amino-DACA (6) involved replacing the 9-
chloro-substituent of 5 with a primary amino group, via an SN Ar reaction, using the 
protocol described by Denny et al. [186] in which dry ammonia gas was bubbled 
through a heated phenolic solution of 5 (see Scheme 2.10). 
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Scheme 2.10 
 
Again a different approach to that reported in the literature [186] was undertaken for 
purification of crude 6.  The method reported by Denny involved diluting the reaction 
mixture with an excess of 40% aqueous solution of sodium hydroxide which, upon 
cooling, gave the crude solid product that then could be re-crystallized.  Following this 
work-up, Denny et al. directly used 6 for a subsequent conversion of 6 into its HCl salt 
and reported an over-all yield of 72 % (for 7).  However, our attempt to reproduce 
Denny’s crystallisation was unsuccessful so instead we purified the crude oil product 
by flash column chromatography which afforded 6 in a 59% yield.  
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A key feature of the 1H-NMR spectrum recorded for 6 was the appearance of a broad 
singlet at 6.50 ppm which was assigned to the 9-NH2 protons. The latter signal 
disappeared upon D2O addition, indicating the exchangeable nature of the primary 
amino protons.  The high value of the signal at 12.38 ppm was attributed to the amide 
proton believed to be engaged in hydrogen bonding with the heterocyclic nitrogen, as 
described for the previous compound 5 in Figure 2.4. Once again, we were unable to 
find any report in the literature which describes NMR data for compound 6 and to the 
best of our knowledge, ours was the first 1H-NMR analysis of this compound.   
Peculiar in this step vii was the use of phenol (as solvent and catalyst) and formation of 
the reaction-facilitating 9-phenoxyacridine intermediate, which allowed for preparation 
of the 9-amino acridine at temperatures 20-40°C lower than without phenol as 
solvent.[199]  
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Scheme 2.11:  the role of phenol in converting 9-chloroacridines into 9-aminoacridines 
(as suggested by Adcock,[200]) 
 
See Scheme 2.11 above for the SN Ar reaction mechanism suggested in the literature.  
In this mechanism the phenol protonated the heterocyclic nitrogen thereby increasing 
the electrophilicity of C9 and facilitating nucleophilic attack at C9, initially by phenol 
or phenoxide which was then substituted by the amine upon addition of the latter to the 
reaction mixture.  It has been reported that aqueous acids can act as catalysts as well 
[201] but due to the sensitivity of the 9-chloro group to hydrolysis this would 
presumably lead to lower yields, hence the use of the organic ‘acid’ phenol.  Another 
possible reason for the established use of phenol (in the discussed substitution 
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reactions) is that it is good solvent for acridines as both compounds (to a degree) are 
amphiphilic. 
 
The last step (viii) in the synthetic pathway towards 9-amino-DACA involved 
conversion of the pure base 6 into its di-hydrochloride salt 7 for which we had to 
develop an alternative protocol to that reported by Denny et al. [186] In Denny’s 
approach, a solution of 6 in methanol was treated with a concentrated solution of 
hydrochloric acid, and the resulting salt 7 was precipitated from the reaction mixture by 
addition of ethyl acetate and re-crystallised from methanol/ethyl acetate.  However, in 
our hands, compound 7 did not precipitate from the reaction mixture.  This was 
probably due to the fact that 7, being a di-hydrochloride salt, was quite well solvated in 
the aqueous, polar, protic environment.  In order to obtain 7 from 6, we decided to treat 
6 with dry methanol saturated with HCl which, after work-up, afforded 7 as yellow 
crystals in an 89 % yield.  
Analysis of the 1H-NMR spectrum recorded for 7, following recrystallisation, 
suggested it was the di-hydrochloride salt.  This conclusion was based on the 
observation that, compared to the 1H-NMR spectrum recorded for the free base 6, two 
extra signals of exchangeable protons were present.  To the best of our knowledge no 
1H-NMR data has been reported for 7.  Compound 7 was sent off for evaluation of anti-
IN activity, the result of which will be discussed later. 
 
In the following sections the ‘Denny route’ strategy was applied to the synthesis of a 
PNA-acridine conjugate 16.  A retrosynthetic analysis of the conjugate 16 is given 
below in Figure 2.5 to illustrate the steps involved. In what follows we separately 
discuss synthesis of the PNA monomer backbone (10) in section 2.5 and a PNA 
nucleobase moiety (11) in section 2.6, to then discuss how both compounds 10 and 11 
were linked to each other and the acridine moiety in section 2.7 (illustrated in Scheme 
2.14, later) 
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Figure 2.5: Retrosynthetic analysis for the thyminyl-PNA-acridine conjugate 16 
 
2.5 Synthesis of the t-Boc-protected PNA-monomer ethyl ester backbone (10) 
 
The t-Boc-protected PNA monomer backbone, or ethyl N-(2-t-butoxycarbonylamino-
ethyl)glycinate (10), was prepared from commercially available 3-amino-1,2-
propanediol and di-t-butyl dicarbonate in three steps, based on well known chemistry 
described by Finn et al.[202] (Scheme 2.12). 
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Scheme 2.12:  PNA-monomer backbone synthesis 
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The N-terminal primary amino function and the C-terminal carboxylic acid moiety in 
10 were protected with a t-Boc and ethyl ester group, respectively.  This ensured that 
the later coupling of thymin-1-yl acetic acid (11) to 10 could only occur with the free 
secondary amino group of 10 (see Scheme 2.14 later). 
 
Thus, in Scheme 2.12, the first step i in the synthesis of 10 involved reaction of 3-
amino-1,2-propanediol with di-t-butyl dicarbonate in which aminolysis of the latter  
lead to the t-Boc-protected intermediate 8,  according to the method described by Finn 
et al. [202] In this procedure the pH of the reaction mixture was maintained above 10 
(by addition of aqueous NaOH) in order to prevent the 1°-amino group of 
aminopropanediol from being protonated by the (CH3)3CHCO3 acid generated in this 
substitution. Compound 8 was obtained in an 81 % yield after work-up (Finn et al. 
reported a yield of 97%).  
The 1H-NMR spectrum recorded for the resulting product was consistent with reported 
data [202] and 8 was deemed to be sufficiently pure for use in the next step of the 
synthetic pathway.  
 
Step ii in the reaction pathway involved oxidation of the diol 8 with sodium periodate 
to its corresponding aldehyde, t-butyloxycarbonylaminoacetaldehyde 9 (Scheme 2.12).  
In this reaction a cyclic 5-membered periodate ester was rapidly formed which 
subsequently slowly decomposed to the aldehyde products and the I(V) species 
HIO3.[203] (See Figure 2.6 below)  
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Figure 2.6: oxidation of the vicinal diol groups in 8 with IO4- proceeds via a cyclic 
periodate ester (electron pair movements shown in the intermediate relate to the slow, 
rate determining step). [222]  
 
Once again, the above reaction was performed according to the method described by 
Finn et al. [202] to yield 9 in a 78 % yield (Finn et al. reported a yield of 94%).  The 
1H-NMR spectrum recorded for 9 was comparable to that reported [202] and 9 was 
deemed to be sufficiently pure for the next step in the synthetic pathway.  A key feature 
of the 1H-NMR spectrum of 9 was the aldehyde proton signal at 9.65 ppm. 
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The final step in this synthetic pathway (Scheme 2.12) involved reductive amination of 
the t-Boc-protected aldehyde (9) in which the latter was treated with a methanol 
solution of glycine ethyl ester hydrochloride and NaBH3CN.  The reaction was 
performed as described by Finn et al.[202] In this reaction the initially formed imine 
picked up a proton (e.g. from the solvent methanol) to form the iminium which was 
subsequently rapidly reduced by the mild reducing agent, generating the secondary 
amine.  No stronger reducing agent was required here because the iminium (carbon) 
was such a good electrophile, in particular compared to aldehydes and ketones with 
which NaBH3CN reacts only very slowly.[226]  This chemoselectivity was convenient 
here because of the aldehyde group in the starting material (9).  The product ethyl N-(2-
t-butoxycarbonylaminoethyl)glycinate (10) was afforded in a 42 % yield (Finn et al. 
reported a yield of 43%).  The recorded 1H-NMR spectrum of 10 was comparable to 
that reported and 10 was deemed to be sufficiently pure to be used in the next coupling 
step with a nucleobase moiety, the synthesis of which is discussed in the next section 
2.6. 
 
2.6 Synthesis of a PNA nucleobase moiety 
 
In PNA, the nucleobase moieties are attached to the secondary amine nitrogen of 10 via 
a methylenecarbonyl linker.  Thus, appropriate acetic acid functionalized nucleobases 
needed to be prepared.  The latter was achieved by reacting the (protected) nucleobase 
with bromoacetic acid (under strong alkaline conditions), which attached selectively at 
the nucleobase N(1), via an SN2 reaction in which the α-bromide was substituted (as in 
Scheme 2.13 below).  The acid functionalized nucleobase moiety was now ready to 
undergo peptide-coupling to the PNA monomer backbone (10). For the purpose of this 
project, we focused on only one of the four possible nucleobases; that of thymine.  The 
reason for this was that it was known to be the simplest nucleobase to work with as its 
heterocyclic ring does not require any protection and it also poses the least problems 
solubility wise.  We envisaged that if the thymine PNA-acridine conjugates proved to 
be effective anti-IN agents worthy of further investigation, that the analogous 
conjugates bearing the other three nucleobases could be similarly prepared.  Thus, 
thymin-1-yl acetic acid 11 was prepared in one step, according to the method reported 
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by Kosinkyna et al., [146] as illustrated below in Scheme 2.13, in 93% yield 
(Kosinkyna et al. reported a yield of 80%).   
N
H
NH
O
O
OH
O
Br N
NH
O
O
OH
O
+
11
  conc. KOH (aq), 40°C  
Thymine
Bromo-acetic acid
(93%)
 
 
Scheme 2.13: Thymin-1-yl acetic acid synthesis 
 
Selective alkylation at N(1) rather than at N(3) of thymine was possible here due to the 
significant difference in pKa for thymine N(1) (pKa=9.86) compared to N(3) 
(pKa=13.96).[204] The recorded 1H-NMR spectrum of 11 was consistent with that 
reported [146] and 11 was deemed to be sufficiently pure to be coupled to the t-Boc-
protected PNA monomer backbone 10 in the next step of the synthetic pathway, as will 
be discussed in the next section 2.7. 
 
2.7 Linking nucleobase moiety, PNA monomer backbone and acridine moiety to 
generate the PNA-acridine conjugate 16 in the ‘Denny route’ approach. 
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Scheme 2.14: intended ‘Denny route’ to a PNA-acridine conjugate 
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Our initial synthetic strategy for synthesis of 16 involved attachment of the thymin-1-yl 
acetic acid derivative 11 to the PNA-monomer backbone 10 followed by t-Boc 
deprotection of the backbone to give 14 (or 21) and subsequent coupling to 9-
chloroacridine-4-carbonyl chloride 4 to give 15 (see Scheme 2.14 above).  Finally, the 
9-chloro substituent of 15 was to be replaced by an amino group, in an identical manner 
to that used previously for the synthesis of 9-amino-DACA 6, to afford the desired 
compound 16 (Scheme 2.14).  Unfortunately, Scheme 2.14 could not be completed 
successfully as step iii did not yield the hoped for conjugate 15.  The attempted steps i, 
ii and iii, outlined above, will be discussed in the following subsections. 
 
2.7.1 Step i: generating the t-Boc-protected thyminyl-PNA-monomer 13 
 
The first step (i) in this synthetic pathway involved coupling thymin-1-yl acetic acid 
(11) to the PNA monomer backbone (10) (see Scheme 2.15). 
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Scheme 2.15 
 
This conversion required treatment of 11 with 2-(1H-benzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU) in the presence of an excess of di-
iso-propylethylamine (DIPEA), according to a similar method described by Finn et al. 
[202]   HBTU acted as an activator of 11’s carboxyl function, providing it with a good 
leaving group and facilitating the coupling (see reaction mechanism below in Figure 
2.7). HBTU is a peptide coupling agent belonging to the triazolols, one of two main 
types of activating groups used in peptide chemistry (the other group being 
carbodiimides).  The initial triazolols (e.g. 1-Hydroxybenzotriazole or HOBt) were 
developed to complement the earlier developed carbodiimides by accelerating the 
coupling reaction and suppressing by-product formation that arose from the single use 
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of carbodiimides (racemisation and N-acyl urea formation).[205] A number of more 
recently developed triazolols, like e.g. HBTU, omit the carbodiimide step entirely.   
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Figure 2.7: the role of HBTU in establishing the 3° amide bond in 13 
 
HBTU was used in step i (Scheme 2.15) mainly because of its established application 
in PNA chemistry. The resulting t-Boc-protected PNA monomer 13 was obtained in a 
69% yield. Finn et al reported a 71% yield of 13 using a different condensing agent 
(TopPipU).  Subsequent 1H-NMR and 13C-NMR analysis data were consistent to those 
reported in the literature [202] and confirmed the structure of 13.  The 1H-NMR and 
13C-NMR spectra of 13 also showed the presence of two rotamers, in a 2:1 ratio, due to 
restricted rotation about the tertiary amide bond.  2-D 1H-NMR NOESY experiments 
reported by Chen et al. [206] and Brown et al. [207] showed that 13 b was the major 
rotational isomer (see Figure 2.8).  They based this conclusion on the observed NOE 
interactions of the nucleobase linking methylene protons with different parts of the 
PNA backbone.   
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Similar NOE interactions will be discussed in more detail for one of our own PNA-
acridine conjugates 53, in subsection 2.15.1. 
 
 
 
Figure 2.8: NOE interactions in the two rotational isomers of compound 13 (a and b), 
as described by Chen et al. [206] and Brown et al. [207] 
 
2.7.2 Step ii: generating the salts 14 and 21 of the thyminyl-PNA-monomer. 
 
The next step (ii) in the synthetic pathway involved t-Boc-deprotection of the PNA-
monomer 13 (Scheme 2.16 below). This was successfully accomplished by treatment 
of 13 with TFA, according to the method described by Breipohl et al. [208], and 
afforded the TFA-salt of the PNA-monomer (14) in an 89% yield.  Breipohl’s 
procedure differed from ours in that he simultaneously removed a t-Boc group and a t-
Butyl group from respectively the primary amino group (as in our case) and the 
carboxyl group of the protected thyminyl-PNA-monomer (Breipohl reported a yield of 
over 100% for his crude product, in our opinion presumably due to insufficient drying). 
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Scheme 2.16 
 
Later on in the project the t-Boc-deprotection of 13 was performed in HCl-saturated 
ethanol, yielding the PNA monomer HCl salt 21 in a 96% yield.  We used the HCl-
ethanol solution to guarantee the integrity of the ethyl ester group and found that the 
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latter procedure not only gave a slightly higher yielding white solid product 21 but as 
such 21 was also easier to handle and could be dried faster and easier than the brown 
gum of the TFA-salt 14.  Compound 14 had to be dried in vacuo at 50°C in a drying 
gun in the presence of phosphorus pentoxide.  Compound 21 was dried by repeated 
(azeotropic) coevaporation of 21 with toluene. 
1H-NMR and 13C-NMR analysis confirmed the structure for 14 and 21. The t-Boc 
signal, at 1.37 ppm in compound 13, had disappeared in 14 and 21, indicating 
successful deprotection.  Again, the 1H-NMR and 13C-NMR spectra of 14 and 21 
showed the presence of two rotamers, in a 2:1 ratio, due to restricted rotation about the 
tertiary amide bond. 
 
2.7.3 Step iii: attempting to link the acridine moiety 4 to the PNA-monomer 14. 
 
Subsequently, coupling of the TFA-salt of the PNA-monomer (14) to the 9-
chloroacridine-4-carbonyl chloride (4) was attempted (see Scheme 2.17). 
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Scheme 2.17 
 
Compound 4 was made as described earlier for the synthesis of 9-amino-DACA (6) 
(see Scheme 2.3 in section 2.4).  Hence, in step iii above, the free 1° amine group of 
14, after being liberated from its salt by DIPEA, was expected to nucleophilically attack 
the acid chloride carbonyl of 4 to yield the conjugate 15.  TLC monitoring of the 
reaction suggested complete conversion of the starting materials.  Due to the high 
polarity of the product(s) it was decided to purify the potential product(s) using 
preparative TLC.  Surprisingly, none of the expected PNA-acridine conjugate (15) 
could be identified upon NMR analysis of the collected bands.  Repeated attempts to 
isolate and identify the product(s) by preparative TLC were unsuccessful and 
cumbersome.  This was partially due to the longer migration time required (1.5 hours) 
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which caused considerable band widening of the bands on the TLC plate resulting in at 
least three yellow overlapping bands, slightly differing in UV activity and ranging 
between Rf 0.7 and the base line.  Due to the overlap with neighbouring bands and low 
solubility of these products (and hence low peak intensity) in used polar deuterated 
solvents like DMSO-d6 or CD3OD, analysis of the afforded yellow solids by 1H- and 
13C-NMR was unreliable and little could be concluded about the nature of the solids.  
Consequently, the next step iv (See Scheme 2.14 earlier), generating the primary 9-
amino functionality in PNA-acridine conjugate 16, could not be attempted. 
A possible interfering factor in this step iii could have been the tendency of the primary 
amine of starting material 14 to react intra-molecularly with the ethyl ester carbonyl 
functionality (See Figure 2.9 below). 
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Figure 2.9: possible side-reaction in the coupling step of thyminyl-PNA-monomer 14 
with acridine acid chloride 4. 
 
In the experiment the PNA monomer salt was deprotonated with DIPEA before the 
addition of the acid chloride.  Although both deprotonation and addition were done at 
0°C and ethoxide is a bad leaving group, the presence of an excess of DIPEA 
(necessary to neutralize the HCl generated by coupling of 14 with the acid chloride 4) 
could have aided the ethyl ester aminolysis, presumably via deprotonation of the 
zwitterionic tetrahedral intermediate (See Figure 2.9 above).  Additionally, the polar 
solvent DMF and the 3° amido functionality (in α-position of the ethyl ester carbonyl) 
could also have aided the ester aminolysis, respectively via stabilisation of the 
zwitterionic tetrahedral intermediate and via the -I effect of the 3° amide nitrogen 
(increasing the ethyl ester carbonyl electrophilicity).  Hence, the ethyl ester aminolysis 
could have resulted in the formation of a cyclic (δ-lactam) thyminyl-PNA-monomer 
(See Figure 2.9 above).  
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Although the latter side-reaction was never thoroughly investigated it seems a more 
plausible explanation for the complications in step iii than the assumption, at the time 
of the experiment, that the hydrolysis-sensitive nature of the acridine acid chloride 4 
and the hygroscopic nature of the PNA-monomer TFA salt 14 were, to a degree, 
incompatible.  Although the latter ‘hydrolysis’ hypothesis was also unsatisfactory, as 
we had thoroughly dried solvent (DMF) and starting materials for the coupling step 
(iii), it led us to investigate an alternative approach in which the order was changed in 
which the PNA-acridine components (acridine, PNA monomer backbone and 
nucleobase moieties) would be linked to each other (as detailed in Scheme 2.18 below). 
 
2.8 Alternative PNA-acridine synthetic strategy in the ‘Denny route’ approach 
 
ON
H
O
N
H
O
O
N
ON
H
O
O
O
N
NH3O
O
N
Cl
O N
H
N
O
O
O
Cl O
N
Cl
O N
H
N
H
O
O
N
NH
O
O
N
O
N
Cl
O N
H
O
O
N
NH
O
O
N
O
N
NH2
O N
H
O
O
N
NH
O
O
OH
O
 
N
Cl
O Cl
+
10
+ _
i
ii
Reagents and Conditions: i  0.4 M Na2CO3 aq., DCM, 0°C-20°;  ii  HCl sat. Ethanol, rt;  iii   DIPEA; CHCl3, ,rt;  
iv  HBr in acetic acid; v  HBTU, DIPEA; DMF; rt;  vi  a) phenol, 50°C b) NH 3, 115°C
                                        
Z
Z
Z
iii
iv
v
vi
17
1819
20
15
16
4
11
Cl
benzyl chloroformate
(71%)
(96%)
 
 
Scheme 2.18: Attempted alternative synthesis of a PNA-acridine conjugate 
 
In Scheme 2.18 above, our intention was to avoid the water-sensitive carboxamide 
formation step between 9-chloroacridine-4-carbonyl chloride (4) and the free base of 
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the (hygroscopic) salt of the polar nucleobase-bearing PNA monomer (14) (as 
described earlier in Scheme 2.14).  Hence, this alternative synthetic pathway would 
involve coupling of the polar nucleobase moiety 11 to the PNA monomer backbone 
moiety, after the PNA backbone 10 had been joined to the intercalator moiety, as in 20 
(see Scheme 2.18). Conveniently, for the coupling of the Z-protected PNA monomer 
backbone (18) to the acridine acid chloride 4, we would be able to use chloroform as 
solvent instead of the more hygroscopic DMF although, admittedly, this was significant 
only in the light of the ‘hydrolysis’ hypothesis mentioned earlier as interfering with the 
coupling step iii in Scheme 2.14 and 2.17.  
Unfortunately again, Scheme 2.18 could not be completed successfully as step iii did 
not yield the hoped for conjugate 17.  The attempted steps outlined above will be 
discussed in the following subsections. 
 
2.8.1 Step i:  Z-protection of the t-Boc-protected PNA-monomer backbone 10 
 
In the first step of Scheme 2.18, the secondary amine of the (t-Boc-protected) PNA 
monomer backbone 10 was protected by a benzyloxycarbonyl group via reaction of 10 
with commercially available benzyl chloroformate to yield 17 (see also Scheme 2.19 
below). In our strategy, Z-protection step was necessary to avoid later reaction of the 
secondary amino group of 10 with the acridine’s acid chloride group in 4. 
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Scheme 2.19 
 
The protection step was done according to a procedure described by Carbonnel et al. in 
which the secondary amine of a piperidine group was Z-protected by benzyl 
chloroformate.[209]  We found that the procedure of Carbonnel worked well for our 
purposes and obtained a 71% yield for 17.  Micro-analysis and 1H-NMR analysis 
confirmed purity and structure of 17, and showed the presence of two rotational 
isomers for 17 due to restricted rotation about the tertiary amide bond, as was the case 
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for the PNA monomer 13 and its salts 14 and 21 (as described in Scheme 2.14), albeit 
in a ratio closer to 1:1 for 17 rather than the 2:1 ratio described earlier for the thyminyl-
bearing PNA monomer intermediates 13, 14 and 21.  This ratio difference existed 
presumably due to the non-polar character of the benzyl moiety for which interactions 
with the different functionalities of the PNA backbone were less energetically 
differentiated compared to the more polarised thyminyl moiety in 13, 14 and 21. 
 
2.8.2 Step ii: t-Boc-deprotection of the Z-protected PNA-monomer backbone 17 
 
In the subsequent step (ii), compound 17 was selectively t-Boc deprotected by 
treatment with HCl-saturated ethanol, generating the HCl salt of the Z-protected PNA 
monomer 18 in a 96 % yield (see Scheme 2.20).  HCl-saturated ethanol was used here 
instead of the usual TFA solution because earlier use (See Boc-deprotection of 13 in 
Scheme 2.16) had shown it produced an easier to handle salt.  
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Scheme 2.20 
 
In the 1H-NMR spectrum of 18, absence of the t-Boc signal was a key feature 
suggesting successful deprotection. Further NMR analysis confirmed the structure of 18 
and, as expected, showed the presence of two rotational isomers due to restricted 
rotation about the tertiary amide bond.  
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Figure 2.10: the rotameric equilibrium for 18 is possibly favoured by electrostatic 
interaction in an intramolecular ring conformation. 
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Although the rotamer ratio for the starting material 17 had been closer to 1:1, for 18 this 
ratio was nearer to 2:1, possibly due to a favourable electrostatic interaction of the 
carbamate carbonyl oxygen to the ammonia hydrogens in an intramolecular ring 
conformation. (See Figure 2.10 above) 
 
2.8.3 Step iii: linking the acridine moiety 4 to the Z-protected PNA-monomer 
backbone 18. 
 
The coupling of 18 to the acid chloride functionalized intercalator moiety 4 was 
investigated next.  In this reaction, the free 1° amine group of 18, after being liberated 
from its salt by DIPEA, was expected to nucleophilically attack the acid chloride 
carbonyl of 4.  If successful, this would yield the desired conjugate 19 (see Scheme 
2.21 below).  
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Scheme 2.21 
 
For this coupling reaction we used chloroform as a solvent rather than DMF, used 
previously in Scheme 2.17.  Assuming that hydrolysis susceptibility of the acid 
chloride 4 had interfered with the coupling step to the PNA monomer backbone (in 
Scheme 2.17), we reasoned that the lower hygroscopic nature of chloroform would 
improve the stability of the acid chloride 4 during the course of the reaction.  
Furthermore, since chloroform was still a reasonably polar organic solvent, we felt that 
the solvation of the now less polar starting materials would not be compromised too 
much. The carboxamide formation reaction in step iii was monitored by TLC which 
showed conversion of the starting material into a number of potential (yellow) 
candidate spots for compound 19.  The lower polarity of the products of this coupling 
reaction (compared to the products formed in the coupling step to the thyminyl-PNA-
monomer discussed earlier for Scheme 2.17) allowed us to subject the reaction mixture 
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residue to flash column chromatography.  However, TLC analysis of the collected 
fractions showed (a) consistent presence of (presumably co-eluted) polar side-
product(s) in all the collected fractions.  Subsequent analysis of the 1H- and 13C-NMR 
spectra of the collected fractions contaminated with the impurities, indicated they were 
not negligible. This was concluded from observations in the 1H-NMR spectrum in 
which the pattern of aromatic proton signals was complex and uninterpretable in terms 
of number of signals and their multiplicity.  In order to find out if 19 was present in the 
collected fractions we decided to attempt to crystallise the obtained solids in different 
solvents, e.g. in ethyl acetate (good solvent) / petrol ether (bad solvent), in 
dichloromethane and in methanol.  Unfortunately, repeated crystallisation attempts 
resulted only in precipitation of a very fine yellow powder that failed to show a 
significant increase in purity of any relevant compound present, in 1H-NMR analysis. 
In our opinion, the complication suggested earlier for the coupling of the thyminyl-
PNA-monomer 14 to the acridine acid chloride 4 (Scheme 2.17), i.e. intra-molecular 
ring closure, were occurring here as well.  The Z-protected-PNA-monomer backbone 
would have reduced, to a degree, the polarity of the product(s) but again, the presence 
of excess of DIPEA to liberate the Z-protected PNA monomer 18 from its salts, prior to 
the addition of acridine acid chloride 4, could have led (even at 0°C) to the same type 
of by-product as discussed/depicted in Figure 2.9.   
 
In hindsight, admittedly, for the problematic coupling steps of the acridine acid chloride 
4 with the PNA monomer moieties 14 and 18, at the time of the experiment, the 
possible formation of by-products due to cyclization of the PNA monomer moiety, had 
been overlooked.  For the coupling steps, a potentially better approach could have been 
to slowly add the DIPEA to a cooled mixture (0°C or lower) of both the acridine acid 
chloride 4 and the PNA monomer moiety 14 or 18.  This might have prevented the 
intra-molecular ethyl ester aminolysis, caused by the excess of DIPEA, present in our 
experiments to deprotonate the 1° amino group in 14 and 18, prior to addition of the 
acid chloride 4.  However, as this reasoning was purely hypothetical, further 
experiments would need to be done to investigate whether this altered approach would 
lead to an improvement. 
At the time of our experiments, failure to obtain the desired PNA-acridine conjugates 
had been attributed to a hydrolytic sensitivity of the acridine/PNA coupling step. 
Although this hydrolytic sensitivity needs to be taken into account in the reaction 
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conditions, it now seems less likely this was the main reason for failure of the coupling 
steps.   
Finally, we concluded that, since we had spent a lot of time on this strategy and since 
the problems encountered did not appear to be easily surmountable, the ‘Denny route’ 
approach should be abandoned at this stage in favour of investigating other routes.  
Subsequently, one of the other routes towards PNA-acridine conjugates that we decided 
to investigate was based on the findings reported by Beal et al. [180], which dealt with 
the solid-phase synthesis of acridine-peptide conjugates.  This shall be described in 
more detail in the following section. 
 
2.9 The ‘Beal route’ 
 
In 2000, Beal et al. reported the development of a strategy for the solid-phase synthesis 
of acridine-peptide conjugates to enable libraries of acridine-peptide to be 
generated.[210] It was envisaged that these would lead to the discovery of new 
structure-specific nucleic acid ligands. We were inspired by the fact that these 
conjugates bore the 9-anilinoacridine-4-carboxamide moiety, similar to our intended 
PNA-acridine conjugates.  We will discuss Beal’s synthesis of acridine-peptide 
conjugates, illustrated in Scheme 2.22 below, and subsequently discuss how we utilised 
a similar strategy to prepare our PNA-acridine conjugates, illustrated in Scheme 2.23.  
 
Beal started off, in step i of Scheme 2.22, with the conversion of the known 9-acridone-
4-carboxylic acid 3 into its iso-propyl ester 22 via reaction of 3 with the coupling agent 
carbonyldiimidazole (CDI) and iso-propanol in tetrahydrofuran.  Compound 22 was 
obtained in a 95% yield after work-up.  The starting material 9-acridone-4-carboxylic 
acid 3 was synthesised by Beal, in two steps, according to Denny’s method [187], in 
which commercially available 2-chlorobenzoic acid and anthranilic acid were 
conjugated, followed by a ring-closure step which generated the 9-acridone-4-
carboxylic acid 3.  Reaction conditions for synthesis of 3 were similar to the ones we 
described earlier for the synthesis of 9-amino-DACA (6) in Scheme 2.5 and step ii of 
Scheme 2.3 (except for the use of methyl anthranilate in Scheme 2.5 instead of 
anthranilic acid here).  In step ii of Scheme 2.22 Beal converted the iso-propyl ester 22 
to the triazole intermediate 25 by treatment of 22 with the triazolating agent phosphoryl 
tristriazolide formed from phosphorus oxychloride, 1,2,4-triazole and triethylamine.   
Chapter 2: Results and Discussion 
92 
N
O
O OH
H
N
N
O O
N
N
N
O O
NH
N
O NHR
NH
N
O O
NH
N
O
O
N
O OH
NH
N
O
O O
H
O
N
H
Y
N
H
O
O
N
Hz
resinR =
(   33%) for v+vi
4
9
4
9
i ii
iii
iv
vvi
with Y,Z= -H, -CH2OH, -CH3, -(CH2)4NH3+
3 22
33
345859
i  CDI, THF, iso-PrOH, rt
ii  1,2,4-triazole, POCl3, TEA, CH3CN, reflux
iii  aniline, TEA, CH3CN, reflux
iv  a) 0.2M LiOH, THF, H2O, rt
    b) 2N HCl
v   DCC, NHS, THF, rt
vi  resin bound peptide RNH2, THF, rt
                                      
Reagents and Conditions
(95%)
(94%) for ii+iii
(99%)
25
 
 
Scheme 2.22: Beal’s synthesis of an acridine-peptide library. 
 
 
The triazole-bearing intermediate 25 was not isolated by Beal but used directly in the 
following step iii of Scheme 2.22.  With the triazolyl leaving group in place, treatment 
of 25 with aniline in acetonitrile, in the presence of triethylamine, gave the iso-propyl-
9-anilinoacridine-4-carboxylate 33 in a 94% yield over the two steps.  Subsequently, in 
step iv, 33 was treated with aqueous lithium hydroxide after which the reaction mixture 
was acidified with aqueous hydrochloric acid to yield the 9-anilino-acridine-4-
carboxylic acid 34 in a 99% yield.  In the next step v, the carboxylic acid group of 34 
was activated as the N-hydroxysuccinimide (NHS) ester, by treatment of a solution of 
34 and NHS, in tetrahydrofuran, with 1,3-dicyclohexylcarbodiimide (DCC).  Without 
further characterization and after removal of dicyclohexylurea, Beal used the residue 
containing N-hydroxysuccinimidyl-9-anilinoacridine-4-carboxylate 58 in the 
subsequent amidation step with the free N-terminus of a solid support bound tripeptide 
to yield 59. After cleavage from the solid support and work-up the (representative) 
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acridine-tripeptide ACR-Gly-Ala-Ala-NH2 was obtained in a 33% yield over two steps 
(relative to the 9-anilino-acridine-4-carboxylic acid 34 starting material) 
 
Hence, in summary, one of the main strategic differences between the ‘Denny route’ 
and the ‘Beal route’ is that, contrary to Denny’s route, in Beal’s protocol an amino 
group (anilino) is introduced at the 9-positon before the carboxamide is generated at the 
acridine’s 4-position.   In order to convert the acridine’s 9-hydroxy group (in 3) into an 
amine, the 4-carboxyl was protected as a hindered iso-propyl ester (as in 22) after 
which the 9-oxo functionality could be converted into a triazol-1-yl substituent (as in 
25).  The latter primed the 9-position for substitution with nitrogen (and oxygen) 
nucleophiles (like aniline in step iii).[210] Once the 9-amino (anilino) group was in 
place in 33, Beal used standard peptide synthesis procedures in step v to activate the 4-
carboxylic acid group of 34 (generated after iso-propyl ester deprotection in step iv) for 
carboxamide formation with the free amino terminus of an oligopeptide (step vi). 
 
Beal’s synthesis of the resin-bound tripeptides and cleavage from the solid support after 
the amidation step vi in the above Scheme 2.22 will not be discussed here as, at this 
stage, they are not relevant to our use of Beal’s strategy in preparing our own 
conjugates.  Although Beal applied solid-phase synthesis when coupling oligopeptides 
to an activated 9-anilinoacridine-4-carboxylic acid we were at this stage attempting to 
couple a PNA monomer (as opposed to peptide oligomers in Beal’s procedure) to the 
activated acridine acid, thereby effectively using solution phase chemistry one step 
further than in Beal’s procedure (i.e. in the acridine’s 4-carboxamide forming step).  
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2.10 Synthesis of PNA-acridine conjugates (via the ‘Beal route’) 
 
In this section we will discuss how we used Beal’s strategy in attempting to synthesise 
our own PNA-acridine conjugates and rationalise and compare our findings to Beal’s 
results.  Our synthetic strategies towards a PNA-acridine conjugate according an initial 
adaptation of Beal’s protocol is outlined below (Scheme 2.23).  Unlike in the procedure 
of Beal, we elected to use the methyl ester (2 in Scheme 2.23) rather than the acridine 
acid (3 in Scheme 2.22) as our starting material for all routes.  The reasons for this 
were two-fold.  Firstly, we had already made this compound (2) for the ‘Denny route’ 
from readily available starting materials and secondly, in our hands, we got a 
significantly higher yield for the synthesis of the next intermediate, iso-propyl ester 
(77%) (22 in Scheme 2.23), by obtaining it via a transesterificiation of the methyl ester 
precursor (2 in Scheme 2.23) rather than by esterification of the acid (51%) as Beal did 
(3 in Scheme 2.22).  We also decided that it would be worthwhile to investigate the 
potential of using a sterically more hindered t-butyl ester (as in 23 in Scheme 2.23) or 
even simply the methyl ester (2 in Scheme 2.23) at this stage of the synthetic route, to 
find out if different 4-carboxyl protection groups would result in better over-all yields 
further down the line. In terms of the latter consideration, for the t-butyl ester 23 the 
potential advantage yield-wise was that it would potentially allow for a subsequent 
milder deprotection step (compared to an iso-propyl ester hydrolysis).  For the methyl 
ester 2 the issue was whether it would survive the harsh conditions of the aromatic 
substitutions in steps v and vi of Scheme 2.23. 
As in Beal’s procedure in Scheme 2.22, we synthesised alkyl-9-triazolylacridine-4-
carboxylate intermediates 24, 25 and 26 in order to activate them for substitution at the 
9-position (conversion of oxygen-substituted heterocycles to triazoles activated them to 
react selectively with a number of different nitrogen and oxygen nucleophiles under 
mildly basic conditions [210]).  Different from Beal’s procedure was that we chose to 
use benzylamine instead of aniline to substitute the 9-triazolyl group in order to 
establish the acridine’s 9-amino functionality.  This was done to allow for later 
generation of a primary amino functionality through hydrogenolysis of the 9-
benzylamino substituent.  A detailed discussion of the individual steps of Scheme 2.23 
now follows. 
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 iii:  i-PropO- +Na; i-Propanol; Molecular Sieves 3A; rt 
 iv:  t-ButO- +Li; THF; 0°C-rt
 v:   a) Triazole, POCl3, TEA; THF; 0°C b) reflux
 vi:  Benzylamine, TEA; CH3CN; reflux
 vii:  a) 0.2 M LiOH (aq)/ dioxan; rt
       b) 2 M HCl (aq)/ dioxan; rt
 viii:  Sulfuric acid; DCM; rt or Yb(OTf)3 (cat); THF/water (4/1); rt
 ix:   HBTU, DIPEA, 14 (free base); DMF; rt  
       or DCC, N-hydroxysuccinimide, 14 (free base); THF, DMF, rt
                                        
 ii:  PPE(2"), CHCl3, reflux
i:  Water/ DMF, K2CO3, Cu (cat), 100°C
 
Reagents and Conditions:
(31%)
(93%)
(77%) (90%)
(72%)
(75%) (75%)
(57%) for 25
(54%) for 26
unsuccessful for 24
 
 
Scheme 2.23: ‘Beal routes’ to a PNA-acridine conjugate. 
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2.10.1 Steps i and ii: generating the acridine intermediate 2 
 
Synthesis of compounds 1 and 2 was discussed in section 2.4: Synthesis of 9-amino-
DACA. 
 
2.10.2 Step iii: transesterifying the acridine methyl ester (2) into the acridine iso-
propyl ester (22) 
 
Methyl-9-oxoacridan-4-carboxylate (2) was transesterified according a procedure 
described by Roelofsen et al. [211] (see Scheme 2.24 below) 
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O
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2 22
1
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3
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6
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10
8
 iii:  i-PropO- +Na; i-Propanol;Molecular Sieves 4A; rt 
                                        
Reagents and Conditions:
(77%)
 
Scheme 2.24 
 
This involved treatment of an iso-propanol solution of methyl ester 2 with sodium iso-
propoxide, in the presence of 4Å molecular sieves (~ 0.6 g / mmol ester) to selectively 
absorb the released methanol, which resulted in a smooth trans-esterification which 
afforded 22 in a 77% yield.  
Generally, the position of the equilibrium in a transesterification reaction will depend 
on the nature of both alcohol and ester.[212] Hence, in order to (swiftly and 
quantitatively) shift the equilibrium towards the iso-propyl ester (in step iii in Scheme 
2.24 above), the replacing alcohol (iso-propanol) was used as solvent and an equimolar 
amount of the more nucleophilic iso-propoxide was used to displace the methoxy group 
(in the starting material 2) which was subsequently removed from the reaction mixture 
as methoxide/methanol by absorption onto the 4Å molecular sieves (inner and outer 
surface).  Hence, the 4Å molecular sieves functioned here as a convenient alternative to 
the usual azeotropic removal of the unwanted alcohol to push the equilibrium towards 
the iso-propyl ester.  Some iso-propoxide/iso-propanol absorption may have occurred 
on the outer surface of the 4Å molecular sieves as well (not within the actual beads due 
to the excluding 4Å pore-size) but clearly not to the extent it would interfere (on the 
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reaction time scale) with the activity of the iso-propoxide nucleophile.  Regarding the 
latter problem, the amount of molecular sieves used seems important and should be no 
more than required to absorb the substituted methoxide/methanol. In the above 
experiment the proportion of molecular sieves used (~ 0.6 g / mmol ester) was based on 
a dimethylterephthalate→di-t-butylterephthalate transesterification in benzene/t-
butanol/K+-t-butoxide at 80°C performed by Roelofsen et al.[211] Although this 
worked reasonably well for our purpose (TLC monitoring of the reaction suggested 
quantitative conversion), some irreversible absorption of the product onto the sieves 
reduced the final yield of 22 to 77%.  Hence, ideally, for different reactions, the optimal 
ester/sieves ratio should be determined experimentally, while the chosen pore-size 
should lead to selective absorption of the substituted alcohol.  In addition, suitable 
crystals of 22 (re-crystallised from methanol) were obtained which allowed for X-ray 
crystal structure determination.  From this structure it was apparent that H-bonding was 
occurring between the ring N(10)H and the carbonyl oxygen.  Key bond distance and 
torsion angle values obtained from the crystal data experiment (see  also Appendix) 
were: 124 pm for C(8)-O(1) (indicating a double bond and confirming the 9-
oxoacridane was the crystallised tautomer for 22) and a torsion angle of 2.8° for C(14)-
C(13)-C(15)-O(3) which brought the H…..O distance in N(1)-H(1)…..O(3) to196 pm, 
which was within the normal H-bond distance range (see Figure 2.11 below for X-ray 
structure of 22).  
 
Figure 2.11: X-ray structure of iso-propyl-9-oxoacridan-4-carboxylate (22) 
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The intramolecular H-bonding had been suggested earlier and 1H-NMR spectra analysis 
for relevant compounds e.g. the acridine-based methyl ester 2, the acridine-based acid 4 
and 9-amino-DACA 6, supported this.  The X-ray crystal structure for 22 now 
confirmed our assumption, the significance of which was that it indicated a pattern that 
will be further discussed at a later stage, when the acridine 4-carboxyl group requires 
activation towards coupling with the PNA monomer.  
Key features of the 1H-NMR recorded for 22 were the appearance of a doublet at δ 1.36 
and a septet at δ 5.24 for the iso-propyl hydrogens but also the lack of the methyl group 
singlet at δ 4.00 which had been present in the 1H-NMR spectrum of 2.  The most 
downfield signal at 11.71 ppm was assigned to N(10)H, its high value being attributed 
to the hydrogen-bonding with the carbonyl oxygen of the ester moiety.   
 
2.10.3 Step iv: transesterifying the acridine methyl ester (2) into the acridine t-butyl 
ester (23) 
 
To convert the methyl ester 2 into the t-butyl ester 23, initially Roelofsen’s 
transesterification method was applied, i.e. the use of sodium t-butoxide in 
tetrahydrofuran and in the presence of molecular sieves (4Å).  However, 
transesterification under these conditions proved to be very slow (only partial 
conversion showed after 24 hours at 40°C).  We found that another procedure, for the 
transesterification of aromatic methyl esters according to Meth-Cohn [213], enabled us 
to convert, at room temperature, the methyl ester 2 into the t-butyl ester 23, faster and, 
based on TLC analysis, apparently quantitatively.   
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Scheme 2.25 
This procedure involved treatment of the methyl ester 2 with the lithium salt of t-
butanol (see Scheme 2.25 above).  We found that the use of up to 7 equivalents of the t-
butanolate was required to achieve complete conversion after 24 h.  Subsequent work-
up led to a very good 90% yield for 23.  The success of this transesterification was 
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attributed to the lower pKa of methanol compared to the higher, branched alcohols 
resulting in the favourable equilibration and to the strong complexation of lithium salts 
to the ester carbonyl.[213] We can assume that the ester carbonyl oxygen-Li 
complexation increased the ester carbonyl carbon electrophilicity, thereby facilitating 
nucleophilic attack of the t-butoxide oxygen. The key features in the 1H-NMR spectrum 
of 23 were the appearance of the t-butyl singlet at δ 1.60 (and the lack of the methyl 
group singlet at δ 4.00 present in the 1H-NMR spectrum of 2).   
 
2.10.4 Step v: activating the acridine’s 9-position towards subsequent substitution. 
 
Intermediates 2, 22 and 23 were successfully substituted with a 1,2,4-triazole group at 
the 9-position of the acridine ring, yielding 24, 25 and 26 respectively, according to the 
protocol described by Beal.[210] (see Scheme 2.26 below) 
 
 v:   a) Triazole, POCl3, TEA; THF; 0°C b) reflux
                                        
Reagents and Conditions:
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v
2    R=Me
22  R=iPr
23  R=tBu
24  R=Me
25  R=iPr
26  R=tBu
72% for 2
75% for 22
75% for 23
 
Scheme 2.26 
 
The active reagent in this substitution was the tri(1,2,4-triazol-1-yl) phosphine oxide (or 
phosphoryl tris-triazole) which was prepared in situ.  Tri(1,2,4-triazol-1-yl) phosphine 
oxide was developed/used originally for the preparation of nucleoside 3’-
phosphotriester intermediates in oligonucleotide synthesis.[214] In the latter 
preparations the initially formed nucleoside 3’-di(1,2,4-triazol-1-yl)-phosphomonoester 
(from reaction of the phosphoryl tris-triazole with the 3’-OH of a nucleoside) was 
treated with the appropriate alcohol(s) at room temperature to generate the nucleoside 
3’-phosphotriesters.  However, in our case, and as suggested by the above Scheme 
2.26, the initially phosphorylated acridine presumably underwent substitution in the 9-
position with a triazolide anion, generating the 9-triazolyl substituted acridine (see 
Figure 2.12 below for our suggested reaction mechanism).  Compared to the ‘original’ 
phosphotriester generating reactions, performed by Kraszewski and Stawiński (at room 
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temperature over a maximum of 24 hours), our reaction required reflux temperatures 
(~70°C) for 96 hours in order to allow, initially, the acridine’s phenolic 9-OH 
substituent to displace a triazolyl group in the phosphoryl tris-triazole and secondly, to 
allow a weakly nucleophilic triazolide to substitute the generated di-triazolyl 
phosphomonoester in the 9-position of the acridine.  Presumably, the first step was the 
faster one as, in the presence of excess TEA, the acridine 9-OH was deprotonated and 
should more easily displace a triazolyl (good leaving group) in the phosphoryl tris-
triazole reagent.  It is unlikely that the generated ditriazolylphosphinate anion, due to its 
charge, would serve again to phosphorylate the acridine in the 9-position.  However, 
these are hypothetical assumptions and the exact reaction mechanism should be 
determined via further investigation.  
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Figure 2.12: suggested SNAr reaction mechanism for the triazolylation of acridine 
intermediates 2, 22 and 23. 
 
Contrary to Beal, we isolated and characterized all three triazolyl-containing acridines 
24 (72% yield), 25 (75% yield) and 26 (75% yield). 
1H-NMR and 13C-NMR analysis of compounds 24, 25 and 26 confirmed their 
structures.  Key features in the 1H-NMR spectrum of all three compounds were the 
appearance of the two triazole proton singlets at δ 8.32 and 8.52 and the disappearance 
of the NH signal at δ 11.65.   
The purpose of generating 9-triazolylated intermediates was, as mentioned earlier, to 
activate them for substitution at the 9-position with benzylamine, as discussed in the 
next step vi. The relatively facile substitution of the 9-triazolyl group again could be 
attributed to it being a good leaving group (triazolide is a weak nucleophile/base). 
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2.10.5 Step vi: generating the 9-benzyl amino substituted acridine esters 27, 28 and 
29 
 
Substitution of the triazolyl group in compounds 24, 25 and 26 with benzylamine was 
performed according an adapted protocol of Carlson and Beal.[210] (see Scheme 2.27 
below) 
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27  R= Me
28  R= iPr
29  R= tBu
vi
9
4
24  R= Me
25  R= iPr
26  R= tBu
unsuccessful for 24
             57% for 25
             54% for 26
 
Scheme 2.27 
 
This involved heating the triazolylated starting material and the benzylamine at reflux 
temperature, in the presence of triethylamine.  Carlson and Beal describe the 9-triazolyl 
substitution of 25 with aniline.  However, we chose to investigate substitution with 
benzylamine because we intended to remove the benzyl group in the final step (after 
coupling of the acridine chromophore to the PNA) by hydrogenolysis, to afford the 
desired PNA-acridine conjugate.  For the 9-triazolyl-acridine-4-methyl ester (24) we 
expected substitution at the 9-position of the acridine ring as well as some substitution 
at the methyl ester carbonyl, giving the (undesired) disubstituted by-product 
benzylamine-9-benzylaminoacridine-4-carboxylate 27* (See Figure 2.13 below).   
 
N
O N
NH
27*
 
 
Figure 2.13: Treating the 9-triazolyl-acridine-4-methyl ester (24) with benzylamine 
mainly led to the disubstituted benzylamine-9-benzylaminoacridine-4-carboxylate 27*. 
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We were however hopeful that, due to some steric hindrance, the latter substitution 
might be minimal.  However, post work-up 1H-NMR analysis of columned active 
fractions suggested that mainly the disubstituted by-product 27* had formed and none 
of the desired monosubstituted benzyl amino methyl ester 27 was observed.  Although 
this was not unexpected we had considered this reaction worthy of investigation (even 
if a lower yield of the desired mono-benzylaminosubstituted 27 had been obtained) as it 
would have spared us from undertaking a transesterification reaction on the methyl-9-
oxoacridan-4-carboxylate 2. 
 
With iso-propyl-9-triazolylacridine-4-carboxylate (25), we were able to selectively 
substitute only the 9-triazolyl substituent.  This was due to the fact that the iso-propyl 
group sterically hindered the carbonyl group thereby making ester aminolysis 
unfavourable.   The desired 9-benzylamino acridine iso-propyl ester 28 was afforded in 
a 57% yield after work-up.  A similar result was also achieved with t-butyl-9-
triazolylacridine-4-carboxylate (26), giving 9-benzylamino acridine t-butyl ester 29 in a 
54% yield.  Unfortunately, no reliable melting points could be taken for 28 and 29 due 
to the oily character of the products) 
For both 28 and 29, 1H-NMR analysis showed the presence, in a 2:1 ratio, of Z- and E-
isomers (due to restricted rotation about the C9-N bond) which could interconvert 
through a zwitterionic intermediate shown in Figure 2.14 below.  It was not determined 
which diastereomer was prevalent (but further 2-D NMR NOE experiments and a 
crystal structure could clarify this).   
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Figure 2.14 
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2.10.6 Steps vii and viii: hydrolysis of alkyl-9-benzylaminoacridine-4-carboxylates 28 
and 29 
 
The next steps vii and viii in the ‘Beal route’ involved deprotection of the esters 28 and 
29.  A number of different approaches were attempted in order to maximise yields (see 
Scheme 2.28 below).  Firstly, we explored basic hydrolysis of the iso-propyl ester 28 as 
described by Beal et al. (step iv in Scheme 2.22 earlier). 
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      or NaI, Si(CH3)3Cl;CH3CN/DCM (1/1); 90°C (unsuccessful)
      or AlCl3; DCM; 0°C-rt (unsuccessful)
viii:  Sulfuric acid; DCM; rt (unsuccessful) or Yb(OTf)3 (cat);THF/water (4/1); rt (unsuccessful)
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vii (for 28) (59%)
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Scheme 2.28 
 
Although we were successful in deprotecting the ester 28, our work-up was different 
from Beal’s (See Scheme 2.22) as our initial attempts to separate salts from product 
(30) by triturating the crude product with chloroform, as in Beal’s procedure, were 
unsuccessful.  In our alternative work-up (in which cooling of the neutral reaction 
mixture led to precipitation of 30) 9-benzylaminoacridine-4-carboxylic acid (30) was 
afforded in a moderate 59 % yield.  The 1H and 13C-NMR spectra, recorded for our 
obtained compound 30, also showed the presence of Z-E isomers, but less obvious than 
for the iso-propyl ester 28.  For example, in the 1H-NMR spectrum, the CH2 signal 
didn’t clearly split into two but was rather broad instead, which was also the case for 
the NH signals.  A possible explanation for this would be that the C(9)-NH bond of the 
acid 30 has less double bond character, hence there was less impeded rotation of this 
bond compared to the analogous bond in the esters 28.  This could be the case because 
for a higher double bond character of C(9)=NH+, the zwitterionic opposing charges 
would on average be (unfavourably) further apart.  Hence, the more relevant canonical 
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structure for 30 would be as depicted in Scheme 2.28 above (with the single C9-NH 
bond). 
As our 59% yield for 30 was still low compared to the 99 % yield Beal et al. had 
obtained for the basic hydrolysis of their iso-propyl-9-anilinoacridine-4-carboxylate (33 
in Scheme 2.22) we wanted to explore other deprotection possibilities.   
 
For example, following a protocol described by Olah et al.[215], we explored iso-
propyl ester (28) cleavage via generation of the in situ equivalent of iodotrimethylsilane 
in the presence of the iso-propyl ester 28.  Subsequent aqueous work-up was expected 
to yield the free acid 30.  Olah’s general reaction conditions for ester cleavage are 
illustrated in Scheme 2.29 below. 
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OSiMe3
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+ Me3SiCl + NaI
CH3CN
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H2O
R=  alkyl or aryl
R'= alkyl
heat
Me3SiOSiMe3 +
 
 
Scheme 2.29:  ester cleavage reaction as reported by Olah et al. [215] 
 
A similar dealkylation of alkyl esters with iodotrimethylsilane (not Olah’s in situ 
equivalent ) was reported earlier by Jung and Lyster.[216] However, due to a number of 
disadvantages linked to the preparation of iodotrimethylsilane (expensive, highly 
susceptible to hydrolysis, has to be prepared freshly and isolated from reaction mixture 
by distillation) Olah developed a more practical, cheaper way by using 
chlorotrimethylsilane and NaI in acetonitrile as an in situ equivalent for the 
iodotrimethylsilane.[215] Of note, Morita et al. reported these ester dealkylations did 
not occur without NaI nor was it possible to prepare iodotrimethylsilane from 
chlorotrimethylsilane and NaI.[217]  According to Olah, initially a complex was 
formed between acetonitrile→trimethylsilyl and iodide driven by simultaneous and 
immediate precipitation of NaCl (See Figure 2.15 below).  
+NaCl[CH 3C N+Si(CH3)3]I
_
CH3CN+(CH3)3SiCl+NaI
 
 
Figure 2.15: acetonitriletrimethylsilyl iodide complex formation described by Olah et 
al.[215] 
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Interestingly, the same complex was formed when using iodotrimethylsilane in 
acetonitrile.  Subsequently and upon heating (to reflux temperature) a 
displacement/substitution of the acetonitrile by the ester carbonyl oxygen was 
suggested after which the associated iodide nucleophilically attacked the alkyl group 
(iso-propyl in our case) to generate an alkyliodide and the trimethylsilyl ester 
intermediate.  In Jung’s experiments with iodotrimethylsilane the latter was claimed to 
be the rate determining step. [216] (See Figure 2.16 below).   
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Figure 2.16: the ester dealkylation-mechanism via iodotrimethylsilane (according to 
Jung and Lyster [216])  
 
Jung used DMSO or chlorinated solvents, not the acetonitrile which was assumed to be 
crucial in Olah’s procedure in which the consequent NaCl precipitation drove the 
formation of the acetonitriletrimethylsilyl iodide complex.  
Regarding our own experiment, in which we attempted to cleave the iso-propyl ester of 
28, TLC monitoring of the reaction suggested that even after sustained heating at reflux 
for over 72 hours little deprotection had taken place.  A 1H- and 13C-NMR analysis of 
the crude reaction mixture residue suggested the iso-propyl ester 28 was still intact.  In 
our opinion, the reason for this was the involvement of the ester carbonyl oxygen in H-
bonding with the ring N(10)H which effectively reduced the carbonyl oxygen 
nucleophilicity required to displace acetonitrile in the acetonitriletrimethylsilyl iodide 
complex (See Figure 2.15 earlier). Hence, it was likely no silylated ester iodide salt 
could form in our experiment. 
 
Another iso-propyl ester cleavage attempt on 28 was inspired by Chee,[218] who had 
reported the selective deprotection of (aromatic and aliphatic) iso-propyl esters (i.e. not 
affecting other alkoxycarbonyl groups present) using aluminium trichloride, followed 
by aqueous work-up.  According to Chee, “cleavage of the O-iso-propyl bond 
presumably occurred via the formation of a stable iso-propyl cation”.  We decided to 
explore this strategy next.  Unfortunately, 1H and 13C-NMR analysis of the yellow 
precipitate afforded, after treatment of 28 with aluminium trichloride under conditions 
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described by Chee, showed almost exclusive presence of 9-aminoacridine-4-carboxylic 
acid 31 (yield 92%).  Thus, both the iso-propyl and the benzyl protection groups had 
been removed in this reaction (see Scheme 2.30 below for our suggested mechanism).   
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Scheme 2.30: both benzyl and iso-propyl protection groups were removed from 28 
under selective iso-propyl ester deprotection conditions described by Chee et al. [218] 
 
As the benzyl cation was a better leaving group than the iso-propyl cation, this outcome 
was far from unexpected.  However, we believed the simple nature of this experiment 
had made it worth trying on a small scale.  
 
So far our attempts to more closely match Beal’s yield of 99% for the deprotection of 
iso-propyl ester 28 had been unsuccessful.   
 
Regarding the alternative route to 9-benzylaminoacridine-4-carboxylic acid, via the t-
butyl deprotection of ester 29, two different approaches were attempted.  Firstly, we 
decided to investigate a procedure selective for t-butyl ester cleavage, described by 
Sridhar et al.[219], which involved using catalytic Yb(OTf)3 Lewis acid in 
nitromethane (solvent) under mild conditions (heating at 45°-50° C for 5 to 24 hours).   
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Scheme 2.31: proposed reaction mechanism for Yb(OTf)3 catalysed selective t-butyl 
ester cleavage as described by Sridhar et al. [219] 
 
No reaction mechanism was suggested by the author but we believe the described 
activation could possibly occur as follows: coordination of the carbonyl oxygen to the 
Chapter 2: Results and Discussion 
107 
Yb(OTf)3 Lewis acid increases the electrophilicity of the carbonyl carbon thereby 
enabling the t-butyl cation to be released.  Subsequently a proton is abstracted from the 
cation by a free (uncoordinated) carboxylate, thereby generating the acid product and 
iso-butene (see Scheme 2.31 above).   
Thus, a solution of 29 in nitromethane was treated with Yb(OTf)3 and heated at 50°C 
for 18 h.  Surprisingly, after work-up (and as already suspected based on TLC 
monitoring of the reaction) the NMR recorded on the crude product afforded showed it 
to be unreacted 29 (73 % recovered).  In our opinion, the reason for this might (again) 
be competition between the acridine N(10)H and the Lewis acid for the carbonyl 
oxygen lone pair(s).  A question one might ask is why the H-bonding here (between 
N(10)H and the ester carbonyl oxygen) would not also, to a degree, catalyse t-butyl 
ester cleavage.  Although it wasn’t investigated, we presume this probably is the case 
and perhaps explains why Beal, when synthesising the acridine-peptide conjugate 
library, chose for the less obvious iso-propyl ester to protect the acridine 4-carboxyl 
group. 
A second procedure which we decided to explore (to cleave the t-butyl ester) was based 
on the work of Strazzolini et al. who had reported efficient cleavage of t-butyl esters 
using H2SO4 in dichloromethane.[220] Thus, the t-butyl-9-benzylaminoacridine-4-
carboxylate 29 was treated accordingly and, after subsequent (partial) work-up, low 
resolution mass spectrometry and NMR analysis was performed on the crude product.  
Although both suggested that the desired carboxylic acid (30) may have been present, it 
was not in a significant amount and other unidentified products were present.  
Unfortunately, attempts to recrystallise 30 (or any of the other products) from the crude 
reaction mixture residue, using e.g. methanol, were unsuccessful.  Presumably, the 
presence of the (acridine and benzyl) aromatic rings made it likely the latter products 
were sulfonated by-products, generated via aromatic electrophilic substitution in and on 
the concentrated sulphuric acid droplets in the (two-phase) emulsion of the sulphuric 
acid in dichloromethane.  However, due to time constraints this was not further 
investigated at the time of the experiment. 
  
Hence, based on our findings and the limited success in generating the 9-benzylamino 
acridine-4-carboxylic acid (30), we decided to abandon the t-butyl ester strategy for 
producing the desired PNA-acridine conjugates and to concentrate our efforts on the 
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iso-propyl route instead.  After all, it had proved possible to cleave the iso-propyl ester 
group, under mildly basic conditions, to afford 30 in a moderate 59% yield. 
 
2.10.7 Step ix: Coupling the PNA monomer 14 or 21 to the activated acridine acid 30  
 
The coupling step was tried in two ways (see Scheme 2.32 below). 
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Scheme 2.32 
 
The first procedure was based on Beal’s protocol (as in Scheme 2.22).[210] In order to 
couple a 9-anilinoacridine-4-carboxylic acid 30 to an oligopeptide, Beal had activated 
the acridine’s 4-carboxyl group as the NHS ester using dicyclohexylcarbodiimide 
(DCC) in the presence of N-hydroxysuccinimide (NHS).  Subsequently, a resin-bound 
oligopeptide had been added to yield the anticipated conjugate in 33% yield after 
cleavage from the solid support.  However, a similar activation of our 9-
benzylaminoacridine-4-carboxylic acid 30 with subsequent addition of the thyminyl-
PNA-monomer (the free base of 21) failed to lead to the desired PNA-acridine 
conjugate 32.  This was not completely unexpected because contrary to Beal’s 
activation of his 9-anilinoacridine-4-carboxylic acid 34 (step v of Scheme 2.22), in our 
attempt to activate the acid 30 as the NHS ester, no solid dicyclohexylurea could be 
observed in the reaction mixture, even after stirring for 48 hours at room temperature.  
Subsequently, the free base of the thyminyl-PNA-monomer 21 was added to the 
reaction mixture.  This was left stirring at room temperature for another 24 h. after 
which the reaction mixture was worked-up.  Purification by flash column 
chromatography did not result in identification of the conjugate 32 in any of the 
collected fractions.  Unclear on why DCC appeared not to be activating the carboxylic 
acid functionality of 30 we decided to use a different peptide coupling agent to see if 
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this would confirm our findings (i.e. the apparent lack of reactivity of the carboxyl 
group). The alternative procedure that we tried involved activation of 30 with HBTU 
(see Scheme 2.33 for mechanism) rather than DCC (based on a procedure for peptide 
bond formation described by Schädel et al.[221]) 
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Scheme 2.33:  general activation mechanism of a carboxylic acid with HBTU and 
subsequent peptide bond formation (Source: Li et al., 2001, [222]). 
 
Thus, a solution of 30 in DMF was treated with HBTU and DIPEA at room temperature 
and left stirring for 24 hours, after which the thyminyl-PNA-monomer (the free base of 
14) was added and the reaction mixture left stirring for another 24 h.  After this time the 
reaction mixture was worked up but after purification by flash chromatography, again 
none of the desired conjugate 32 could be identified.  
 
Without dismissing that successful coupling may still have been compromised by a 
competing cyclization side-reaction, mentioned earlier for the free base of the PNA 
monomer (14 or 21) (Figure 2.9 p. 85), at this point it became clear that possibly the 
alkyl-9-benzylaminoacridine-4-carboxylate intermediate 30 was not compatible with 
Beal’s pathway for producing 9-aminoacridine-4-carboxamides.  In our opinion, the 
problem lay with the basicity of the heterocyclic ring nitrogen N(10) of 9-
aminoacridine.  We reasoned that, with a secondary amine group in the 9-position of 
acridine and with this amine linked to a methylene, the free electron pair of the 
exocyclic nitrogen in 30 only delocalised into the aromatic three-ring system of 
acridine.  This would, in particular, increase the electron density on the heterocyclic 
ring nitrogen N(10) and make it more basic.  This also partially accounted for the 
increased polarity observed on going from 9-oxo-acridans to 9-aminoacridines.  
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In addition to the above, the close proximity of the 4-carboxyl group of the acridine (in 
30) to the ring nitrogen N(10) increased the former’s acidity and lead to the formation 
of a stable internal salt (zwitter ion), as depicted in Figure 2.17 below.  This made the 
4-carboxyl group in 30 less susceptible to activation.  
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_
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+
 
 
Figure 2.17:  two canonical forms of zwitterion 30 
 
 
2.11 Investigating potential electronic effects of acridine’s 9-anilino substituent on 
the acridine’s ring nitrogen N(10) basicity. 
 
The reasons mentioned above suggested that the exocyclic nitrogen of the 9-
aminoacridine needed to be bound to a second moiety (beside the acridine system) 
involved in mesomeric delocalisation of the exocyclic nitrogen lone pair in order to 
allow for activation of the 9-aminoacridine’s 4-carboxyl functionality.   
We therefore decided to investigate the plausibility of this rationale by examining the 
ability of the analogous 9-anilinoacridine-4-carboxylic acid 34 to couple to N,N-
dimethylamino ethylene diamine and then, if successful, the thyminyl-PNA-monomer 
(free base of 14 or 21) to afford 35 and 36 respectively (see Scheme 2.34 below).  
These were just model studies to validate our approach.  Beal had used the acridine acid 
34 for his couplings (see Scheme 2.22) which was why we considered it a worthy 
model to support our ideas and make sure that the thyminyl-PNA-monomer was not a 
barrier to the coupling.  If we were to prepare our PNA-acridine conjugates via this 
strategy we would choose to have a mesomerically withdrawing group attached to the 
9-aminoacridine function that could be removed more easily than the phenyl group 
after coupling to yield the free 1° amino moiety.   
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Scheme 2.34: Synthetic approach in the model study towards generation of 9-
anilinoacridine-4-carboxamides 35 and 36 
 
The latter strategy is explained in detail later after the discussion of our model study 
now following and summarized in Scheme 2.34 above.  
 
2.11.1 Step i: generating the iso-propyl-9-anilinoacridine-4-carboxylate 33 
 
The first step in this pathway involved substitution of the 9-triazolyl substituent of 25 
with aniline, according to Carlson and Beal’s protocol (see Scheme 2.35 below).[210]  
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Scheme 2.35 
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Thus, 25 was treated with aniline to yield 9-anilinoacridine iso-propyl ester 33 in a 
moderate yield (67%) after work-up.  Key features of the 1H-NMR spectrum for 33 
were the disappearance of the triazole proton signals and appearance of the downfield 
signal at δ 11.0-11.4 suggesting that hydrogen bonding was now occurring between the 
ring N(10)H and the side-chain carbonyl oxygen.  Unlike for the previous 9-benzyl 
analogue 28, for 33 none of the signals in the 1H-NMR and 13C-NMR were ‘split’.  A 
likely explanation for this observation would be that for 33, unlike for 28, the Z and E 
isomers (about C(9)=N) interconverted  rapidly on the NMR timescale.  However, 
sterical hindrance between phenyl and acridine aromatic hydrogens made it unlikely 
that either the Z or E isomer were very stable.  Possibly a partial negative charge was 
present on the exocyclic N (and partial positive charge on the ring N(10)), implying a 
degree of rotation for the C9-N bond fast enough, on the NMR timescale, not to 
generate ‘split’ signals. 
 
2.11.2 Step ii: ester hydrolysis of the acridine iso-propyl ester 33. 
 
Again, Beal’s procedure [210] was followed which involved basic aqueous hydrolysis 
of 33 followed by acidification to neutral pH to obtain the 9-anilinoacridine-4-
carboxylic acid 34 (see Scheme 2.36 below).  However, unlike Beal et al., during 
work-up we were not able to successfully separate the LiCl salt by-product from the 
product 34 by re-dissolving the crude reaction mixture residue, afforded after 
evaporation, in chloroform and filtering off the salt impurity.   
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Scheme 2.36 
 
In our hands, the product 34 in the crude reaction mixture only dissolved sparingly in 
chloroform, even after vigorous sonication and use of other more polar solvents (e.g. 
methanol, ethanol).  Due to these purification problems, we therefore decided to take 
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the crude product through to the next stage as it was.  We envisaged that the presence 
of the LiCl salt would not hamper the subsequent reaction.  NMR and mass 
spectrometry analysis suggested that compound 34 was present in the crude reaction 
mixture (ie iso-propyl hydrogen signals had disappeared from the NMR spectrum and a 
LRMS EI spectrum showed the M+ peak for 34 at 100%) 
 
2.11.3 Step iii: coupling N,N-dimethylethylenediamine to the acridine acid 34 
 
Beal’s peptide coupling protocol (as in steps v and vi of Scheme 2.22) was followed 
[210] in which 34 was treated with dicyclohexylcarbodiimide (DCC) and N-
hydroxysuccinimide (NHS) followed by addition of excess N,N-
dimethylethylenediamine (see Scheme 2.37 below).  Subsequent work-up yielded the 
desired product 35 in a moderate 46% yield (over steps ii + iii).   
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Scheme 2.37 
 
As expected, and contrary to our earlier attempt to couple an amine to 9-
benzylaminoacridine-4-carboxylic acid 30 (step ix in Scheme 2.23), after activating the 
acid 34 we did see precipitation of dicyclohexylurea side-product.  This was removed 
by filtration before the N,N-dimethylethylenediamine was added.   
1H-NMR spectrum analysis for 35 suggested the presence of rotamers 35a and 35b.  In 
our opinion this led to the splitting up of the two (exchangeable) proton signals, in a 4/1 
ratio and to a generally broad appearance of the remaining signals in the 1H-NMR 
spectrum for 35.  Admittedly, although providing an interpretation of the 1H-NMR 
spectrum for 35, the above considerations are hypothetical and need further 
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investigation (e.g. crystal structures and further NMR experiments, 2-D NOE and 
variable T, would be appropriate).   
 
2.11.4 Step iv: coupling the PNA monomer 21 to the activated acridine acid 34. 
 
Activation of the acid 34 was done, as in step iii, according to Beal’s procedure,  in 
which a solution of 34 was treated with dicyclohexylcarbodiimide (DCC) and N-
hydroxysuccinimide (NHS) followed by addition of the free base of the thyminyl-PNA-
monomer 21 (see Scheme 2.38 below).  Subsequent work-up yielded the desired 
product 36 in a 64 % yield.  
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Scheme 2.38   
 
1H-NMR analysis suggested the presence of rotamers, presumably due to restricted 
rotation about the tertiary amide bond of the PNA moiety as this also was the case for 
the (t-Boc protected) thyminyl-PNA monomer 13 and the thyminyl-PNA monomer 
ammonium salts 14 and 21.  However, in 36, restricted bond rotations could also occur 
about the 2° amide bond and the C(4)–(2° amide carbonyl carbon)-bond, potentially 
leading to 23 rotamers.  Figure 2.18 below shows four different rotameric isomers 
generated (only) by restricted amide bond rotations. The assignment of the 1H-NMR 
signals for 36 was based on comparison of signals for homologous groups in a similar 
PNA-acridine conjugate (53) for which a number of two-dimensional NMR 
experiments had been done (see later in Scheme 2.51 and subsequent discussion in 
subsection 2.15.1).   
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Figure 2.18: four rotameric isomers of PNA-acridine conjugate 36 in random 
conformations (amide bonds with restricted rotation are shown in bold) 
 
From these 2-D experiments a more complete assignment of multiple (rotamer) signals 
to specific protons was possible.  Thus, based on our one-dimensional 1H-NMR 
analysis for the PNA-acridine conjugate 36 three rotameric isomers appeared to be 
present but little more could be said about the exact conformation of these rotamers.  
Most important was that we had shown in this experiment that it was possible to link 
the thyminyl-PNA-monomer 21 to the activated acid 34 and a potential PNA-monomer 
cyclization side-reaction was certainly not a barrier to the coupling step under reaction 
conditions applied for generating the PNA-acridine conjugate 36.  
 
This work on the 9-anilinoacridine models therefore verified our proposal that Beal’s 
procedure for activation of the 4-carboxyl functionality and subsequent generation of 
the 4-carboxamide group worked well providing that the acridine’s 9-amino free 
electron pair was involved in resonance delocalisation outside of the acridine system, 
thereby lowering the ring nitrogen’s N(10) basicity.  As this was not the case with a 
benzylamino substituent in the acridine’s 9-position we decided to investigate the 
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potential of replacing this 9-benzylamino group with alternative 9-substituents.  These 
substituents should allow for activation of the acridine’s 4-carboxylic function but 
subsequently also allow generating the required primary 9-amino functionality at the 
end of the synthesis.  We thus reasoned that if the primary 9-amino functionality could 
be prepared first then the 4-alkyl ester group could be hydrolysed and the generated 
acid could be activated followed by the peptide coupling step and 9-amino 
deprotection.   This strategy will be discussed in detail in the following section.  As the 
strategy uses Beal’s chemistry, regarding conversions of the acridine’s 4-substituent, 
and our own approach regarding protection of the 9-amino substituent to enable 
selective peptide coupling in the 4-position, it is referred to as the ‘revised Beal route’.   
 
2.12 The ‘revised Beal Route’ 
 
Scheme 2.39 (below) shows a general outline of the ‘revised Beal route’ and partially 
recapitulates the initial ‘Beal route’.  It also shows the ‘Beal route’ compounds that 
were used to develop the ‘revised Beal route’.  So far, in the initial ‘Beal route’ we had 
come to the conclusion that the acridine ring required a 9-amino substituent, different 
from 9-benzylamino (as in 28 and 30 in Scheme 2.39), for which nitrogen’s free 
electron pair was not only in conjugation with the aromatic acridine moiety but 
conjugation would extend outside of the acridine rings. 
Thus for the ‘revised Beal route’ we decided to investigate the potential of 
converting/protecting the primary 9-amino substituent of the acridine ring (as in 40 and 
44 in Scheme 2.39) to a number of urethane derivatives (by attaching 
benzyloxycarbonyl-, tertiary-butyloxycarbonyl- or allyloxycarbonyl-protection groups). 
We were hopeful that the presence of such a protected 9-amino substituent would allow 
for activation of the carboxyl functionality (towards a peptide coupling step) in the 4- 
position of the acridine ring, further down the synthetic route.  It was hypothesised 
earlier that activation of the 4-carboxylic acid of the acridine was not occurring due to 
the ring N(10) basicity being too high.  We had reasoned the latter was caused by 
unidirectional delocalisation of the lone electron pair of the exocyclic nitrogen of the 9-
aminoacridine onto the ring nitrogen N10 of the acridine.   
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Scheme 2.39: Using ‘Beal route’ intermediates as precursors to alkyl-9-NH2-acridine 
carboxylates 40 and 44 (boxed) in the ‘revised Beal route’  
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In the ‘revised Beal route’ a urethane moiety in the acridine 9 position would serve both 
requirements of extended conjugation of the lone electron pair of the exocyclic nitrogen 
and allowing generation of the primary 9-amino substituent by deprotecting the latter at 
the end of the synthesis.  
In order to establish urethane-based substituents we intended to establish first a primary 
9-amino substituent on the acridine ring followed by the relevant 9-amino protection 
step.  In Scheme 2.39 above, the focus is on the use of ‘Beal route’ intermediates (2, 
22, 24, 25 and 28) in order to get to the alkyl-9-NH2-acridine carboxylates 44 and 40 
(boxed).   Each of these reactions (Steps viii, ix, x, xi, xii and xiii in Scheme 2.39) will 
now be discussed in more detail in section 2.13 below.  The subsequent steps in the 
‘revised Beal route’ also outlined in Scheme 2.39 and starting with the 9-NH2-bearing 
intermediates 40 and 44, will be discussed thereafter in more detail in a new section. 
 
2.13 Synthesis of the alkyl-9-NH2-acridine-4-carboxylates 40 and 44 in the ‘revised 
Beal route’ (as in Scheme 2.39) 
 
2.13.1 Step viii: Hydrogenolysis of iso-propyl-9-benzylamino-4-carboxylate 28 
 
Although the use of 28 for synthesis of 40 seemed an unnecessary detour, because the 
triazolylated precursor 25 (of 28) was activated for substitution with N-nucleophiles in 
the 9-position and a primary amino functionality might be established directly (as in 
step x in Scheme 2.39), we considered this an interesting experiment as we had already 
synthesised 28 and wanted to investigate hydrogenolysis of the benzylamino group on 
28 (see Scheme 2.40 below).   
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viii
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Scheme 2.40 
 
Thus, a palladium-catalysed hydrogenolysis of the (exocyclic) NH-C bond was 
undertaken according a procedure described by Naylor et al.[223], in which 28 was 
subjected to a H2 atmosphere (balloon) in the presence of the palladium catalyst. 
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After work-up the desired product was afforded in an 18% yield and 65 % of starting 
material 28 was recovered.  This was not unexpected as TLC monitoring already had 
indicated only partial conversion of the starting material but because several by-
products were appearing it was decided to proceed to work-up to determine whether 
and to what extent the desired product 40 had been formed.  Due to time constraints and 
because it was more desirable to find a more direct way to establish the (1°) 9-amino 
functionality, it was decided not to investigate at this stage whether changes to reaction 
conditions (e.g. higher pressure and/or higher reaction T) would lead to better yields 
and/or shorter reaction times (which had been > 96 h. in this experiment). 
 
2.13.2 Steps ix: converting the triazolyl-substituent in 24 and 25 to a primary amino 
group in 44 and 40 respectively. 
 
The esters 24 and 25 had been synthesised earlier in the ‘Beal route’ (Steps v in 
Scheme 2.23) and their 9-triazolyl group primed these compounds for substitution with 
N-nucleophiles in the 9-position.  For this reason we decided to investigate whether the 
triazolylated ‘Beal route’ intermediates 24 and 25 were susceptible to substitution with 
ammonia (see Scheme 2.41 below).  We chose reaction conditions based on Beal’s 
procedure for converting the iso-propyl ester 25 to the 9-anilino substituted derivative 
33 (see step iii in Scheme 2.22) in which Beal heated 25 to reflux in the presence of 
aniline. [210].   
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Scheme 2.41 
 
Thus, in our experiment, anhydrous gaseous ammonia was bubbled through separate 
solutions of the esters 24 and 25 in acetonitrile/dimethylformamide (1/1) while heating 
to up to 100°C.  Post work-up, the starting materials 24 and 25 were recovered in their 
respective experiments at 13% and 68% and for both experiments a number of 
unidentified by-products were observed.  Identification of the latter was severely 
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hindered by their tendency to coelute in column chromatography and their reluctancy to 
recrystallise in different solvent(s) (combinations), e.g. methanol/diethyl ether, 
acetone/diethyl ether or chloroform/toluene.  Although we did not obtain unambiguous 
evidence, probably some amide formation had taken place, particularly for the least 
sterically hindered methyl ester 24. 
Overall, we could conclude that for step ix (in Scheme 2.41  above) the problem was 
that at the reaction temperature of around 100°C by-products started to appear before 
the desired substitution had taken place to any significant extent.  In the earlier 
discussed step vi of the ‘Beal route’ (see Scheme 2.23), substitution of the 9-triazolyl 
with benzylamine had required 24 hours reaction time at reflux temperature of 81°C in 
acetonitrile. In step ix (in Scheme 2.41 above) we had hoped that using 
acetonitrile/dimethylformamide (1/1), which  allowed for a higher reaction temperature 
(100°C), would shorten necessary reaction times but this unfortunately resulted in 
(unidentified) by-product formation rather than faster formation of the desired products 
40 or 44.  
The reason we wanted to reduce reaction times in step ix was to avoid the wasteful 
character of bubbling ammonia for 24 hours suggested in Beal’s protocol to be 
necessary to substitute the 9-triazolyl substituent.  However, because none of the 
desired products 40 or 44 could be identified and due to the fact the reaction set-up was 
cumbersome, wasteful and by-products had formed we decided no longer to consider 
this reaction as a potential intermediate step in the over-all pathway.   
 
2.13.3 Step x: converting the triazolyl-substituent in 25 to an -NH2 group in 40 
 
Another way of substituting the triazolyl group in 25 with a primary amino group was 
inspired by Kamaike et al.[224] They reported in 1995 that the nitrotriazolyl group in 
4-(3’-nitrotriazol-1’-yl)-1-β-D-ribofuranosylpyrimidine-2(1H)-one (10’) could be 
substituted with phthalimide in the presence of triethylamine, generating 11’ in Scheme 
2.42 (below).  In the latter scheme subsequently the phthalimide group of 11’ was 
unmasked to yield the primary amino functionality in 12’, by treatment with 
H2O/pyridine for 1 hour. Inspired by these reactions we wanted to investigate if similar 
conversions could take place for our triazolylated starting material 25.   
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Scheme 2.42: primary amine generation via triazole substitution (according to Kamaike 
et al.)[224] 
 
Hence, a solution of tetrachlorophthalimide in DMF was deprotonated with 
triethylamine and added to a solution, in DMF, of iso-propyl-9-(1,2,4-triazol-1-
yl)acridine-4-carboxylate (25)(see Scheme 2.43 below).  
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Scheme 2.43 
 
For the conversion of Kamaike’s compound 10’ to compound 11’ in the above Scheme 
2.42 Kamaike et al. had reported 24 hours of reaction time at room temperature. 
However, for step xa (substitution of the triazolyl group in 25 with a N-3,4,5,6-
tetrachlorophtaloyl group), post work-up NMR-analysis of the active (chromatography) 
fractions suggested only starting material 25 was present in significant amounts.  This 
was not a surprising outcome as our triazole substituent clearly would be not as good a 
leaving group as the 3-nitrotriazolyl substituent in Kamaike’s experiment (due to both –
I and –M effects of the nitro-group).  In addition, the tetrachlorophthalimide we used 
would be a worse nucleophile, due to the –I effect of the chloro substituents, compared 
to the phthalimide used by Kamaike.  Admittedly, the lack of reactivity in our reaction 
xa in Scheme 2.43  above was expected, but we still considered it a worthwhile 
experiment as it was simple, tetrachlorophtalimide was readily available and if 
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successful (even in low yields), this meant the earlier prepared starting material 25 (for 
the unsuccessful Beal route) was still useful.  
 
So far, unfortunately, attempts to generate a primary amino group in the 9-position of 
the acridine ring by substitution in the 9-triazolylated intermediates 24 and 25 or 
hydrogenolysis of the 9-benzylamino-bearing intermediate 28 had been unsuccessful.  
Thus, we decided to focus on earlier ‘Beal route’ intermediates 2 and 22 (see Scheme 
2.39) and use some of the earlier chemistry described by Denny to activate the 9-oxo 
functionality of 2 and 22 towards substitution in the acridine ring 9-position.  These 
reactions are discussed below. 
 
2.13.4 Steps xi: converting the 9-oxo group in 2 and 22 into a 9-chloro group in 43 
and 42 respectively. 
 
Substitution of a 9-oxo-functionality (as in 2 and 22 in Scheme 2.44 below) with a 
chloro-group had been demonstrated before by Denny in the synthesis of 9-NH2-DACA 
(see step v in Scheme 2.3).[186] Denny had treated 9-oxoacridine-4-carboxylic acid 3 
with thionyl chloride (used as solvent and reagent) to synthesise 9-chloroacridine-4-
carbonyl chloride 4.  Thus, in 4 both the 9-position and the 4-carbonyl had become 
activated towards substitution.  This had allowed Denny to subsequently generate the 4-
carboxamide side-chain and the primary 9-NH2 group in 9-NH2-DACA (see steps vi 
and vii in Scheme 2.3).   
 
N
H
O O
R
O
N
O O
Cl
R
Reagents and conditions xi :   SOCl2, DMFcat; rt  
  2  R = Me
22  R= iPr
xi
43  R = Me
42  R= iPr
(98% for 2)
(97% for 22)
 
Scheme 2.44 
 
In step xi, in Scheme 2.44, only the 9-oxo/9-hydroxy was susceptible towards 
conversion to the 9-chloro group and if successful this would afford the desired 
intermediates 42 and 43.  Thus, according to Denny’s procedure, thionyl chloride was 
used as solvent and reagent for the substrates 2 and 22, which afforded the respective 
products in high yields (98% for 43 and 97% for 42).  Key feature in the NMR-spectra 
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analyses of the crude reaction mixtures of compounds 42 and 43 was the lack of the 
high value (downfield) N(10)H signal at respectively 11.60 and 11.71 ppm due to the 
lack of  intramolecular H-bonding in 42 and 43.  The latter would be used directly in 
the following 9-chloro substitution steps xii and xiii of the ‘revised Beal route’, without 
further purification.  
 
2.13.5 Steps xii and xiii: converting the 9-chloro substituent in 42 and 43 into the 9-
NH2 substituent in 40 and 44 respectively. 
 
In Denny’s 9-NH2-DACA (6) synthesis, 9-amino DACA 6 was formed from the 9-
chloro-DACA (5) by treatment with anhydrous gaseous NH3 in phenol at reflux (see 
step vii in Scheme 2.3).[186] In our revised Beal route methyl-9-aminoacridine-4-
carboxylate 43 was treated accordingly (see step xiii in Scheme 2.45 below) 
 
N
O O
NH2
R
N
O O
Cl
R
 xiii:  a) Phenol; heat  b) NH3; heat
 
Reagents and conditions
 xii:   a) Phenol; heat  b) NH4HCO3; heat  
xii (81% for 42 and 61% 43)
xiii (39% for 43)
44 R= Me
40 R= iPr
43 R= Me
42 R= iPr
9
 
Scheme 2.45 
 
However, as TLC monitoring suggested substantial conversion of starting material into 
more than one product we proceeded to work-up prior to complete conversion of the 
starting material 43.  Subsequent NMR analysis of (chromatography derived) active 
fractions containing the major product suggested it was the desired 44, which was 
obtained in a modest 39% yield.   Unambiguous identification of side products was 
complicated due to partial (chromatographic) coelution of the latter, but some 1°-amide 
formation (via methyl ester aminolysis) was likely to have taken place.   A key feature 
in the 1H-NMR spectrum of 44 was the reappearance of the high value (downfield) 
signal for the intramolecular H-bonded N(10)H at 10.95 ppm. The yield for 44 was 
considerably lower (39%) than for Denny’s conversion of the 9-chloro group, in 5, to a 
primary amino group in 9-NH2-DACA 6 (59% yield, see step vii in Scheme 2.3).  The 
lower yield and the longer reaction time required (2 hours compared to 20 minutes for 
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Denny’s 9-NH2-DACA 6) might have been due to the absence of the 2° carboxamide 
functionality at the acridine’s 4-position in our starting material 43 but which was 
present in 9-chloro-DACA 5. This meant that in 43 no hydrogen bonding was possible 
involving the ring nitrogen N(10) and the carboxamide side-chain hydrogen (see 
Figure 2.19 below).  
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Figure 2.19:  due to N10 hydrogen bonding in compound 5 the 9-chloro substituent is 
more susceptible to substitution than in compound 43.  
 
This potentially left the C(9) in 43 less susceptible to nucleophilic substitution than that 
in 5, where the acridine ring nitrogen N10 carried a partial positive charge due to the 
intramolecular H-bonding.   
In order to find a higher yielding reaction to substitute the 9-chloro group in 43 with a 
primary amino group, we tested a protocol designed for this purpose by Albert and 
Ritchie in which they used (NH4)2CO3 instead of ammonia for the 9-chloro substitution 
of several multi-substituted 9-chloroacridines.[225](See also Scheme 2.45 above) TLC 
monitoring suggested substantial conversion of the starting material 43 with some by-
product formation (likely to be 1° amide formation in the acridine 4-position). 
Subsequent MS and NMR analysis confirmed presence and structure of the desired 
product 44, which now was obtained in an improved but moderate 61% yield.  
 
The iso-propyl-9-chloroacridine-4-carboxylate 42 was converted to the 9-NH2-bearing 
product 40 according the same procedure used for conversion of 43 (above) and as 
described by Albert and Ritchie.[225] (See Scheme 2.45 above) TLC monitoring 
suggested substantial conversion of the starting material 42 with again some by-
products starting to appear.  Post work-up microanalysis and NMR analysis confirmed 
respectively the purity and structure of the desired product 40, which was obtained in 
an 81% yield. 
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So far, our attempts to establish a primary amino group in the acridine’s 9-position had 
been ‘most’ successful via the activated alkyl-9-chloroacridine-4-carboxylate ‘Beal 
route’ intermediates 42 and 43.  The recorded yields for subsequent substitution in the 
9-position with a primary 9-NH2 group using NH4HCO3 (in step xii of the ‘revised Beal 
route’, Scheme 2.39) were an improvement (61% for 44 and 81% for 40) compared to 
the use of NH3 for this purpose in step xiii (39 % yield for 44). Noteworthy in steps xii 
and xiii was that the methyl ester group in 43 had stayed largely intact after treatment 
with ammonia or ammonia-generating NH4HCO3, although formation of the 
carboxamide by-product probably explains the lower yields (39% and 61%) for the 
methyl ester 44 compared to 81% for the more robust iso-propyl ester 40.  
Unclear as to why the use of NH4HCO3 (instead of gaseous NH3) made a difference 
yield-wise, one obvious physical difference between the experiments was the presence 
of solid NH4HCO3, in the phenol solution, which may have led to higher localised NH3 
activity at the solid/liquid interface. A possible reaction mechanism for these 9-
chloro→9-amino substitutions with ammonia in phenol was discussed earlier in 
subsection 2.4.5. 
 
Thus, having established our goal of synthesising the alkyl-9-NH2-acridine-4-
carboxylates 40 and 44 we subsequently focused our efforts on the next step in the 
‘revised Beal route’ in Scheme 2.39.  This will be discussed in the following section. 
 
2.14  Carbamate NH2-protection of alkyl-9-aminoacridine-4-carboxylates (44, 40) 
in the ‘revised Beal route’ 
  
The next step in the ‘revised Beal route’ (Scheme 2.39) involved protection of the 
primary 9-amino functionality of compounds 44 and 40.  As mentioned earlier this 
would be accomplished by utilisation of carbamate protecting groups for the amino 
group in the 9-position. The reasons for using carbamate protection were fourfold: the 
exocyclic nitrogen’s free electron pair would be involved in resonance delocalisation 
outside of the acridine ring system, we could choose the carbamates designed to 
withstand the basic hydrolysis conditions of the subsequent ester hydrolysis step in the 
revised Beal route,  in the following step in the ‘revised Beal route’ the acridine’s 
primary 9-amino group would be prevented from interfering in the peptide coupling 
between the activated acridine acid and the PNA and finally, the carbamate moieties 
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could be readily removed at the end of the synthesis thereby liberating the acridine’s 
primary 9-amino functionality (see Scheme 2.39).  Hence, in what follows we discuss 
how appropriate urethane-based 9-amino protection was established for both methyl-9-
aminoacridine-4-carboxylate 44 and iso-propyl-9-aminoacridine-4-carboxylate 40.  
However, because the iso-propyl ester group was established earlier by conversion of 
the 9-oxo-bearing methyl ester 2 into the 9-oxo-bearing iso-propyl ester 22 (see step iii 
in Scheme 2.23) but the overall yield for the 9-amino-bearing iso-propyl ester 40 was 
very similar to the overall yield for 9-amino-bearing methyl ester 44, it was deemed the 
methyl ester 44 would be the most appropriate for further use because the extra 
synthetic step for generating the iso-propyl ester 40 could be omitted.  Additionally, the 
methyl ester cleavage of 44 would take less time than the iso-propyl cleavage of 40 (i.e. 
45 mins for 44 vs. 24 h. for 40, in ~ 0.2 M LiOH (aq)).  Originally, in the ‘Beal route’, 
the iso-propyl group was put in place to prevent carboxamide formation in the 
acridine’s 4-position when substituting the 9-triazolyl substituent with an amine (as e.g. 
in step iii in Scheme 2.22). In the ‘revised Beal route’ this probably led to higher yields 
(in step xii of Scheme 2.39) for the 9-amino-bearing iso-propyl ester 40 (81%) 
compared to only 61% yield for the less bulky 9-amino-bearing methyl ester 44 but this 
advantage was balanced out by the (only) 77% yield for synthesis of the iso-propyl 
ester 22 (using the methyl ester 2 as starting material), in the first place (see step iii in 
Scheme 2.23). 
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iii  (unsuccessful for 45)
iv  (37% for 45)
v  (43% for 47)
vi  (33% for 48)
 
 
Scheme 2.46: protecting the primary amino group of the alkyl-9-aminoacridine-4-
carboxylates 44 and 40. 
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We chose to investigate three different carbamate protection groups for the 9-amino 
group of methyl ester 44 i.e. t-butyloxycarbonyl (t-Boc), benzyloxycarbonyl (Cbz) and 
allyloxycarbonyl (Alloc) and one for the 9-amino group of the iso-propyl ester 40 i.e. t-
butyloxycarbonyl (t-Boc) (see Scheme 2.46 above). 
These protection groups were chosen for no other reason than that they complied with 
the requirements described above and we intended to compare the three different 
carbamate protection groups and identify the highest yielding option. 
All three carbamates were stable under basic conditions.[226] This would be necessary 
to survive the subsequent ester cleavage in basic aqueous conditions. At the end of the 
synthesis we would then be able to remove the t-Boc and Cbz carbamate protection 
groups respectively under mild acidic aqueous conditions and under stronger acidic 
conditions, while removal of the Alloc protection group would require Pd(0) under 
neutral conditions.[226] 
In Scheme 2.46 above we summarize the reactions undertaken to establish the relevant 
carbamate protection groups.  Each reaction is now discussed separately. 
 
2.14.1 Steps i and ii: t-Boc protection of iso-propyl-9-aminoacridine-4-carboxylate 
(40). 
 
According the procedure described by Finn et al.[202] for t-Boc-protection of amines 
(also applied earlier in step i in Scheme 2.12 for protection of 3-amino-1,2-propanediol 
4), intermediate 40 was treated with di-t-butyl dicarboxylate in order to generate the t-
Boc carbamate in the 9-position of the acridine (see step i in Scheme 2.47 below). 
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Scheme 2.47 
 
TLC monitoring of the reaction mixture suggested little conversion had taken place and 
subsequent post work-up 1H- and 13C-NMR analysis of the resulting solid suggested 
presence of starting material 40 only. 
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The likely reason for failure in this step was that di-t-butyl dicarboxylate was a fairly 
weak, sterically hindered electrophile which does not react well with sterically hindered 
arylamines. 
 
Because, for 40, we couldn’t increase the nucleophilicity of the (sterically hindered) 9-
amino/imino group we decided to increase the reactivity of the electrophile in order to 
put the 9-amino carbamate protection group in place.  We envisaged this could be 
accomplished by using a procedure, described by Adebambo et al. [227], in which 
phosgene had reacted with the amino group of t-butyl (2-amino-6-chloro-9H-purin-9-
yl)acetate (13’ in Scheme 2.48) to form the isocyanate intermediate that subsequently 
reacted with benzyl alcohol to establish the Cbz protection in 14’ (80% yield) (see 
Scheme 2.48). Thus, based on Adebambo’s procedure, in step ii (see Scheme 2.47 
above) our compound 40 was treated initially with triphosgene in order to generate the 
isocyanate bearing intermediate.  
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Reagents and conditions: 1) triphosgene, TEA; THF; heat 2) Benzyl alcohol; heat
13' 14'
(80%)
 
 
Scheme 2.48: Cbz carbamate protection of the primary amino group in 13’ using 
trisphosgene and benzyl alcohol (according to Adebambo et al.)[227] 
 
TLC monitoring of this reaction suggested substantial but incomplete conversion of 
starting material 40 into at least 2 products.  For this reason we proceeded to the next 
step in which the presumed isocyanate intermediate was treated with t-butanol to 
generate the carbamate protected iso-propyl-9-t-butyloxycarbonylaminoacridine-4-
carboxylate (46). Subsequent work-up afforded the desired title compound 46 in 
moderate yield (0.14 g, 41 %).  Key feature of the 1H-NMR spectrum of 46 was the 
appearance of the t-Boc signal at 1.56 ppm. The 1H-NMR analysis also showed the 
downfield chemical shift value δ 11.56 which was assigned to the ring N(10)H and 
indicative of a predominant 9-imino tautomer for the product 46.  The low yield (41%) 
was not unexpected as step ii in Scheme 2.47 (above) was far from being 
chemoselective for the desired product but this, we found, was the price to be paid for 
protecting the sterically hindered 9-NH2 group in 40. 
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Figure 2.20: potential by-products formed during t-Boc protection of iso-propyl-9-
aminoacridine-4-carboxylate (40), according a procedure described by Adebambo et 
al.[227] 
 
Regarding by-product formation, besides generating a 9-NCO group, phosgene was 
also likely to react with the more sterically hindered but more basic ring N(10) leading 
to a reactive intermediate that would react further with available nucleophiles like the 
starting material 40 or the t-butanol, or even Intramolecular (See Figure 2.20 above).  
The chromatographic purification during work-up had yielded a number of unidentified 
co-eluting impurities (to a small extent with the product 46) that however, due to the 
co-elution and reluctancy to be purified via repeated recrystallisation attempts, could 
not unambiguously be identified as the above suggested by-products. In addition, time 
constraints prompted us to focus on proceeding with the intended products rather than 
pursuing complete purification and characterization of by-products. 
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2.14.2 Steps iii and iv: Cbz protection of the primary 9-amino group of 44. 
 
Initially, in step iii (see Scheme 2.49 below) we attempted to protect the 9-amino group 
of 44 by treating it with benzyl chloroformate, according a procedure described by 
Dueholm et al. for the NH2-protection of cytosine.[228]  
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 iii:  Benzyl chloroformate; pyridine; heat
                              OR
 iv:  1) Phosgene, TEA; o-DCB; heat  2) Benzyl alcohol; o-DCB; heat
                                   
 
iii (unsuccessful)
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Scheme 2.49 
 
TLC monitoring of the reaction suggested little conversion was taking place and this 
was confirmed by post work-up NMR analysis of collected fractions which suggested 
nothing more than starting material 44 was present (95% of 44 was recovered).  The 
likely reason for this was similar to the one discussed earlier (in step i of Scheme 2.47) 
i.e. the 9-imino group of the predominant tautomer of 44 was sterically too hindered to 
substitute the chloride in benzyl chloroformate. 
For this reason, in step iv (see Scheme 2.49) we anticipated we could successfully use 
the phosgene method, as reported by Adebambo et al.,[227] to establish the carbamate 
protection for the 9-amino group of 44 as this method had successfully solved the same 
problem for 40 in step ii (as discussed earlier in 2.14.1). 
TLC monitoring of the reaction (in step iv of Scheme 2.49) suggested little change took 
place but based on our earlier experience it was decided to work-up the reaction 
mixture which did afford the title compound 45, however contaminated with a small 
amount of a co-eluted impurity.  Hence, crude 45 was recrystallised and this afforded 
the pure compound 45 as orange crystals in a very moderate 37 %.  The reason for the 
low yield again being the low chemoselectivity for the desired product under the 
described reaction conditions leading to formation of several potential by-products 
(presumably of the sort described earlier in Figure 2.20).  Chromatographic 
purification during work-up had yielded a number of co-eluting impurities that could 
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not unambiguously be identified as the type of by-products suggested earlier (in Figure 
2.20) due to the co-elution and their reluctancy to be purified via repeated 
recrystallisation attempts.  Also, time constraints prompted us to focus on proceeding 
with the obtained intended product. 
 
An X-ray crystal structure was obtained for 45, which confirmed the presumed 
predominance of the imino tautomer for 45 (as presumed for the starting material 44) 
and in it the H-bond between the ring N(10)H and the methyl ester carbonyl oxygen. 
Key bond distance and torsion angle values obtained from the crystal data experiment 
(See  appendix) were: 129 pm for C(12)-N(2) (indicating a double bond and confirming 
the 9-iminoacridane was the crystallised tautomer for 45) and a torsion angle of 1.7° for 
C(5)-C(4)-C(14)-O(1) which brought the H…..O distance in N(1)-H(1)…..O(1) to193 pm, 
which was within the typical H-bond distance range (see Figure 2.21 for the X-ray 
structure of 45).   
.  
 
Figure 2.21: X-ray structure of Methyl-9-benzyloxycarbonylaminoacridine-4-
carboxylate (45). 
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2.14.3 Steps v and vi: t-Boc- and Alloc-protection of the primary 9-amino group of 
44. 
 
For the t-Boc- and Alloc-protection of methyl-9-aminoacridine-4-carboxylate (44) the 
phosgene method according to Adebambo et al. was applied again [227] (see Scheme 
2.50 below).  
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Scheme 2.50 
 
The above procedure afforded the t-Boc protected compound 47 (step v) in a modest 
43% yield and the Alloc-protected compound 48 (step vi) in a modest 33% yield.  As in 
step earlier steps, TLC analysis in both Steps v and vi also suggested presence of a 
number of unidentified co-eluting by-products/impurities, which could not be identified 
unambiguously due to their reluctance to be resolved by column chromatography or 
purified by repeated crystallisation attempts.  
 
So far, our attempts to protect the primary 9-amino group of methyl-9-aminoacridine-4-
carboxylate 44 and iso-propyl-9-aminoacridine-4-carboxylate 40, by converting the 
group into a carbamate, had succeeded although yields were moderate, presumably due 
to the low chemoselectivity for the intended products under the applied reaction 
conditions.  t-Boc-, Alloc- and Cbz-protections of 44 (the methyl ester) were 
established in respective yields of 43% for 47, 33% for 48 and 37% for 45.  t-Boc-
protection of 40 (the iso-propyl ester) was established in a 41% yield for 46.  Now that 
the primary 9-amino functionality was appropriately protected we subsequently focused 
our efforts on the next steps in the ‘revised Beal route’ in Scheme 2.39.  This will be 
discussed in the following section.  
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2.15 Methyl ester cleavage and subsequent acid activation of acridine 
intermediates 45, 47 and 48 towards coupling with a PNA monomer (as part of the 
‘revised Beal route’). 
 
In the revised Beal route the methyl ester group of compounds 45, 47 and 48 now 
needed to be hydrolyzed to in order to free the acridine’s 4-carboxylic acid group so 
that it could be activated to enable the peptide coupling step with a PNA.  The 
chemistry applied to accomplish this was based on similar synthetic steps in Beal’s 
successful approach in his development of an acridine-peptide library (see Steps iv and 
v in Scheme 2.22).  In step iv of Scheme 2.22 Beal had treated iso-propyl-9-
anilinoacridine (33 in Scheme 2.22) with aqueous LiOH followed by neutralisation 
with aqueous hydrochloric acid after which he was able to separate LiCl salts from the 
product 9-anilinoacridine-4-carboxylic acid (34 in Scheme 2.22, 99% yield) by 
redissolving the solid residue (obtained after first solvent evaporation) in chloroform 
and filtering the suspension.  Subsequently Beal activated the 9-anilinoacridine-4-
carboxylic acid 34 by converting it to the N-hydroxysuccinimide (NHS) ester.  The 
obtained crude NHS activated acid 34 was used in the following peptide coupling step 
with resin-bound tripeptides (see step vi in Scheme 2.22).  Yield over the two steps 
(based on the acid 34) was 33%.  For our own compounds 45, 47 and 48 analogous 
conversions as described above are summarized below in Scheme 2.51 which are 
subsequently discussed in more detail and compared to Beal’s results.  
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for R=Cbz (45, 49, 52) (unsuccessful)
for R=Alloc (48, 51, 54) (yield over i+ii, 51%) 
 
 
Scheme 2.51: Linking the thyminyl-PNA-monomer to the N-hydroxysuccinimide 
activated acridine acids. 
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2.15.1 Steps i and ii: acid generation and activation for the t-Boc-protected 9-
aminoacridine intermediate 47 and subsequent linking to a PNA monomer. 
 
To generate the acid 50 from the methyl ester 47 the latter was cleaved under basic 
aqueous conditions according to the procedure described by Beal (See Scheme 2.52 
below).[210] TLC monitoring suggested complete conversion of the starting material 
47.   
N
H
O O
N
O
O
N
O O
NH
H
O
O
O
NH
O
O
N
H
N
O
N
N
H
O
O
OO
N
 47 50
i
+
_
ii
53
Reagents and conditions:
 i: 1) Aqueous LiOH 0.2 M;THF; 0°C to  rt  2) Aqueo us HCl 0.5 M; rt
ii: 1) DCC, N-OH succinimide; DMF; rt  2) PNA monomer salt 21, TEA; DMF; rt
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Scheme 2.52 
 
In the work-up, unlike in Beal’s procedure, we were not able to separate the LiCl salts 
from the product by redissolving the reaction residue and subsequently filtering off the 
solid salt residue.  We therefore decided to take the crude product 50 through to the 
next stage as we didn’t expect the LiCl salt would hamper the following reaction in step 
ii (Scheme 2.52). 
Thus, a solution of the crude compound 50 was treated with N-hydroxysuccinimide and 
dicyclohexylcarbodiimide (according to Beal’s procedure) after which the 
dicyclohexylurea by-product was removed (by filtration) and the N-(aminoethyl)-N-
(thymin-1-ylacetyl) glycine ethyl ester 21 was added to generate the desired conjugate 
53. Subsequent work-up afforded the title compound 53 in a modest 24% over both 
Steps i and ii (based on starting material 47) 
Analysis of 1-D and 2-D NMR experiments showed rotamer presence, due to restricted 
rotation about the tertiary amide bond.  While the presence of rotamers complicated 
unambiguous interpretation of the 1-D spectrum, the 2-D NMR experiments allowed 
for a more precise assignment of chemical shifts.  In addition, comparison of signals 
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recorded in literature [202] and by ourselves, for the (unconjugated) PNA-monomer 13, 
was also helpful in assigning the signals of the corresponding protons in 53.  Initially, a 
ROESY (Rotational Overhauser Effect SpectroscopY) spectrum of 53 (see Figure 
2.23) allowed us to identify the rotamer generated signals, i.e. chemical shifts 
connected by off-diagonal negative (red) peaks indicating chemical exchange, and it 
allowed us to observe NOE contacts, i.e. chemical shifts connected by off-diagonal 
positive (black) peaks between protons (nearby in space) of different parts of 
compound 53, in different rotameric conformations.  Subsequently, in order to identify 
the relevant rotameric conformations and to determine their relative stabilities we had 
to assign the NMR peaks correctly.  For this, other 2-D NMR experiments, HSQC 
(Heteronuclear Single Quantum Coherence, see Figure 2.24) and HMBC (Hetero-
nuclear Multiple Bond Coherence, see Figure 2.25), were useful because direct C-H 
coupling (HSQC) and longer range coupling (2-4 bonds in HMBC) was recorded.  
Thus, a first correct assignment of a chemical shift to a (group of) proton(s) in the 
HSQC experiment subsequently allowed, in the HMBC experiment, to deduce 
assignments for nearby protons, because in the long range coupling between the 
initially assigned proton(s) and nearby carbons, the latter in turn each showed different 
(additional) couplings to other (nearby) protons.  Via trial and error, assignments (for 
both C and H) could thus be made systematically and this lead to a better assignment of 
the majority of NMR peaks for both C and H.  Assignments of aromatic protons and 
quaternary carbons were more problematic because not all ambiguities could be 
eliminated via this deduction method.  A discussion of how the 2-D NMR experiments 
helped in assignment of certain NMR peaks, rotamer ratio determination and rotamer 
stability follows below.  For this purpose a (randomly) C-atom labelled representation 
of the PNA-acridine conjugate 53 is depicted in Figure 2.22 below.   
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Figure 2.22:  C-labelled representation of the PNA-acridine conjugate 53 
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In the NMR spectra one of the ‘split’ rotamer signals was assigned to the thymine 
methyl protons (C(29)H3 in Figure 2.22).  In the 1-D 1H-NMR spectrum the 
corresponding chemical shifts were at 1.10/1.69 ppm (in a 4/1 ratio).  We believed this 
assignment to be correct because in the ROESY spectrum the two thymine methyl 
shifts at 1.10/1.69 ppm were connected by chemical exchange peaks and showed NOE 
interactions with the split signal for the thymine C(27)H at 6.07/6.83 ppm (in a 4/1 
ratio) (See Figure 2.23 below for ROESY spectrum).   
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Figure 2.23: ROESY spectrum for 53 indicating chemical exchange and NOE 
interaction cross peaks. 
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Figure 2.24: HSQC spectrum for 53 showing direct C-H coupling (the unassigned 
peaks between 120 and 140 ppm on the C-axis are aromatic tertiary carbons, 
Q=quaternary carbon) 
 
The split thymine C(27)H signals at 6.07/6.83 ppm also were connected  by chemical 
exchange peaks in the ROESY spectrum which proved their identical (rotameric) 
origin.  The same observation was made for the C(26)H2 shifts (4.31/4.61 ppm) i.e. they 
were connected by chemical exchange peaks in the ROESY spectrum which irrefutably 
proved their identical (rotameric) origin.  Rotamer generated split signals were also 
present for the ethyl C(23)H2 and C(24)H3.  The t-butyl C(17)H3 signal at 1.49 ppm in 
the 1-D H-NMR spectrum was unusually broad which suggested an impeded rotation 
about one or more bonds of the 9-t-Boc-amino moiety.  The ROESY experiment 
showed NOE interaction between the t-Boc signal and acridine aromatic hydrogens at 
8.15 and 8.32 ppm.  This suggested certain conformational preferences for the t-butyl 
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group, possibly stabilised by hydrophobic interaction forces, with non-polar parts of the 
acridine system and in turn this would explain the broad appearance of the t-butyl 
signal. 
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Figure 2.25: HMBC spectrum for 53 showing longer range C-H coupling (the 
unassigned peaks between 120 and 140 ppm on the C-axis are aromatic tertiary 
carbons, Q=quaternary carbon) 
 
For C(20)H2, at 3.68/3.77 ppm, the ROESY spectrum suggested NOE interactions with 
C(21)H2 and C(26)H2.  The stronger/most stable rotamer component signal of C(20)H2, 
at 3.77 ppm, showed NOE interaction with the stronger/most stable rotamer component 
signal of C(26)H2 at 4.61 ppm, suggesting rotamer 53b (see Figure 2.26  later) was 
most stable. The stronger rotamer signal of C(20)H2 also showed NOE interaction with 
the stronger C(21)H2 signal at 4.18 ppm. As the distance between the latter protons did 
not change in either rotamer, NOE interaction should remain for the less stable rotamer, 
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however, the relevant cross-peaks were not observed, presumably due to the inherent 
lower presence of the weaker rotamer. Again, this did not contradict nor exclude 
rotamer presence as this was irrefutably shown by chemical exchange cross-peaks for 
the involved protons C(20)H2, C(21)H2 and C(26)H2. 
The ROESY spectrum suggested NOE interactions between the stronger rotamer 
signals of C(19)H2 (at 3.90 ppm), C(21)H2 (at 4.18 ppm) and C(26)H2 (at 4.61 ppm).  
There was also NOE interaction between the weaker signal of C(19)H2 (at 3.84 ppm) 
and, presumably, the weaker C(21)H2 signal (at 4.18 ppm).  The latter interaction was 
not entirely clear as the weaker C(21)H2 signal overlapped (in the 1-D spectrum) with 
the strong signal for ethyl C(23)H2. 
For C(21)H2, The ROESY spectrum suggested spatial interactions with C(20)H2 and 
C(19)H2 (partially discussed above). The anticipated NOE interaction (for the less 
stable rotamer 53a) between the weaker C(21)H2 signal, at 4.23 ppm, and the weaker 
C(26)H2 signal, at 4.31 ppm, seemed to be present but, due to the signals being close 
together (and overlapping with the broad negative diagonal), this could not be observed 
unambiguously in the ROESY spectrum.  
Additional (weak and strong) NOE interactions were observed, in the ROESY 
spectrum, between C(27)H2 and C(26)H2, and between C(27)H2 and C(29)H3.   
The tertiary carbons of the aromatic acridine and the remaining quaternary carbons 
could not be assigned unambiguously. However, a DEPT spectrum in the 1-D 1H-NMR 
experiment confirmed the presence of the expected eight major CH signals which also 
allowed, by elimination, to identify the remaining quaternary carbons.  
 
Hence, analysis of the chemical exchange cross-peaks and the observed NOE 
interactions (in the ROESY spectrum) of the nucleobase-linking methylene protons 
with different parts of the PNA backbone suggested the existence of two major 
rotational isomers (a and b) for 53 present in a 4:1 ratio (see Figure 2.26 below).  The 
ratio was determined by comparing integral traces for the (rotamer generated) double 
singlet signals of the thymine –CH3 at δ 1.10 and δ 1.69 or the thymine-CH at δ 6.07 
and δ 6.83.  The preferred rotameric conformation for the tertiary amide bond in 53b 
was the same as the one reported for the t-Boc-protected thyminyl-PNA-monomer 13 
by Chen et al. [206] and Brown et al., [207] albeit in a 2:1 ratio for 13.   
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Figure 2.26:  The NOE contacts in the ROESY spectrum of compound 53 allow 
rotational isomers a/b (generated due to restricted rotation about the 3° amide bond) to 
be distinguished. (Except for the latter restriction the depicted conformation is 
arbitrary) 
 
2.15.2 Steps i and ii: acid generation and activation for the Cbz-protected 9-
aminoacridine intermediate 45 and subsequent linking to a PNA monomer. 
 
Reaction conditions in step i and ii (in Scheme 2.53 below) applied here for 45 were 
identical to the conditions described for t-butyloxy protected methyl ester 47 (in 
Scheme 2.52).  After the hydrolysis in step i the crude residue containing the acid 49 
was used in step ii.  
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Scheme 2.53 
 
However, acid activation of 49 had generated no observable solid dicyclohexylurea but, 
as this didn’t necessarily exclude activation of 49 had taken place, we proceeded to the 
next part of step ii (addition of the free base of the PNA monomer salt 21) in order to 
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potentially generate the desired conjugate 52.  Subsequent work-up led to the isolation 
of two acridine-containing products; one was unreacted acid 49 and the second 
remained unidentified.  The latter’s low solubility in NMR solvents and signal (shift) 
broadening did not allow proper NMR analysis.  Electrospray Mass Spectrometry (ES 
MS) suggested that the PNA-acridine conjugate 52 was not present in the collected 
fractions.  Unclear as to why this coupling attempt had failed, the most likely 
explanation was human error since the reaction had worked earlier for the t-Boc-
protected 9-aminoacridine intermediate 47, in subsection 2.15.1.  However, although 
only one unsuccessful attempt was undertaken, due to time constraints it was decided 
not to further investigate this problem at this point. 
  
2.15.3 Steps i and ii: acid generation and activation for the Alloc-protected 9-
aminoacridine intermediate 48 and subsequent linking to a PNA monomer. 
 
As for 45 and 47, the methyl ester of 48 was hydrolysed and the resulting acid 51 in the 
crude residue of step i was subsequently activated (this time solid dicyclohexylurea was 
observed) and coupled to the free base of the PNA monomer salt 21 in step ii (see 
Scheme 2.54 below).   
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Scheme 2.54 
 
Subsequent work-up yielded 54 in a 51% yield.  Hetero-nuclear Single Quantum 
Coherence (HSQC) and Hetero-nuclear Multiple Bond Correlation (HMBC) NMR 
experiments suggested rotamer presence due to restricted rotation about the tertiary 
amide bonds.  However, limited solubility and signal broadening limited significantly 
the spectra analysis’ value.  The latter problems prevented us from obtaining a good 
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ROESY spectrum and for this reason we were unable to unambiguously distinguish 
between all rotamer generated ‘split’ signals.  An attempt to assign chemical shifts for 
54, albeit less detailed, was undertaken nevertheless based on the recorded spectra and 
comparison with the existing data for the t-Boc protected PNA-acridine conjugate 53.  
54 only differed from 53 in the type of amino carbamate protection and we reasoned 
that the chemical shift values for the PNA moiety of 54 and 53 should not differ too 
much.   In particular the rotameric chemical shift values in our product 54 at δ 1.19 and 
δ 1.77 for thyminyl–CH3 protons compared well with the values for 53 at δ 1.10 and δ 
1.69 for thyminyl–CH3.  In the 1H-NMR spectrum for 54 the integral trace for the 
thyminyl –CH peaks suggested a 3:1 ratio for the two (observable) rotamers.  Other 
rotameric ‘split’ signals mostly appeared as multiplets due to overlap and poor 
resolution.  Particularly the signals for the allyl protons in 54 appeared broad, which 
could be interpreted as for the unusual broad t-Boc signal in 53, where peak broadening 
seemed to be caused by impeded freedom of rotation for the t-Boc group. 
 
2.16 Final steps in the ‘revised Beal route’: deprotection of the acridine 9-amino 
group and the PNA C-terminus carboxyl group of PNA-acridine conjugates 53 
and 54. 
 
In summary, so far our attempts to couple the urethane protected 9-aminoacridine to the 
thyminyl-PNA-monomer had yielded two PNA-acridine conjugates (53 and 54) that 
subsequently needed to be de-protected. Both 53 and 54 carried a urethane protection 
group and had their PNA C-terminus carboxyl group protected in the form of an ethyl 
ester.  Because there was no reason to remove either of these groups in a particular 
order it was arbitrarily decided for 53, the t-Boc protected PNA-acridine, to first 
remove the t-Boc group.  This would liberate the primary 9-amino group of the acridine 
53, after which the ethyl ester could be hydrolysed.  For 54, the Alloc protected 
conjugate, the ethyl ester was hydrolysed before an attempt was made to remove the 
Alloc group.  These reactions are illustrated below in Scheme 2.55.  Each step will now 
be discussed separately. 
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Scheme 2.55: De-protecting PNA-acridine conjugates 53 and 54 (due to purification 
problems in steps iii and iv, yields could not be determined) 
 
 
2.16.1 Step i: t-Boc deprotection of PNA-acridine conjugate 53 
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Scheme 2.56 
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In the above depicted urethane acidolysis (Scheme 2.56), protonation of the urethane 
carboxyl oxygen lead to the release of the t-butyl cation followed by carbon dioxide 
release thus generating the free 9-amino group on the middle acridine ring.  Hence, 53 
was treated with trifluoroacetic acid according an adapted protocol described by 
Englund et al. for the t-Boc-deprotection of an amino acid α-NH2 [229], and subsequent 
work-up afforded the title compound 55 as a fine yellow powder (95% yield).   
Analysis of the 1H-NMR spectrum for 55 suggested the expected presence of two 
rotamers, now in a 1:1 ratio (due to restricted rotation about the tertiary amide bond) 
(see Figure 2.27 below).  The ratio was determined by comparing integral traces for the 
(rotamer generated) double singlet signals of the thymine –CH3 at δ 1.65 and δ 1.80 or 
the thymine-CH at δ 7.11 and δ 7.23.  A key feature in the 1H-NMR spectrum of 55 was 
the disappearance of the t-Boc peak present in the 1H-NMR spectrum of the starting 
material 53.  Assignment of peaks in the 1H-NMR spectra of 55 was again aided by 
comparison with the spectra recorded for the starting material (the t-Boc protected 
PNA-acridine conjugate 53).   
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Figure 2.27: The two major rotamers a and b for PNA-acridine conjugate 55 due to 
restricted rotation around the tertiary amide bond (except for the latter restriction the 
depicted conformation is arbitrary) 
 
 
55 only differed from 53 in bearing an amino carbamate protection and we reasoned 
that the chemical shift values for the PNA moiety of 55 and 53 should not differ too 
much.  The different rotamer ratio, 1:1 for 55, compared to 1:4 for 53, at this point 
could only be rationalised by assuming the reduced bulkiness of the acridine moiety 
somehow allowed for a less impeded rotamer interconversion. 
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2.16.2 Step ii: C-terminus ethyl ester basic hydrolysis of PNA-acridine conjugate 55. 
 
In step ii, the ethyl ester component of the TFA salt of 55 underwent aqueous basic 
hydrolysis after which the generated carboxylate-bearing PNA-acridine conjugate was 
converted to 56 via neutralisation with aqueous HCl (see Scheme 2.57 below).   
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Scheme 2.57 
 
Subsequent work-up afforded a crude residue that contained the desired product 56 (98 
% yield) and a NaCl residue.  Recrystallisation attempts, e.g. using ethanol or 
methanol, to remove the NaCl were unfortunately not successful.  The consequence of 
this was a low solubility of the crude precipitate in NMR solvents and only a 1D-1H-
NMR spectrum could be recorded as signal strength was low.  Nevertheless, subsequent 
analysis of the 1H-NMR spectrum of 56 suggested the presence of 2 rotamers in a 1:1 
ratio due to restricted rotation about the tertiary amide bond (see Figure 2.28 below).   
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Figure 2.28: The two major rotamers a and b for PNA-acridine conjugate 56. 
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The ratio was determined by comparing integral traces for the (rotamer generated) 
double singlet signals of the thymine –CH3 at δ 1.20 and δ 1.55 or the thymine-CH at δ 
6.34 and δ 6.94 in the 1H-NMR spectrum of 56. 
A key feature in the 1H-NMR spectrum of 56 was the disappearance of the –CH2CH3 
peaks present in the 1H-NMR spectrum of the starting material 55.  Analysis of the 
latter spectrum and comparison with the 1H-NMR spectrum of 53 also (again) aided the 
assignment of peaks for 56. 
 
2.16.3 Step iii: C-terminus ethyl ester basic hydrolysis of PNA-acridine conjugate 54.  
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Scheme 2.58 
 
As for compound 55 in the former step ii, here in step iii the PNA-acridine conjugate 54 
underwent aqueous basic hydrolysis after which the (intermediate) generated 
carboxylate-bearing PNA-acridine conjugate was converted to 57 via neutralisation 
with aqueous HCl.  Subsequent work-up afforded a crude residue containing the 
product 57, NaCl and a number of unidentified by-products.  Recrystallision of the 
crude residue, using methanol, afforded a fine yellow powder that however still 
contained a substantial amount of unidentified impurities as suggested by analysis 1H-
NMR data for the crude yellow precipitate.   
Because analysis of the latter data could not exclude presence of the desired 
intermediate 57, it was decided to take the yellow precipitate through to the next step 
(i.e. Pd(0) catalysed Alloc cleavage in step iv).  A subsequent successful work-up of the 
reaction in step iv could potentially still afford the desired end-product 56 via this route. 
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2.16.4 Step iv: Alloc-deprotection of PNA-acridine conjugate 57.  
 
The crude residue, produced in the former step iii and containing the PNA-acridine 
conjugate 57, was treated with catalytic amounts of 
tetrakis(triphenylphosphine)palladium(0) in the presence of triethylammonium formate 
as the allyl accepting nucleophile, according an N-alloc deprotection method 
successfully used by Kanda et al.[230] (see Scheme 2.59  below)  
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Scheme 2.59   
 
In the latter procedure, the (unreactive) tetrakis(triphenylphosphine)Pd(0) was in 
equilibrium with (stable) tri(triphenylphosphine)Pd(0) and this in turn was in 
equilibrium with (reactive) di(triphenylphosphine)Pd(0).[226]  The latter Pd(0) species 
initiated cleavage of the allylcarbamate via the formation of a Pd π–allyl complex.   
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Figure 2.29: General mechanism for Pd(0) catalysed allylcarbamate cleavage using 
triethylammoniumformate as allyl acceptor (as suggested by Roos et al., 1995,[231]) 
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Presence of nucleophilic formate (the allyl acceptor) subsequently generated the free 
amine 56, CO2 and allylformate (see Figure 2.29 above for the reaction 
mechanism).[231]   
In the reaction work-up a crude yellow precipitate was isolated for which 1H-NMR data 
analysis suggested presence of the desired PNA-acridine conjugate 56 but also (a 
number of) undesired, unidentified by-product(s), the 9-allylamine, generated due to 
competition with formate for the allyl electrophile, being a likely candidate for the 
latter (see Figure 2.29  above).[231]   
Unfortunately, subsequent repeated attempts to re-crystallise 56 in e.g. ethanol/diethyl 
ether, methanol/diethyl ether and methanol/THF were not successful in significantly 
separating/isolating 56 from the by-product(s) and unambiguous identification of either 
was not possible.  Due to time constraints it was decided at this point to no longer 
pursue the complete purification of compound 56 via this route as we had obtained a 
better result in doing this via steps i and ii of Scheme 2.55, which dealt with 
deprotection of the t-Boc, ethyl ester protected PNA-acridine 53. Although in steps i 
and ii of Scheme 2.55 we had obtained 56 with a NaCl impurity, it still allowed us to 
partially characterize the desired conjugate 56. 
 
2.17 Bioactivity of two acridine intermediates 
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O N
H
N
N
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     IC50= 22 µM                                  IC50= 100 µM 
 
Scheme 2.60: Bioactivity of two 9-aminoacridines in an IN-activity assay. (Assay was 
performed by J-F Mouscadet from the Laboratoire de Biotechnologies et Pharmacologie 
Génétique Appliquée, CNRS UMR 8113, Ecole Normale Supérieure de Cachan, 61 av 
du Président Wilson, 94235 Cachan, France.) 
 
IC50 values were determined for two acridine intermediates synthesised during our 
project (see Scheme 2.60 above). The dihydrochloride salt of 9-amino-DACA (7) and 
iso-propyl-9-benzylaminoacridine-4-carboxylate (28) showed respective IC50 values of 
22 µM and 100 µM in an IN-activity assay, described by Maurin et al.: "Full IN 
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activity reactions (i.e. 3'-processing + strand transfer) were performed in triplicate in 
96-well plates using 0.25 pmol of labelled U5A/U5B double-stranded DNA substrate, 
12 pmol of ST1/ST2 3-biotinylated target DNA and 2 pmol of integrase in buffer A [20 
mM Hepes (pH 7.2), 10 mM MgCl2, 25 mM NaCl, and 1 mM DTT] in a final volume 
of 40 mL. Radiolabelled reaction products were bound to Streptavidin-coated magnetic 
beads (DynaL), washed twice in buffer B (PBS buffer supplemented with 0.025% 
Tween 20 and 10 mg/ml BSA) and quantified on a beta radiation counter. Inhibition in 
the presence of drugs was expressed as the fractional product in percent of the control 
without drug."[232] Oligonucleotides used in the assay were purchased from 
Eurogentec and further purified, by Maurin et al., on 18% acrylamide/urea denaturing 
gel (U5B: GTGTGGAAAATCTCTAGCA; U5A: 5’-ACTGCTAGAGATTT 
TCCACAC; ST1: AGTGAATTAGCCCTTGGTCA-biotin; ST2: 5’-TGACCA 
AGGGCTAATTCACT-biotin; U5B was radio labelled using T4 polynucleotide kinase 
for 3’-processing and strand transfer reactions). 
Hence, for our compounds 7 (IC50= 22 µM) and 28 (IC50= 100 µM) this meant that at 
their respective concentrations of 22 µM and 100 µM only 50% of the radioactivity 
recorded for the control test (without drug) was observed.  Although the tested 
compounds were not PNA-acridine conjugates and presented only moderate anti-IN 
activities, we considered this result a strong argument for the use of the 4-substituted 9-
aminoacridine moiety in the development of PNA-acridine conjugates as potential HIV 
inhibitors. 
 
2.18 Conclusion 
 
When we set out a strategy to synthesise 9-aminoacridines conjugated to a PNA 
monomer in the acridine’s 4-position we initially found inspiration in the synthetic 
route towards 9-amino-DACA 6, an anti-tumour agent developed by Denny.  Although 
we were able to apply this strategy successfully to the synthesis of 9-amino-DACA 6 
and the types of chemical conversions were identical to the ones required for our 
purposes we were unsuccessful in the ‘Denny route’ towards the synthesis of the 
desired PNA-acridine conjugates.  Due to repeated purification problems and apparent 
side-product formation in the latter’s carboxamide formation step, we decided to 
investigate an alternative approach in which the order was changed in which the PNA-
acridine components (acridine, PNA monomer backbone and nucleobase moieties) 
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would be linked to each other.  Unfortunately, this alternative carboxamide formation 
step was also characterized by repeated purification problems and apparent side-
product formation.  A possible explanation for the encountered problems, when linking 
the acridine to the PNA moiety, could have been intra-molecular cyclization reaction 
involving the ethyl ester carbonyl of the PNA moiety and the primary amine of the 
latter and/or the hydrolytic sensitivity of the 9-chloroacridine-4-carbonyl chloride 4.  
Since the problems encountered did not appear to be easily surmountable we decided to 
rethink our strategy to obtain the desired PNA-acridine conjugates.   
Inspiration was found in Beal’s reported strategy for the solid-phase synthesis of 
acridine-peptide conjugates to enable libraries of acridine-peptide to be generated. We 
were inspired by the fact that these conjugates bore the 9-anilinoacridine-4-
carboxamide moiety similar to our intended PNA-acridine conjugates.  The main 
difference with the ‘Denny route’ was the order in which the 9-amino and 4-
carboxamide functionalities were established.  We reasoned that by using Beal’s 
synthetic strategy but establishing the acridine substituents with the amines relevant to 
our purpose, i.e. a 9-benzylamino and a 4-PNA substituent, this would provide us with 
a reproducible pathway towards the desired 9-NH2-4-PNA-acridine conjugates. It was 
envisaged that once the 9-benzylamino-4-PNA-acridine conjugate had been synthesised 
only the 9-benzylamino substituent needed to be subjected to hydrogenolysis to 
establish the primary 9-amino substituent desired in our PNA-acridine conjugates.  
Unfortunately, before the latter step was reached, a problem arose that prevented us 
from establishing an acridine 4-PNA (monomer) substituent in the presence of a 9-
benzylamino substituent.  We also found that for the 9-anilino substituted acridine, 
activation of the 4-carboxyl substituent (via NHS-ester formation) and the subsequent 
carboxamide forming step did work, resulting in the synthesis of 9-anilino-DACA 35 
and a 9-anilinoacridine-4-PNA conjugate 36.  This result inspired us to revise the ‘Beal 
route’ and led us to the development of several 9-aminoacridine intermediates in which 
the 9-amino group was converted into a carbamate group.  The three urethane moieties 
established in the acridine’s 9-position were the benzyloxycarbonylamino, the 
allyloxycarbonylamino and the t-butyloxycarbonylamino group.  All three 
intermediates fulfilled the main condition to allow subsequent acridine-4-carboxyl 
activation, i.e. they had an electron withdrawing effect on the acridine’s exocyclic 
nitrogen which decreased the (acridine) ring nitrogen N10 basicity.  Although all three 
carbamate-bearing intermediates could be considered equally valuable in the synthetic 
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route towards the desired PNA-acridine conjugates, only the t-Boc-protected and the 
alloc protected 9-amino-4-PNA-acridine intermediates 53 and 54 were synthesised 
successfully.   Subsequent deprotection steps for the t-Boc-bearing intermediate 53 (t-
Boc and PNA monomer ethyl ester cleavage) led to the desired 9-NH2-4-PNA-acridine 
conjugate 56.  Due to time constraints and purification complications for the 
deprotection steps of the 9-alloc-bearing intermediate 54 we were not able to 
characterize and determine the yield for the end product 56 via this route.  
Nevertheless, the complete synthetic route towards the PNA-acridine conjugate 56 
(over-all yield 4%) was successfully accomplished via the 9-t-Boc-bearing intermediate 
53 and is summarized below in Scheme 2.63. 
 
O
O
I
NH2
O O
N
H
O O
O
OH
Ph
N
H
O
O O
N
O O
NH2
N
O O
Cl
N
O O
NH
O
O
N
O O
NH
H
O
O
O
NH
O
O
N
H
N
O
N
N
H
O
O
OO
N
O
NH2
N
H
N
O
N
N
H
O
O
OO
N
O
NH2
N
H
N
O
N
N
H
OH
O
OO
N
vi:  a)  Aq. LiOH 0.2 M;THF; 0°C to  rt  b) Aq. HCl 0 .5 M; rt.  vii: a)  DCC, N-OH succinimide; DMF; rt       
 b) PNA monomer salt 21, TEA; DMF; rt.
 viii:  TFA; DCM; rt.   ix:  a) Aq. NaOH 0.3 M; THF; rt b) Aq. HCl 0.1 M; rt 
Reagents and
Conditions: iv:  a) Phenol; 70°C  b) NH 4HCO3; 120°C.   v:  a) Phosgene, TEA; o-DCB; 110°C  b)  t-Butanol; o -DCB; 110°C.
                                   
 i:   Cu-acetate (cat); DMF; 90°C.  ii:   PPE(2"); CHCl3; reflux.  iii:   SOCl2, DMFcat; rt  
++
.H20
1 2
i ii
4
3 1' 2'
3'
4'
5'
6'
1
2
6
5
1
2
3
45
6
7
8
9
10
1
2
3
4
5
6
80% 93%
44 43
9
iii
iv
98%
61%
47
43%
v
50
+
_
vii
53
vi
24% (vi + vii)
55 56
viii ix
95% 98%
 DPIC
Methylanthranilate
 
Scheme 2.63:  Synthetic route towards the PNA-acridine conjugate 56. 
 
Hence, a crucial achievement of this project was the development of the chemistry 
necessary to establish the acridine-PNA carboxamide link in the acridine’s 4-position 
and this in the presence of a (carbamate protected) primary amino group in the 
acridine’s 9-position.  Although our intention to retain a primary 9-amino functionality 
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in our final PNA-acridine conjugates had seriously complicated our attempts to link the 
acridine moiety to the PNA, we had found a practical way to circumvent the associated 
problems by making use of 9-amino protecting carbamates.  This allowed us to 
successfully complete the synthetic route towards the desired PNA-acridine conjugate 
56 (see Scheme 2.63 above), the chemistry of which is an important step towards the 
further development of PNA-acridine conjugates as potential HIV-IN inhibitors. 
 
 
2.19 Future Work 
 
Although all our compounds were prepared in solution phase, it is believed a solid-
phase based strategy is the way forward in the synthesis of PNA-oligomer-Acridine 
conjugates.  Similar to the strategy of Beal for the solid-phase synthesis of acridine-
peptide libraries, PNA oligomers/polymers could be synthesised in solid-phase and 
subsequently peptide-linked to the acridine’s NHS-activated 4-carboxyl substituent.  
Development of the latter (activated) acridine has been an important achievement of 
our project but we also believe the alternative, earlier abandoned ‘Denny route’, in 
which an acid chloride (in the acridine 4-position) would enable 4-carboxamide 
formation, should be re-examined.  In particular, the suggested hypotheses that PNA-
acridine coupling may have been compromised, by a competing cyclization side-
reactions of the free base of the PNA monomer (14 or 21) or by hydrolytic sensitivity 
of the acridine acid chloride 4, require further scrutiny as it was shown at a later stage 
in our project that the thyminyl-PNA-monomer (14 or 21) was not a barrier to the 
coupling step nor had (potential) hydrolytic sensitivity of 4 prevented us from making 
9-NH2-DACA via the acridine acid chloride.  When investigating the latter potential 
problems, particular attention should be given to the prevention of intra-molecular ethyl 
ester aminolysis of the free base of the PNA monomer (14 or 21) e.g. by slow 
deprotonation of the latter salts, at lowered temperature and in the presence of the 
acridine acid chloride 4.  Extra attention should be given to rigorous drying of solvents 
and reagents to eliminate potential hydrolysis of the acid chloride 4.  In addition, the 
use of preparative reversed phase HPLC, unfortunately unavailable at the time of our 
experiments, would be essential to isolate the polar PNA-acridine conjugate(s) from 
any formed by-products (a complication we were not fully able to resolve). 
Hence, providing one would be able to successfully develop the (liquid phase) ‘Denny 
route’ to PNA-acridine conjugates this would offer a useful alternative to our ‘revised 
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Beal route’ and to the envisaged subsequent (solid phase) linking of PNA to the 9-
chloroacridine acid chloride 4.  With regards to the latter, any substitutions in the 9-
position of the acridine could be potentially achieved after the solid phase PNA-
acridine peptide linking step. 
It is believed the chemistry developed so far in the ‘revised Beal route’ provides a solid 
starting point for further development of PNA(oligomer)-acridine conjugates as 
potential (nucleic acid sequence selective) novel inhibitors of HIV-1 integrase (IN).     
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Chapter 3: Experimental 
 
 3.1 General materials and methods: 
 
Commercially available reagents and starting materials were purchased from Alfa 
Aesar U.K. and from Sigma Aldrich, U.K.  Solvents referred to as ‘dry’ or ‘anhydrous’ 
were dried using standard procedures.[233] Analytical thin layer chromatography 
(TLC) was carried out on aluminium sheet silica gel 60 F254 plates (Merck).  
Preparative thin layer chromatography was carried out on Fisher Silica Gel Preparative 
TLC Plates 20 x 20 cm, 2.00 mm. thickness.  Visualisation was achieved under UV 
light (254 nm) or by treatment with a KMnO4 stain (1.5g of KMnO4, 10g K2CO3, and 
1.25mL 10% NaOH in 200mL water).  All (flash) column chromatography was carried 
out with Fisher silica gel 60 (230-400 mesh).  Acidic cation-exchange resin used was 
DOWEX 50W-X8(H)-100 purchased from Lancaster U.K.  Infrared spectra were 
recorded, using a Perkin Elmer 1600 series FTIR spectrophotometer.  1H-NMR and 
13C-NMR spectra were recorded on Bruker AC 200 and Bruker DPX 400 
spectrometers.  Chemical shifts were recorded in ppm, using the residual non-
deuterated solvent signal as a reference. Coupling constants were quoted in Hz.  
Mixtures of two rotational isomers were observed for some of the products containing 
tertiary amide bonds.  Cis-trans isomers were observed for certain 9-aminoacridines 
due to restricted rotation about the acridine C9-N bond. Consequently, a number of 
NMR signals for these products were doubled and are indicated as (max) for the major, 
and (min) for the minor isomer.  One mixture of three rotational isomers was observed 
due to secondary and tertiary amide bond restricted rotation, in which case a fraction of 
protons was assigned to the doubled or tripled signals. Melting points were measured 
using an electrothermal melting point apparatus and are uncorrected.  Compound 
crystal structures were determined from single crystal data recorded with a Bruker 
Nonius X8-Apex2 CCD diffractometer. Elemental analyses for C, H and N were 
carried out on Exeter Analytical CE440 analyser.  Low and high resolution mass 
spectrometric analyses (CI, EI and ESI) were performed at the EPSRC National Mass 
Spectrometry Service Centre, University of Wales, Swansea. 
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3.2 Experimental procedures 
 
2-(2-Methoxycarbonylphenylamino)-benzoic acid (1)[187]  
 
METHOD A: via phenyliodide substitution in DPIC 
Methyl anthranilate (3.16 g, 20.9 mmol, 1.80 eq), DPIC (4.00 
g, 11.7 mmol, 1.00 eq) and a catalytic amount of 
copper(II)acetate (0.08 g, 0.4 mmol, 0.04 eq) were suspended 
in anhydrous DMF (300 mL) and this suspension was heated 
with stirring at 90°C for 12 h.  The solvent was removed in 
vacuo and the residue (green oil) was dissolved in ethyl acetate (150 mL).  The 
resulting organic solution was washed with 0.1 M (aq) hydrochloric acid (150 mL) 
before being extracted with a 0.1 M (aq) solution of ammonia (3 x 100 mL).  The 
combined aqueous ammonia extracts were slowly poured into a 0.1 M (aq) solution of 
hydrochloric acid (700 mL).  The white-green precipitate afforded was isolated and 
washed with hot water (2 x 50 mL).  The title product 1 was obtained as a green solid 
(2.55 g, 80%).  This product showed sufficient purity to be used in a next step without 
further purification. mp 194-198°C (from toluene/acetone) (Lit.[187] 196-198°C); Rf 0.47 
(Petroleum ether (40-60 °C) : ethyl acetate : acetic acid, 99: 99: 2); (Found: C, 66.0; H, 
4.8; N, 5.0. C15H13NO4 requires C, 66.4; H, 4.8; N, 5.2%.); max(KBr)/cm–1 3339, 
2946(br), 1709, 1660, 1600, 1581, 1517, 1450, 1325, 1278, 755; δH(200 MHz; CDCl3) 
3.55 (1 H, br s, NH), 3.85 (3H, s, OCH3 ), 6.88-7.00 (2 H, m, Ar-H), 7.35-7.45 (2 H, m, 
Ar-H), 7.51-7.57 (2 H, m, Ar-H), 8.00 (1 H, dd, J 7.9 and 1.7, Ar-H), 8.09 (1 H, dd, J 
7.9 and 1.3, Ar-H), 10.85 (1 H, s, COOH); δC(50 MHz; CDCl3) 52.0 (q), 117.3 (d), 
118.2 (s), 118.6 (d), 119.7 (d), 120.5 (d), 131.85 (d), 132.5 (s), 132.7 (d), 133.1 (d), 
134.3 (d), 143.4 (s), 145.2 (s), 167.5 (s), 182.9 (s). 
 
METHOD B: via chloride substitution in o-Chlorobenzoic acid 
Methyl anthranilate (6.15 g, 40.7 mmol, 1.80 eq), o-chlorobenzoic acid (3.54 g, 22.6 
mmol, 1.00 eq), anhydrous potassium carbonate (1.56 g, 11.3 mmol, 1.00 eq) and a 
catalytic amount of copper metal powder (0.15 g, 2.4 mmol, 0.10 eq) were 
suspended/dissolved in a 3:1 mixture of H2O:DMF (25 mL).  This mixture was then 
heated at 100°C with stirring for 48 h.  The solvent was removed under vacuum and the 
residue (green-black oil) was dissolved in ethyl acetate (125 mL).  The resulting 
N
H
O O
O
OH
1
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organic solution was washed with 0.1 M (aq) hydrochloric acid (200 mL) before being 
extracted with a 0.1 M (aq) solution of ammonia (3 x 100 mL).  The combined aqueous 
ammonia extracts were acidified with 2.0 M (aq) hydrochloric acid to pH 4.  The 
precipitate was isolated and washed with hot water (150 mL) to afford the title 
compound 1 (1.90 g, 31%) as a green solid.  This product showed sufficient purity to be 
used in a next step without further purification. The analysis of this product was 
identical to that obtained for the product yielded by method A. 
 
Methyl-9-oxoacridan-4-carboxylate (2)[187] 
 
2-(2-Methoxycarbonylphenylamino)benzoic acid (1) (1.42 g, 
5.23 mmol, 1.00 eq) was suspended in a mixture of tetraethyl 
tetrametaphosphates (2”) (50.00 g, 115.7 mmol, 22.10 eq) and 
dry chloroform (80 mL).  The resulting mixture was heated under 
reflux with stirring until all the solids had dissolved.  The solvent 
was then allowed to evaporate at atmospheric pressure to give a red oil which was 
subsequently heated on a water bath for 1.5 h. at 100°C.  The oil was diluted with 
methanol (8 mL). Slowly, water (38 mL) was added to this solution to precipitate the 
crude product as a yellow solid.  This was isolated by filtration, washed with a 50% 
aqueous solution of methanol containing 1% triethylamine (40 mL), dried and stored 
over P2O5.  The title compound 2 (1.23 g, 93%) was obtained as a yellow solid.  This 
product showed sufficient purity to be used for synthetic purposes without further 
purification. mp 159-162°C (from acetone/diethyl ether) (Lit.[234]172°C); Rf 0.64 
(Petroleum ether (40-60 °C) : ethyl acetate : acetic acid, 99: 99: 2); (Found: C, 70.6; H, 
4.2; N, 5.4. C15H11NO3 requires C, 71.1; H, 4.4; N, 5.5%); max(film)/cm–1 3269, 2947, 
1690, 1637, 1617, 1590, 1524 and 1442, 1283, 755; δH (200 MHz; CDCl3 ): 3.98 (3 H, 
s, OCH3), 7.18-7.40 (3 H, m, Ar-H), 7.58-7.69 (1 H, m, Ar-H), 8.41 (2 H, dd, J 7.5 and 
1.7, Ar-H), 8.69 (1 H, dd, J 7.9 and 1.7, Ar-H), 11.60 (1 H, s, NH); δC (50 MHz; 
CDCl3): 52.5 (q), 113.5 (s), 117.5 (d), 119.9 (d), 121.5 (s), 122.4 (d), 127.05 (d), 134.0 
(d), 134.05 (d), 136.5 (d), 140.0 (s), 141.7 (s), 142.9 (s), 168.4 (s), 177.9 (s); LRMS 
m/z (EI) (%) 253 (M+, 74), 221 (100), 193 (29), 178 (56);  HRMS (EI) found 253.0731, 
calcd. for C15H11N1O3 [M+] 253.0733.  
 
 
N
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Tetraethyl tetrametaphosphates or cyclotetraphosphoric acid ethyl esters 2” [139]  
 
Anhydrous phosphorus pentoxide (50.00 g, 
176.0 mmol, 1.00 eq), chloroform (100 
mL) and diethyl ether (50.0 mL, 482 
mmol, 2.74 eq) were combined and heated 
under reflux under nitrogen with stirring for 15-30 h.  The clear solution was then 
filtered through glass wool and the solvent removed in vacuo.  The crude product 2” 
(71.6 g, 94%) was afforded as light-yellow viscous oil, which needed no further 
purification for synthetic purposes.  max (film)/cm–1 2990, 2941, 1479, 1446, 1397, 
1373, 1310, 950-1100. 
 
9-Oxoacridan-4-carboxylic acid (3)[187] 
 
Compound 2 (1.10 g, 4.33 mmol, 1.00 eq) was suspended in a 
mixture of absolute ethanol (110 mL) and a 2 M (aq) solution of 
sodium hydroxide (110 mL).  The resulting mixture was heated 
at reflux for 10 min.  Then, the clear yellow solution was filtered 
and DOWEX cation-exchange resin (150 g) was added.  The suspension was shaken for 
1h.  Any precipitated product was re-dissolved by the addition of a further quantity of 
absolute ethanol (100 mL).  Subsequently, the resin was removed by filtration and 
washed with absolute ethanol (3 x 100 mL).  Removal of the solvent in vacuo followed 
by azeotropic drying with first toluene (4 x 75 mL) then diethyl ether (4 x 75 mL), gave 
the title compound 3 (0.94 g, 91%) as a yellow solid.  mp 322-325°C (from EtOH) 
(Lit.[187] 324-325 °C); Rf 0.22 (Petroleum ether (40-60 °C) : ethyl acetate : acetic acid, 
99: 99: 2); max(KBr)/cm-1 3227, 2931br, 1693, 1620, 1597, 1580, 1568, 1524, 1461, 
1443, 755; δH (200 MHz; DMSO-d6) 7.28-7.40 (2 H, m, Ar-H), 7.73-7.80 (2 H, m, Ar-
H), 8.25 (1 H, d, J 7.9, Ar-H), 8.45 (1 H, dd, J 7.5 and 1.7, Ar-H), 8.55 (1 H, dd, J 8.3 
and 1.66, Ar-H), 11.95 (1H, s, OH), 13.95 (1H, br s, N(10)H); δC (50 MHz, DMSO-d6): 
118.4 (d), 120.0 (d), 120.6 (s), 121.2 (d), 121.3 (s), 126.4 (d), 128.1 (d), 133.8 (d), 
136.0 (d), 140.4 (s), 142.2 (s), 169.9 (s), 177.2 (s); LRMS m/z (EI) (%) 239 (M+, 84), 
221 (100), 193 (60), 164 (51), 110 (50); HRMS (EI) found 239.0620, calcd. for 
C14H9NO3 [M+] 239.0582. 
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9-Chloroacridine-4-carbonyl chloride (4) [186] 
 
Compound 3 (0.35 g, 1.5 mmol, 1.00 eq) was suspended in 
thionyl chloride (2.20 mL, 30.0 mmol, 20.5 eq) and a catalytic 
amount of DMF was added (one drop).  The resulting 
suspension was heated gently under reflux, while stirring and 
under nitrogen, until all the solid material had dissolved.  The homogeneous solution 
was then left at reflux for a further 45 mins, whereupon the reaction mixture was 
allowed to cool to rt.  The bulk of the thionyl chloride was removed in vacuo, whilst 
keeping the temperature below 40°C.  The final traces of thionyl chloride were 
removed by re-suspending the residue in toluene (3 x 5 mL) and removing the solvent 
in vacuo.  This yielded the title crude compound 4 (0.40 g, 99%) as a yellow-reddish 
solid.  The product was used without further purification.  mp 132-137°C (from CHCl3 
/ Petroleum ether); Rf 0.32 (Petroleum ether (40-60 °C) : ethyl acetate : acetic acid, 99: 
99: 2 ). 
 
N-[2-(Dimethylamino) ethyl]-9-chloroacridine-4-carboxamide (5)[186] 
 
Crude compound 4 (0.40 g, 1.4 mmol, 1.00 eq) was 
dissolved in dry dichloromethane (2 mL) and the 
resulting solution was cooled to -5°C.  Subsequently, 
an ice cooled solution of N,N-
dimethylethylenediamine (0.63 mL, 5.7 mmol, 3.92 
eq) in dry dichloromethane (4 mL) was added, whilst stirring under nitrogen.  The 
reaction mixture was then heated to 30°C until all the solid material had disappeared 
and then left for a further 15 min.  Subsequently, the reaction mixture was allowed to 
cool before being washed with a 10% (aq) solution of sodium carbonate (2 x 6 mL) 
followed by a saturated aqueous sodium chloride solution (6 mL).  The organic layer 
was separated and dried over anhydrous Na2SO4.  Filtration followed by solvent 
evaporation afforded a crude oil, which slowly solidified on standing.  Purification was 
effected by flash column chromatography (dichloromethane : methanol : triethylamine, 
90:10:1) to afford the title compound 5 (0.31 g, 67%) as a yellow oil which slowly 
solidified on standing.  mp 153-158°C (from CHCl3 / Petroleum ether); Rf 0.36 
(dichloromethane : methanol : triethylamine, 90:10:1). δH (200 MHz; CDCl3) 2.45 (6 H, 
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s, N(CH3)2), 2.72 (2 H, t, J 6.2, CH2N(CH3)2), 3.79 (2 H, td, J 6.2 and J 5.0, 
CONHCH2), 7.66-7.93 (3 H, m, Ar-H), 8.27 (1 H, m, Ar-H), 8.46 (1 H, m, Ar-H), 8.64 
(1 H, dd, J 8.8 and 1.7, Ar-H), 9.07 (1 H, m, Ar-H), 11.90 (1 H, br s, CONH).  
 
N-[2-(Dimethylamino)ethyl]-9-aminoacridine-4-carboxamide (6)[186] 
 
Compound 5 (0.19 g, 0.57 mmol, 1.00 eq) was 
dissolved in dry phenol (0.66 g, 7.0 mmol, 7.00 eq) 
and the mixture was heated slowly to 50 °C.  Once 
this temperature had been reached, a stream of 
gaseous ammonia was bubbled through the solution 
and this was continued while the temperature of the reaction was raised slowly to 
115°C.  The reaction mixture was kept at this temperature for a further 20 mins.  The 
bulk of the solvent was then removed in vacuo and the residue was co-evaporated with 
toluene (4 x 10 mL).  The crude dark brown-yellow residue was purified by flash 
column chromatography (dichloromethane : methanol : triethylamine,  90:10:1).  This 
gave the title compound 6 (0.12 g, 59%) as brown-yellow oil.  Rf 0.18 (dichloromethane 
: methanol : triethylamine, 90:10:1); δH (200 MHz; CDCl3) 2.47 (6 H, s, N(CH3)2), 2.78 
(2 H, t, J 5.8, CH2N(CH3)2 ), 3.80 (2 H, m, CONHCH2), 6.50 (2 H, br s, NH2), 7.10 (1 
H, dd, J 7.1 and 1.7, Ar-H), 7.21-7.30 (1 H, m, Ar-H), 7.51-7.60 (1 H, m, Ar-H), 7.63-
7.70 (1 H, m, Ar-H), 7.80-7.88 (2 H, m, Ar-H), 8.60 (1 H, dd, J 7.1 and 1.3, Ar-H), 
12.38 (1 H, br s, CONH).   
 
Dihydrochloride salt of N-[2-(dimethylamino)ethyl]-9-aminoacridine-4-
carboxamide (7) [186] 
 
Compound 6 (0.09 g, 0.3 mmol, 1.00 eq) was 
dissolved in a hydrochloric acid saturated solution of 
dry methanol (50 mL) and the resulting mixture was 
left to stir at rt for 45 mins.  Subsequently, the solvent 
was removed in vacuo and the crude material afforded 
was purified by recrystallisation from a 1:1 mixture of methanol : diethyl ether.  The 
title compound 7 (0.08 g, 89%) was obtained as yellow crystals which were collected 
by filtration, washed with cold diethyl ether and dried in vacuo over phosphorus 
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pentoxide.  mp 284-289°C (from MeOH/Diethyl ether) (Lit.[186] 292-293 °C); δH (200 
MHz; DMSO-d6) 2.87 (6 H, s, NH(CH3)2), 3.40 (2 H, m, CH2NH(CH3)2), 3.78 (2 H, m, 
CONHCH2 ), 7.50-7.65 (2 H, m, Ar-H), 7.90-8.10 (2 H, m, Ar-H), 8.73 (1 H, d, J 7.5, 
Ar-H), 8.85 (1 H, d, J 8.7, Ar-H), 9.05 (1 H, d, J 8.7, Ar-H), 9.85 (1 H, br s, 
NH(CH3)2), 10.58 (2 H, br s, C(9)NH2), 10.90 (1 H, br s , CONH), 13.60 (1 H, br s, 
N(10)H); δC (50 MHz, DMSO-d6) 35.3 (t), 43.1 (q), 56.2 (t), 112.1 (s), 112.9 (s), 120.0 
(s), 120.3 (d), 123.2 (d), 125.3 (d), 125.6 (d), 129.8 (d), 136.6 (d), 136.9 (d), 138.8 (s), 
139.0 (s), 158.7 (s), 168.2 (s); LRMS m/z (ESI) (%) 309 ([M+H]+, 82), 264 (12), 155 
(100), 133 (10); HRMS (ESI) found 309.1709, calcd. for C18H21N4O [M+H]+ 309.1710.  
 
t-Butoxycarbonylamino-1,2-propanediol (8)[202] 
 
To a solution of 3-amino-1,2-propanediol (4.80 g, 52.8 
mmol, 1.00 eq) in water (100 mL) was added dropwise at 
0°C with stirring, a solution of di-t-butyl dicarbonate (12.12 
g, 54.80 mmol, 1.04 eq) in dioxane (50 mL).  The solution 
was warmed to rt while the pH was maintained above 10.5 by addition of (aq) 1 M 
NaOH.  After evaporation of the solvent in vacuo, the remaining paste was triturated 
with DCM.  The suspension was filtered and the organic phase was dried over 
anhydrous Na2SO4.  Filtration followed by solvent evaporation in vacuo, yielded the 
title product 8 (8.21 g, 81%) as an oil which solidified (white solid) upon cooling (4°C). 
mp 53-57°C (Lit.[235] 55-58°C)  Rf 0.49 (Ethyl acetate : methanol, 8:2); δH (200 MHz; 
CDCl3) 1.42 (9 H, s, (CH3)3), 3.21 (2 H, m, NHCH2), 3.54 (2 H, m, CH2OH), 3.72 (1 H, 
m, CH), 4.25 (2H, br s, 2 x OH), 5.65 (1 H, t, NH). 
 
t-Butoxycarbonylaminoacetaldehyde (9)[202] 
 
To a solution of the diol 8 (7.10 g, 37.0 mmol, 1.00 eq) in 
water (90 mL), was added sodium periodate
 
(9.50 g, 44.4 
mmol, 1.20 eq) and the solution was then left to stir for 1 h at 
rt.  The mixture was then filtered and the aqueous filtrate 
extracted with dichloromethane (3 x 50 ml).  The organic phase was dried over 
anhydrous MgSO4.  Filtration followed by solvent evaporation in vacuo afforded the 
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title compound 9 (4.58 g, 78%) as a colourless oil. δH (200 MHz; CDCl3) 1.45 (9 H, s, 
(CH3)3), 4.08 (2 H, s, CH2), 5.43 (1 H, br s, NH), 9.65 (1 H, s, CHO). 
 
Ethyl N-(2-t-butoxycarbonylaminoethyl)glycinate (10)[202] 
 
Glycine ethyl ester hydrochloride (8.78 g, 63.0 
mmol, 2.50 eq) and NaBH3CN (1.59 g, 25.2 mmol, 
1.00 eq)) were added to a solution of t-
butoxycarbonylaminoacetaldehyde (9) (4.00 g, 25,2 
mmol, 1.00 eq) in methanol (100 mL).  The solution was stirred for 18 h at rt.  Then the 
solvent was removed under reduced pressure and the crude residue afforded was re-
dissolved in water (120 mL).  The pH of the resulting aqueous solution was increased 
to 8 by addition of 2M (aq) sodium hydroxide.  This solution was extracted with 
dichloromethane (3 x 100 mL) and the combined organic fractions were dried over 
anhydrous MgSO4.   Filtration followed by solvent evaporation in vacuo gave a crude 
brownish oil.  This crude mixture was purified by flash column chromatography 
(dichloromethane : methanol, 97.5:2.5) to afford the title compound 10 (2.60 g, 42%) as 
a brown coloured oil. Rf 0.27 (Dichloromethane : methanol 97.5:2.5); δH (200 MHz; 
CDCl3) 1.25 (3 H, t, J 7.0, CH2CH3), 1.42 (9 H, s, (CH3)3), 2.72 (2 H, t, J 6.0, 
CH2CH2NHCH2), 3.19 (3 H, m, BocNHCH2 and CH2CH2NHCH2), 3.38 (2 H, s, 
CH2COOEt), 4.17 (2 H, q, J 7.0, CH2CH3), 5.04 (1 H, br s, BocNH) 
 
Thymin-1-yl acetic acid (11)[146] 
 
Thymine (1.07 g, 7.30 mmol, 1.00 eq) was added to a 5.5 M (aq) KOH 
solution (6 mL).  To this solution was added dropwise, while stirring at 
40°C, bromoacetic acid (1.77 g, 12.7 mmol, 1.74 eq).  Heating was 
continued for a further 60 min.  After cooling to room temperature, the 
pH of the reaction mixture was adjusted to 5.5 by addition of a 
concentrated HCl solution and the resulting solution was cooled to 4 °C for 2 h.  The 
remaining precipitate was removed by filtration and the pH of the filtrate was then 
lowered to 2 by addition of a concentrated HCl solution.  The filtrate was cooled again 
at 4°C for 2 h after which the crude product was collected by filtration, washed with 
cold water (20 mL) and dried in vacuo over P2O5.  This afforded the title compound 11 
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(1.254 g, 93%) as a white solid which was used in a subsequent step without further 
purification. mp 290-293°C (from MeOH); δH (200 MHz; DMSO-d6) 1.75 (3 H, s, CH3 
), 4.36 (2 H, s, CH2 ), 7.49 (1 H, s, C=CH), 11.36 (1 H, s, COOH), 12.95 (1 H, br s, 
NH). 
 
N-(2-t-butoxycarbonylaminoethyl)-N-(thymin-1-ylacetyl) glycine ethyl ester (13)[202] 
 
Thymin-1-yl acetic acid (11) (0.80 g, 4.4 mmol, 1.1 
eq), ethyl-N-(2-t-butoxycarbonyl-aminoethyl)glycinate 
(10) (0.98 g, 4.0 mmol, 1.0 eq) and di-iso-
propylethylamine (2.07 mL, 11.9 mmol, 2.96 eq) were 
dissolved in DMF (10 mL).  HBTU (1.57 g, 4.15 
mmol, 1.0 eq) was then added and the resulting mixture 
was left to stir for 18 h at rt.  Subsequently the solvent was removed in vacuo and the 
residue was re-dissolved in dichloromethane (75 mL).  The organic solution was then 
washed, respectively, with 1M (aq) NaHCO3 (3 x 50 mL), 1M (aq) KHSO4 (2 x 50 
mL), water (50 mL) and, finally, brine (50 mL).  The organic phase was separated and 
dried over anhydrous MgSO4.  Filtration followed by solvent evaporation in vacuo 
afforded a crude, cream coloured foamy solid.  This was purified by flash column 
chromatography (dichloromethane : methanol, 97:3).  The title compound 13 (1.13 g, 
69%) was obtained as colourless foam.  Rf 0.35 (Dichloromethane : methanol, 97:3); δH 
(200 MHz; CDCl3) (2 rotational isomers in a 2:1 ratio observed due to restricted 
rotation about the tertiary amide bond) 1.20 (max) and 1.25 (min) (3 H, t, J 7.2, 
CH2CH3), 1.37 (9 H, s, (CH3)3), 1.83 (3 H, s, C(5)CH3), 3.12-3.34 (2 H, m, 
CH2CH2CON), 3.42-3.54 (2 H, m, CH2CH2NCO), 4.01 (max) and 4.18 (min) (2 H, s, 
NCH2CO2Et), 4.13 (max) and 4.19 (min) (2 H, q, J 7.2, CH2CH3), 4.40 (min) and 4.55 
(max) (2 H, s, NCH2CON), 5.72 (1 H, t, J 6.2, BocNH), 6.95 (max) and 7.00 (min) (1 
H, s, C(6)-H), 9.93 (1 H, br s, CON(3)HCO); δC (50 MHz; CDCl3 ) (2 rotational 
isomers observed due to restricted rotation about the tertiary amide bond) 12.0 (q), 13.7 
(q), 28.0 (q), 38.3 (t), 47.5 (t), 48.3 (t), 48.7 (t), 50.06 (t), 61.3 (t), 61.9 (t), 79.03 (s), 
79.47 (s), 110.3 (s), 140.7 (d), 151.0 (s), 155.8 (s), 164.3 (s), 167.1 (s), 167.5 (s), 169.1 
(s), 169.3 (s). 
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Trifluoroacetic acid salt of N-(aminoethyl)-N-
(thymin-1-ylacetyl) glycine ethyl ester. (14) 
 
N-(2-t-butoxycarbonylaminoethyl)-N-(thymin-1-
ylacetyl) glycine ethyl ester (13) (0.50 g, 1.2 mmol, 
1.0 eq) and trifluoroacetic acid (10.0 mL) were 
dissolved in dichloromethane (30 mL).  This solution was stirred at rt for 1 h.  The 
solvent was then removed in vacuo and the resulting crude product 14 subsequently 
dried in vacuo in a drying pistol over P2O5 at 50° C.  This yielded the title compound 
14 (0.46 g, 89%) as a brownish gum.  δH (200 MHz; CD3OD) (2 rotational isomers in a 
2:1 ratio observed due to restricted rotation about the tertiary amide bond) 1.16 (min) 
and 1.20 (max) (3 H, J 7.5, CH2CH3), 1.77 (3 H, s, C(5)CH3), 3.05 (max) and 3.20 
(min) (2 H, t, J 5.8 and 6.2, CH2CH2NCO), 3.60 (max) and 3.74 (min) (2 H, t, J 5.8 and 
6.2, CH2CH2NCO), 4.09 (min) and 4.17 (max) (2 H, q, J 7.1, CH2CH3), 4.05 (min) and 
4.27 (max) (2 H, s, NCH2COOEt), 4.48 (max) and 4.64 (min) (2 H, s, NCH2CON), 7.18 
(max) and 7.26 (min) (1 H, s, C(6)H); δC (50 MHz; CD3OD) (2 rotational isomers 
observed due to restricted rotation about the tertiary amide bond) 12.10 (q), 15.27 (q), 
38.48 (t), 39.06 (t), 46.82 (t), 47,01 (t), 49.57 (t), 49.63 (t), 50.14 (t), 62.82 (t), 63.18 (t), 
111.03 (s), 111.17 (s), 143.41 (d), 143.64 (d), 153.00 (s), 153.11 (s), 166.73 (s), 169.85 
(s), 171.04 (s), 171.80 (s). 
 
Attempted synthesis of ethyl 2-(N-(2-(9-chloroacridine-4-carboxamido)ethyl)-2-
(thymin-1-yl) acetamido) acetate (15) 
 
A solution of 9-chloroacridine-4-carbonyl 
chloride (4) (0.10 g., 0.34 mmol, 1.0 eq) in dry 
DMF (10 mL) was added dropwise, and under a 
N2 atmosphere, to a stirred solution, at 0° C, of the 
trifluoroacetic acid salt of N-(aminoethyl)-N-
(thymin-1-ylacetyl) glycine ethyl ester (14) (0.15 
g., 0.34 mmol, 1.0 eq) in dry DMF (10 mL) containing excess DIPEA (0.20 mL, 1.1 
mmol, 3.3 eq).  The reaction mixture was allowed to warm to room temperature after 
which it was left to stir for 2 h.  After this time, the solvent was removed in vacuo and 
the crude reaction residue obtained was subjected to purification using preparative TLC 
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(methanol : ethyl acetate : acetic acid, 99:99:2).  Unfortunately, none of the bands 
yielded the title compound 15 upon analysis by 1H-NMR-spectroscopy.   
 
      N-(2-t-butoxycarbonylaminoethyl)-N-(benzyloxycarbonyl) glycine ethyl ester (17) 
 
Ethyl-N-(2-t-butoxycarbonyl-aminoethyl)-glycinate 
(10) (0.50 g, 2.0 mmol, 1.0 eq) was dissolved in 
dichloromethane (75 mL) and a 0.4 M (aq)
 
solution of 
sodium carbonate was added (10.1 mL, 4.06 mmol, 2.0 
eq).  The resulting two-phase mixture was stirred and 
cooled to 0°C.  Subsequently, benzyl chloroformate (0.44 mL, 3.0 mmol, 1.5 eq) was 
added dropwise while the temperature was kept at 0°C.  After the slurry had warmed up 
to rt it was left to stir for 2 h. at rt whereupon the organic phase was separated and the 
aqueous layer was extracted with dichloromethane (50 mL).  The combined organic 
extracts were dried over anhydrous MgSO4.  Filtration followed by solvent evaporation 
in vacuo afforded a crude foamy white residue. This was purified by flash column 
chromatography (cyclohexane : ethyl acetate, 7:1).  The obtained title compound 17 
(0.55 g, 71%) was obtained as a colourless viscous liquid. Rf 0.21 (Cyclohexane : ethyl 
acetate, 7:1); (Found: C, 60.1; H, 7.3; N, 7.4. C19H28O6N2 requires C, 60.0; H, 7.4; N, 
7.4%); max(film)/cm–1 3366, 2972, 2931, 1744, 1715, 1703 , 1520, 1511, 1494, 1469, 
1458, 1365, 1241, 1199, 1173;  δH (200 MHz; CDCl3) (2 rotational isomers in a 1:1 
ratio observed due to restricted rotation about the tertiary amide bond) 0.98 and 1.07 (3 
H, t, J 7.2, CH2CH3), 1.20 and 1.22 (9 H, s, (CH3)3), 2.97-3.15 (2 H, m, 
BocNHCH2CH2), 3.20-3.31 (2 H, m, BocNHCH2CH2), 3.77 and 3.80 (2 H, s, 
NCH2CO2Et), 3.91 and 4.00 (2 H, q, J 7.2, CH2CH3), 4.91 and 4.95 (2 H, s, PhCH2O), 
5.10-5.25 (1 H, m, BocNH), 7.03-7.21 (5 H, m, Ar-H); δC (50 MHz, CDCl3 ): ( 
rotational isomers observed due to restricted rotation about the tertiary amide bond) 
13.7 (q), 28.0 (q), 38.7 (t), 47.5 (t), 48.3 (t), 48.7 (t), 49.6 (t), 49.7 (t), 61.0 (t), 67.2 (t), 
78.8 (s), 127.3 (d), 127.45 (d), 127.7 (d), 128.1 (d), 128.2 (d),  136.0 (s), 155.8 (s), 
156.1 (s), 167.7 (s), 167.9 (s). 
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Hydrogen chloride salt of N-(2-aminoethyl)-N-(benzyloxycarbonyl) glycine ethyl 
ester (18) 
 
N-(2-t-Butoxycarbonylaminoethyl)-N-
(benzyloxycarbonyl) glycine ethyl ester (17) (0.45 g, 1.2 
mmol, 1.0 eq) was dissolved in hydrogen chloride 
saturated solution of absolute ethanol (50 mL).  This 
solution was stirred at room temperature for 1 h. after 
which the solvent was removed in vacuo to yield a crude white solid.  The residue was 
dried azeotropically by the addition of toluene (3 x 50 mL) followed by solvent 
removal in vacuo to yield the desired compound 18 (0.43 g, 96 %) as a white solid.  
The product showed satisfactory purity for use in subsequent experiments.  Mp 184°C 
(dec.) (from EtOH); δH (200 MHz; CD3OD) (2 rotational isomers in a 2:1 ratio 
observed due to restricted rotation about the tertiary amide bond) 1.17 (max) and 1.25 
(min) (3H, t, J 7.1, CH2CH3), 3.10-3.26 (2H, m, CH2CH2NCO), 3.70 (2H, t, J 6.2, 
CH2CH2NCO), 4.04-4.28 (4H, m, CH2CH3 and NCH2CON), 5.12 (max) and 5.29 (min) 
(2H, s, OCH2Ph), 7.25 - 7.46 (5H, m, Ar-H);  δC (50 MHz; CD3OD) (2 rotational 
isomers observed due to restricted rotation about the tertiary amide bond) 14.8 (q), 39.8 
(t), 47.5 (t), 48.1 (t), 51.1 (t), 51.5 (t), 62.9 (t), 69.2 (t), 69.3 (t), 129.1 (d), 129.6 (d), 
129.9 (d), 137.7 (s), 137.8 (s), 158.0 (s), 158.3 (s), 172.4 (s), 172.5 (s). 
 
Attempted synthesis of ethyl 2-(N-(2-(9-chloroacridine-4-carboxamido)ethyl)-N-
(benzyloxycarbonyl) amino)acetate (19) 
 
A solution of 9-chloroacridine-4-carbonyl chloride 
(4) (0.20 g., 0.86 mmol, 1.0 eq) in dry chloroform 
(15 mL) was added dropwise, and under a N2 
atmosphere, to a cooled (0°C) stirred solution of the 
hydrogen chloride salt of N-(aminoethyl)-N-
(benzyloxycarbonyl) glycine ethyl ester (18) (0.28 
g., 0.86 mmol, 1.00 eq) in dry chloroform (30.0 mL) containing di-iso-
propylethylamine (0.45 mL, 2.5 mmol, 2.9 eq).  The reaction mixture was allowed to 
warm to rt and left to stir at rt for 2 h. Subsequently, the solution was washed with a 
10% aqueous solution of Na2CO3 (3 x 15 mL) followed by brine (20 mL).  The organic 
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phase was separated and dried over anhydrous MgSO4.  After filtration, the solvent was 
removed in vacuo and the crude reaction mixture residue subjected to purification by 
using flash column chromatography (petroleum ether : ethyl acetate, 60:40).  All the 
collected fractions contained (a) persistent baseline impurity(s).  In order to find out if 
19 was present in the collected fractions, recrystallisation of the solid (yellow) products 
in the active fractions was attempted, e.g. in ethyl acetate (good solvent) / petrol ether 
(bad solvent), in dichloromethane and in methanol.  Unfortunately, the recrystallisation 
attempts yielded very fine yellow precipitates with persistent impurities and subsequent 
NMR analysis showed that in none of the precipitates the title compound 19 could be 
unambiguously identified.  
 
Hydrochloric acid salt of N-(2-aminoethyl)-N-(thymin-1-ylacetyl) glycine ethyl 
ester (21)  
 
N-(2-t-butoxycarbonylaminoethyl)-N-(thymin-1-ylacetyl) 
glycine ethyl ester (13) (1.02g, 2.47 mmol, 1.00 eq) was 
dissolved in a hydrogen chloride saturated solution of absolute 
ethanol (75 mL).  This solution was stirred at rt for 1 h. 
whereupon the solvent was removed in vacuo to yield a crude 
white solid.  The residue was azeotropically dried by re-
suspending in toluene (3 x 50 mL) followed by solvent removal in vacuo to yield the 
title compound 21 (0.83 g, 96 %) as a white solid.  The product was used in subsequent 
reactions without further purification. mp 224°C (dec) (from MeOH); δH (200 MHz; 
CD3OD) (2 rotational isomers in a 2:1 ratio observed due to restricted rotation about the 
tertiary amide bond) 1.00 (min) and 1.15 (max) (3H, t, J 7.1, CH2CH3), 1.68 (3H, s, 
C(5)CH3), 3.00 (max) and 3.11 (min) (2H, t, J 5.4 and J 6.2, CH2CH2NCO), 3.58 (max) 
and 3.70 (min) (2H, t, J 5.4 and J 6.2, CH2CH2NCO), 4.02 (min) and 4.10 (max) (2H, 
q, J 7.1, CH2CH3), 4.00 (min) and 4.21 (max) (2H, s, NCH2COOEt), 4.47 (max) and 
4.65 (min) (2H, s, NCH2CON), 7.20 (max) and 7.25 (min) (1H, s, C(6)H); δC (50 MHz; 
CD3OD) (2 rotational isomers observed due to restricted rotation about the tertiary 
amide bond) 12.6 (q), 14.8 (q), 39.0 (t), 39.6 (t), 47.3 (t), 47.4 (t), 49.9 (t), 50.0 (t), 51.0 
(t), 63.3 (t), 63.6 (t), 111.4 (s), 111.5 (s), 144.0 (d), 144.2 (d), 153.4 (s), 153.6 (s), 167.2 
(s), 170.4 (s), 171.5 (s), 171.6 (s), 172.3 (s). 
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Iso-propyl-9-oxoacridan-4-carboxylate (22)[210] 
 
METHOD A: Via esterification of 9-oxoacridan-4-carboxylic acid (3): 
To a solution of 9-oxoacridan-4-carboxylic acid (3) (0.30g, 1.3 
mmol, 1.0 eq) in THF (10 mL) was added, 
carbonyldiimidazole (0.42 g, 2.6 mmol, 2.0 eq) and iso-propyl 
alcohol (0.72 g, 12 mmol, 9.5 eq).  This solution was stirred for 
6 h. at rt.  Subsequently, the solvent was removed in vacuo and 
the residue re-dissolved in dichloromethane (50 mL).  The resulting organic solution 
was then washed with a 1 M (aq) solution of ammonium hydroxide (50 mL) followed 
by water (50 mL) then brine (50 mL).  The organic layer was separated and dried over 
anhydrous MgSO4.  Filtration followed by solvent evaporation afforded a crude solid 
residue which was purified by flash column chromatography (petroleum ether (40-
60°C) : ethyl acetate : acetic acid, 70:29:1).  This afforded the title compound 22 (0.18 
g, 51%) as a yellow solid.  mp 149-150 °C (from EtOH); Rf 0.34 (petroleum ether (40-
60°C) : ethyl acetate : acetic acid, 70:29:1); (Found: C, 72.3; H, 5.3; N, 5.0. C17H15NO3 
requires C, 72.6; H, 5.4; N, 5.0%); max(film)/cm–1 3264, 2981, 1687, 1638, 1620, 
1599, 1523, 1441, 1277, 1176, 1146, 1101, 752, 675; δH (200 MHz; CDCl3) 1.36 (6 H, 
d, J 6.2, CH(CH3)2), 5.24 (1 H, septet, J 6.2, CH(CH3)2), 7.10-7.29 (3 H, m, Ar-H), 
7.57 (1 H, t, J 7.9, Ar-H), 8.30-8.35 (2 H, m, Ar-H), 8.60 (1 H, d, J  7.9, Ar-H), 11.71 
(1 H, s, NH); δC (50 MHz; CDCl3) 21.7 (q), 69.2 (d), 113.8 (s), 117.2 (d), 119.4 (d), 
121.1 (s), 121.9 (d), 126.6 (d), 133.2 (d), 133.5 (d), 136.1 (d), 139.7 (s), 141.4 (s), 167.2 
(s), 177.6 (s); LRMS m/z (EI) (%) 281 (M+, 34), 239 (15), 221 (100), 193 (10); HRMS 
(ESI) found 282.1123, calcd. for C17H16ON3 [M+H]+ 282.1125.  
 
METHOD B: Via transesterification of methyl-9-oxoacridan-4-carboxylate (2):    
Sodium (0.16 g, 4.0 mmol, 1.0 eq) was dissolved in dry isopropanol (40 mL) and to this 
solution was added methyl-9-oxoacridan-4-carboxylate (2) (1.00 g, 3.95 mmol, 1.00 eq) 
and activated 4Å molecular sieves (2.4 g).  The mixture was stirred gently for 5 hours 
at rt.  After filtration followed by solvent evaporation in vacuo, the crude solid residue 
afforded was dissolved in dichloromethane (50 mL).  The resulting organic solution 
was washed with a 0.1 M (aq) solution of hydrochloric acid (50 mL) followed by water 
(50 mL) then brine (50 mL).  The organic layer was separated and dried over anhydrous 
MgSO4.  Filtration followed by solvent evaporation in vacuo afforded the title 
N
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compound 22 (0.85 g, 77 %) as a yellow solid.  The analysis of this product was 
identical to that obtained for the product yielded by method A. 
 
t-Butyl-9-oxoacridane-4-carboxylate (23) 
 
A solution of t-butanol (2.94 g, 39.7 mmol, 7.00 eq) in dry 
THF (50 mL) was cooled to 0°C and a 2.5 M solution of n-
butyllithium (15.9 mL, 39.7 mmol, 7.00 eq) in hexane was 
added under nitrogen and whith stirring.  The resulting solution 
was allowed to warm to rt whereupon methyl-9-oxoacridan-4-
carboxylate (2) was added (1.44 g, 5.66 mmol, 1.00 eq).  The reaction mixture was left 
to stir at rt, under nitrogen, for 24 h, after which the solvent was removed in vacuo. The 
crude solid residue afforded was dissolved in dichloromethane (100 mL) and the 
resulting organic solution was washed with water (50 mL) followed by brine (50 mL) 
and then dried over anhydrous MgSO4.  Filtration followed by solvent evaporation 
afforded the title compound 23 (1.50 g, 90.0 %) as a yellow solid. mp 145-148°C (from 
EtOH); Rf 0.63 (Petroleum ether (40-60 °C) : ethyl acetate, 50:50); max(film)/cm–1: 
3268, 2976, 2912, 1683, 1639, 1618, 1600, 1523, 1442, 1294, 1255, 1166, 1138, 754, 
67; δH (200 MHz; CDCl3) 1.60 (9 H, s, C(CH3)3), 7.10-7.30 (3 H, m, Ar-H), 7.49-7.59 
(1 H, m, Ar-H), 8.23 (1 H, dd, J 7.5 and 1.7, Ar-H), 8.31 (1 H, dd, J  8.3 and 1.7, Ar-
H), 8.56 (1 H, dd, J 7.9 and 1.3, Ar-H), 11.76 (1 H, s, NH). δC (50 MHz. CDCl3) 27.7 
(q), 82.3 (s), 114.5 (s), 117.0 (d), 119.1 (d), 120.8 (s), 121.6 (d), 121.7 (s), 126.4 (d), 
132.7 (d), 133.2 (d), 136.05 (d), 139.5 (s), 141.2 (s), 166.8 (s), 177.1 (s). LRMS m/z 
(EI) (%) 295 (M+, 10), 239
 
(48), 221 (100), 193 (17), 164 (22), 139 (24); HRMS (ESI) 
found 296.1283, calcd. for C18H18NO3 (M+H)+ 296.1281. 
 
Methyl-9-(1,2,4-triazol-1-yl)acridine-4-carboxylate (24) 
 
1,2,4-triazole (0.44 g, 6.4 mmol, 10 eq) was dissolved in dry 
acetonitrile (10 mL) and cooled to 0° C.  To this solution was 
added dropwise, freshly distilled phosphorus oxychloride (0.18 
mL, 1.92 mmol, 3.0 eq) followed by freshly distilled TEA (1.07 
mL, 7.68 mmol, 12.0 eq) with stirring under nitrogen.  This 
N
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solution was then allowed to warm to rt whereupon it was left to stir at rt for 30 mins.   
A solution of methyl-9-oxoacridan-4-carboxylate (2) (0.16 g, 0.64 mmol, 1.0 eq) in 
dichloromethane (3 mL) was added and the mixture was heated at reflux for 96 h.  
After cooling, the reaction was quenched by addition of water (0.20 mL) followed by 
TEA (1.10 mL) and left to stir for 10 min. Subsequently the solvent was removed in 
vacuo and the crude greenish solid residue afforded was dissolved in dichloromethane 
(50 mL).  The resulting organic solution was washed with a saturated aqueous solution 
of NaHCO3 (2 x 25 mL) followed by brine (50 mL).  The combined aqueous layers 
were back-extracted with dichloromethane (50 mL).  The combined organic phases 
were dried over anhydrous Na2SO4.  Filtration followed by solvent evaporation 
afforded a crude solid residue which was purified by flash column chromatography 
(petroleum ether (40-60°C) : ethyl acetate : methanol 29:70:1).  The title compound 24 
(0.14 g, 72 %) was afforded as a green solid.  mp 135 °C (dec.) (from CHCl3 / 
Petroleum ether); Rf 0.34 (Petroleum ether (40-60°C) : ethyl acetate : methanol 
29:70:1); (Found: C, 67.0; H, 3.9; N, 18.1. C17H12O2N4 requires C, 67.1; H, 4.0; N, 
18.4%); δH (200 MHz; CDCl3 ) 4.03 (3 H, s, OCH3), 7.43-7.56 (4 H, m, Ar-H), 7.70 (1 
H, ddd, J 8.8, J 6.2 and J 1.7, Ar-H), 8.01 (1 H, dd, J 6.2 and 1.7, Ar-H), 8.23 (1 H, d, J 
8.8, Ar-H), 8.33 (1 H, s, NCHN), 8.59 (1 H, s, NCHN); δC (50 MHz; CDCl3) 52.5 (q), 
121.8 (d), 122.0 (s), 125.4 (d), 126.5 (d), 128.5 (d), 130.3 (d), 130.8 (d), 131.2 (d), 
132.0 (s), 137.3 (s), 145.8 (s), 146.3 (d), 149.3 (s), 153.1 (d), 167.6 (s), 170.9 (s); 
LRMS m/z (EI) (%) 304 (M+,46), 273 (27), 246 (94), 83 (54), 69 (85), 55 (70), 43 
(100).  
 
Iso-propyl-9-(1,2,4-triazol-1-yl)acridine-4-carboxylate (25)    
 
1,2,4-triazole (0.44 g, 6.4 mmol, 10 eq ) was dissolved in dry 
acetonitrile (10 mL) and the resulting solution was cooled to 0° 
C.  To this solution was added dropwise, freshly distilled 
phosphorus oxychloride (0.18 mL, 1.9 mmol, 3.0 eq) followed 
by freshly distilled TEA (1.07 mL, 7.68 mmol, 12 eq) with 
stirring under nitrogen.  The resulting mixture was warmed to rt 
before being left to stir for 30 min. at rt.  A solution of iso-propyl-9-oxoacridan-4-
carboxylate (22) (0.18 g, 0.64 mmol, 1.0 eq) in dichloromethane (3 mL) was added and 
the mixture was heated at reflux for 96 h.  After cooling, the reaction was quenched by 
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addition of water (0.20 mL) followed by TEA (1.10 mL) and left to stir for 10 min.  
Subsequently the solvent was removed in vacuo and the crude greenish solid residue 
afforded was dissolved in dichloromethane (50 mL).  The resulting organic solution 
was washed with a saturated aqueous solution of NaHCO3 (2 x 25 mL) followed by 
brine (50 mL).  The combined aqueous layers were back extracted with 
dichloromethane (50 mL).  The combined organic phases were dried over anhydrous 
Na2SO4.  Filtration followed by solvent evaporation afforded a crude solid residue 
which was purified by flash column chromatography (petrol ether (40-60°C) : ethyl 
acetate : methanol 32:65:3). This afforded the title compound 25 (0.16 g, 75%) as a 
dark green solid. mp 149-153°C (from CH2Cl2 / Petroleum ether); Rf 0.28 (Petroleum 
ether (40-60 °C) : ethyl acetate : methanol, 32:65:3); max(KBr)/cm–1 3086, 2979, 1720, 
1556, 1524, 1503, 1440, 1422, 1304, 750, 694, 675, 662; δH (200 MHz; CDCl3 ) 1.44 (6 
H, d, J 6.2, CH(CH3)2), 5.47 (1 H, septet, J 6.2, CH(CH3)2), 7.40-7.57 (4 H, m, Ar-H), 
7.73-7.81 (1 H, m, Ar-H), 7.99 (1 H, dd, J 5.8 and 2.5, Ar-H), 8.26 (1 H, d, J 8.0, Ar-
H), 8.35 (1 H, s, NCHN), 8.48 (1 H, s, NCHN); δC (50 MHz; CDCl3) 21.5 (q), 68.8 (d), 
121.5 (d), 124.5 (d), 126.4 (d), 127.7 (s), 128.2 (d), 128.5 (s), 130.0 (d), 130.1 (d), 
130.4 (d), 132.8 (s), 136.8 (s), 145.7 (s), 145.9 (d), 149.1 (s), 152.9 (d), 166.7 (s); 
LRMS m/z (EI) (%) 332 (M+, 12), 273 (14), 246 (78), 86 (53), 69 (72), 43 (100); 
HRMS (ESI) found 333.1345, calcd. for C19H17O2N4 [M+H]+  333.1346. 
 
t-Butyl-9-(1,2,4-triazol-1-yl)acridine-4-carboxylate (26) 
 
1,2,4-triazole (2.37 g, 34.4 mmol, 10 eq) was dissolved in dry 
acetonitrile (50 mL) and cooled to 0° C.  To this solution was 
added dropwise, freshly distilled phosphorus oxychloride (0.95 
mL, 10 mmol, 3.0 eq) followed by freshly distilled TEA (5.67 
mL, 40.7 mmol, 12 eq) with stirring under nitrogen. The 
resulting mixture was warmed to rt before being left to stir for 30 
min. at rt.  A solution of t-butyl-9-oxoacridane-4-carboxylate (23) (0.98 g, 3.3 mmol, 
1.0 eq) in dichloromethane (15 mL) was added and the resulting mixture was heated at 
reflux for 96 h. After cooling, the reaction was quenched by addition of water (1.10 
mL) followed by TEA (5.67 mL) and left to stir for 10 min.   Subsequently the solvent 
was removed in vacuo and the greenish solid residue was dissolved in dichloromethane 
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(250 mL).  The resulting organic solution was washed with a saturated aqueous solution 
of NaHCO3 (2 x 125 mL) followed by brine (250 mL).  The combined aqueous layers 
were back extracted with dichloromethane (150 mL).  The combined organic phases 
were dried over anhydrous Na2SO4.  Filtration followed by solvent evaporation 
afforded a crude solid residue which was purified by flash column chromatography 
(petroleum ether (40-60°C) : ethyl acetate : methanol, 33.5:65.0:1.5).  This afforded the 
title compound 26 (0.86 g, 75%) as a dark green solid. mp 143-147°C (from CHCl3 / 
Petroleum ether); Rf 0.26 (petroleum ether (40-60°C) : ethyl acetate : methanol, 
33.5:65.0:1.5); δH (200 MHz; CDCl3) 1.66 (9 H, s, C(CH3)3), 7.36-7.51 (4 H, m, Ar-H), 
7.68-7.76 (1 H, m, Ar-H), 7.88 (1 H, dd, J 4.9 and 3.3, Ar-H), 8.21 (1 H, d, J 8.8, Ar-
H), 8.32 (1 H, s, NCHN), 8.52 (1 H, s, NCHN); δC (50 MHz, CDCl3): 28.1 (q), 82.2 (s), 
121.7 (d), 121.8 (s), 121.9 (s), 124.2 (d), 126.7 (d), 128.3 (d), 129.4 (d), 130.2 (d), 
130.5 (d), 134.2 (s), 136.9 (s), 145.8 (s), 146.2 (d), 149.1 (s), 153.0 (d), 166.9 (s); 
LRMS m/z (EI) (%) 346 (M+, 8), 246 (100), 192 (24), 179 (16), 57 (48); HRMS (ESI) 
found 347.1501, calcd. for C20H19O2N4 [M+H]+ 347.1503. 
 
Attempted preparation of methyl-9-benzylaminoacridine-4-carboxylate (27) (led to 
benzylamine-9-benzylaminoacridine-4-carboxylate 27* instead) 
 
Methyl-9-(1,2,4-triazol-1-yl)acridine-4-
carboxylate (24) (0.14 g, 0.41 mmol, 1.0 
eq) was dissolved in dry acetonitrile (10 
mL).  To this solution was added dry 
benzylamine (0.45 mL, 4.1 mmol, 10 eq) 
followed by dry TEA (0.90 mL, 6.4 
mmol, 16 eq).  The reaction mixture was 
heated to reflux, with stirring under a nitrogen atmosphere, and left at this temperature 
for 24 h. Subsequently, the reaction mixture was allowed to cool and the solvent was 
removed in vacuo.  A crude solid residue was afforded which was purified by flash 
column chromatography (ethyl acetate : petrol ether : triethylamine, 60:39:1). 1H-NMR 
analysis of active fractions suggested exclusive presence of the undesired benzyl-9-
benzylaminoacridine-4-carboxamide by-product 27* (1H-NMR data for 27* are 
reported below) 
N
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δH (200 MHz; DMSO-d6) 4.81 (2H, d, J 4.0, CH2), 5.15 (2H, d, J 8.4, CH2), 7.18-7.61 
(12H, m, Ar-H), 7.71-7.89 (3H, m, Ar-H),  8.29-8.74 (2H, m, Ar-H), 12.71 (1H, t, J 
8.4, NH) 
 
Iso-propyl-9-benzylaminoacridine-4-carboxylate (28) 
 
Iso-propyl-9-(1,2,4-triazol-1-yl)acridine-4-carboxylate (25) (0.32 g, 
0.95 mmol, 1.0 eq) was dissolved in dry acetonitrile (20 mL).  To 
this solution was added dry benzylamine (1.04 mL, 9.53 mmol, 10 
eq) followed by dry TEA (2.08 mL, 15.0 mmol, 16 eq).  The 
reaction mixture was heated to reflux, with stirring under a nitrogen 
atmosphere, and left at this temperature for 24 h. Subsequently, the 
reaction mixture was allowed to cool and the solvent was removed 
in vacuo.  A crude solid residue was afforded which was purified by flash column 
chromatography (petroleum ether (40-60°C) : diethyl ether : ethanol : triethylamine, 
80:15:4:1).  The title compound 28 (0.20 g, 57%) was obtained as a yellow oily solid. 
Rf  0.28 (petroleum ether (40-60°C) : diethyl ether : ethanol : triethylamine, 80:15:4:1); 
max(film)/cm–1: 3309, 3062, 3028, 2979, 2960, 2933, 2872, 1682, 1647, 1609, 1578, 
1515, 1494, 1446, 1270, 1188, 1150, 1088, 775, 750, 725, 700; δH (200 MHz; CDCl3) 
(cis-trans isomers observed in a 2:1 ratio due to restricted rotation about the C9-N 
bond) 1.37 (6 H, d, J 6.2, CH(CH3)2), 5.10 (min) and 5.15 (max) (2 H, s, CH2Ph), 5.25 
(1 H, septet, J 6.2, CH(CH3)2), 6.88-7.50 (9 H, m, Ar-H), 7.84-7.99 (1 H, m, Ar-H), 
8.08-8.15 (1 H, m, Ar-H), 8.28-8.57 (1 H, m, Ar-H), 10.91 (max) and 11.13 (min) (1 H, 
s, N(10)H); δC (50 MHz; CDCl3) (cis-trans isomers observed due to restricted rotation 
about the C9-N bond) 22.13 (q), 56.95 (t), 68.94 (d), 112.40 (s), 113.19 (s), 115.85 (d), 
117.31 (d), 117.45 (d), 117.90 (s), 119.92 (d), 120.26 (d), 122.50 (d), 125.56 (d), 
125.83 (d), 126.16 (d), 126.62 (d), 127.10 (d), 127.60 (d), 127.78 (d), 128.29 (d), 
128.37 (d), 128.56 (d), 129.26 (d), 130.54 (d), 131.10 (d), 132.61 (d), 133.41 (d), 
135.03 (d), 137.72 (s), 140.91 (s), 141.02 (s), 142.40 (s), 143.96 (s), 153.88 (s), 167.90 
(s), 168.07 (s); LRMS m/z (EI) (%) 370 (M+, 21), 327 (16), 283 (5), 205 (19), 177 (20), 
91 (51), 43 (100); HRMS (ESI) found 371.1756, calcd. for C24H23O2N2 [M+H]+ 
371.1754. 
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t-Butyl-9-benzylaminoacridine-4-carboxylate (29) 
 
t-Butyl-9-(1,2,4-triazol-1-yl)acridine-4-carboxylate (26) (1.21 g, 
3.39 mmol, 1.00 eq) was dissolved in dry acetonitrile (50 mL).  To 
this solution was added dry benzylamine (3.62 mL, 33.2 mmol, 
9.78 eq) followed by dry TEA (6.92 mL, 49.8 mmol, 14.7 eq).  The 
resulting mixture was stirred under nitrogen and heated at reflux for 
24 h. Subsequently, the reaction mixture was allowed to cool down 
and the solvent was removed in vacuo.  This afforded a crude 
yellow oily residue which was purified by flash column chromatography (petroleum 
ether (40-60°C) : ethyl acetate : triethylamine 90:9:1).  The title compound 29 (0.63 g, 
54%) was obtained as slowly solidifying yellow oil.  Rf 0.27 (petroleum ether (40-
60°C) : ethyl acetate : triethylamine 90:9:1); max(film)/cm–1 3313, 3052, 3018, 2973, 
2960, 2924, 1683, 1645, 1608, 1578, 1521, 1494, 1449, 1284, 1256, 1170, 1138, 759, 
747, 735, 700; δH (200 MHz; CDCl3 ) (cis-trans isomers observed in a 2:1 ratio due to 
restricted rotation about the C9-N bond) 1.55 (9H, s, C(CH3)3), 5.04 (min) and 5 .09 
(max) (2H, s, CH2Ph),  6.90-7.45 (9 H, m, Ar-H), 7.84-7.99 (1 H, m, Ar-H), 8.18-8.28 
(1 H, m, Ar-H), 8.40-8.50 (1 H, m, Ar-H), 10.87 (max) and 11.11 (min) (1 H, s, 
N(10)H); δC (50 MHz; CDCl3) (cis-trans isomers observed due to restricted rotation 
about the C9-N bond)  28.1(q), 56.6 (t), 81.7 (s), 82.0 (s), 113.0 (s), 113.7 (s), 115.5 (d), 
116.9 (d), 117.5 (s), 119.4 (d), 119.8 (d), 122.0 (s), 124.0 (s), 125.2 (d), 125.8 (d), 126.2 
(d), 126.8 (d), 127.2 (d), 127.8 (d), 128.1 (d), 128.2 (d), 128.3(d), 128.4 (d), 128.9 (d), 
129.5 (d), 130.1 (d), 130.5 (d), 130.6 (d), 132.0 (d), 132.8 (d), 133.2 (d), 134.4 (d), 
136.0 (s), 137.4 (s), 139.2 (s), 140.6 (s), 142.1 (s), 143.6 (s), 153.5 (s), 153.7 (s), 167.4 
(s), 167.6 (s); LRMS m/z (EI) (%) 384 (M+, 30), 327 (100), 282 (61), 279 (11), 177 
(78); HRMS (ESI) found 385.1913, calcd. for C25H25O2N2 [M+H]+ 385.1911. 
 
9-benzylaminoacridine-4-carboxylic acid (30) 
 
METHOD A: Via hydrolysis of iso-propyl-9-benzylaminoacridine-4-carboxylate 
(28) under basic aqueous conditions: 
A solution of iso-propyl-9-benzylaminoacridine-4-carboxylate (28) 
(0.050 g, 0.14 mmol, 1.0 eq) in dioxane (2mL) and a 0.6 M 
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aqueous lithium hydroxide solution (1.0 mL, 0.60 mmol, 4.3 eq) were combined with 
stirring at rt for 24 h.  Subsequently, the reaction mixture was neutralised with 2.0 M 
HCl and cooled to 4 °C for 24 hours, after which a yellow solid had precipitated.  The 
solid was filtered off and washed with cold water (0°C) (20.0 mL) followed by diethyl 
ether (20.0 mL) and dried in vacuo over P2O5. This afforded the product 30 (0.028 g, 59 
%) as a yellow solid that was used in a subsequent step without further purification. mp 
236°C (dec) (from MeOH).  δH (200 MHz; DMSO-d6) (cis-trans isomers observed in a 
2:1 ratio due to restricted rotation about the C9-N bond) 5.45 (min) and 5.51 (max) (2 
H, s, CH2Ph), 7.46-7.80 (7 H, m, Ar-H), 7.88-8.10 (2 H, m, Ar-H), 8.39-8.91 (3 H, m, 
Ar-H), 11.69 (max) and 11.90 (min) (1 H, s, CH2NH), 13.71 (1 H, br s, COOH); δC (50 
MHz; DMSO-d6) (cis-trans isomers observed due to restricted rotation about the C9-N 
bond) 51.0 (t), 111.7 (s), 113.0 (s), 113.4 (s), 118.2 (d) , 119.6 (d), 120.2 (s), 120.9 (d), 
121.0 (d), 121.7 (d), 122.0 (s), 123.1 (d), 123.4 (d), 125.6 (d), 126.0 (d), 126.7 (d), 
127.5 (d), 128.0 (d), 128.8 (d), 133.4 (d), 134.0 (d), 135.7 (d), 136.1 (d), 137.9 (s), 
140.1 (s), 141.2 (s), 141.8 (s), 143.1 (s), 156.3 (s), 167.9 (s), 172.0 (s), 177.0 (s), 201.3 
(s); LRMS m/z (ESI) (%) 327 ([M-H]-, 3), 238 (8), 77 (4), 75 (100); HRMS (ESI) 
found 327.1140, calcd. for C21H15O2N2 [M-H]- 327.1139. 
 
METHOD B:  Attempted preparation of 9-benzylaminoacridine-4-carboxylic acid 
(30) via ester cleavage of iso-propyl-9-benzylaminoacridine-4-carboxylate (28) 
with iodotrimethylsilane. 
Iso-propyl-9-benzylaminoacridine-4-carboxylate (28) (0.050 g, 0.14 mmol, 1.0 eq) and 
sodium iodide (0.040 g, 0.26 mmol, 2.0 eq) were dissolved in acetonitrile (4 mL).  To 
this solution was added, with stirring and under nitrogen, trimethylsilyl chloride (0.03 
mL, 0.3 mmol, 2 eq).  The reaction mixture was then heated at 85°C for 72 hours, with 
stirring under nitrogen atmosphere, whereupon the mixture was cooled to rt and the 
reaction was quenched by addition of water (3.5 mL).  The reaction mixture was left to 
stir at rt for 30 mins whereupon the solvent was removed in vacuo and the crude 
residue analysed by NMR.  This analysis showed little or no deprotection had taken 
place. 
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METHOD C:  Attempted preparation of 9-benzylaminoacridine-4-carboxylic acid 
(30) via ester cleavage of iso-propyl-9-benzylaminoacridine-4-carboxylate (28) 
with AlCl3. 
To a cooled solution (0°C) of AlCl3 (0.22 g, 1.6 mmol, 4.0 eq) in dry DCM (2 mL) was 
added dropwise a solution of iso-propyl-9-benzylaminoacridine-4-carboxylate (28) 
(0.15 g, 0.41 mmol, 1.0 eq) in dry DCM (1 mL).  The reaction mixture was stirred for 1 
h at rt and then poured into an ice-slurry (15 mL) whereupon the resulting suspension 
was filtered and the separated yellow solid washed with water (15 mL) followed by 
diethyl ether (15mL) and dried in vacuo over phosphorus pentoxide.  NMR analysis of 
the yellow precipitate suggested almost exclusive presence of 9-aminoacridine-4-
carboxylic acid 31 (0.09 g, 92 %), not the expected 9-benzylamino acridine-4-
carboxylic acid 30. 
 
METHOD D:  Attempted preparation of 9-benzylaminoacridine-4-carboxylic acid 
(30) via selective ester cleavage of t-butyl-9-benzylaminoacridine-4-carboxylate 
(29) with Yb(OTf)3  
t-Butyl-9-benzylaminoacridine-4-carboxylate (29) (0.20 g, 0.58 mmol, 1.0 eq) was 
dissolved in nitro methane (3 mL) and to the resulting solution was added 0.02 g (5 
mol%) of Yb(OTf)3. The resulting reaction mixture was stirred for 18 hours at 50°C.  
Subsequently, the solvent was removed in vacuo and the crude solid residue was taken 
up in dioxane and filtered through a Celite pad.  The filtrate was cooled (4°C) for 24 h 
whereupon a yellow precipitate was separated by filtration and washed with water (10 
mL) followed by diethyl ether (10 mL) and dried in vacuo over P2O5.  NMR analysis of 
the yellow solid revealed almost exclusive presence of the starting material 29. 
  
METHOD E:  Attempted preparation of 9-benzylaminoacridine-4-carboxylic acid 
(30) via acid ester hydrolysis of t-butyl-9-benzylaminoacridine-4-carboxylate (29) 
with sulphuric acid  
A solution of t-butyl-9-benzylaminoacridine-4-carboxylate (29) (0.070 g, 0.18 mmol, 
1.0 eq) in dichloromethane (5 mL) was added dropwise into a cooled (0° C), stirred 
emulsion of concentrated sulphuric acid (0.005 mL, 0.2 mmol, 1 eq) in 
dichloromethane (5 mL).  The resulting mixture was stirred for six hours at room 
temperature.  Solvents were removed in vacuo and the crude solid yellow residue was 
re-suspended in water (5 mL) and stirred for 5 mins. Subsequently, the yellow solid 
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was separated by filtration, washed with diethyl ether (5 mL) and dried in vacuo over 
P2O5.  MS and NMR analysis of the yellow solid did however suggest very little of the 
expected 9-benzylaminoacridine-4-carboxylic acid (30) was present besides a number 
of unidentified by-products. 
 
Attempted preparation of Ethyl 2-(N-(2-(9-benzylaminoacridine-4-carboxamido) 
ethyl)-2-(thymin-1-yl)acetamido)acetate (32)  
 
METHOD A: Via acid activation of 9-benzylaminoacridine-4-carboxylic acid (30) 
with dicyclohexylcarbodiimide and N-hydroxysuccinimide: 
To a solution of 9-benzylaminoacridine-4-carboxylic 
acid (30) (0.16 g, 0.49 mmol, 1.0 eq) and N-
hydroxysuccinimide (0.070 g, 0.62 mmol, 1.2 eq) in 
DMF (5 mL) was added, slowly, 
dicyclohexylcarbodiimide (0.21 g, 0.62 mmol, 1.2 
eq) in DMF (5 mL) and the resulting mixture was 
stirred for 48 h. at rt.  To this mixture was then added a solution of the hydrochloric 
acid salt of N-(aminoethyl)-N-(thymin-1-ylacetyl) glycine ethyl ester (21) (0.22 g, 0.62 
mmol, 1.2 eq) and TEA (172 µL, 1.24 mmol, 2.5 eq) in dimethylformamide (5 mL) and 
this was stirred for 24 h. at rt.  Subsequently, the solvent was removed in vacuo and the 
crude solid residue was purified by flash column chromatography (petroleum ether : 
ethyl acetate : methanol : triethylamine, 40:45:14:1).  Unfortunately, neither MS nor 
NMR analysis confirmed presence of the potential conjugate 32 in any of the collected 
fractions. 
 
METHOD B: Via acid activation of 9-benzylaminoacridine-4-carboxylic acid (30) 
with O-Benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate 
(HBTU): 
To a solution of 9-Benzylaminoacridine-4-carboxylic acid (30) (0.070 g, 0.20 mmol, 
1.0 eq) in dimethylformamide (3 mL) was added HBTU (0.080 g, 0.20 mmol, 1.0 eq) 
and DIPEA (0.10 mL, 0.55 mmol, 2.7 eq).  The resulting mixture was stirred for 24 h. 
at rt. whereupon a solution of the trifluoroacetic acid salt of N-(aminoethyl)-N-(thymin-
1-ylacetyl) glycine ethyl ester (0.22 g, 0.62 mmol, 1.2 eq) 14 and TEA (172 µL, 1.24 
mmol, 2.5 eq) in DMF (5 mL) was added.  The resulting mixture was stirred for another 
N
NH
O N
H
N
O
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24 h. at rt.  Subsequently, the reaction was quenched with a 5% (aq) solution of NH4Cl 
(1 mL) and left to stir at rt for 10 mins.  The solvent was removed in vacuo and the 
crude reaction residue was purified by flash column chromatography (petroleum ether : 
ethyl acetate : methanol : triethylamine, 40:45:14:1).  Unfortunately, neither MS nor 
NMR analysis confirmed presence of the potential conjugate 32 in any of the collected 
fractions. 
 
Iso-propyl-9-anilinoacridine-4-carboxylate (33)[210] 
 
To a solution of Iso-propyl-9-(1,2,4-triazol-1-yl)acridine-4-
carboxylate (25) (0.32 g, 0.95 mmol, 1.0 eq) in dry 
acetonitrile (20 mL) was added dry aniline (0.87 mL, 9.5 
mmol, 10 eq) and dry TEA (2.1 mL, 14 mmol, 15 eq).  The 
resulting mixture was heated at reflux while stirring and 
under nitrogen for 24 h. Subsequently, the reaction mixture 
was allowed to cool down and the solvent was removed in vacuo.  This afforded a solid 
residue which was purified by flash column chromatography (petroleum ether (40-
60°C) : ethyl acetate : triethylamine, 95:4:1).  The title compound 33 (0.23 g, 67 %) 
was obtained as an orange-red solid. mp 135-137°C (from dichloromethane/petrol 
ether); Rf 0.26 (Petroleum ether (40-60°C) : ethyl acetate : triethylamine, 95:4:1); 
(Found: C, 77.2; H, 5.8; N, 7.5. C23H20N2O2 requires C, 77.5; H, 5.7; N, 7.8%); 
max(film)/cm–1: 3285, 3067, 2980, 2938, 1680, 1612, 1587, 1519, 1478, 1446, 1276, 
1141, 1104, 776, 750, 696; δH (200 MHz; CDCl3 ) 1.33 (6 H, d, J 6.2, CH(CH3)2), 5.22 
(1 H, septet, J 6.2, CH(CH3)2), 6.48-6.66 (1 H, m, Ar-H), 6.78 (2 H, d, J 8.3, Ar-H), 
6.92 (1 H, t, J 7.5, Ar-H), 7.05 (2 H, t, J 7.1, Ar-H), 7.28 (4 H, t, J 7.5, Ar-H), 8.09 (1 
H, s, Ar-H), 8.60 (1 H, s, Ar-H), 11.20 (1 H, br s, N(10)H); δC (50 MHz; CDCl3) 21.4 
(q), 68.4 (d), 112.4 (s), 116.9 (d), 117.7 (d), 119.0 (s), 120.1 (d), 121.3 (d), 124.8 (d), 
127.7 (d), 128.5 (d), 129.2 (d), 130.8 (d), 133.1 (s), 133.4 (d), 139.5 (s), 140.8 (s), 150.4 
(s), 152.9 (s), 167.2 (s);  LRMS m/z (ESI) (%) 357 ([M+H]+, 100), 60 (2); HRMS (ESI) 
found 357.1602, calcd. for C23H21O2N2 [M+H]+ 357.1598. 
 
 
 
 
N
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9-anilinoacridine-4-carboxylic acid (34)[210] 
 
To a solution of iso-propyl-9-anilinoacridine-4-carboxylate (33) 
(0.21 g, 0.58 mmol, 1.0 eq) in tetrahydrofuran (4 mL) was added 
a 1.0 M (aq) lithium hydroxide solution (1.00 mL, 1.00 mmol, 
1.7 eq).  The resulting mixture was stirred at rt for 48 h 
whereupon the reaction mixture was quenched by addition of a 
2.0 M (aq) HCl solution until a neutral pH was reached.  
Subsequently, solvents were removed in vacuo and the crude orange solid residue 
containing the 9-anilinoacridine-4-carboxylic acid (34) and LiCl was not purified 
further for use in the subsequent (activation) step.  Rf 0.32 (Petroleum ether (40-60 °C) : 
ethyl acetate : methanol : triethylamine, 40:40:19:1); max(KBr)/cm–1 3416br, 1622, 
1587, 1568, 1552, 1525, 1452, 1432, 1400, 1356, 1273, 1156; δH (200 MHz; CD3OD ) 
7.30-7.53 (7 H, m, Ar-H), 7.78-7.92 (2 H, m, Ar-H), 8.01 (1 H, d, J 9.1, Ar-H), 8.35 (1 
H, dd, J 8.7 and 1.2, Ar-H), 8.60 (1 H, dd, J 7.5 and 1.2, Ar-H); δC (50 MHz; CD3OD) 
115.2 (s), 115.8 (s), 119.0 (s), 121.5 (d), 124.4 (d), 126.3 (d), 126.4 (d), 127.3 (d), 130.0 
(d), 131.9 (d), 132.8 (d), 137.9 (d), 140.8 (d), 141.1 (s), 141.9 (s), 142.0 (s), 158.2 (s), 
171.0 (s); LRMS m/z (EI) (%) 314 (M+, 100), 270 (61), 246 (27), 176 (8). 
 
N-[2-(dimethylamino)ethyl]-9-anilinoacridine-4-carboxamide (35) 
 
To a solution of 9-anilinoacridine-4-carboxylic acid (34) 
(0.14 g, 0.43 mmol, 1.0 eq) and N-hydroxysuccinimide (0.10 
g, 0.87 mmol, 2.0 eq), in dimethylformamide (5 mL), was 
added slowly dicyclohexylcarbodiimide (0.18 g, 0.54 mmol, 
1.2 eq) in dimethylformamide (3 mL).  The resulting mixture 
was stirred for 24 h. at rt. whereupon the dicyclohexylurea by-product was removed by 
filtration.  To the filtrate was subsequently added an excess of N,N-
dimethylethylenediamine (5.00 mL, 45.0 mmol, 105 eq) and the resulting mixture was 
stirred for another 24 h. at rt.  After removing the solvent in vacuo the reaction mixture 
residue was purified by flash column chromatography (ethyl acetate : methanol : 
triethylamine, 90:9:1).  This afforded the title compound 35 (0.08 g, 46 %) as a yellow-
orange oily solid. Unfortunately, the oily solid character of 35 prevented us from taking 
a reliable mp.  Rf 0.29 (ethyl acetate : methanol : triethylamine, 90:9:1); max (film)/cm–
N
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1: 3262, 3166, 3059, 2975, 2945, 2860, 2821, 2774, 1773, 1698, 1640, 1620, 1600, 
1587, 1558, 1525, 1496, 1471, 1438, 1417, 1360, 1293, 1272, 1252; δH (200 MHz; 
DMSO-d6)  (rotational isomers observed in a 4:1 ratio due to restricted rotation about 
C(4)–CONH) 2.45 (6 H, s, N(CH3)2), 2.69 (2 H, m, CH2N(CH3)2), 3.79 (2 H, m, 
CONHCH2), 6.86 (1 H, m, Ar-H), 6.91-7.10 (2 H, m, Ar-H), 7.21-7.32 (2 H, m, Ar-H), 
7.45-7.63 (2 H, m, Ar-H), 7.85-7.98 (1 H, m, Ar-H), 8.15-8.31 (2 H, m, Ar-H), 8.42 (1 
H, d, J 8.7, Ar-H), 8.74 (1 H, d, J 6.6, Ar-H), 8.88 (min) and 9.60 (max) (1H, s, 
CONH), 11.90 (min) and 12.16 (max) (1H, s, N(10)H); δC (50 MHz, DMSO-d6): 37.9 
(t), 45.9 (q), 65.8 (t), 118.7 (d), 119.8 (s), 120.7 (s), 122.3 (d), 124.0 (d), 125.5 (d), 
125.7 (d), 129.2 (d), 130.1 (d), 130.6 (s), 132.3 (d), 134.0 (d), 135.1 (d), 146.2 (s), 
147.8 (s), 147.9 (s), 149.0 (s), 165.6 (s); LRMS m/z (ESI) (%) 385 ([M+H]+, 100), 193 
(3); HRMS (ESI) found 385.2023, calcd. for C24H25O1N4 [M+H]+ 385.2022. 
 
 
Ethyl 2-(N-(2-(9-anilinoacridine-4-carboxamido)ethyl)-2-(thymin-1-yl)acetamido) 
acetate (36) 
 
To a solution of 9-anilinoacridine-4-carboxylic acid 
(34) (0.18 g, 0.58 mmol, 1.0 eq) and N-
hydroxysuccinimide (0.13 g, 1.2 mmol, 2.0 eq) in 
dimethylformamide (5 mL) was added slowly 
dicyclohexylcarbodiimide (0.24 g, 0.72 mmol, 1.2 
eq) in dimethylformamide (3 mL).  The resulting mixture was stirred for 24 h. at rt, 
whereupon the dicyclohexylurea by-product was removed by filtration.  To the filtrate 
was added a solution of the hydrochloric acid salt of the thyminyl-PNA-monomer 21 
(0.25 g, 0.72 mmol, 1.2 eq) and triethylamine (0.20 mL, 1.4 mmol, 2.5 eq) in 
dimethylformamide (5 mL).  The resulting mixture was stirred for another 24 h. at rt.  
Subsequently, the solvent was removed in vacuo and the reaction residue was purified 
by flash column chromatography (petroleum ether : ethyl acetate : methanol : 
triethylamine, 50:50:4:1) as the eluent.  This afforded the title compound 36 (0.23 g, 
64.4 %) as a yellow oily solid. Unfortunately, the oily solid character of 36 prevented 
us from taking a reliable mp.  Rf 0.35 (petroleum ether : ethyl acetate : methanol : 
triethylamine, 50:50:4:1); max(KBr)/cm–1 3185, 3052, 2981, 2946, 1744, 1689, 1674, 
1641, 1619, 1602, 1560, 1525, 1494, 1473, 1442, 1435, 1424, 1363, 1334, 1299, 1262, 
N
NH
O N
H
N
O
N
NH
O
O
O
O
36
Chapter 3: Experimental 
180 
1212, 1190, 1166, 1150, 1096, 1036, 1021, 962, 760; δH (400 MHz; DMSO-d6) 
(rotational isomers observed in a 6:3:1 or 9:1 ratio due to restricted rotation about the 
tertiary and secondary amide bond) 1.18 (0.3 H) and 1.20 (2.7 H) (3 H, t, J 7.1, 
CH2CH3), 1.24 (1.8 H) and 1.54 (0.3 H) and 1.68 (0.9 H) (3 H, s, CHCCH3), 3.45-3.59 
(0.4 H) and 3.60-3.73 (1.2 H) and 3.73-3.85 (2.4 H) (4 H, m, CH2CH2NCO), 4.10 (0.2 
H) and 4.12 (1.8 H) (2H, q, J 7.1, CH2CH3), 4.21 (1.2 H) and 4.39 (0.2 H) and 4.46 (0.2 
H) and 4.51 (0.6 H) and 4.73 (1.8 H) (4 H, s, NCH2COOEt and NCH2CON), 6.52-7.04 
(4 H, m, Ar-H and CHCCH3 ), 7.14-7.36 (3 H, m, Ar-H), 7.40-7.57 (2 H, m, Ar-H), 
7.78-8.08 (1 H, m, Ar-H), 8.15 and 8.28 (1 H, d, J 8.60, Ar-H), 8.31-8.38 (1 H, m, Ar-
H), 8.62-8.70 (1 H, m, Ar-H), 9.50 and 9.54 (1 H, br s, NH), 11.28 and 11.36 (1 H, br s, 
NH), 11.70-11.92 (1 H, br s, NH); δC (100 MHz; DMSO-d6) (rotational isomers 
observed in a 6:3:1 ratio due to restricted rotation about the tertiary and secondary 
amide bond )11.4 (q), 11.7 (q), 11.8 (q), 14.0 (q), 30.4 (q), 37.6 (t), 46.5 (t), 47.7 (t), 
47.8 (t), 48.4 (t), 60.6 (t), 107.8 (d), 108.1 (d), 117.8 (d), 117.9 (d), 119.0 (s), 119.8 (s), 
121.4 (d), 121.5 (d), 121.7 (d), 123.1 (d), 124.3 (d), 124.7 (d), 128.3 (s), 128.5 (d), 
128.7 (d), 129.2 (d), 129.5 (d), 129.7 (d), 131.0 (d), 131.3 (d), 131.8 (d), 134.2 (d), 
134.5 (d), 141.35 (d), 141.8 (d), 141.9 (d), 145.1 (s), 145.3 (s), 146.75 (s), 147.1 
(s),148.1 (s), 150.8 (s), 150.9 (s), 164.1 (s), 164.3 (s), 165.7 (s), 167.3 (s), 169.0 (s), 
169.5 (s), 177.2 (s); LRMS m/z (ESI) (%) 609 ([M+H]+, 100), 105 (10); HRMS (ESI) 
found 609.2450, calcd. for C33H33O6N6 [M+H]+ 609.2456. 
 
Iso-propyl-9-aminoacridine-4-carboxylate (40) 
 
METHOD A: Via 9-chloro substitution in iso-propyl-9-chloroacridine-4-
carboxylate (42) using NH4HCO3 
 Iso-propyl-9-chloroacridine-4-carboxylate (42) (0.30 g, 1.0 
mmol, 1.0 eq) was dissolved in phenol (1.50 g, 15.9 mmol, 
16 eq) at 70°C.  To the resulting solution was then added 
NH4HCO3 (0.16 g, 2.0 mmol, 2.0 eq) whereupon the 
temperature was increased to 120° C and maintained for 2 h. 
with stirring.  Subsequently, the reaction mixture was cooled down to rt and phenol was 
removed in vacuo by co-evaporation with toluene.  The reaction residue was purified 
by flash column chromatography (petroleum ether (40-60°C) : ethyl acetate : methanol 
: triethylamine, 45:45:10:1).  This afforded the title compound 40 (0.24 g, 81%) as 
N
NH2
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slowly solidifying green-yellow oil. mp 198°C (dec) (from CHCl3/petroleum ether); Rf 
0.12 (Petroleum ether (40-60°C) : ethyl acetate : methanol : triethylamine, 45:45:10:1); 
(Found: C, 72.5; H, 5.6; N, 9.7. C17H16N2O2 requires C, 72.8; H, 5.7; N, 10.0%); max 
(film)/cm–1 3305, 3280, 2980, 2927, 1682, 1613, 1558, 1523, 1465, 1448, 1373, 1269, 
776, 749, 713; δH (200 MHz; CDCl3) 1.37 (6 H, d, J 6.4, CH(CH3 )2), 5.21 (1 H, septet, 
J 6.4, CH(CH3)2), 6.98-7.12 (3 H, m, Ar-H), 7.36-7.44 (1 H, m, Ar-H), 7.99 (1 H, dd, J 
8.3 and J 1.7, Ar-H), 8.15 (1 H, d, J 7.5 and J 1.7, Ar-H), 8.49 (1 H, d, J 7.9 and J 1.7, 
Ar-H), 11.15 (1 H, br s, N(10)H); δC (50 MHz; CDCl3) 21.70 (q), 68.81 (d), 113.05 (s), 
117.18 (d), 118.50 (s), 119.08 (d), 120.26 (s), 121.72 (d), 124.31 (d), 131.19 (d), 131.70 
(d), 134.30 (d), 137.55 (s), 140.48 (s), 161.33 (s), 167.40 (s); LRMS m/z (EI) (%) 280 
([M]+, 21), 252 (13), 238 (10), 221 (17), 220 (100), 192 (35), 166 (12), 165 (21), 164 
(25); HRMS m/z (EI) found 280.1209, calcd. for C17H16N2O2 [M]+ 280.1206. 
 
METHOD B: Preparation of iso-propyl-9-aminoacridine-4-carboxylate (40) via 
hydrogenolysis of iso-propyl-9-benzylaminoacridine-4-carboxylate (28)  
Iso-propyl-9-benzylaminoacridine-4-carboxylate (28) (0.86 g, 2.3 mmol, 1.0 eq) was 
dissolved in ethyl acetate/ethanol 1/1 (50mL) after which palladium (10% on charcoal) 
was added (0.08 g).  The resulting suspension was left stirring at rt for 96 h. under a 
hydrogen atmosphere.  Subsequently, the suspension was filtered through a Celite pad 
(5 cm in height) and the filtrate solvents removed in vacuo.  The resulting crude 
reaction residue was subjected to flash column chromatography (petroleum ether : ethyl 
acetate : triethylamine, 90:9:1). This afforded the title compound 40 as a green-yellow 
solid in a very moderate 18% (0.12 g) yield.  The analysis of this product was identical 
to that obtained for the product yielded by method A.  65% of the starting material (28) 
was recovered. 
 
METHOD C:  Attempted preparation of 40 via substitution of the 9-triazole 
substituent in iso-propyl-9-(1,2,4-triazol-1-yl)acridine-4-carboxylate (25) with 
ammonia. 
Iso-propyl-9-(1,2,4-triazol-1-yl)acridine-4-carboxylate (25) (0.050 g, 0.15 mmol, 1.0 
eq) was dissolved in acetonitrile/dimethylformamide 1/1 (15 mL) whereupon ammonia 
was bubbled through the solution while the temperature was increased from rt up to 
100° C.  Bubbling ammonia was maintained for another 3 h. at 100°C.   Subsequently, 
the reaction mixture was cooled to rt, solvents were removed in vacuo and the resulting 
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reaction residue was subjected to flash column chromatography (ethyl acetate : petrol 
ether: triethylamine, 60:40:1).  NMR analysis of active, columned fractions showed the 
presence of starting material (25) (68% of 25 was recovered) and at least two more 
unidentified compounds. 
 
METHOD D: Attempted preparation of 40 via substitution of the 9-triazole 
substituent in iso-propyl-9-(1,2,4-triazol-1-yl)acridine-4-carboxylate (25) with 
3,4,5,6-tetrachlorophthalimide followed by unmasking of the N-3,4,5,6-
tetrachlorophthaloyl group. 
Triethylamine (0.50 mL, 3.6 mmol, 5.0 eq) and tetrachlorophthalimide (0.24 g, 0.83 
mmol, 1.1 eq) were dissolved in dimethylformamide (5 mL) whereupon this mixture 
was added to a solution of iso-propyl-9-(1,2,4-triazol-1-yl)acridine-4-carboxylate (25) 
(0.24 g, 0.72 mmol, 1.0 eq) in dimethylformamide (6 mL).  The resulting solution was 
stirred for 24 hours at room temperature under a nitrogen atmosphere, after which time 
the reaction mixture was heated to 80° C for another 24 hours, with stirring under 
nitrogen.  Subsequently, the solvent was removed in vacuo and the crude reaction 
residue was subjected to flash column chromatography (ethyl acetate : petrol ether :  
triethylamine, 50:50:1).  NMR analysis of collected fractions suggested mainly 
presence of the starting material (25).  None of the expected intermediate 
tetrachlorophthalimide (41) could be identified. 
 
Iso-propyl-9-chloroacridine-4-carboxylate (42) 
Iso-propyl-9-oxoacridan-4-carboxylate (22) (2.81 g, 10.0 
mmol, 1.00 eq) was suspended in excess thionyl chloride (25 
mL) and a catalytic amount of dimethylformamide was added 
(one drop).  The resulting suspension was heated gently at 
reflux, while stirring and under nitrogen, until all solid material 
was dissolved.  The homogeneous solution was then left at reflux temperature for 45 
minutes, whereupon the reaction mixture was allowed to cool to room temperature.  
Subsequently, the remaining thionyl chloride was removed in vacuo whilst keeping the 
temperature below 40°C. The last traces of thionyl chloride were removed by 
resuspending the residue in toluene (3 x 15 mL) and removing the solvent in vacuo to 
yield the title compound 42 (2.91 g, 97%) as an orange solid.  The product was used 
N
Cl
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without further purification in a subsequent step. mp 152-154°C (from CHCl3 / 
Petroleum ether); Rf 0.66 (Petroleum ether (40-60 °C) : ethyl acetate : triethylamine, 
50:50:1); δH (200 MHz; CDCl3) 1.41 (6 H, d, J 6.2, CH(CH3)2), 5.35 (1 H, septet, J 6.2, 
CH(CH3)2), 7.59-7.69 (3 H, m, Ar-H), 8.21-8.27 (1 H, m, Ar-H), 8.40 (2 H, dd, J 7.5 
and 1.7, Ar-H), 8.70 (1 H, dd, J 8.3 and 1.2, Ar-H); δC (50 MHz; CDCl3) 21.77 (q), 
69.12 (d), 123.80 (s), 124.00 (s), 124.22 (d), 125.62 (d), 127.26 (d), 127.38 (d), 129.80 
(d), 130.72 (d), 130.98 (d), 132.40 (s), 141.90 (s), 145.00 (s), 148.23 (s), 167.11 (s). 
 
Methyl-9-chloroacridine-4-carboxylate (43)  
 
Methyl-9-oxoacridan-4-carboxylate (2) (2.53 g, 10.0 mmol, 
1.00 eq) was suspended in excess thionyl chloride (25 mL) and 
a catalytic amount of dimethylformamide was added (one 
drop). The resulting suspension was heated gently at reflux, 
while stirring and under nitrogen, until all solid material had 
dissolved. The homogeneous solution was then left at reflux for 45 minutes, whereupon 
the reaction mixture was allowed to cool to room temperature. Subsequently, the 
remaining thionyl chloride was removed in vacuo whilst keeping the temperature below 
40°C. The last traces of thionyl chloride were removed by resuspending the residue in 
toluene (3 x 15 mL) and removing the solvent in vacuo to yield the title compound 43 
(2.66 g, 98 %) as an orange-red solid. The product was used without further purification 
in a subsequent step. mp 154-158°C (from CHCl3 / Petroleum ether); Rf 0.61 
(Petroleum ether (40-60 °C) : ethyl acetate : triethylamine, 50:50:1); δH (200 MHz; 
CDCl3) 4.22 (3 H, s, CH3), 7.90-8.04 (2 H, m, Ar-H), 8.25 (1 H, t, J 7.5, Ar-H), 8.60 (1 
H, d, J 8.7, Ar-H), 8.74 (1 H, d, J 7.1, Ar-H), 8.85 (1 H, d, J 8.3, Ar-H), 9.27 (1 H, d, J 
8.7, Ar-H); δC (50 MHz; CDCl3) 54.4 (q), 122.5 (s), 122.7 (d), 124.5 (s), 124.8 (s), 
125.6 (d), 128.0 (s), 128.3 (d), 130.2 (d), 130.5 (d), 136.8 (s), 138.5 (d), 140.2 (d), 
154.4 (s), 165.2 (s). 
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Methyl-9-aminoacridine-4-carboxylate (44)  
 
METHOD A: Via 9-chloro substitution in methyl-9-chloroacridine-4-carboxylate 
(43) using NH4HCO3 
Methyl-9-chloroacridine-4-carboxylate (43) (0.27 g, 1.0 mmol, 
1.0 eq) was dissolved in phenol (1.50 g, 15.9 mmol, 16 eq) at 
70°C and to this solution was then added NH4HCO3 (0.16 g, 2.0 
mmol, 2.0 eq) whereupon the temperature was increased to 
120°C and maintained for 2h. with stirring. Subsequently, the 
reaction mixture was cooled down to rt and and phenol was removed in vacuo by co-
evaporation with toluene. The crude reaction residue was purified by flash column 
chromatography (petroleum ether (40-60°C) : ethyl acetate : methanol : triethylamine, 
45:45:10:1). This afforded the title compound 44 (0.16 g, 61%) as a greenish yellow 
solid. mp 205-209°C (from MeOH);  Rf 0.13 (Petroleum ether (40-60°C) : ethyl acetate 
: methanol : triethylamine, 45:45:10:1); max (film)/cm–1 3293, 3285, 2952, 2913, 1693, 
1614, 1556, 1524, 1488, 1448, 1271, 776, 747, 713; δH (200 MHz; CDCl3) 3.88 (3 H, s, 
CH3), 6.95-7.12 (3 H, m, Ar-H), 7.33-7.43 (1 H, m, Ar-H), 7.99 (1 H, d, J 8.3, Ar-H), 
8.11 (1 H, dd, J 7.5 and J 1.7, Ar-H), 8.45 (1 H, dd, J 8.3 and J 1.2, Ar-H), 10.95 (1 H, 
br s, N(10)H); δC (50 MHz; CDCl3) 52.4 (q), 112.7 (s), 117.5 (d), 118.9 (s), 119.5 (d), 
120.6 (s), 122.1 (d), 124.6 (d), 131.7 (d), 132.1 (d), 134.6 (d), 137.8 (s), 140.8 (s), 161.6 
(s), 168.6 (s); LRMS m/z (ESI) (%) 253 ([M+H]+, 100), 74 (5); HRMS (ESI) found 
253.0976, calcd. for C15H13N2O2 [M+H]+ 253.0972. 
 
METHOD B: Via 9-chloro substitution in methyl-9-chloroacridine-4-carboxylate 
(43) using NH3  
Methyl-9-chloroacridine-4-carboxylate (43) (0.050 g, 0.18 mmol, 1.0 eq) was dissolved 
in dry phenol and the mixture was heated slowly to 115 °C during which time, above 
50 °C , a stream of gaseous ammonia was bubbled through the solution and continued 
for 2 hours 115 °C. Subsequently, the solvent was removed in vacuo by co-evaporation 
with toluene and the crude reaction residue was purified by flash column 
chromatography (petroleum ether (40-60°C) : ethyl acetate : methanol : triethylamine, 
45:45:10:1).  This afforded the title compound 44 (0.02 g, 39%) as a greenish yellow 
solid.  The analysis of this product was identical to that obtained for the product yielded 
by method A. 
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METHOD C: Attempted preparation of 44 via substitution of the 9-triazole 
substituent in methyl-9-(1,2,4-triazol-1-yl)acridine-4-carboxylate (24) with 
ammonia. 
Methyl-9-(1,2,4-triazol-1-yl)acridine-4-carboxylate (24) (0.050 g, 0.15 mmol, 1.0 eq) 
was dissolved in acetonitrile/dimethylformamide 1/1 (15 mL) whereupon ammonia was 
bubbled through the solution while the temperature was increased from rt up to 100° C 
over a period of one hour.  Bubbling ammonia was maintained for another 3 h. at 
100°C.   Subsequently, the reaction mixture was cooled to rt, solvents were removed in 
vacuo and the resulting reaction residue was subjected to flash column chromatography 
(ethyl acetate : dioxane : triethylamine, 80:20:1).  NMR analysis of active, columed 
fractions suggested the presence of starting material (24) (13% of 24 was recovered) 
and at least two more unidentified compounds. 
 
Methyl-9-benzyloxycarbonylaminoacridine-4-carboxylate (45)  
 
METHOD A: Via treatment of methyl-9-aminoacridine-4-carboxylate (44) with 
phosgene followed by benzyl alcohol. 
Methyl-9-aminoacridine-4-carboxylate (44) (1.50 g, 5.95 
mmol, 1.0 eq) was dissolved in dichlorobenzene (75 mL) and 
to this mixture was added, successively, triethylamine (2.48 
mL, 17.8 mmol, 3.0 eq) and triphosgene (0.88 g, 8.9 mmol, 
1.2 eq).  The resulting solution was heated to 110°C and kept 
at this temperature for 2 h., with stirring under nitrogen.  
Subsequently, benzyl alcohol (1.82 mL, 17.8 mmol, 3.0 eq) was added and the reaction 
mixture was heated at 110°C for another 3 h.  After this time the reaction mixture was 
cooled down to rt and the solvent was removed in vacuo. This afforded a crude orange-
red oily reaction residue which was separated by flash column chromatography 
(petroleum ether (40-60°C) : ethyl acetate : triethylamine, 50:50:1).  This afforded the 
title compound 45 (0.85 g., 37 %) as slowly solidifying orange oil. mp 131-133°C 
(from chloroform / petrol ether); Rf 0.33 (Petroleum ether (40-60°C) : ethyl acetate : 
triethylamine, 50:50:1); (Found: C, 71.0; H, 4.4; N, 7.1. C23H18N2O4 requires C, 71.5; 
H, 4.7; N, 7.2%); max(film)/cm–1 3270, 3053, 3035, 3030, 2975, 2952, 1692, 1675, 
1614, 1597, 1525, 1494, 1447, 1289, 1270, 780, 750, 698; δH (200 MHz; CDCl3) 3.79 
(3 H, s, CH3), 5.28 (2 H, s, CH2), 6.90-7.02 (2 H, m, Ar-H), 7.16 (1 H, d, J 8.3, Ar-H), 
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7.32-7.39 (3 H, m, Ar-H), 7.42-7.50 (3 H, m, Ar-H), 7.87 (1 H, d, J 8.3, Ar-H), 8.17 (1 
H, dd, J 7.5 and J 1.7, Ar-H), 8.33 (1 H, dd, J 7.9 and J 1.7, Ar-H), 11.42 (1 H, s, 
N(10)H); δC (50 MHz; CDCl3) 52.3 (q), 67.6 (t), 112.7 (s), 116.9 (s), 117.5 (d), 119.1 
(s), 119.8 (d), 122.2 (d), 127.0 (d), 128.1 (d), 128.4 (d), 129.0 (d), 133.0 (d), 133.6 (d), 
135.5 (d), 136.0 (s), 138.5 (s), 140.3 (s), 153.9 (s), 163.2 (s), 168.0 (s); LRMS m/z 
(ESI) (%) 387 ([M+H]+, 100), 238 (6), 91 (3), 60 (3); HRMS (ESI) found 387.1340, 
calcd. for C23H19N2O4 [M+H]+ 387.1339. 
 
METHOD B: Attempted preparation of methyl-9-benzyloxycarbonylamino 
acridine-4-carboxylate (45) via reaction of methyl-9-aminoacridine-4-carboxylate 
(44) with benzyl chloroformate  
Methyl-9-aminoacridine-4-carboxylate (44) (0.17 g, 0.67 mmol, 1.0 eq) was dissolved 
in pyridine (5 mL) and to this mixture was added, dropwise, a solution of benzyl 
chloroformate (0.24 mL, 1.7 mmol, 2.5 eq) in pyridine (1 mL), with stirring under 
nitrogen.  The resulting solution was stirred for 24 h. at rt, whereupon the temperature 
was raised first to 50°C for 8 hours, then to 80° C for another 16 hours. Subsequently, 
the reaction mixture was cooled to rt and water (1 mL) was added to quench the 
reaction.  The solvent was removed in vacuo and the crude reaction residue was 
subjected to flash column chromatography (ethyl acetate : petroleum ether : methanol : 
triethylamine, 45:45:10:1).  Unfortunately, subsequent NMR analysis of collected 
fractions suggested mainly presence of starting material. 
Iso-propyl-9-t-butyloxycarbonylaminoacridine-4-carboxylate (46) 
 
METHOD A: Via treatment of iso-propyl-9-aminoacridine-4-carboxylate (40) 
with phosgene followed by t-butanol 
Iso-propyl-9-aminoacridine-4-carboxylate (40) (0.24 g, 0.86 
mmol, 1.0 eq) was dissolved in dichlorobenzene (12 mL) and 
to this mixture was added, successively, triethylamine (0.36 
mL, 2.6 mmol, 3.0 eq) and triphosgene (0.13 g, 1.3 mmol, 
1.5 eq).  The resulting solution was then heated to 110°C, 
which was maintained for 2 h, with stirring under nitrogen.  
Subsequently, t-butanol (0.24 mL, 2.6 mmol, 3.0 eq) was 
added and the reaction mixture was heated at 110°C for another 3 h.  After this time the 
N
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reaction mixture was cooled down and the solvent removed in vacuo to leave a crude 
yellow oily residue which was separated by flash column chromatography (petroleum 
ether (40-60°C) : ethyl acetate : triethylamine, 50:50:1).  This afforded the title 
compound 46 (0.14 g, 41 %) as yellow oil; Rf 0.35 (Petroleum ether (40-60°C) : ethyl 
acetate : triethylamine, 50:50:1); max(film)/cm–1: 3269, 3066, 2979, 2933, 1717, 1688, 
1615, 1598, 1524, 1465, 1448, 1366, 1271, 1166, 1135, 1105, 780, 750, 682; δH (200 
MHz; CDCl3) 1.37 (6 H, d, J 6.4, CH(CH3 )2), 1.56 (9 H, s, C(CH3)3), 5.22 (1 H, septet, 
J 6.4, CH(CH3)2), 6.98-7.22 (2 H, m, Ar-H), 7.29-7.37 (1 H, m, Ar-H), 7.42-7.50 (1 H, 
m, Ar-H), 8.09 (1 H, dd, J 8.3 and J 1.2, Ar-H), 8.22 (1 H, dd, J  7.9 and J 1.7, Ar-H), 
8.45 (1 H, dd, J 8.3 and J 1.2, Ar-H) 11.56 (1H, br s, N(10)H
 
); δC (50 MHz; CDCl3) 
21.4 (q), 27.7 (q), 68.8 (d), 80.3 (s), 112.9 (s), 117.0 (d), 119.1 (d), 121.4 (d), 126.9 (d), 
130.0 (s), 132.0 (s), 132.3 (d), 133.3 (d), 134.9 (d), 138.3 (s), 140.4 (s), 152.3 (s),  
162.3 (s), 167.0 (s); LRMS m/z (ESI) (%) 381 ([M+H]+, 100), 325 (55), 265 (42), 239 
(23); HRMS (ESI) found 381.1810, calcd. for C22H25N2O4 [M+H]+ 381.1809. 
 
METHOD B: Attempted preparation of iso-propyl-9-t-butyloxycarbonylamino 
acridine-4-carboxylate (46) via reaction of iso-propyl-9-aminoacridine-4-
carboxylate (40) with di-t-butyl dicarboxylate. 
Iso-propyl-9-aminoacridine-4-carboxylate (40) (0.060 g, 0.21 mmol, 1.0 eq) was 
dissolved in dioxane/H2O 2/1 (15 mL) and cooled to 0°C, whereupon di-t-butyl 
dicarboxylate (0.070 g, 0.32 mmol, 1.5 eq) was added to the reaction mixture.  The 
resulting solution was allowed to warm up to rt while the pH was kept above 11 with a 
1.0 M (aq) sodium hydroxide solution.  Solvents were removed in vacuo after which 
the residue was triturated with dichloromethane. The suspension was filtered and the 
organic phase was dried over anhydrous MgSO4.  Filtration followed by solvent 
evaporation in vacuo yielded a green solid residue.  Unfortunately, subsequent NMR 
analysis of the afforded solid showed exclusively starting material 40. 
 
Methyl-9-t-butyloxycarbonylaminoacridine-4-carboxylate (47) 
To a solution of methyl-9-aminoacridine-4-carboxylate (44) (1.24 g, 
4.91 mmol, 1.0 eq) in dichlorobenzene (50 mL) was added, N
NH
O
O
O O47
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successively, triethylamine (2.05 mL, 14.7 mmol, 3.0 eq) and triphosgene (0.73 g, 7.4 
mmol, 1.5 eq) whereupon the resulting solution was heated to 110°C and kept at this 
temperature for 2 h. with stirring under nitrogen.  Subsequently, t-butyl alcohol (1.39 
mL, 14.7 mmol, 3.0 eq) was added and the reaction mixture was heated at 110°C for 
another 2 h.  After this time the reaction mixture was cooled and the solvent removed in 
vacuo to leave an orange oily residue which was separated by flash column 
chromatography (petroleum ether (40-60°C) : ethyl acetate : triethylamine, 50:50:1).  
This afforded the title compound 47 (0.78 g, 43.0 %) as slowly solidifying orange oil. 
mp 107-111°C (from CHCl3 / Petroleum ether); Rf 0.28 (Petroleum ether (40-60°C) : 
ethyl acetate : triethylamine, 50:50:1); max(film)/cm–1 3275, 2998, 2975, 2925, 2905, 
1690, 1677, 1615, 1599, 1524, 1448, 1285, 1272, 780, 750, 684; δH (200 MHz; CDCl3) 
1.58 (9 H, s, C(CH3)3), 3.92 (3 H, s, CH3), 7.00-7.22 (3 H, m, Ar-H), 7.40-7.52 (1 H, m, 
Ar-H), 8.09 (1 H, d, J 8.3, Ar-H), 8.20 (1 H, d, J 7.5, Ar-H), 8.47 (1 H, d, J 7.9, Ar-H) 
11.44 (1 H, br s, N(10)H
 
); δC (50 MHz; CDCl3) 28.2 (q), 52.3 (q), 80.8 (s), 112.7 (s), 
117.4 (d), 119.6 (d), 121.7 (s), 121.9 (d), 127.4 (d), 129.0 (s), 132.8 (d), 133.9 (d), 
135.4 (d), 138.7 (s), 140.7 (s), 152.6 (s), 162.7 (s), 168.3 (s); LRMS m/z (ESI) (%) 353 
([M+H]+, 100); HRMS (ESI) found 353.1492, calcd. for C20H21N2O4 [M+H]+ 
353.1496. 
 
Methyl-9-allyloxycarbonylaminoacridine-4-carboxylate (48) 
 
To a solution of methyl-9-aminoacridine-4-carboxylate (44) 
(0.45 g, 1.8 mmol, 1.0 eq) in dichlorobenzene (25 mL) was 
added, successively, triethylamine (0.75 mL, 5.3 mmol, 3.0 eq) 
and triphosgene (0.27 g, 2.7 mmol, 1.5 eq) whereupon the 
resulting solution was heated to 110°C and kept at this 
temperature for 2 h. with stirring under nitrogen.  
Subsequently, allyl alcohol (0.37 mL, 5.3 mmol, 3.0 eq) was added and the reaction 
mixture was heated at 110°C for another 2 hours.  After this time the reaction mixture 
was cooled and the solvent removed in vacuo to leave an orange oily residue which was 
separated by flash column chromatography (petroleum ether (40-60°C) : ethyl acetate : 
triethylamine, 50:50:1).  This afforded the title compound 48 (0.20 g, 33 %) as slowly 
solidifying yellow oil.  mp 110-113°C (from CHCl3 / Petroleum ether); Rf 0.22 
(Petroleum ether (40-60°C) : ethyl acetate : triethylamine, 50:50:1); max (film)/cm–1: 
N
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3271, 2939, 2913, 1693, 1674, 1628, 1615, 1598, 1524, 1465, 1448, 1366, 1290, 1266, 
780, 750, 666; δH (200 MHz; CDCl3) 3.95 (3 H, s, CH3), 4.78 (2 H, dt, J 5.8 and J 1.2, 
CH2), 5.23 (1 H, dq, J 10.4 and J 1.2, =CHH), 5.37 (1 H, dq, J 17.0 and J 1.2, =CHH), 
6.01 (1 H, ddt , J 17.0, J 10.4 and J 5.8, CH2=CH), 7.04-7.32 (3 H, m, Ar-H), 7.49-7.59 
(1 H, m, Ar-H), 8.03 (1 H, d, J 7.9, Ar-H), 8.29 (1 H, dd, J 7.5 and J 1.7 , Ar-H), 8.48 
(1 H, dd, J 7.9 and J 1.7, Ar-H), 11.63 (1 H, br s, N(10)H); δC (50 MHz; CDCl3) 52.8 
(q), 67.0 (t), 113.2 (s), 117.4 (s), 118.0 (d), 119.1 (t), 119.8 (s), 120.3 (d), 122.2 (s), 
122.8 (d), 127.6 (d), 132.8 (d), 133.5 (d), 134.3 (d), 136.1 (d), 139.2 (s), 141.0 (s),  
163.7 (s), 168.8 (s); LRMS m/z (EI) (%) 336 (M+, 40), 278 (73), 253 (84), 221 (100), 
193 (66); HRMS (ESI) found 337.1183, calcd. for C19H17N2O4 [M+H]+ 337.1183. 
 
9-benzyloxycarbonylaminoacridine-4-carboxylic acid (49) 
 
To a cooled solution (0°C) of methyl-9-benzyloxy 
carbonylaminoacridine-4-carboxylate (45) (0.58 g, 1.5 mmol, 
1.0 eq) in THF (5 mL) was added a cooled (0°C) 0.6 M (aq) 
LiOH solution (3.50 mL, 2.10 mmol, 1.4 eq) and the resulting 
solution was kept at 0°C for 45 minutes, with stirring, 
whereupon the mixture was allowed to warm to  rt.  
Subsequently, the reaction was quenched by addition of 0.5 M (aq) HCl solution until 
neutral pH was reached.  The solvents were removed in vacuo and the crude reaction 
residue (a yellow solid) containing the title compound 49 and LiCl was used without 
further purification in a subsequent activation step.  Rf 0.40 (Petroleum ether (40-60 °C) 
: ethyl acetate : methanol : triethylamine, 40:40:20:1) 
 
9-t-butyloxycarbonylaminoacridine-4-carboxylic acid (50) 
 
To a cooled solution (0°C) of methyl-9-t-butyloxycarbonyl 
aminoacridine-4-carboxylate (47) (0.060 g, 0.17 mmol, 1.0 eq) in 
tetrahydrofuran (1.5 mL) was added a cooled (0°C) 1.2 M (aq) 
LiOH solution (0.28 mL, 0.34 mmol, 2.0 eq) and the resulting 
solution was kept at 0°C for 45 minutes, with stirring, whereupon 
the mixture was allowed to warm to  rt.  Subsequently, the reaction was quenched by 
addition of 0.5 M (aq) HCl solution until neutral pH was reached.  The solvents were 
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removed in vacuo and the crude reaction residue (a yellow solid) containing the title 
compound 50 and LiCl was used without further purification in a subsequent activation 
step. Rf 0.35 (Petroleum ether (40-60 °C) : ethyl acetate : methanol : triethylamine, 
40:40:20:1)  
 
9-allyloxycarbonylaminoacridine-4-carboxylic acid (51) 
 
To a cooled (0°C) solution of methyl-9-allyloxycarbonyl 
aminoacridine-4-carboxylate (48) (0.23 g, 0.67 mmol, 1.0 eq) 
in tetrahydrofuran (2.4 mL) was added a cooled (0°C) 0.6 M 
(aq) LiOH solution (1.2 mL, 0.72 mmol, 1.1 eq) and the 
resulting solution was kept at 0°C for 45 minutes, with stirring, 
whereupon the mixture was allowed to warm to  rt.  Subsequently, the reaction was 
quenched by addition of 0.5 M (aq) HCl solution until neutral pH was reached.  The 
solvents were removed in vacuo and the crude reaction residue (a yellow solid) 
containing the title compound 51 and LiCl was used without further purification in a 
subsequent activation step.  Rf 0.37 (Petroleum ether (40-60 °C) : ethyl acetate : 
methanol : triethylamine, 40:40:20:1); δH (200 MHz; DMSO-d6) 4.70 (2 H, d, J 5.4, 
CH2), 5.26 (1 H, dd, J 10.4 and J 1.2, =CHH), 5.38 (1 H, dd, J 17.0 and J 1.2, =CHH), 
6.02 (1 H, ddt , J 17.0, J 10.4 and J 5.4, CH2=CH), 7.60-7.76 (2 H, m, Ar-H), 7.91-8.02 
(1 H, m, Ar-H), 8.10-8.26 (2 H, m, Ar-H), 8.32-8.48 (1 H, m, Ar-H), 8.65 (1 H, dd, J 
7.1 and J 1.2 Ar-H), 13.88 (1 H, br s, COOH
 
); δC (50 MHz; DMSO-d6) 65.7 (t), 117.8 
(d), 118.5 (t), 121.4 (d), 123.1 (s), 124.7 (s), 125.1 (d), 125.5 (s), 125.9 (d), 130.0 (d), 
133.0 (d), 133.3 (d), 133.8 (s), 134.7 (s), 136.3 (d), 144.9 (s), 156.0 (s), 167.0 (s). 
 
Attempted preparation of ethyl 2-(N-(2-(9-(benzyloxycarbonylamino)acridine-4-
carboxamido)ethyl)-2-(thymin-1-yl)acetamido)acetate (52) 
 
A solution of 9-benzyloxycarbonyl 
aminoacridine-4-carboxylic acid (49) (0.56 g, 
1.5 mmol, 1.0 eq), N-hydroxysuccinimide 
(0.42 g, 3.6 mmol, 2.4 eq), and 
dicyclohexylcarbodiimide (0.72 g, 2.2 mmol, 
N
NH
O
O
O OH51
N
NH
O N
H
N
O
N
NH
O
O
O
O
O
O
52
Chapter 3: Experimental 
191 
1.4 eq) in DMF (40 mL) was stirred for 48 h. at rt.  Subsequently, a solution of the 
hydrochloric acid salt of N-(aminoethyl)-N-(thymin-1-ylacetyl) glycine ethyl ester 21 
(0.77 g, 1.9 mmol, 1.2 eq) and triethylamine (520 µL, 3.75 mmol, 2.5 eq) in DMF (10 
mL) was added and the resulting solution was stirred for another 24 h. at rt.  After 
removing the solvent in vacuo, the reaction residue was purified by flash column 
chromatography (ethyl acetate : methanol :  triethylamine, 90:10:1).  Unfortunately, 
neither MS nor NMR-analysis of the collected fractions could confirm the desired 
product 52 was present in significant amounts.  
 
Ethyl 2-(N-(2-(9-(t-butoxycarbonylamino)acridine-4-carboxamido)ethyl)-2-
(thymin-1-yl)acetamido)acetate (53)  
 
A solution of 9-t-butyloxycarbonylaminoacridine-
4-carboxylic acid (50) (0.060 g, 0.17 mmol, 1.0 
eq), N-hydroxysuccinimide (0.050 g, 0.43 mmol, 
2.4 eq), and dicyclohexylcarbodiimide (0.090 g, 
0.26 mmol, 1.4 eq) in DMF (3 mL) was stirred for 
48 h. at rt.  Subsequently, the dicyclohexylurea by-product was separated by filtration 
and to the filtrate was added a solution of the hydrochloric acid salt of N-(aminoethyl)-
N-(thymin-1-ylacetyl) glycine ethyl ester 21 (0.070 g, 0.19 mmol, 1.0 eq) and 
triethylamine (0.050 mL, 0.34 mmol, 1.9 eq) in DMF (3 mL).  The resulting solution 
was stirred for another 24 h. at rt.  After removing the solvent in vacuo, the reaction 
residue was purified by flash column chromatography (petroleum ether : ethyl acetate : 
methanol : triethylamine, 45:45:10:1).  This afforded the title compound 53 (0.025 g, 
24%) as a yellow-orange oily solid. No reliable mp could be taken due to the oily 
nature of 53; Rf 0.21 (petroleum ether : ethyl acetate : methanol : triethylamine, 
45:45:10:1); max (film)/cm–1 : 3288, 3182, 2952, 2930, 1739, 1700, 1660, 1623, 1563, 
1526, 1470, 1370, 1340, 1231, 1208, 1158, 1113, 1047, 1022, 896; δH (400 MHz; 
CDCl3) (2 rotational isomers observed in a 4:1 ratio due to restricted rotation about the 
tertiary amide bond) 1.20 (min) and 1.30 (max) (3 H, t, J 7.1, CH2CH3), 1.10 (max) and 
1.69 (min) (3 H, s, CHCCH3), 1.49 (9 H, br s, C(CH3)3), 1.74 (1 H, br s, NH), 3.68 
(min) and 3.77 (max) (2 H, t, J 5.3, CH2CH2NCO), 3.84 (min) and 3.90 (max) (2 H, m, 
CH2CH2NCO), 4.18 (max) and 4.23 (min) (2 H, s, NCH2COOEt), 4.11 (min) and 4.26 
(max) (2 H, q, J 7.1, CH2CH3), 4.31 (min) and 4.61 (max) (2 H, s, NCH2CON), 6.07 
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(max) and 6.83 (min) (1 H, s, CHCCH3), 7.55-7.62 (1 H, m, Ar-H), 7.59 (1 H, br s, 
NH), 7.65 (1 H, m, Ar-H), 7.78 (1 H, m, Ar-H), 8.08 (min) and 8.13 (max) (1 H, d, J 
8.5, Ar-H), 8.29 (1 H, d, J 8.8, Ar-H), 8.32 (1 H, dd, J 8.8 and 1.5, Ar-H), 8.60 (1H, br 
s, NH), 8.85 (min) and 8.89 (max) (1H, dd, J 7.1 and 1.2, Ar-H). 11.68 (max) and 11.75 
(min) (1H, br t, J, CONH(CH2)2); δC (100 MHz; CDCl3) (rotational isomers observed 
due to restricted rotation about the tertiary amide bond) 11.5 and 12.1 (CHCCH3), 14.0 
and 14.2 (CH2CH3), 28.2 (C(CH3)3), 38.3 (NHCH2CH2), 47.5 and 47.9 (NCH2CON), 
49.5 (NHCH2CH2), 49.8 (NCH2COO), 61.7 and 62.0 (CH2CH3), 82.0 and 82.1 
(C(CH3)3), 110.0 (CHCCH3), 122.4 (s), 123.1 (s), 123.3 (d), 125.5 (d), 126.9 (d), 128.2 
(d), 129.7 (d), 131.6 (d), 135.0 (s), 135.7 (d), 140.8 and 141.0 (CHCCH3), 146.8 (s), 
148.3 (s), 150.9 (CONHCON), 153.5 (s), 163.9 (CONHCON), 166.6 (CONHCH2CH2), 
167.4 (NCH2CON), 169.2 and 169.9 (NCH2COO); LRMS m/z (ESI) (%) 633 ([M+H]+, 
100), 322 (8), 242 (36), 74 (68); HRMS (ESI) found 633.2667, calcd. for C32H37N6O8 
[M+H]+ 633.2668. 
 
Ethyl 2-(N-(2-(9-(allyloxycarbonylamino)acridine-4-carboxamido)ethyl)-2-
(thymin-1-yl)acetamido)acetate (54)  
 
A solution of 9-allyloxycarbonylaminoacridine-4-
carboxylic acid (51) (0.10 g, 0.30 mmol, 1.0 eq), 
N-hydroxysuccinimide (0.070 g, 0.60 mmol, 2.0 
eq), and dicyclohexylcarbodiimide (0.13 g, 0.38 
mmol, 1.2 eq) in DMF (5 mL) was stirred for 48 
h. at rt.  Subsequently, the dicyclohexylurea by-
product was separated by filtration and to the filtrate was added a solution of the 
hydrochloric acid salt of N-(aminoethyl)-N-(thymin-1-ylacetyl) glycine ethyl ester 21 
(0.13 g, 0.38 mmol, 1.2 eq) and triethylamine (0.13 mL, 0.94 mmol, 3.1 eq) in DMF (5 
mL).  The resulting solution was stirred for another 24 h. at rt.  After removing the 
solvent in vacuo, the reaction mixture residue was purified by flash column 
chromatography (petrol ether : ethyl acetate : methanol : triethylamine, 50:50:5:1).  
This afforded the title compound 54 (0.095 g, 51 %) as a yellow-orange oily solid. No 
reliable mp could be taken due to oily nature of compound 54; Rf 0.29 (petrol ether : 
ethyl acetate : methanol : triethylamine, 50:50:5:1); max (film)/cm–1 : 3198, 3061, 3019, 
2952, 2929, 1737, 1709, 1684, 1673, 1649, 1621, 1561, 1524, 1468, 1375, 1356, 1246, 
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1216, 1160, 1117, 1098, 1046, 756, 666; δH (400 MHz; DMSO-d6) (rotational isomers 
present in a 3:1 ratio due to restricted rotation about the tertiary amide bond) 1.11-1.22 
(3 H, m, CH2CH3), 1.19 (max) and 1.77 (min)  (3 H, s, CHCCH3), 3.60-3.81 (4 H, m, 
CH2CH2NCO), 4.05-4.42 (4 H, m, CH2CH3 + NCH2COOEt), 4.50-4.75 (4 H, m, 
NCH2CON + CH2CH=CH2), 5.20-5.34 (2 H, m, CH=CH2), 5.91-6.10 (1 H, m, 
CH=CH2), 6.53 (max) and 6.98 (min) (1 H, s, CHCCH3), 7.66-7.80 (2 H, m, Ar-H), 
7.89-7.95 (1 H, m, Ar-H), 8.15-8.24 (1 H, m, Ar-H), 8.32-8.46 (2 H, m, Ar-H), 8.68-
8.75 (1 H, m, Ar-H), 11.20-11.45 (1 H, m, CONH(CH2)2); δC (100 MHz; DMSO-d6) 
(rotational isomers present due to restricted rotation about the tertiary amide bond) 11.4 
(q), 13.9 (q), 14.0 (q), 37.69 (t), 47.8 (t), 47.6 (t), 48.4 (t), 60.6 (t), 65.5 (t), 107.9 (s), 
117.6 (s), 122.2 (s), 122.8 (s), 124.1 (d), 125.3 (s), 126.7 (d), 128.2 (s), 128.4 (d), 128.8 
(s), 128.9 (s), 129 3 (d), 131.6 (d), 133.1 (d), 134.6 (d), 137.3 (s), 141.3 (s), 141.7 (d), 
146.1 (s), 147.8 (s), 150.8 (s), 154.3 (s), 164.1 (s), 165.5 (s), 167.4 (s), 169.5 (s); LRMS 
m/z (ESI) (%) 617 ([M+H]+, 100), 102 (48), 60 (78); HRMS (ESI) found 617.2350, 
calcd. for C31H33O8N6 [M+H]+ 617.2354. 
 
Trifluoroacetic acid salt of ethyl 2-(N-(2-(9-aminoacridine-4-carboxamido)ethyl)-
2-(thymin-1-yl)acetamido)acetate (55) 
 
To a solution of ethyl 2-(N-(2-(9-(t-
butoxycarbonylamino)acridine-4-carboxamido) 
ethyl)-2-(thymin-1-yl)acetamido) acetate (53) 
(0.020 g, 0.030 mmol, 1.0 eq) in 
dichloromethane (1 mL) was added excess TFA 
99% (1.00 mL).  The resulting mixture was left stirring for 45 mins at rt and 
subsequently the solvent and excess TFA were removed in vacuo.  This afforded the 
title compound 55 (0.02 g, 95%) as a very fine yellow powder which was used without 
purification in a subsequent step.  mp 253°C (dec) (from MeOH); δH (400 MHz; 
CD3OD) (rotational isomers present in a 1:1 ratio due to restricted rotation about the 
tertiary amide bond) 1.25-1.35 (3 H, m, CH2CH3), 1.65 and 1.80   (3 H, s, CHCCH3), 
3.62-3.88 (4 H, m, CH2CH2NCO), 4.20-4.30 (2 H, m, CH2CH3 ), 4.25 and 4.42 (2 H, s, 
NCH2COOEt), 4.50 and 4.81 (2 H, s, NCH2CON), 7.11 and 7.23 (1 H, s, CHCCH3), 
7.58-7.71 (2 H, m, Ar-H), 7.90-8.05 (2 H, m, Ar-H), 8.25 (0.5 H, d, J 7.3, Ar-H), 8.46-
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8.54 (1.5 H, m, Ar-H), 8.69 (1 H, d, J 8.5, Ar-H); LRMS m/z (ESI) (%) 533 ([M+H]+, 
100), 102 (45); HRMS (ESI) found 533.2146, calcd. for C27H29O6N6 [M+H]+ 533.2143. 
 
2-(N-(2-(9-aminoacridine-4-carboxamido)ethyl)-2-(thymin-1-yl)acetamido)acetic 
acid (56) 
 
METHOD A: Via aqueous basic hydrolysis of the ethyl ester 55 
A solution of the trifluoroacetic acid salt of ethyl 2-
(N-(2-(9-aminoacridine-4-carboxamido)ethyl)-2-
(thymin-1-yl)acetamido) acetate (55) (0.020 g, 0.030 
mmol, 1.0 eq) in 1.2 M (aq) sodium hydroxide / 
tetrahydrofuran (0.1 mL / 0.3 mL) was stirred at rt for 
4 h.  Subsequently, the reaction mixture was quenched 
with a 0.1 M (aq) HCl solution (1.2 mL) until neutral pH was reached.  The solvents 
were removed in vacuo which afforded a crude yellow precipitate containing the title 
compound 56 (0.015 g, 98%) and NaCl (0.005 g).  δH (400 MHz; DMSO-d6) (rotational 
isomers present in a 1:1 ratio due to restricted rotation about the tertiary amide bond) 
1.20 and 1.55 (3 H, s, CHCCH3), 3.58-3.90 (4 H, m, CH2CH2NCO), 3.98 and 4.11 (2 
H, s, NCH2COOEt), 4.50 and 4.68 (2 H, s, NCH2CON), 6.34 and 6.94 (1 H, s, 
CHCCH3), 7.11-7.44 (3 H, m, Ar-H), 7.30 (1 H, m, Ar-H), 8.06 (1 H, m, Ar-H), 8.35 
and 8.42 (1 H, br s, NH), 8.48 (1 H, m, Ar-H), 8.64 (1 H, m, Ar-H),  11.16 and 11.21 (1 
H, s, COOH), 12.28 and 12.40 (2 H, br s, NH2), 13.00 (1 H, br s , CONHCH2); LRMS 
m/z (ESI) (%) 505.2 ([M+H]+, 100), 81.0 (44), 59.2 (31); HRMS (ESI) found 505.1829, 
calcd. for C25H25O6 N6 [M+H]+ 505.1830. 
 
METHOD B: Attempted preparation of 56 via Palladium catalyzed 
allyloxycarbonyl deprotection of compound 57 
To a solution of 2-(N-(2-(9-(allyloxycarbonylamino)acridine-4-carboxamido)ethyl)-2-
(thymin-1-yl)acetamido)acetic acid (57) (0.070 g, 0.15 mmol, 1.0 eq) in 1/1 
tetrahydrofuran/dimethylformamide (10 mL) was added tetrakis(triphenylphosphine) 
palladium(0) catalyst (0.020 g, 0.020 mmol, 0.12 eq) and triethylammonium formate 
(0.050 mL, 0.30 mmol, 2.0 eq). This mixture was stirred overnight at rt after which a 
yellow precipitate had formed.  Subsequently this solid was separated by filtration, 
washed with DCM and recrystallisation was attempted in several solvent systems e.g. 
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ethanol/ diethyl ether, methanol/diethyl ether and methanol/THF.  Unfortunatly, the 
resulting yellow solid still contained a number of unidentified impurities besides an 
undetermined amount of the title compound 56 (according to LR and HR mass 
spectrometry analysis). 
 
2-(N-(2-(9-(allyloxycarbonylamino)acridine-4-carboxamido)ethyl)-2-(thymin-1-
yl)acetamido)acetic acid (57) 
 
A solution of Ethyl 2-(N-(2-(9-(allyloxy 
carbonylamino)acridine-4-carboxamido) ethyl)-2-
(thymin-1-yl)acetamido) acetate (54) (0.090 g, 0.15 
mmol, 1.0 eq) in aqueous sodium hydroxide 1.2 M / 
tetrahydrofuran ( 1.5 mL / 4.5 mL) was stirred at rt 
for 4 h. Subsequently, the reaction mixture was 
neutralised with a 0.4 M (aq) HCl (4.5 mL) solution until a neutral pH was reached.  
The solvents were removed in vacuo, affording a crude yellow precipitate containing 
the product 57 that was used in a subsequent step without further purification. 
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Table 1.  Crystal data and structure refinement for iso-propyl-9-aminoacridan-4-carboxylate (22). 
Identification code  twin5 
Empirical formula  C17 H15 N O3 
Formula weight  281.30 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 7.9450(10) Å α= 77.264(2)°. 
 b = 8.4506(11) Å β= 88.763(4)°. 
 c = 11.1255(12) Å γ = 67.982(4)°. 
 212 
                                                                                                                                       
Volume 673.91(14) Å3 
Z 2 
Density (calculated) 1.386 Mg/m3 
Absorption coefficient 0.096 mm-1 
F(000) 296 
Crystal size 0.38 x 0.24 x 0.06 mm3 
Theta range for data collection 2.67 to 30.57°. 
Index ranges -11<=h<=11, -11<=k<=12, 0<=l<=15 
Reflections collected 25508 
Independent reflections 3964 [R(int) = 0.0346] 
Completeness to theta = 25.00° 98.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9943 and 0.8977 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3964 / 1 / 200 
Goodness-of-fit on F2 0.944 
Final R indices [I>2sigma(I)] R1 = 0.0440, wR2 = 0.1055 
R indices (all data) R1 = 0.0774, wR2 = 0.1175 
Largest diff. peak and hole 0.440 and -0.227 e.Å-3 
Table 2.   Bond lengths [Å] and angles [°] for iso-propyl-9-aminoacridan-4-carboxylate (22). 
_____________________________________________________ 
N(1)-C(14)  1.3696(15) 
N(1)-C(2)  1.3772(15) 
N(1)-H(1)  0.890(11) 
O(1)-C(8)  1.2368(14) 
C(2)-C(7)  1.4025(16) 
C(2)-C(3)  1.4046(16) 
O(2)-C(15)  1.3338(14) 
O(2)-C(16)  1.4697(14) 
C(3)-C(4)  1.3757(17) 
C(3)-H(3)  0.9500 
O(3)-C(15)  1.2200(14) 
C(4)-C(5)  1.3997(17) 
C(4)-H(4)  0.9500 
C(5)-C(6)  1.3719(17) 
C(5)-H(5)  0.9500 
C(6)-C(7)  1.4054(16) 
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C(6)-H(6)  0.9500 
C(7)-C(8)  1.4625(16) 
C(8)-C(9)  1.4745(16) 
C(9)-C(10)  1.3961(16) 
C(9)-C(14)  1.4082(16) 
C(10)-C(11)  1.3769(17) 
C(10)-H(10)  0.9500 
C(11)-C(12)  1.3922(16) 
C(11)-H(11)  0.9500 
C(12)-C(13)  1.3865(16) 
C(12)-H(12)  0.9500 
C(13)-C(14)  1.4261(16) 
C(13)-C(15)  1.4827(16) 
C(16)-C(17)  1.5063(18) 
C(16)-C(19)  1.5102(17) 
C(16)-H(16)  0.973(12) 
C(17)-H(17A)  0.9800 
C(17)-H(17B)  0.9800 
C(17)-H(17C)  0.9800 
C(19)-H(19A)  0.9800 
C(19)-H(19B)  0.9800 
C(19)-H(19C)  0.9800 
 
C(14)-N(1)-C(2) 122.80(10) 
C(14)-N(1)-H(1) 115.6(8) 
C(2)-N(1)-H(1) 121.6(8) 
N(1)-C(2)-C(7) 120.36(11) 
N(1)-C(2)-C(3) 119.78(11) 
C(7)-C(2)-C(3) 119.86(11) 
C(15)-O(2)-C(16) 118.89(9) 
C(4)-C(3)-C(2) 119.86(11) 
C(4)-C(3)-H(3) 120.1 
C(2)-C(3)-H(3) 120.1 
C(3)-C(4)-C(5) 120.77(12) 
C(3)-C(4)-H(4) 119.6 
C(5)-C(4)-H(4) 119.6 
C(6)-C(5)-C(4) 119.55(12) 
C(6)-C(5)-H(5) 120.2 
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C(4)-C(5)-H(5) 120.2 
C(5)-C(6)-C(7) 121.09(11) 
C(5)-C(6)-H(6) 119.5 
C(7)-C(6)-H(6) 119.5 
C(2)-C(7)-C(6) 118.85(11) 
C(2)-C(7)-C(8) 120.46(11) 
C(6)-C(7)-C(8) 120.69(11) 
O(1)-C(8)-C(7) 122.39(11) 
O(1)-C(8)-C(9) 121.83(11) 
C(7)-C(8)-C(9) 115.77(10) 
C(10)-C(9)-C(14) 119.73(11) 
C(10)-C(9)-C(8) 119.69(10) 
C(14)-C(9)-C(8) 120.58(11) 
C(11)-C(10)-C(9) 121.30(11) 
C(11)-C(10)-H(10) 119.4 
C(9)-C(10)-H(10) 119.4 
C(10)-C(11)-C(12) 119.13(11) 
C(10)-C(11)-H(11) 120.4 
C(12)-C(11)-H(11) 120.4 
C(13)-C(12)-C(11) 121.89(11) 
C(13)-C(12)-H(12) 119.1 
C(11)-C(12)-H(12) 119.1 
C(12)-C(13)-C(14) 118.82(11) 
C(12)-C(13)-C(15) 120.30(11) 
C(14)-C(13)-C(15) 120.88(10) 
N(1)-C(14)-C(9) 119.84(11) 
N(1)-C(14)-C(13) 121.04(10) 
C(9)-C(14)-C(13) 119.13(11) 
O(3)-C(15)-O(2) 123.66(11) 
O(3)-C(15)-C(13) 124.73(11) 
O(2)-C(15)-C(13) 111.61(10) 
O(2)-C(16)-C(17) 104.84(9) 
O(2)-C(16)-C(19) 108.33(10) 
C(17)-C(16)-C(19) 113.64(10) 
O(2)-C(16)-H(16) 107.2(7) 
C(17)-C(16)-H(16) 110.6(8) 
C(19)-C(16)-H(16) 111.8(7) 
C(16)-C(17)-H(17A) 109.5 
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C(16)-C(17)-H(17B) 109.5 
H(17A)-C(17)-H(17B) 109.5 
C(16)-C(17)-H(17C) 109.5 
H(17A)-C(17)-H(17C) 109.5 
H(17B)-C(17)-H(17C) 109.5 
C(16)-C(19)-H(19A) 109.5 
C(16)-C(19)-H(19B) 109.5 
H(19A)-C(19)-H(19B) 109.5 
C(16)-C(19)-H(19C) 109.5 
H(19A)-C(19)-H(19C) 109.5 
H(19B)-C(19)-H(19C) 109.5 
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
  
Table 3.  Torsion angles [°] for iso-propyl-9-aminoacridan-4-carboxylate (22). 
________________________________________________________________ 
C(14)-N(1)-C(2)-C(7) -4.44(18) 
C(14)-N(1)-C(2)-C(3) 175.45(10) 
N(1)-C(2)-C(3)-C(4) 179.42(11) 
C(7)-C(2)-C(3)-C(4) -0.70(17) 
C(2)-C(3)-C(4)-C(5) -0.44(19) 
C(3)-C(4)-C(5)-C(6) 0.78(19) 
C(4)-C(5)-C(6)-C(7) 0.01(18) 
N(1)-C(2)-C(7)-C(6) -178.66(11) 
C(3)-C(2)-C(7)-C(6) 1.45(17) 
N(1)-C(2)-C(7)-C(8) 1.55(17) 
C(3)-C(2)-C(7)-C(8) -178.34(10) 
C(5)-C(6)-C(7)-C(2) -1.12(18) 
C(5)-C(6)-C(7)-C(8) 178.68(11) 
C(2)-C(7)-C(8)-O(1) -178.27(11) 
C(6)-C(7)-C(8)-O(1) 1.94(18) 
C(2)-C(7)-C(8)-C(9) 2.38(16) 
C(6)-C(7)-C(8)-C(9) -177.41(11) 
O(1)-C(8)-C(9)-C(10) -3.06(18) 
C(7)-C(8)-C(9)-C(10) 176.30(10) 
O(1)-C(8)-C(9)-C(14) 176.87(11) 
C(7)-C(8)-C(9)-C(14) -3.77(17) 
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C(14)-C(9)-C(10)-C(11) -0.94(18) 
C(8)-C(9)-C(10)-C(11) 178.99(11) 
C(9)-C(10)-C(11)-C(12) 0.63(18) 
C(10)-C(11)-C(12)-C(13) -0.38(18) 
C(11)-C(12)-C(13)-C(14) 0.43(17) 
C(11)-C(12)-C(13)-C(15) -179.90(11) 
C(2)-N(1)-C(14)-C(9) 2.99(17) 
C(2)-N(1)-C(14)-C(13) -176.80(11) 
C(10)-C(9)-C(14)-N(1) -178.81(10) 
C(8)-C(9)-C(14)-N(1) 1.26(17) 
C(10)-C(9)-C(14)-C(13) 0.98(17) 
C(8)-C(9)-C(14)-C(13) -178.95(10) 
C(12)-C(13)-C(14)-N(1) 179.07(10) 
C(15)-C(13)-C(14)-N(1) -0.60(17) 
C(12)-C(13)-C(14)-C(9) -0.72(17) 
C(15)-C(13)-C(14)-C(9) 179.61(10) 
C(16)-O(2)-C(15)-O(3) 0.30(17) 
C(16)-O(2)-C(15)-C(13) -179.55(9) 
C(12)-C(13)-C(15)-O(3) -176.87(11) 
C(14)-C(13)-C(15)-O(3) 2.79(19) 
C(12)-C(13)-C(15)-O(2) 2.97(16) 
C(14)-C(13)-C(15)-O(2) -177.36(10) 
C(15)-O(2)-C(16)-C(17) 148.05(10) 
C(15)-O(2)-C(16)-C(19) -90.30(12) 
________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
  
Table 4.  Hydrogen bonds for iso-propyl-9-aminoacridan-4-carboxylate (22) [Å and °]. 
____________________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________ 
 N(1)-H(1)...O(3) 0.890(11) 1.957(12) 2.6791(13) 137.2(11) 
____________________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
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Table 1.  Crystal data and structure refinement for methyl-9-benzyloxycarbonylaminoacridine-4-
carboxylate (45). 
 
 
Identification code  x81821_0m 
Empirical formula  C23 H18 N2 O4 
Formula weight  386.39 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
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Unit cell dimensions a = 9.528(2) Å α= 90°. 
 b = 8.325(2) Å β= 100.896(8)°. 
 c = 23.478(6) Å γ = 90°. 
Volume 1828.7(8) Å3 
Z 4 
Density (calculated) 1.403 Mg/m3 
Absorption coefficient 0.097 mm-1 
F(000) 808 
Crystal size 0.62 x 0.18 x 0.04 mm3 
Theta range for data collection 2.50 to 30.10°. 
Index ranges -13<=h<=13, -10<=k<=11, -33<=l<=33 
Reflections collected 36840 
Independent reflections 5356 [R(int) = 0.1126] 
Completeness to theta = 25.00° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9961 and 0.7106 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5356 / 0 / 267 
Goodness-of-fit on F2 1.009 
Final R indices [I>2sigma(I)] R1 = 0.0643, wR2 = 0.1249 
R indices (all data) R1 = 0.1640, wR2 = 0.1563 
Largest diff. peak and hole 0.251 and -0.345 e.Å-3 
Table 2.   Bond lengths [Å] and angles [°] for methyl-9-benzyloxycarbonylaminoacridine-4-
carboxylate (45). 
_____________________________________________________ 
N(1)-C(5)  1.368(3) 
N(1)-C(6)  1.376(3) 
N(1)-H(1N)  0.90(2) 
N(2)-C(12)  1.292(3) 
N(2)-C(16)  1.381(3) 
O(1)-C(14)  1.215(3) 
O(2)-C(14)  1.343(3) 
O(2)-C(15)  1.450(3) 
O(3)-C(16)  1.212(3) 
O(4)-C(16)  1.351(3) 
O(4)-C(17)  1.462(3) 
C(1)-C(2)  1.376(3) 
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C(1)-C(13)  1.397(3) 
C(1)-H(1)  0.9500 
C(2)-C(3)  1.382(3) 
C(2)-H(2)  0.9500 
C(3)-C(4)  1.387(3) 
C(3)-H(3)  0.9500 
C(4)-C(5)  1.424(3) 
C(4)-C(14)  1.471(3) 
C(5)-C(13)  1.411(3) 
C(6)-C(11)  1.405(3) 
C(6)-C(7)  1.407(3) 
C(7)-C(8)  1.367(3) 
C(7)-H(7)  0.9500 
C(8)-C(9)  1.391(3) 
C(8)-H(8)  0.9500 
C(9)-C(10)  1.371(3) 
C(9)-H(9)  0.9500 
C(10)-C(11)  1.409(3) 
C(10)-H(10)  0.9500 
C(11)-C(12)  1.462(3) 
C(12)-C(13)  1.468(3) 
C(15)-H(15A)  0.9800 
C(15)-H(15B)  0.9800 
C(15)-H(15C)  0.9800 
C(17)-C(18)  1.501(3) 
C(17)-H(17A)  0.9900 
C(17)-H(17B)  0.9900 
C(18)-C(19)  1.390(3) 
C(18)-C(23)  1.393(3) 
C(19)-C(20)  1.394(3) 
C(19)-H(19)  0.9500 
C(20)-C(21)  1.372(3) 
C(20)-H(20)  0.9500 
C(21)-C(22)  1.386(3) 
C(21)-H(21)  0.9500 
C(22)-C(23)  1.384(3) 
C(22)-H(22)  0.9500 
C(23)-H(23)  0.9500 
 220 
                                                                                                                                       
 
C(5)-N(1)-C(6) 122.81(18) 
C(5)-N(1)-H(1N) 114.6(15) 
C(6)-N(1)-H(1N) 122.6(15) 
C(12)-N(2)-C(16) 126.38(19) 
C(14)-O(2)-C(15) 115.87(18) 
C(16)-O(4)-C(17) 117.78(18) 
C(2)-C(1)-C(13) 121.0(2) 
C(2)-C(1)-H(1) 119.5 
C(13)-C(1)-H(1) 119.5 
C(1)-C(2)-C(3) 120.0(2) 
C(1)-C(2)-H(2) 120.0 
C(3)-C(2)-H(2) 120.0 
C(2)-C(3)-C(4) 121.5(2) 
C(2)-C(3)-H(3) 119.3 
C(4)-C(3)-H(3) 119.3 
C(3)-C(4)-C(5) 118.85(19) 
C(3)-C(4)-C(14) 120.8(2) 
C(5)-C(4)-C(14) 120.39(19) 
N(1)-C(5)-C(13) 119.33(19) 
N(1)-C(5)-C(4) 121.28(18) 
C(13)-C(5)-C(4) 119.38(19) 
N(1)-C(6)-C(11) 120.85(19) 
N(1)-C(6)-C(7) 118.83(18) 
C(11)-C(6)-C(7) 120.32(19) 
C(8)-C(7)-C(6) 119.91(19) 
C(8)-C(7)-H(7) 120.0 
C(6)-C(7)-H(7) 120.0 
C(7)-C(8)-C(9) 120.7(2) 
C(7)-C(8)-H(8) 119.6 
C(9)-C(8)-H(8) 119.6 
C(10)-C(9)-C(8) 119.7(2) 
C(10)-C(9)-H(9) 120.1 
C(8)-C(9)-H(9) 120.1 
C(9)-C(10)-C(11) 121.6(2) 
C(9)-C(10)-H(10) 119.2 
C(11)-C(10)-H(10) 119.2 
C(6)-C(11)-C(10) 117.61(19) 
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C(6)-C(11)-C(12) 119.00(19) 
C(10)-C(11)-C(12) 123.35(18) 
N(2)-C(12)-C(11) 127.5(2) 
N(2)-C(12)-C(13) 116.36(19) 
C(11)-C(12)-C(13) 116.12(18) 
C(1)-C(13)-C(5) 119.30(19) 
C(1)-C(13)-C(12) 120.33(18) 
C(5)-C(13)-C(12) 120.27(19) 
O(1)-C(14)-O(2) 122.1(2) 
O(1)-C(14)-C(4) 125.4(2) 
O(2)-C(14)-C(4) 112.47(19) 
O(2)-C(15)-H(15A) 109.5 
O(2)-C(15)-H(15B) 109.5 
H(15A)-C(15)-H(15B) 109.5 
O(2)-C(15)-H(15C) 109.5 
H(15A)-C(15)-H(15C) 109.5 
H(15B)-C(15)-H(15C) 109.5 
O(3)-C(16)-O(4) 125.0(2) 
O(3)-C(16)-N(2) 125.5(2) 
O(4)-C(16)-N(2) 109.13(19) 
O(4)-C(17)-C(18) 108.35(17) 
O(4)-C(17)-H(17A) 110.0 
C(18)-C(17)-H(17A) 110.0 
O(4)-C(17)-H(17B) 110.0 
C(18)-C(17)-H(17B) 110.0 
H(17A)-C(17)-H(17B) 108.4 
C(19)-C(18)-C(23) 119.2(2) 
C(19)-C(18)-C(17) 120.5(2) 
C(23)-C(18)-C(17) 120.2(2) 
C(18)-C(19)-C(20) 120.3(2) 
C(18)-C(19)-H(19) 119.8 
C(20)-C(19)-H(19) 119.8 
C(21)-C(20)-C(19) 120.2(2) 
C(21)-C(20)-H(20) 119.9 
C(19)-C(20)-H(20) 119.9 
C(20)-C(21)-C(22) 119.8(2) 
C(20)-C(21)-H(21) 120.1 
C(22)-C(21)-H(21) 120.1 
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C(23)-C(22)-C(21) 120.7(2) 
C(23)-C(22)-H(22) 119.7 
C(21)-C(22)-H(22) 119.7 
C(22)-C(23)-C(18) 119.9(2) 
C(22)-C(23)-H(23) 120.0 
C(18)-C(23)-H(23) 120.0 
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
  
Table 3.  Torsion angles [°] for methyl-9-benzyloxycarbonylaminoacridine-4-carboxylate 
(45).________________________________________________________________ 
C(13)-C(1)-C(2)-C(3) 0.5(3) 
C(1)-C(2)-C(3)-C(4) -0.4(3) 
C(2)-C(3)-C(4)-C(5) -0.5(3) 
C(2)-C(3)-C(4)-C(14) -179.9(2) 
C(6)-N(1)-C(5)-C(13) -4.5(3) 
C(6)-N(1)-C(5)-C(4) 176.21(19) 
C(3)-C(4)-C(5)-N(1) -179.39(19) 
C(14)-C(4)-C(5)-N(1) 0.1(3) 
C(3)-C(4)-C(5)-C(13) 1.3(3) 
C(14)-C(4)-C(5)-C(13) -179.23(19) 
C(5)-N(1)-C(6)-C(11) 3.6(3) 
C(5)-N(1)-C(6)-C(7) -176.28(19) 
N(1)-C(6)-C(7)-C(8) 178.75(19) 
C(11)-C(6)-C(7)-C(8) -1.1(3) 
C(6)-C(7)-C(8)-C(9) -2.4(3) 
C(7)-C(8)-C(9)-C(10) 3.4(3) 
C(8)-C(9)-C(10)-C(11) -0.8(3) 
N(1)-C(6)-C(11)-C(10) -176.27(19) 
C(7)-C(6)-C(11)-C(10) 3.6(3) 
N(1)-C(6)-C(11)-C(12) 6.1(3) 
C(7)-C(6)-C(11)-C(12) -174.00(19) 
C(9)-C(10)-C(11)-C(6) -2.7(3) 
C(9)-C(10)-C(11)-C(12) 174.8(2) 
C(16)-N(2)-C(12)-C(11) -11.6(4) 
C(16)-N(2)-C(12)-C(13) 167.3(2) 
C(6)-C(11)-C(12)-N(2) 164.9(2) 
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C(10)-C(11)-C(12)-N(2) -12.6(3) 
C(6)-C(11)-C(12)-C(13) -14.0(3) 
C(10)-C(11)-C(12)-C(13) 168.52(19) 
C(2)-C(1)-C(13)-C(5) 0.3(3) 
C(2)-C(1)-C(13)-C(12) -175.9(2) 
N(1)-C(5)-C(13)-C(1) 179.44(19) 
C(4)-C(5)-C(13)-C(1) -1.3(3) 
N(1)-C(5)-C(13)-C(12) -4.4(3) 
C(4)-C(5)-C(13)-C(12) 174.95(19) 
N(2)-C(12)-C(13)-C(1) 10.4(3) 
C(11)-C(12)-C(13)-C(1) -170.55(19) 
N(2)-C(12)-C(13)-C(5) -165.76(19) 
C(11)-C(12)-C(13)-C(5) 13.3(3) 
C(15)-O(2)-C(14)-O(1) -5.1(3) 
C(15)-O(2)-C(14)-C(4) 174.94(18) 
C(3)-C(4)-C(14)-O(1) 177.8(2) 
C(5)-C(4)-C(14)-O(1) -1.7(3) 
C(3)-C(4)-C(14)-O(2) -2.2(3) 
C(5)-C(4)-C(14)-O(2) 178.31(18) 
C(17)-O(4)-C(16)-O(3) 5.5(3) 
C(17)-O(4)-C(16)-N(2) 179.05(16) 
C(12)-N(2)-C(16)-O(3) -71.5(3) 
C(12)-N(2)-C(16)-O(4) 115.0(2) 
C(16)-O(4)-C(17)-C(18) 102.3(2) 
O(4)-C(17)-C(18)-C(19) 88.7(2) 
O(4)-C(17)-C(18)-C(23) -87.6(2) 
C(23)-C(18)-C(19)-C(20) -0.1(3) 
C(17)-C(18)-C(19)-C(20) -176.4(2) 
C(18)-C(19)-C(20)-C(21) 0.8(3) 
C(19)-C(20)-C(21)-C(22) -0.7(3) 
C(20)-C(21)-C(22)-C(23) -0.1(3) 
C(21)-C(22)-C(23)-C(18) 0.8(3) 
C(19)-C(18)-C(23)-C(22) -0.7(3) 
C(17)-C(18)-C(23)-C(22) 175.6(2) 
________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
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Table 4.  Hydrogen bonds for methyl-9-benzyloxycarbonylaminoacridine-4-carboxylate (45). [Å and °]. 
____________________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________ 
 N(1)-H(1N)...O(1) 0.90(2) 1.93(2) 2.670(2) 138(2) 
____________________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
 
